0001171843-19-002172.txt : 20190402 0001171843-19-002172.hdr.sgml : 20190402 20190402140207 ACCESSION NUMBER: 0001171843-19-002172 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190402 DATE AS OF CHANGE: 20190402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Precision Therapeutics Inc. CENTRAL INDEX KEY: 0001446159 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 331007393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36790 FILM NUMBER: 19723802 BUSINESS ADDRESS: STREET 1: 2915 COMMERS DRIVE, STREET 2: SUITE 900 CITY: EAGAN STATE: MN ZIP: 55121 BUSINESS PHONE: 651-389-4800 MAIL ADDRESS: STREET 1: 2915 COMMERS DRIVE, STREET 2: SUITE 900 CITY: EAGAN STATE: MN ZIP: 55121 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutic Inc. DATE OF NAME CHANGE: 20180208 FORMER COMPANY: FORMER CONFORMED NAME: Skyline Medical Inc. DATE OF NAME CHANGE: 20130807 FORMER COMPANY: FORMER CONFORMED NAME: BioDrain Medical, Inc. DATE OF NAME CHANGE: 20080925 10-K/A 1 f10ka_040219.htm FORM 10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2018

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ____________

COMMISSION FILE NUMBER: 001-36790

PRECISION THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware	33-1007393
(State or other jurisdiction	(IRS Employer
of incorporation or organization)	Identification No.)

2915 Commers Drive, Suite 900

Eagan, Minnesota 55121

(Address and Zip Code of principal executive offices)

(Registrant’s telephone number, including area code): (651) 389-4800

Securities registered pursuant to Section 12(b) of the Act:

Common Stock par value $0.01 per share	NASDAQ Capital Market

Securities registered under Section 12(g) of the Act: None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark if disclosures of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒.

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrants most recently completed second fiscal quarter: $13,584,316.47 as of June 30, 2018, based upon 12,089,446 shares at $1.13 per share as reported on NASDAQ Capital Market.

APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the last practicable date: As of March 26, 2019, the registrant had 15,792,586 shares of common stock, par value $.01 per share outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None.

EXPLANATORY NOTE

Precision Therapeutics Inc. is filing this Form 10-K/A (Amendment No. 1) to our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 1, 2019. This amendment modifies Item 8 for the purpose of including the report of the Registrant’s former auditor, Olsen Thielen & Co., on the financial statements for the year ended December 31, 2017, which was inadvertently omitted from Item 8. Such Olsen report on the 2017 financial statements is identical to the Olsen report that was filed on April 2, 2018 with the Registrant’s Form 10-K for the year ended December 31, 2017, except that the version of such report to be included in the 2018 10-K is dated as of a later date (April 1, 2019) as to Note 12. This Amendment No. 1 also reflect exhibits filed with this Amendment No. 1.

Except as described above, this Form 10-K/A does not modify or update other disclosures in the Form 10-K, including the nature and character of such disclosure to reflect events occurring after the filing date of the original Form 10-K. The filing of this Form 10-K/A is not an admission that the original 10-K, when filed, was not complete.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Our financial statements and supplementary data are included on pages F-1 to F-28 of this report.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

The following exhibits and financial statements are filed as part of, or are incorporated by reference into, this report:

(1) Financial Statements

The following financial statements are filed with this Annual Report and can be found beginning at page F-1 of this report:

	•	Report of Independent Registered Public Accounting Firm dated April 1, 2019;

	•	Report of Independent Registered Public Accounting Firm dated April 2, 2018 (except for Note 12 as to which the date is April 1, 2019);

•

Balance Sheets as of December 31, 2018 and December 31, 2017;

•

Statements of Comprehensive Income for the Years Ended December 31, 2018 and December 31, 2017;

•

Statements of Stockholders’ Equity (Deficit) from December 31, 2016 to December 31, 2018;

•

Statements of Cash Flows for the Years Ended December 31, 2018 and December 31, 2017; and

•

Notes to Financial Statements.

(2) Financial Statement Schedules

All schedules have been omitted because the information required to be shown in the schedules is not applicable or is included elsewhere in the financial statements and Notes to Financial Statements.

(3) Exhibits

See “Exhibit Index” following the signature page of this Form 10-K/A for a description of the documents that are filed as Exhibits to this Annual Report on Form 10-K or incorporated by reference herein.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 to Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 2, 2019

Precision Therapeutics Inc.

/s/ Bob Myers

Bob Myers

Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this amendment has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures	Title

/s/ Carl Schwartz	Chief Executive Officer and Director	April 2, 2019
Carl Schwartz	(principal executive officer)
/s/ Bob Myers	Chief Financial Officer	April 2, 2019
Bob Myers	(principal financial and accounting officer)

EXHIBIT INDEX

PRECISION THERAPEUTICS INC.

FORM 10-K/A – AMENDMENT NO. 1

Exhibit Number		Description
1.1		Placement Agency Agreement with Dawson James Securities, Inc. dated February 27, 2019 (47) Exhibit 1.1

2.1		Agreement and Plan of Merger, dated December 16, 2013, between Skyline Medical Inc., a Minnesota corporation, and the registrant (1) Exhibit 2.1

2.2		Amended and Restated Agreement and Plan of Merger dated October 22, 2018 (38) Exhibit 2.2

3.1		Certificate of Incorporation (1) Exhibit 3.1

3.2		Certificate of Amendment to Certificate of Incorporation to effect reverse stock split and reduction in authorized share capital filed with the Delaware Secretary of State on October 20, 2014 (19) Exhibit 3.2

3.3		Certificate of Amendment to Certificate of Incorporation regarding increase in share capital, filed with the Delaware Secretary of State on July 24, 2015 (20) Exhibit 3.3

3.4		Certificate of Amendment to Certificate of Incorporation to increase authorized share capital, filed with the Delaware Secretary of State on September 16, 2016 (27) Exhibit 3.4

3.5		Certificate of Amendment to Certificate of Incorporation to effect reverse stock split and reduction in authorized share capital, fled with the Delaware Secretary of State on October 26, 2016 (28) Exhibit 3.5

3.6		Certificate of Amendment to Certificate of Incorporation regarding increase in share capital, filed with the Delaware Secretary of State on January 26, 2017 (29) Exhibit 3.6

3.7		Certificate of Amendment to Certificate of Incorporation to effect reverse stock split, filed with the Delaware Secretary of State on January 2, 2018 (41) Exhibit 3.7

3.8		Certificate of Amendment to Certificate of Incorporation to effect name change, filed with the Delaware Secretary of State on February 1, 2018 (21) Exhibit 3.8

3.9		Certificate of Amendment to Certificate of Incorporation to increase authorized share capital and establish a classified Board of Directors (44) Exhibit 3.9

3.10		Amended and Restated Bylaws (21) Exhibit 3.10

3.11		First Amendment to Amended and Restated Bylaws (44) Exhibit 3.11

3.12		Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (22) Exhibit 3.12

3.13		Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (40) Exhibit 3.13

4.1		Form of Warrant (2) Exhibit 4.1

4.2		Form of Warrant (7) Exhibit 4.2

4.3		Form of Warrant (11) Exhibit 4.3

4.4		Form of Warrant (15) Exhibit 4.4

4.5		Form of Warrant (16) Exhibit 4.5

4.6		Amended and Restated 2012 Stock Incentive Plan (3)** Exhibit 4.6

4.7		Form of Senior Convertible Note (23) Exhibit 4.7

4.8		Form of Warrant issued to investors of Convertible Notes (23) Exhibit 4.8

4.9		Form of Registration Rights Agreement (23) Exhibit 4.9

4.10		Form Waiver and Consent of, and Notice to, Holder of Preferred Stock of the registrant (23) Exhibit 4.10

4.11		Form of Series A Warrant Agency Agreement by and between Skyline Medical Inc. and Corporate Stock Transfer, Inc. and Form of Warrant Certificate (24) Exhibit 4.11

4.12		Form of Series A Warrant Certificate (included as part of Exhibit 4.11) (24) Exhibit 4.12

4.13		Form of unit Purchase Option issued in connection with offering of Units (25) Exhibit 4.13

4.14		Form of Exchange Agreement with holders of Series A Preferred Stock (26) Exhibit 4.14

4.15		Form of Amendment to Senior Convertible Notes and Agreement by and between Skyline Medical Inc. and Senior Convertible Notes (26) Exhibit 4.15

4.16		Form of specimen certificate evidencing shares of Series B Convertible Preferred Stock (25) Exhibit 4.16

4.17		Form of Unit Agreement (including form of Unit Certificate) (24) Exhibit 4.17

4.18		Form of New Warrant Agency Agreement by and between Skyline Medical Inc. and Form of Warrant Certificate for Series B Warrant (30) Exhibit 4.18

4.19		Form of Series B Warrant Certificate (included as part of Exhibit 4.18) Exhibit 4.19

4.20		Form of Series C Warrant (33) Exhibit 4.20

4.21		Form of Unit Purchase Option (33) Exhibit 4.21

4.22		Form of Series D Warrant Agency Agreement by and between Skyline Medical Inc. and Corporate Stock Transfer, Inc. and Form of Series D Warrant Certificate (34) Exhibit 4.22

4.23		Form of Series D Warrant Certificate (included as part of Exhibit 4.22) Exhibit 4.23

4.24		Form of Amendment to Warrant (21) Exhibit 4.24

4.25		Investor Warrant (40) Exhibit 4.25

4.26		Series E Warrant Agency Agreement by and between Skyline Medical Inc. and Corporate Stock Transfer, Inc. dated January 9, 2018 (42) Exhibit 4.26

4.27		Form of Series E Warrant Certificate (42) Exhibit 4.27

4.28		Common Stock Purchase Warrant issued to L2 Capital, LLC dated September 28, 2018 (44) Exhibit 4.28

4.29		Common Stock Purchase Warrant issued to Peak One Opportunity Fund, LP dated September 28, 2018 (44) Exhibit 4.29

4.30		Second Amended and Restated Common Stock Purchase Warrant issued to Carl Schwartz dated February 6, 2019 (46) Exhibit 4.30

4.31		Form of Warrant (47) Exhibit 4.31

4.32		Form of Unit Purchase Option (47) Exhibit 4.32

4.33		Common Stock Purchase Warrant issued to Carl Schwartz dated November 30, 2018 (48) Exhibit 4.33

4.34		Amended and Restated Common Stock Purchase Warrant issued to Carl Schwartz dated January 8, 2019 (49) Exhibit 4.34

10.1		Form of Securities Purchase Agreement, dated as of February 4, 2014, by and among the Company and certain Purchasers (2) Exhibit 10.1

10.2		Settlement Agreement and Mutual General Release dated September 18, 2013, entered into by and among Kevin Davidson, Skyline Medical Inc., Atlantic Partners Alliance, LLC, SOK Partners, LLC, Joshua Kornberg and Dr. Samuel Herschkowitz (4) Exhibit 10.2

10.3		Amended and Restated Executive Employment Agreement with Joshua Kornberg, signed on June 17, 2013 and effective March 14, 2013 (6)** Exhibit 10.3

10.4		BioDrain Medical, Inc., 2012 Stock Incentive Plan Restricted Stock Award Agreement with Joshua Kornberg, signed on June 17, 2013 and effective March 14, 2013 (6)** Exhibit 10.4

10.5		Form of Convertible Promissory Note (7) Exhibit 10.5

10.6		Promissory Note in the Principal amount of $100,000 in favor of Brookline Group, LLC, dated as of March 8, 2013 (9) Exhibit 10.6

10.7		Form of Securities Purchase Agreement (11) Exhibit 10.7

10.8		Office Lease Agreement between the registrant and Roseville Properties Management Company, as agent for Lexington Business Park, LLC (12) Exhibit 10.8

10.9		Form of Non-Qualified Stock Option Agreement under the 2012 Stock Incentive Plan (13)** Exhibit 10.9

10.10		Employment Agreement with Josh Kornberg dated July 24, 2012 (13)** Exhibit 10.10

10.11		Non-Qualified Stock Option Agreement with Josh Kornberg dated August 13, 2012 (13)** Exhibit 10.11

10.12		Employment Agreement with Robert Myers dated August 11, 2012 (13)** Exhibit 10.12

10.13		Employment Agreement with David Johnson dated August 11, 2012 (13)** Exhibit 10.13

10.14		Settlement Agreement and Mutual General Release with Kevin Davidson effective October 11, 2012 (13)** Exhibit 10.14

10.15		Note Purchase Agreement, dated as of November 6, 2012, between Dr. Samuel Herschkowitz and BioDrain Medical, Inc. (14) Exhibit 10.15

10.16		Note Purchase Agreement, dated as of November 6, 2012, between Dr. Samuel Herschkowitz and BioDrain Medical, Inc. (14) Exhibit 10.16

10.17		Note Purchase Agreement, dated as of November 6, 2012, between Dr. Samuel Herschkowitz and BioDrain Medical, Inc. (14) Exhibit 10.17

10.18		Note Purchase Agreement, dated as of November 6, 2012, between Dr. Samuel Herschkowitz and BioDrain Medical, Inc. (14) Exhibit 10.18

10.19		Amended Lease with Roseville Properties Management Company, Inc. dated January 29, 2013 (14) Exhibit 10.19

10.20		Form of Convertible Promissory Note (15) Exhibit 10.20

10.21		Forbearance and Settlement Agreement among the registrant, Dr. Samuel Herschkowitz and SOK Partners, LLC dated August 15, 2012 (13) Exhibit 10.21

10.22		Form of Securities Purchase Agreement (16) Exhibit 10.22

10.23		Convertible Note Purchase Agreement between the Company and SOK Partners, LLC dated March 28, 2012, including the form of Convertible Promissory Grid Note (18) Exhibit 10.23

10.24		Amended and Restated Note Purchase Agreement between the Company and Dr. Samuel Herschkowitz dated as of December 20, 2011, including the form of Convertible Promissory Note (issued in the amount of $240,000) (18) Exhibit 10.24

10.25		Letter Agreement, dated August 22, 2013, among Dr. Samuel Herschkowitz, SOK Partners, LLC and Skyline Medical Inc. (5) Exhibit 10.25

10.26		Letter Agreement, dated April 25, 2013, among Dr. Samuel Herschkowitz, SOK Partners, LLC and BioDrain Medical, Inc. (8) Exhibit 10.26

10.27		Letter Agreement, dated March 14, 2013, among Dr. Samuel Herschkowitz, SOK Partners, LLC and BioDrain Medical, Inc. (10) Exhibit 10.27

10.28		Form of Securities Purchase Agreement with investors in Convertible Notes (23) Exhibit 10.28

10.29		Separation Agreement and Release between Skyline Medical Inc. and Joshua Kornberg, dated June 13, 2016 (31) Exhibit 10.29

10.30		Amended and Restated 2012 Stock Incentive Plan (45) Exhibit 10.30

10.31		Form of Common Stock Purchase Agreement (33) Exhibit 10.31

10.32		Form of Stock Option Agreement effective as of July 1, 2016 (36) Exhibit 10.32

10.33		Form of Stock Option Agreement for Executive Officers (39) Exhibit 10.33

10.34		Form of Stock Option Agreement for Directors (39) Exhibit 10.34

10.35		Securities Purchase Agreement dated November 28, 2017 (40) Exhibit 10.35

10.36		Registration Rights Agreement dated November 28, 2017 (40) Exhibit 10.36

10.37		Share Exchange Agreement between Skyline Medical Inc. and Helomics Holding Corporation, dated January 11, 2018, including the form of Certificate of Designation of Helomics Series A Preferred Stock and the form of Escrow Agreement (43) Exhibit 10.37

10.38		Securities Purchase Agreement by and between the Company and L2 Capital, LLC dated September 28, 2018 (44) Exhibit 10.38

10.39		Senior Secured Promissory Note issued to L2 Capital, LLC dated September 28, 2018 (44) Exhibit 10.39

10.40		Registration Rights Agreement by and between the Company and L2 Capital, LLC dated September 28, 2018 (44) Exhibit 10.40

10.41		Security Agreement by and between the Company and L2 Capital, LLC dated September 28, 2018 (44) Exhibit 10.41

10.42		Securities Purchase Agreement by and between the Company and Peak One Opportunity Fund, LP dated September 28, 2018 (44) Exhibit 10.42

10.43		Senior Secured Promissory Note issued to Peak One Opportunity Fund, LP dated September 28, 2018 (44) Exhibit 10.43

10.44		Registration Rights Agreement by and between the Company and Peak One Opportunity Fund, LP dated September 28, 2018 (44) Exhibit 10.44

10.45		Security Agreement by and between the Company and Peak One Opportunity Fund, LP dated September 28, 2018 (44) Exhibit 10.45

10.46		Amended and Restated Promissory Note issued to Carl Schwartz dated February 6, 2019 (46) Exhibit 10.46

10.47		Forbearance Agreement by and between L2 Capital, LLC and the Company dated February 7, 2019 (46) Exhibit 10.47

10.48		Forbearance Agreement by and between Peak One Opportunity Fund, LP and the Company dated February 7, 2019 (46) Exhibit 10.48

10.49		Amended and Restated Promissory Note issued to L2 Capital, LLC dated February 7, 2019 (46) Exhibit 10.49

10.50		Amended and Restated Promissory Note issued to Peak One Opportunity Fund, LP dated February 7, 2019 (46) Exhibit 10.50

10.51		Promissory Note issued to Carl Schwartz dated November 30, 2018 (48) Exhibit 10.51

10.52		Amended and Restated Promissory Note issued to Carl Schwartz dated January 8, 2019 (49) Exhibit 10.52

10.53		Subscription Agreement by and between Carl Schwartz and the Company dated January 8, 2019 (49) Exhibit 10.53

10.54		Employment Agreement by and between Carl Schwartz and Issuer dated November 10, 2017 (50)** Exhibit 10.54

10.55		Amendment to Employment Agreement by and between the Issuer and Carl Schwartz dated August 20, 2018 (50)** Exhibit 10.55

10.56***		Amendment to Employment Agreement by and between the Issuer and Bob Myers dated August 20, 2018** Exhibit 10.56

14.1		Code of Ethics (17) Exhibit 14.1

23.1***		Consent of Independent Registered Public Accounting Firm: Deloitte & Touche LLP Exhibit 23.1

23.2*		Consent of Independent Registered Public Accounting Firm: Olsen Thielen & Co., Ltd.

31.1*		Certification of principal executive officer required by Rule 13a-14(a)

31.2*		Certification of principal financial officer required by Rule 13a-14(a)

32.1*		Section 1350 Certification

99.1		Binding Letter of Intent with CytoBioscience, Inc. dated July 21, 2017 (37) Exhibit 99.1

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*Filed herewith.

**Compensatory Plan or arrangement required to be filed pursuant to Item 15(b) of Form 10-K.

*** Filed previously with Form 10-K.

	(1)	Filed on December 19, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(2)	Filed on February 5, 2014 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(3)	Filed on August 27, 2013 as an exhibit to our Proxy Statement on Schedule 14A and incorporated herein by reference.

	(4)	Filed on November 14, 2013 as an exhibit to our Quarterly Report on Form 10-Q and incorporated herein by reference.

	(5)	Filed on August 28, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(6)	Filed on June 18, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(7)	Filed on June 12, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(8)	Filed on May 1, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(9)	Filed on March 14, 2013 as an exhibit to our Current report on Form 8-K and incorporated herein by reference.

	(10)	Filed on March 12, 2013 as an exhibit to our Current Report on Form 8-K (by incorporation by reference from the Schedule 13D/A filed by Dr. Herschkowitz and other parties on March 8, 2013) and incorporated herein by reference.

(11)

Filed on February 26, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(12)	Filed on November 12, 2008 as an exhibit to our Registration Statement on Form S-1 and incorporated herein by reference.

	(13)	Filed on November 5, 2012 as an exhibit to our Registration Statement on Form S-1 and incorporated herein by reference.

	(14)	Filed on February 8, 2013 as an exhibit to our Registration Statement on Form S-1 (except for Exhibit 10.19, by incorporation by reference from the Schedule 13D/A filed by Dr. Herschkowitz and other parties on November 8, 2012) and incorporated herein by reference.

	(15)	Filed on January 15, 2013 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(16)	Filed on June 21, 2012 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(17)	Filed on April 16, 2012 as an exhibit to our Annual Report on Form 10-K and incorporated herein by reference.

	(18)	Filed on April 3, 2012 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(19)	Filed on October 24, 2014 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(20)	Filed on June 30, 2015 as an appendix to our Information Statement on Schedule 14C and incorporated herein by reference.

	(21)	Filed on February 6, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(22)	Filed on August 20, 2015 as an exhibit to our Registration Statement on Form S-1 (File No. 333-198962) and incorporated herein by reference.

	(23)	Filed on July 24, 2014 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(24)	Filed on August 20, 2015 as an exhibit to our Registration Statement on Form S-1 (File No. 333-198962) and incorporated herein by reference.

	(25)	Filed on August 10, 2015 as an exhibit to our Registration Statement on Form S-1 (File No. 333-198962) and incorporated herein by reference.

	(26)	Filed on July 24, 2015 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(27)	Filed on September 16, 2016 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(28)	Filed on October 27, 2016 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(29)	Filed on January 27, 2017 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(30)	Filed on March 25, 2016 as an exhibit to our Registration Statement on Form S-4 (File No. 333-210398) and incorporated herein by reference.

	(31)	Filed on June 17, 2016 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(32)	Filed on December 4, 2017 as an exhibit to our Proxy Statement on Schedule 14A and incorporated herein by reference.

	(33)	Filed on November 30, 2016 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(34)	Filed on January 10, 2017 as an exhibit to our Registration Statement on Form S-1 (File No. 333-215005) and incorporated herein by reference.

	(35)	[Reserved]

	(36)	Filed on March 15, 2017 as an exhibit to our Registration Statement on Form S-8 and incorporated herein by reference.

	(37)	Filed on August 2, 2017 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(38)	Filed on October 30, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(39)	Filed on August 14, 2017 as an exhibit to our Quarterly Report on Form 10-Q and incorporated herein by reference.

	(40)	Filed on November 29, 2017 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(41)	Filed on January 2, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(42)	Filed on January 10, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(43)	Filed on January 16, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(44)	Filed on October 4, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(45)	Filed on March 22, 2019 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(46)	Filed on February 12, 2019 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(47)	Filed on March 1, 2019 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(48)	Filed on December 7, 2018 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(49)	Filed on January 14, 2019 as an exhibit to our Current Report on Form 8-K and incorporated herein by reference.

	(50)	Filed on January 25, 2019 as an exhibit to the Schedule 13D report filed by Carl Schwartz and incorporated herein by reference.

The audited financial statements for the periods ended December 31, 2018 and December 31, 2017 are included on the following pages:

INDEX TO FINANCIAL STATEMENTS

	Page
Financial Statements:
Report of Independent Registered Public Accounting Firm	F-1
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets	F-3
Consolidated Statements of Comprehensive Loss	F-4
Consolidated Statements of Stockholders’ Equity	F-5
Consolidated Statements of Cash Flows	F-6
Consolidated Notes to Financial Statements	F-7

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Precision Therapeutics Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Precision Therapeutics Inc. (the "Company") as of December 31, 2018, the related consolidated statements of comprehensive loss, stockholders’ equity, and cash flows, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018, and the results of its operations and its cash flows for the year ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company does not expect to generate sufficient operating cashflows to sustain its operations in the near-term, and needs to raise significant additional capital to meet its operating needs, and pay debt obligations coming due, which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion.

Minneapolis, Minnesota

April 1, 2019

We have served as the Company's auditor since 2018.

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and stockholders of

Precision Therapeutics Inc., f/k/a Skyline Medical, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Precision Therapeutics, Inc. f/k/a Skyline Medical, Inc. (the Company) as of December 31, 2017 and 2016 and the related statements of comprehensive income (loss), stockholders' equity and cash flows for each of the years in the two-year period ended December 31, 2017, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.

Emphasis of a Matter - Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred losses since inception, has an accumulated deficit and has not yet received significant revenue from sales of products or services. These factors raise substantial doubt about its (the Company's) ability to continue as a going concern. Management's plans in regard to these matters are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Roseville, Minnesota

April 2, 2018, except for Note 12 as to

which the date is April 1, 2019

We have served as the Company's auditor since 2002.

F-2

PART 1. FINANCIAL INFORMATION

Item 1. Financial Statements

PRECISION THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETS

	December 31, 2018			December 31, 2017
ASSETS
Current Assets:
Cash & cash equivalents	$	162,152		$	766,189
Certificates of deposit		-			244,971
Accounts Receivable		232,602			137,499
Notes Receivable (inclusive of $452,775 in advances to Helomics)		497,276			667,512
Inventories		241,066			265,045
Prepaid Expense and other assets		318,431			289,966
Total Current Assets		1,451,527			2,371,182

Notes Receivable		1,112,524			1,070,000
Fixed Assets, net		180,453			87,716
Intangibles, net		964,495			95,356

Total Assets	$	3,708,999		$	3,624,254

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts Payable	$	445,689		$	140,462
Notes Payable – Bridge Loan Net of Discount		1,327,942			-
Notes Payable – Net of Discount		306,972			-
Accrued Expenses		1,279,114			785,215
Derivative Liability		272,745			-
Deferred Revenue		23,065			6,663
Total Current Liabilities		3,655,527			932,340

Total Liabilities		3,655,527			932,340
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 79,246 outstanding		792			792
Series C Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 0 and 647,819 outstanding		-			6,479
Common Stock, $.01 par value, 50,000,000 authorized, 14,091,748 and 6,943,283 outstanding		140,917			69,432
Additional paid-in capital		63,019,708			55,636,680
Accumulated deficit		(63,107,945	)		(53,021,469	)
Total Stockholders' Equity		53,472			2,691,914

Total Liabilities and Stockholders' Equity	$	3,708,999		$	3,624,254

See Notes to Consolidated Financial Statements

F-3

PRECISION THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Year Ended December 31,
	2018			2017
Revenue	$	1,411,655		$	654,836

Cost of goods sold		415,764			148,045

Gross margin		995,891			506,791

General and administrative expense		4,626,997			4,050,307

Operations expense		1,861,121			1,414,774

Sales and marketing expense		2,369,152			1,095,232

Total operating loss		7,861,379			6,053,523

Other income		510,254			53,734

Other expense		441,772			3,228

Loss on equity method investment		(2,293,580	)		-

Net loss available to common shareholders	$	(10,086,477	)	$	(6,003,017	)

Loss per common share - basic and diluted	$	(0.79	)	$	(0.94	)

Weighted average shares used in computation - basic and diluted		12,816,289			6,362,989

See Notes to Consolidated Financial Statements

F-4

PRECISION THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED

DECEMBER 31, 2018 and 2017

									Common Stock
	Preferred Stock			# Shares Preferred C			# Shares Preferred B		Shares			Amount			Paid-in Capital		Deficit			Other Comprehensive Income			Total
Balance at 12/31/2016	$	792			-			79,246		4,564,428		$	45,644		$	47,894,196	$	(47,018,451	)	$	1,501		$	923,682
Shares issued pursuant to the public offering, net										1,750,000			17,500			3,403,688								3,421,188
Shares issued pursuant to the overallotment agreement in the public offering										175,000			1,750			392,000								393,750

Vesting Expense																2,298,680								2,298,680
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement										(400,000	)		(4,000	)										(4,000	)
Shares issued pursuant to consulting agreement										100,000			1,000			219,000								220,000
Unrealized (loss) from marketable securities																		(1	)		(1,501	)		(1,501	)
Shares issued pursuant to consulting agreement										43,333			433			63,699								64,132
Shares issued at $1.58 per share to an investor relations consultant										50,000			500			78,500								79,000
Shares issued pursuant to a private placement		12,138			1,213,819											1,201,681								1,213,819
Preferred conversion to common shares pursuant to a private placement agreement		(5,659	)		(566,000	)				660,522			6,604			85,236								86,182
Net loss																.		(6,003,017	)					(6,003,017	)
Balance at 12/31/2017	$	7,271			647,819			79,246		6,943,283		$	69,432		$	55,636,680	$	(53,021,469	)	$	-		$	2,691,914
Preferred conversion to common shares pursuant to private placement agreement		(6,479	)		(647,819	)				589,747			5,897			582								-
Shares issued pursuant to S-3 public offering										2,900,000			29,000			2,726,087								2,755,087
Investment in Subsidiary pursuant to Helomics 20% acquisition										1,100,000			11,000			1,031,250								1,042,250
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share										145,396			1,454			143,942								145,396
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share										215,247			2,153			202,268		1						204,422
Re-priced warrant exercise pursuant to 2016 private investment										504,666			5,046			499,619								504,665
Shares issued pursuant to a consultant contract @ $1.18 per share										150,000			1,500			175,500								177,000
Shares issued pursuant to a consultant contract @ $1.18 per share										100,000			1,000			117,000								118,000
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share										750,000			7,500			870,000								877,500
Debt Discount on Warrants per Bridge Loan																183,187								183,187
Shares issued as inducement for Bridge Loan										650,000			6,500			200,105								206,605
Shares issued to employee in lieu of bonus										43,409			435			39,803								40,238
Warrants issued from loan by CEO																68,757								68,757
Vesting Expense																1,124,928								1,124,928
Net loss																		(10,086,477	)					(10,086,477	)
Balance at 12/31/2018	$	792			-			79,246		14,091,748		$	140,917		$	63,019,708	$	(63,107,945	)	$	-		$	53,472

See Notes to Consolidated Financial Statements

F-5

PRECISION THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,
	2018			2017
Cash flow from operating activities:
Net loss	$	(10,086,477	)	$	(6,003,017	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment		2,293,580			-
Depreciation and amortization		147,628			71,562
Vesting expense for stock options and warrants		1,124,928			2,298,680
Equity instruments issued for management and consulting		335,238			359,133
Amortization of debt discount		385,111			-
Gain from sale of marketable securities		-			(1,837	)
Gain on valuation of equity-linked instruments		(372,263	)		-
Changes in assets and liabilities:
Accounts receivable		(95,103	)		(98,580	)
Inventories		23,979			7,163
Prepaid expense and other assets		139,895			(141,329	)
Accounts payable		305,227			(79,650	)
Accrued expenses		493,899			(870,540	)
Deferred revenue		16,402			(1,335	)
Net cash used in operating activities:		(5,287,956	)		(4,459,750	)
Cash flow from investing activities:
Proceeds from sale of marketable securities		-			284,665
Purchase of certificates of deposit		-			(3,084,971	)
Redemption of certificates of deposit		244,971			2,940,000
Advances on notes receivable		(1,123,619	)		(1,737,512	)
Purchase of fixed assets		(177,732	)		(45,093	)
Purchase of intangibles		(54,271	)		(10,179	)
Net cash used in investing activities		(1,110,651	)		(1,653,090	)

Cash flow from financing activities:
Proceeds from exercise of warrants into common stock		650,061			-
Proceeds from debt issuance		2,185,000			-
Net proceeds from issuance of preferred stock		-			1,300,001
Net proceeds from issuance of common stock		2,959,509			3,814,938
Net cash provided by financing activities		5,794,570			5,114,939

Net decrease in cash		(604,037	)		(997,901	)
Cash at beginning of period		766,189			1,764,090
Cash at end of period	$	162,152		$	766,189
Non-cash transactions in investing and financing activities
Conversion of preferred stock to common stock	$	6,479		$	-
Equity method investment – Helomics		1,542,250			-
Licensing fee for TumorGenesis		877,500			-

See Notes to Consolidated Financial Statements

F-6

PRECISION THERAPEUTICS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

The Company was originally incorporated on April 23, 2002 in Minnesota as BioDrain Medical, Inc. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On August 31, 2015, the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On February 1, 2018, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change the Company’s corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective February 1, 2018. Because of this change, the Company’s common stock began trading under the new ticker symbol “AIPT,” effective February 2, 2018. Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of December 31, 2018, the registrant had 14,091,748 shares of common stock, par value $.01 per share, outstanding. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of its proprietary cleaning fluid and filters to users of the STREAMWAY systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired 25% of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the first quarter of 2018, and in April 2018 the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In June 2018, the Company and Helomics entered into a definitive merger agreement – see Note 4. The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over 149,000 tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis, formed during the first quarter, is presented as part of the consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $63,107,945. The Company does not expect to generate sufficient operating revenue to sustain its operations in the near-term. In 2018, the Company incurred negative operating cash flows of approximately $441,000 per month. Although the Company has attempted to curtail expenses, there is no guarantee that the Company will be able to reduce these expenses significantly, and expenses may need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of $162,152 as of December 31, 2018 and needs to raise significant additional capital to meet its operating needs, pay debt obligations coming due, and the continued operating needs of Helomics, therefore there is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-3, with which the Company has raised approximately $2.1 million in net proceeds in early 2019. The Company may raise up to approximately $1.7 million in additional gross proceeds in the next calendar year using the shelf registration statement. This amount of available financing will increase to approximately $6.4 million in additional gross proceeds, once the Helomics acquisition is completed.

Since inception to December 31, 2018, the Company raised approximately $36,490,000 in equity and $7,870,000 in debt financing. Equity raises include: a January 2017 public offering of units with gross proceeds to the Company of $3,937,500; a November 2017 private placement with gross proceeds of $1,300,000; and, a January 2018 public offering with gross proceeds of $2,755,000. Included in debt financing were raises in September 2018 on senior secured promissory notes with net proceeds of $1,815,000, and in November 2018 the Company received a loan from the CEO for $370,000. Subsequent to December 31, 2018, the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional $1,300,000.

The Company has no commitments or contingencies.

Recent Accounting Developments

Accounting Policies and Estimates

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on January 1, 2018 using the modified retrospective method applied to those contracts which were not completed as of December 31, 2017. Results for reporting periods beginning January 1, 2018 are presented under Topic 606, while prior-period amounts have not been retrospectively adjusted and continue to be reported in accordance with Topic 605, Revenue Recognition. Based upon the Company’s contracts which were not completed as of December 31, 2017, the Company was not required to make an adjustment to the opening balance of retained earnings as of January 1, 2018, and there was no material impact. See Note 3 for further discussion.

F-7

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of January 1, 2018. As of December 31, 2018, there is no material impact on the Company’s financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company adopted ASU 2016-02 on January 1, 2019, using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The adoption resulted in no material impact to the Company’s balance sheet, results of operations, equity or cash flows.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company adopted the standard as of January 1, 2018. As of December 31, 2018, there is no material impact on the Company’s financial statements and disclosures.

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment in accordance with ASC 360 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. The Company’s intangible assets are definite lived and currently solely the costs of obtaining licensing fees, trademarks, and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were $43,548 in 2018 and $37,060 in 2017.

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately $526,000 and $289,000 for 2018 and 2017, respectively.

F-8

Revenue Recognition

The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases.

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses.

Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than one year but greater than three months when purchased. Certificates with maturity dates beyond one year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

F-9

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Certification (ASC) 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC 820 establishes a three-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities, which in 2018 are cash equivalents only, were determined based on Level 1 inputs.

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts. Changes to the valuation allowance have not been material to the financial statements.

Inventories

Inventories are stated at the net realizable value, with cost determined on a first-in, first-out basis. Inventory balances are as follows:

	December 31, 2018		December 31, 2017

Finished goods	$	58,701	$	62,932
Raw materials		127,003		141,028
Work-In-Process		55,362		61,085
Total	$	241,066	$	265,045

F-10

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation is shown in the financial statements under fixed assets, net on the balance sheet, and amortization is shown under intangibles, net on the balance sheet. Estimated useful asset life by classification is as follows:

The Company’s investment in fixed assets consists of the following:

	December 31, 2018		December 31, 2017
Computers and office equipment	$	204,903	$	183,528
Leasehold Improvements		140,114		25,635
Manufacturing Tooling		108,955		108,955
Demo Equipment		85,246		43,368
Total		539,218		361,486
Less: Accumulated Depreciation		358,765		273,770
Total Fixed Assets, Net	$	180,453	$	87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was $84,995 in 2018 and $58,872 in 2017.

Intangible Assets

The components of intangible assets all of which are finite-lived were as follows:

	12/31/2018							12/31/2017
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	318,304	$	(182,559	)	$	135,745	$	264,032	$	(168,676	)	$	95,356
Licensing Fees		877,500		(48,750	)		828,750		-		-			-
Total	$	1,195,804	$	(231,309	)	$	964,495	$	264,032	$	(168,676	)	$	95,356

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2018

Year ending	Expense
2019		72,383
2020		72,383
2021		72,383
2022		72,383
2023		72,383
Thereafter		602,580
Total		964,495

Intangible assets consist of trademarks, patent costs and licensing fees. Amortization expense was $62,633 in 2018 and $12,689 in 2017. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

F-11

Income Taxes

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate income tax rates from 34% to 21%. As a result of the enacted law, the Company was required to value its deferred tax assets and liabilities at the new enacted rate. There was no income tax impact from the re-measurement due to the 100% valuation allowance on the Company’s deferred tax assets.

The Company accounts for income taxes in accordance with ASC 740 - Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

F-12

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company has no credit risk concentration because there are no funds in excess of insurance limits in a single bank.

Product Warranty Costs

In 2018 and in 2017, the Company incurred approximately $10,682 and $6,209, respectively in warranty costs.

Segments

The Company operates in two segments for the sale of its medical device and consumable products. These segments are its domestic operations and international operations. Substantially all the Company’s assets, revenues, and expenses for the years ended December 31, 2018 and 2017 were located at or derived from operations in the United States. In 2018 and 2017, business activity within the Company’s international segment was immaterial.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

NOTE 2 – EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. Summarized financial information for Helomics is presented below:

Helomics Holdings Corporation

	December 31, 2018

Current assets	$	419,266

Non-current assets	$	2,046,347

Total assets	$	2,465,613

Current liabilities	$	12,247,174

Total liabilities	$	12,247,174

	For the Year-ended Ended
	December 31, 2018
Revenue	$	523,546

Gross margin	$	214,426

Net loss on operations	$	(5,056,725	)

Net loss	$	(9,452,835	)

Net Loss to investee	$	(7,159,255	)¹

¹The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 – February 27, 2018, and then at 75% for the remainder of the twelve-month period at the current equity investment percentage owned by the Company.

Helomics’ first year predominantly included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have generated approximately $31,000 of revenue in the year-to-date.

The Helomics loss reduces the equity method investment asset on the balance sheet. The recorded investor losses have exceeded the equity method investment originally recorded total. As such, the equity method investment recorded to the balance sheet has been reduced to zero, and all subsequent losses reduced the note receivable due from Helomics. The note receivable on the balance sheet includes $413,683, not including interest, for Helomics. The actual note due to the Company as of December 31, 2018 is $1,165,013. The amount exceeding the original equity method investment and thus reducing the note receivable balance is $751,330.

NOTE 3 – REVENUE RECOGNITION

Revenue from Product Sales

F-13

Variable Consideration

Warranty

The Company generally provides one-year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2018, and December 31, 2017, accounts receivable totaled $232,602 and $137,499, respectively.

F-14

The Company deferred revenues related primarily to maintenance plans of $23,065 and $6,663 as of December 31, 2018 and December 31, 2017, respectively.

Practical Expedients

The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

NOTE 4 – STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS

2017 Firm Commitment Public Offering

On January 19, 2017, the Company closed a firm commitment public offering for 1,750,000 Units at $2.25 per Unit. The Units comprised one share of common stock and 0.2 Series D Warrants with each whole Series D Warrant purchasing one share of the Company’s common stock at an exercise price of $2.25 per share. The Company received gross proceeds of $3,937,500. Subsequently the underwriter exercised over-allotment for 175,000 shares of common stock and for Series D warrants to purchase 35,000 shares of common stock at $0.01 per warrant. The Company received net proceeds from the over-allotment of $358,312.

2017 Private Placement

On November 30, 2017, the Company closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York based Family Office. Pursuant to the Securities Purchase Agreement, the investor purchased 1,213,819 shares of Series C stock at a purchase price of $1.071 per Series C Share, together with a warrant to purchase up to 606,910 shares of common stock. The warrant has an exercise price of $1.26 per share, subject to adjustment, has a five- and one-half-year term and is exercisable commencing six months following the date of issuance. Total gross proceeds to the Company were $1,300,000 before deducting expenses and will be used for general working capital. In connection with the offering and pursuant to a registration rights agreement, the Company has agreed to file a “resale” registration statement covering all of the shares of common stock issuable upon conversion of the warrant. Pursuant to the Securities Purchase agreement, and as of this filing date, all the Preferred Series C shares were converted at a conversion rate of 1.167 to a maximum of 1,250,269 shares of common stock. The remaining 142,466 shares of Preferred Series C stock were cancelled with a redemption payment to the holder for $189,285.

2018 Firm Commitment Public Offering

In January 2018, the Company completed a firm commitment underwritten public offering of 2,900,000 Units at an offering price of $0.95 per Unit, with each Unit consisting of one share of the Company’s common stock and 0.3 of a Series E Warrant, with each whole Series E Warrant purchasing one share of common stock at an exercise price of $1.00 per whole share. The shares of common stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately $2,755,000, before deducting expenses. The Company granted the underwriter a 45-day option to purchase an additional (i) up to 290,000 additional shares of common stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to 87,000 additional shares of common stock at a purchase price of $0.001 per Series E Warrant to cover over-allotments, if any. On February 21, 2018, the underwriter exercised on 215,247 shares of common stock, par value $0.01, at $0.9497 per share as described in the Underwriting Agreement. The Company received net proceeds of $188,066 after deductions of $16,354 representing the underwriter’s discount of 8% of the purchase price of the shares.

Share Exchange Agreement with Helomics

On January 11, 2018, the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement, Helomics issued 2,500,000 shares of its Series A Preferred Stock in exchange for 1,100,000 shares of common stock. Under the share exchange agreement, in March 2018 the Company converted $500,000 in secured notes into another 5% of Helomics’ outstanding shares, which resulted in the Company owning 25% of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of $500,000 to Helomics. The 1,100,000 shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Company’s shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Company shares will be released to Helomics following a determination that Helomics’ revenues in any 12-month period have been equal or greater than $8,000,000. The Helomics Preferred Stock issued to the Company is convertible into an aggregate of 20% of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics may take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.

F-15

Merger Agreement with Helomics

On June 28, 2018, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. On October 26, 2018, the Merger Agreement was amended and restated. The Merger Agreement contemplated a reverse triangular merger with Helomics surviving the merger and becoming a wholly-owned operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock not already held by the Company were to be converted into the right to receive a proportionate share of 7.5 million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the 1.1 million shares of the Company’s common stock already issued to Helomics for the Company’s initial 20% ownership in Helomics. Additionally, 860,000 shares of the merger consideration were to be held in escrow for 18 months to satisfy indemnification claims. Helomics currently has outstanding $7.6 million in promissory notes and warrants to purchase 18.7 million shares at an exercise price of $1.00 per share of Helomics common stock held by the investors in the promissory notes. As a result of the Merger, the holders of said promissory notes and warrants would be entitled to additional warrants to purchase up to 5.0 million additional shares of Helomics common stock at an exercise price of $1.00 per share. Helomics agreed to use commercially reasonable efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least 75% of the $7.6 million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of 0.6 Precision warrants for each Helomics warrant, with an exercise price of $1.00 per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated 23.7 million shares of the Company’s common stock and warrants to purchase an additional 14.2 million shares of the Company’s common stock at $1.00 per share. In addition, Helomics currently has 995,000 warrants held by other parties at an exercise price of $0.01 per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase 597,000 shares of Precision common stock at $0.01 per share.

Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.

At a special meeting of stockholders on March 22, 2019, the Company’s stockholders approved the Merger Agreement.

On July 10 and 11, 2018, the Company issued 250,000 shares of common stock, par value $0.01, at $1.18 per share for consulting fees pursuant to the TumorGenesis license fees contract, and 750,000 shares of common stock, par value $0.01, at $1.17 per share, in escrow, for TumorGenesis license fees pursuant to the TumorGenesis license fees contract.

F-16

Increases in Authorized Shares

At a special meeting of the stockholders on January 29, 2017, the stockholders approved a proposal to increase the number of authorized shares of common stock from 8,000,000 shares to 24,000,000 shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on December 28, 2017, the stockholders approved a proposal to increase the number of authorized shares of common stock from 24,000,000 to 50,000,000 shares of common stock, $0.01 par value. The amendment to the certificate of incorporation to affect this increase was filed on January 2, 2018.

At the special meeting of stockholders on March 22, 2019, the stockholders approved a proposal to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 shares of common stock, $0.01 par value. The amendment to the certificate of incorporation to affect this increase was filed on March 22, 2019.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years.

Accounting for share-based payment

ASC 718 – Compensation – Stock Compensation, (“ASC 718”) requires that a company that issues equity as compensation needs to record compensation expense on its statements of comprehensive loss that corresponds to the estimated cost of those equity grants. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company policy is to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company has been on the NASDAQ Capital Market since 2015 and has had a volatile stock including reverse stock splits. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

F-17

On April 19, 2017, the Company terminated the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC and thereby received 400,000 shares of common stock, par value $0.01, from escrow.

For grants of stock options and warrants in 2017 the Company used a 1.92% to 2.40% risk free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $0.6541 to $1.5489 per share.

On January 15, 2018, the Company issued inducement stock options in accordance with NASDAQ listing rule for 50,000 shares of common stock, par value $0.01 at $0.97 per share to the Company’s newly hired International Vice President of Sales. The options will vest in four equal increments: on the first, second, third and fourth quarters of the hiring date anniversary.

On March 12, 2018, the Company issued inducement stock options in accordance with NASDAQ rule for 111,112 shares of common stock, par value $0.01 at $1.35 per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in four equal increments: on the first, second, third and fourth quarters of the hiring date anniversary.

For grants of stock option and warrants in 2018 the Company used 2.33% to 3.07% risk free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $0.3816 to $1.0044 per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		1,098,858			1.01		2,336,154			1.07
Expired		(194,564	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at December 31, 2018		3,669,277		$	1.70		3,626,643		$	4.17

At December 31, 2018, 2,946,488 stock options are fully vested and currently exercisable with a weighted average exercise price of $1.79 and a weighted average remaining term of 8.86 years. There are 2,247,489 warrants that are fully vested and exercisable. Stock-based compensation recognized in 2018 and 2017 was $1,124,928 and $2,298,680, respectively. The Company has $741,922 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 20 months.

F-18

The following summarizes the status of options and warrants outstanding at December 31, 2018:

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options:
$0.619		201,908		10.00
$0.82		60,000		9.91
$0.91		10,000		9.30
$0.965		3,000		9.38
$0.97		191,753		9.02
$1.01		149,110		9.12
$1.06		23,585		9.76
$1.10		86,958		9.46
$1.13		195,931		9.55
$1.15		21,740		9.59
$1.16		66,451		9.59
$1.18		30,000		9.61
$1.20		41,668		9.59
$1.21		30,000		9.61
$1.35		111,112		9.20
$1.454		17,200		8.75
$1.47		2,305,790		8.48
$2.10		14,286		8.25
$2.25		293		7.65
$2.42		20,640		7.64
$2.80		57,145		8.01
$3.75		4,000		7.50
$4.125		3,636		7.75
$4.1975		7,147		7.72
$4.25		3,529		7.25
$5.125		3,902		7.69
$65.75		190		6.81
$73.50		1,157		7.01
$77.50		2,323		6.50
$80.25		187		6.75
$86.25		232		6.25
$131.25		81		3.69
$148.125		928		4.21
$150.00		1,760		3.63
$162.50		123		6.01
$206.25		121		5.75
$248.4375		121		4.54
$262.50		130		4.54
$281.25		529		4.04
$318.75		3		4.35
$346.875		72		5.25
$431.25		306		5.19
$506.25		188		5.00
$596.25		42		4.75
Total		3,669,277

Warrants:
$0.836		221,292		4.92
$1.00		1,063,935		3.76
$1.07		697,946		3.85
$1.155		1,071,776		4.75
$1.3125		86,086		4.75
$2.25		385,000		3.06
$123.75		94,084		1.67
$243.75		2,529		0.59
$309.375		2,850		0.61
$309.50		222		0.85
$506.25		59		0.12
$609.375		862		0.09
Total		3,626,643

Stock options and warrants expire on various dates from January 2019 to December 2028.

F-19

The Company’s board of directors had determined that the Company would require additional authorized shares for anticipated equity financings, future equity offerings, strategic acquisition opportunities, and the continued issuance of equity awards under our stock incentive plan to recruit and retain key employees, and for other proper corporate purposes. As a result, the board of directors called a special meeting of the stockholders that took place on January 29, 2017. The vote, a proposal to increase the number of authorized shares of common stock from 8,000,000 shares to 24,000,000 shares of common stock under the Company’s certificate of incorporation passed. On December 28, 2017, the Company held its annual meeting. Pursuant to the meeting on January 2, 2018, the Certificate of Incorporation of the Company was amended to increase the number of authorized shares of common stock from 24,000,000 to 50,000,000 shares of common stock, $0.01 par value. Additionally, the stockholders approved an amendment to the Company’s 2012 Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to 5,000,000, (ii) to increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. Pursuant to the annual meeting and the aforementioned approvals, and as explained in the Company’s definitive proxy statement filed with the SEC on December 4, 2017, amendments to the 2012 Plan were considered at the 2016 annual meeting but were not approved by the required vote. For options to purchase approximately 2.5 million shares granted after the 2016 annual meeting, the grantees agreed not to exercise the options prior to further stockholder approval of an increase in the reserve under the 2012 Plan. As a result of the stockholder approval of the amendments at the 2017 annual meeting, these restrictions on exercise were removed on December 28, 2017. Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately $1.9 million in the fourth quarter of 2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of outstanding stock options and warrants as of December 31, 2018 by year of grant:

Stock Options:

Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,294		2.25	–	5.13
2017		2,461,634		1.01	–	2.10
2018		1,098,858		0.62	–	1.35
Total		3,669,277		$0.62	–	596.25

Warrants:

Year	Shares		Price
2014		6,455		243.75	–	609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	–	2.25
2018		2,190,758		0.84	–	1.3125
Total		3,626,643		$0.00	–	609.38

F-20

NOTE 5– NOTES RECEIVABLE

In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of (8%) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. CytoBioscience was current in its payments to the Company through and including July 2018. The Company had not received the scheduled interest payments from CytoBioscience for August through yearend. On September 27 and 28, 2018 CytoBioscience, through its parent company (WestMountain; now named InventaBioTech, OTC symbol INVB), made public filings indicating that their notes payable was in default. In October 2018, CytoBioscience communicated to the Company that CytoBioscience is raising capital that it believes will allow it to resume debt service payments, and that CytoBioscience wishes to negotiate an extension to the note. The Company has reached agreement with CytoBioscience on repayment and in February and March 2019 received payments towards the interest due and a portion of the principal. As of December 31, 2018, the Company does not believe a reserve is needed.

In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. Additionally, in December 2017, the Company advanced $67,512 to De Lage Landen, a vendor of Helomics, as a fifty percent (50%) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics. The Company now has an equity stake in Helomics totaling 25%.

In September 2018, the Company advanced an additional $60,000 for working capital for Helomics’ business. The balance due to the Company is $163,468, plus interest as of September 30, 2018. Subsequently in October 2018, the Company advanced $907,500 for working capital for Helomics’ business. In December 2018, the Company advanced $30,000 to Helomics under the same note. The balance due to the Company at December 31, 2018, is $1,165,013 in principal, plus interest of $29,215. On the balance sheet there is a reduction to the loan of $751,330 due to the equity method accounting losses incurred from Helomics ownership; see Note 2. In January and February 2019, the Company also advanced Helomics $305,000. In March 2019, the Company advanced an additional $420,000 to Helomics from the Form S-3 public offering that netted the Company approximately $1.1M. The balance to date owed by Helomics is $1,890,013 plus interest. The Company expects that additional advances will be required before the merger is complete. All additional advances are covered by the security interest in certain equipment of Helomics. In addition, Helomics pledged all of its assets as security for the Company’s convertible secured note financing. Upon completion of the merger with Helomics all intercompany notes would be eliminated in their entirety.

F-21

NOTE 6 – CONVERTIBLE DEBT AND DERIVATIVE LIABILITY

Effective September 28, 2018 (the “Effective Date”), the Company issued convertible secured promissory notes to two private investors in the original principal amount of an aggregate $2,297,727 (the “bridge loan”). The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a second investment of an aggregate of $500,000 by the investors at the consummation of the Merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become $2,865,909. As additional consideration for the investment, the Company issued an aggregate 650,000 shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate 1,071,776 shares of the Company’s common stock at an exercise price of $1.155 per share. Upon the closing of the second tranche investment, the warrants would be increased to cover an aggregate total of 1,336,805 shares. Each warrant is exercisable by the investor beginning on the sixth month anniversary of the effective date through the fifth-year anniversary thereof.

The notes accrue interest at a rate of 8% per annum (with twelve months of interest guaranteed). The maturity date of the notes is twelve months from the Effective Date. Upon the earlier to occur of an event of default (as defined in the notes) or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) $1.00 and (ii) 70% of the lowest volume-weighted average price (the “VWAP”) of the Company’s common stock during the 20-trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that may be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate 2,678,328 shares.

Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% of the VWAP for the 20 trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required.

The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of 2.94% over five years with a 59% volatility rate pursuant to the Company’s established warrant volatility and a calculated value per warrant of .5361 resulting in a fair value of $574,631. Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements. In December 2018, the derivative liability was adjusted for the change in the 70% of the VWAP for the 20 days preceding the balance sheet date and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The derivative liability recorded in September 2018 was $645,008. The fair value of the derivative liability as of December 31, 2018 is $272,745. An unrealized gain for the corresponding change in fair value was recorded to other income in 2018.

The value of the embedded derivative was based upon level 3 inputs – see the Fair Value Caption in Note 1.

F-22

NOTE 7 - LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2018			2017
Numerator:
Net loss available in basic and diluted	$	(10,086,477	)	$	(6,003,017	)

Denominator:
Weighted average common shares outstanding-basic		12,816,289			6,362,989

Effect of dilutive stock options warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-diluted		12,816,289			6,362,989

Loss per common share-basic and diluted	$	(0.79	)	$	(0.94	)

(1) The number of shares underlying options and warrants outstanding as of December 31, 2018 and December 31, 2017 are 7,295,921 and 4,716,240, respectively. The number of shares underlying the preferred stock as of December 31, 2018 is 79,246 for Series B Convertible. The number of shares underlying the convertible debt is 3,294,087. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

NOTE 8– INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Tax Reform Act was enacted December 22, 2017. Effective January 1, 2018 the Tax Reform Act reduced corporate income tax rates from 34% to 21%. Other changes effect operating loss carry-forwards and carrybacks, as well as a repeal of the corporate alternative minimum tax. As a result of the Tax Reform Act, deferred tax assets and liabilities were re-measured to account for the lower tax rates. There was no income tax impact from the re-measurement due to the 100% valuation allowance on the Company’s deferred tax assets.

There is no federal or state income tax provision in the accompanying statements of comprehensive loss due to the cumulative operating losses incurred and 100% valuation allowance for the deferred tax assets.

Actual income tax benefit (expense) differs from statutory federal income tax benefit (expense) as follows for the years ended December 31:

	2018			2017
Statutory federal income tax benefit	$	2,118,160		$	2,633,841
State tax benefit, net of federal taxes		66,117			76,922
Foreign tax benefit		132,931			-
Foreign operations tax rate differential		(94,373	)		-
State rate adjustment		15,355			(77,556	)
R&D tax credit		22,532			-
Nondeductible/nontaxable items		(118,905	)		(757,149	)
State NOL adjustment		746,479			-
OID and derivatives		(159,037	)		-
NQSO adjustment		-			537,884
New federal rate adjustment		-			(4,974,121	)
Other		47,868			(8,336	)
Valuation allowance decrease (increase)		(2,777,127	)		2,568,515
Total income tax benefit (expense)	$	-		$	-

F-23

Deferred taxes consist of the following as of December 31:

	2018			2017
Deferred tax assets:
Noncurrent:
Depreciation	$	4,488		$	3,251
Inventory		6,991			6,950
Compensation accruals		60,905			50,436
Accruals and reserves		77,777			64,732
Charitable contribution carryover		3,972			4,068
Derivatives		57,276			-
Related party investments		481,652			-
Intangibles		2,020			-
NQSO compensation		1,019,139			766,648
NOL and credits		9,655,388			7,479,505
Total deferred tax assets		11,369,608			8,375,590

Deferred tax liabilities:
Noncurrent:
Original issue discount		(216,891	)		-
Total deferred tax liabilities		(216,891	)		-

Net deferred tax assets		11,152,717			8,375,590
Less: valuation allowance		(11,152,717	)		(8,375,590	)
Total	$	-		$	-

The Company has determined, based upon its history, that it is probable that future taxable income may be insufficient to fully realize the benefits of the net operating loss carryforwards and other deferred tax assets. As such, the Company has determined that a full valuation allowance is warranted. Future events and changes in circumstances could cause this valuation allowance to change.

During December 2013, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The Company may have experienced additional “ownership change(s)” since December 2013, but a formal study has not yet been performed. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

At December 31, 2017, the Company had approximately $34,529,255 of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2018, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $12,261,799 of gross NOLs to reduce future state taxable income at December 31, 2017. The state NOL’s will expire beginning in 2022 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2017, the federal and state valuation allowances were $8,129,778 and $245,812, respectively.

At December 31, 2018, the Company had approximately $40,094,472 of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2019, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $12,940,458 of gross NOLs to reduce future state taxable income at December 31, 2018. The state NOL’s will expire beginning in 2022 if unused. The Company also had approximately $421,782 in gross foreign NOLs to reduce future Belgian taxable income at December 31, 2018. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2018, the federal, state and foreign valuation allowances were $9,603,237, $1,416,758 and $132,722, respectively.

Tax years subsequent to 2014 remain open to examination by federal and state tax authorities. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2018 and 2017, the Company recorded no accrued interest or penalties related to uncertain tax positions.

F-24

NOTE 9– RENT OBLIGATION

Precision’s corporate offices are located at 2915 Commers Drive, Suite 900, Eagan, Minnesota 55121. On November 22, 2017, the Company signed a second amendment to its lease last amended on January 28, 2013. The lease as amended has a three-year term effective February 1, 2018 ending January 31, 2021. The Company leases 5,773 square feet at this location, of which 2,945 square feet is used for office space and 2,828 is used for manufacturing. The Company expects that this space will be adequate for our current office and manufacturing needs.

Skyline Medical Europe’s offices are located at 9 Chemin de la Fraite – 1380 Ohain, Belgium. The lease agreement was signed April 24, 2018 and started on June 15, 2018. The Company leases around 2,000 square feet at this location, 300 of which is used for storage and 1,250 for office space. The lease is effective through June 14, 2027. We expect that this space will be adequate for our current office and storage needs. Rent expense is 3,000 Euros Per month.

Rent expense was $69,013 and $66,122 for 2018 and 2017, respectively.

The Company’s rent obligation for the next five years are as follows:

2019	$	80,320
2020		82,320
2021		43,320
2022		40,320
2023		40,320
Thereafter		161,280

NOTE 10 - RELATED PARTY TRANSACTIONS

The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements.

One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date.

Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis the 100% wholly-owned subsidiary of the Company. Mr. Gabriel receives $12,000 per month pursuant to a renewable six-month contract. The contract extends to March 31, 2019.

On November 30, 2018, our CEO, Carl Schwartz, made an investment of $370,000 in the Company and received a note and a common stock purchase warrant for 221,292 warrant shares at $0.836 per share. Effective as of January 8, 2019, Dr. Schwartz made an additional investment of $950,000 and received an amended and restated note in the original principal amount of $1,320,000 and an amended and restated warrant, which added a second tranche of 742,188 warrant shares at an exercise price of $0.704. Each tranche is exercisable beginning on the sixth month anniversary of the date of the related investment through the fifth-year anniversary of the date of the related investment. On January 8, 2019, Dr. Schwartz also purchased 78,125 shares of the Company’s common stock in a private investment for $50,000, representing a price of $0.64 per share, pursuant to a subscription agreement. On February 6, 2019, Dr. Schwartz made an additional investment of $300,000 in the Company and received an amended and restated note in the original principal amount of $1,620,000 and an amended and restated warrant, which added a third tranche of 138,889 warrant shares at an exercise price of $1.188 per share. On February 1, 2019 and the first day of each calendar month thereafter while the note and the warrant remain outstanding, a number of additional shares will be added to the second tranche and the third tranche equal to (1) one-half percent (1/2%) of the outstanding principal balance of the Note on such date, divided by (2) the closing price of the Company’s common stock on that date. The number of warrant shares will be subject to a share limit such that the total of (a) the 78,128 shares of common stock purchased by Dr. Schwartz on January 8, 2019, and (b) the total number of warrant shares (1,108,596 warrant shares as of February 6, 2019) may not exceed 2,818,350 shares (equal to 19.9% of the outstanding shares of common stock on January 8, 2019). If the second tranche and/or third tranche cannot be increased as required herein due to the share limit, then in lieu of any such increase, the Company shall pay to Dr. Schwartz a cash amount equal to one-half percent (1/2%) of the principal balance of the Schwartz note in lieu of such increase.

NOTE 11 – RETIREMENT SAVINGS PLANS

The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2017, and again in 2018, the Company matched 100%, of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $51,647 and $29,952 in 2018 and 2017, respectively. There were no discretionary contributions to the plan in 2018 and 2017.

F-25

NOTE 12 – CORRECTION OF IMMATERIAL MISSTATEMENT TO PRIOR PERIOD FINANCIAL STATEMENTS

During fiscal 2018, the Company identified certain warrants issued in 2016 and 2017, which were incorrectly recognized as expense in 2017 when the warrants vested. As a result, investors stock compensation expense and additional paid-in capital were overstated by $2,150,097 for the year ended December 31, 2017.

Also during fiscal 2018, the Company identified that employee stock compensation expense was incorrectly recognized in 2017. As a result, employee stock compensation expenses and additional paid-in capital were understated by $406,522 for the year ended December 31, 2017.

Lastly during fiscal 2018, the Company identified that certain nonqualified stock options were excluded from the Company’s tax provision calculation in 2017. As a result, deferred tax assets and the valuation allowance on these assets were understated by $767,000 as of December 31, 2017.

Based on an analysis of Accounting Standards Codification (“ASC”) 250 – “Accounting Changes and Error Corrections” (ASC 250”), Staff Accounting Bulletin 99 – “Materiality” (“SAB 99”) and Staff Accounting Bulletin 108 – Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (“SAB 108”), the Company determined that these costs were immaterial to the previously-issued financial statements. The Company analyzed and considered all relevant quantitative and qualitative factors and determined that the prior fiscal year financial statements should be corrected, even though such revision previously was and continues to be immaterial to the prior year financial statements. Management also determined that such correction to prior fiscal year financial statement for immaterial misstatements would not require previously filed reports to be amended and that such corrections may be made the next time the Company files the prior year financial statements.

Accordingly, the Company restated its presentation of general and administrative, sales and marketing, and operating expenses as well as retained earnings and additional paid-in capital in the consolidated financial statements for the year ended December 31, 2018 to reflect such corrections as if they had been recorded in the appropriate fiscal period as of December 31, 2017. Specifically, the adjustments were reflected and corrected in the last quarter of 2017 for the period ended December 31, 2017, by reducing investors stock compensation expense under general and administrative expenses and reducing additional paid-in capital by $2,150,097; and, by increasing employee stock compensation expenses under general and administrative, selling and operating expense and increasing additional paid-in capital by a total of $406,522 on the comparative balance sheet for the period ended December 31, 2017. In addition, the Company restated Note 4 – Stockholders’ Equity (Deficit), Stock Options and Warrants, and Note 8 – Income Taxes, to reflect the impact of these restatements on the footnote disclosures as of and for the year ended December 31, 2017.

F-26

NOTE 13 – SUBSEQUENT EVENTS

Registered Offering of Common Stock and Warrants

On February 27, 2019, Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold 1,385,000 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 692,500 shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.5 of a share of the Company’s Common Stock at an exercise price of $1.00 per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the fifth anniversary of issuance.

The Units were sold at a price of $0.90 per Unit, resulting in gross proceeds to the Company of approximately $1.25 million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately $1.08 million.

The closing of the Offering occurred on March 1, 2019.

Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 8% of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to $30,000, and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of $5,000. The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature.

Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of March 1, 2019 (the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of 69,250 Units (which represents 5% of the Units sold to investors in the offering) at an exercise price equal to 125% of the public offering price of the Units in the offering, or $1.125 per Unit. The Unit Purchase Options shall expire on February 27, 2024.

On March 12, 2019, Peak One, one of the noteholders from the bridge loan, converted 71,046 shares of stock reducing the principal of the loan by $44,475. The value was computed, pursuant to the agreement, by calculating the average VWAP for the prior 20 days and multiplying that average by 70%.

Dr. Carl Schwartz, the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional $1,300,000, see Note 10 – Related party Transactions.

The Company entered into a forbearance agreement with L2 Capital, LLC and Peak One Opportunity Fund, LP. AS part of the agreement the Company added 15% to the principal of the note and issued inducement shares of common stock. The Company accrued approximately $503,000 in penalty expenses as a result as of December 31, 2018. This penalty expense is recorded in accrued expenses on the balance sheet.

On March 26, 2019, Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold 1,478,750 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 739,375 shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.5 of a share of the Company’s Common Stock at an exercise price of $1.00 per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the fifth anniversary of issuance.

F-27

The Units were sold at a price of $0.80 per Unit, resulting in gross proceeds to the Company of approximately $1.18 million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately $1.05 million.

The closing of the Offering occurred on March 29, 2019.

Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of March 29, 2019 (the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of 73,938 Units (which represents 5% of the Units sold to investors in the offering) at an exercise price equal to 125% of the public offering price of the Units in the offering, or $1.00 per Unit. The Unit Purchase Options shall expire on March 29, 2024.

The securities in the Offerings were offered and sold pursuant to the Company’s “shelf” registration statement (File No. 333-213766), which was declared effective by the United States Securities and Exchange Commission on October 4, 2016.

F-28

EX-23.2 2 exh_232.htm EXHIBIT 23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements of our report dated April 2, 2018, except for Note 12 as to which the date is April 1, 2019, which expresses an unqualified opinion and includes an explanatory paragraph relating to the Company's ability to continue as a going concern for the year ended December 31, 2017, appearing in this Amendment No. 1 to Annual Report on Form 10-K/A of Skyline Medical, Inc. for the year ended December 31, 2018.

Registration Statement on Form S-8 Nos. 333-169556 relating to the 2008 Equity Incentive Plan, as amended; 333-175565 relating to 2008 Equity Incentive Plan, as amended; 333-186464 relating to the 2012 Stock Incentive Plan; 333-188510 relating to the Amended and Restated 2012 Stock Incentive Plan; 333-198378 relating to the Amended and Restated 2012 Stock Incentive Plan; 333- 213742 related to the Amended and Restated 2012 Stock Incentive Plan, and 333-216711 related to inducement option.

Registration Statement on Form S-3 Nos. 333-213766, 333-221966, 333-228908, and 333-229664.

Olsen Thielen & Co., Ltd.

Roseville, Minnesota

April 2, 2019

EX-31.1 3 exh_311.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Carl Schwartz, certify that:

I have reviewed this Amendment No. 1 to annual report on Form 10-K/A of Precision Therapeutics Inc.;

Based on my knowledge, this Amendment No. 1 does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this Amendment No. 1, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 2, 2019		/s/ Carl Schwartz
		Carl Schwartz
		Chief Executive Officer (Principal Executive Officer)

EX-31.2 4 exh_312.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, Bob Myers, certify that:

I have reviewed this Amendment No. 1 to annual report on Form 10-K/A of Precision Therapeutics Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 2, 2019		/s/ Bob Myers
		Bob Myers
		Chief Financial Officer (Principal Financial Officer)

EX-32.1 5 exh_321.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSWUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with Amendment No. 1 to Annual Report on Form 10-K/A of Precision Therapeutics Inc. (the “Company”) for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Amendment”), I, Carl Schwartz, Chief Executive Officer, and I, Bob Myers, Chief Financial Officer, of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. § 1350, that to our knowledge:

(1)

The Amendment fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)

The information contained in the Amendment fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 2, 2019

/s/ Carl Schwartz

Carl Schwartz

Chief Executive Officer

(Principal Executive Officer)

/s/ Bob Myers

Bob Myers

Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 aipt-20181231.xml XBRL INSTANCE FILE 1700000 23700000 860000 P1Y180D 0.6 1 0.005 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Certificates of Deposit</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0">Short-term interest-bearing investments are those with maturities of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year but greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months when purchased. Certificates with maturity dates beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.</div></div></div></div></div></div></div></div></div></div></div> 14200000 0.005 0.5361 0.2 0.3 2247489 P4Y335D P3Y277D P3Y310D P4Y273D P4Y273D P3Y21D P1Y244D P215D P222D P310D P43D P32D 78128 1108596 2818350 0.199 P180D P180D 2678328 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> – CONVERTIBLE DEBT AND DERIVATIVE LIABILITY</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0">Effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 28, 2018 (</div>the “Effective Date”), the Company issued convertible secured promissory notes to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> private investors in the original principal amount of an aggregate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,297,727</div> (the “bridge loan”). The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> investment of an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div> by the investors at the consummation of the Merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,865,909.</div> As additional consideration for the investment, the Company issued an aggregate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">650,000</div> shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,071,776</div> shares of the Company’s common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.155</div> per share. Upon the closing of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> tranche investment, the warrants would be increased to cover an aggregate total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,336,805</div> shares. Each warrant is exercisable by the investor beginning on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">sixth</div> month anniversary of the effective date through the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fifth</div>-year anniversary thereof.</div> <div style=" font-size: 10pt; text-align: left; margin: 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The notes accrue interest at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> per annum (with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months of interest guaranteed). The maturity date of the notes is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months from the Effective Date. Upon the earlier to occur of an event of default (as defined in the notes) or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the lowest volume-weighted average price (the “VWAP”) of the Company’s common stock during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div>-trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,678,328</div> shares.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the VWAP for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.94%</div> over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59%</div> volatility rate pursuant to the Company’s established warrant volatility and a calculated value per warrant of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.5361</div> resulting in a fair value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$574,631.</div> Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018, </div>the derivative liability was adjusted for the change in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the VWAP for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> days preceding the balance sheet date and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The derivative liability recorded in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$645,008.</div> The fair value of the derivative liability as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$272,745.</div> An unrealized gain for the corresponding change in fair value was recorded to other income in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The value of the embedded derivative was based upon level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs – see the Fair Value Caption in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> 0.2 0.2 0.7 503000 11152717 8375590 1019139 766648 9655388 7479505 216891 51647 29952 132931 537884 -159037 746479 15355 -77556 335238 359133 -751330 -751330 P1Y 0.25 0.5 3000 P1Y 441000 0.08 0.08 P2Y 4 4 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Offering Costs</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.</div></div></div></div></div></div></div></div></div></div></div> 1 0.75 5000 5000 30000 30000 0.08 1080000 1050000 244971 2940000 188066 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="5" style="white-space: nowrap; text-align: center"><div style="display: inline; font-size: 10pt">Years</div></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Computers and office equipment</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3 </div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">- </div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%"><div style="display: inline; font-size: 10pt">Leasehold improvements</div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5</div></div></td> <td style="width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Manufacturing Tooling</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3 </div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">- </div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td><div style="display: inline; font-size: 10pt">Demo Equipment</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td> </td> </tr> </table></div> P180D 12000 P1Y 400000 400000 4000 4000 1.25 1.25 0.05 0.05 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company is subject to risks common to companies in the medical device industry, including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.</div></div></div></div></div></div></div></div></div></div></div> 0.001 290000 87000 P45D <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Range of Exercise Prices</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Shares</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Weighted <br /> Average <br /> Remaining <br /> Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Options:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-size: 10pt; text-align: left">$0.619</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">201,908</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.00</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$0.82</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.91</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$0.91</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.30</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$0.965</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.38</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$0.97</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191,753</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.02</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.01</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">149,110</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.12</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.06</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,585</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.76</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.10</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86,958</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.46</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.13</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">195,931</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.55</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.15</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,740</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.16</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66,451</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.18</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.61</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.20</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,668</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.21</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.61</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.35</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111,112</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.20</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.454</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,200</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.47</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,305,790</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.48</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$2.10</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,286</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$2.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.65</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$2.42</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,640</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.64</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$2.80</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,145</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$3.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.50</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$4.125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,636</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$4.1975</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,147</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.72</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$4.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,529</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$5.125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,902</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.69</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$65.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.81</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$73.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,157</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$77.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.50</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$80.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">187</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$86.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">232</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$131.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.69</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$148.125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">928</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.21</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$150.00</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,760</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.63</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$162.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$206.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$248.4375</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.54</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$262.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.54</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$281.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.04</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$318.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.35</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$346.875</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$431.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">306</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.19</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$506.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">188</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.00</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">$596.25</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-align: left">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,669,277</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Warrants:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$0.836</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">221,292</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.92</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.00</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,063,935</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.76</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.07</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">697,946</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.85</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.155</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,071,776</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.3125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86,086</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$2.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.06</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$123.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94,084</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.67</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$243.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,529</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$309.375</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,850</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.61</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$309.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.85</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$506.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.12</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">$609.375</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">862</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.09</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-align: left">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,626,643</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> </tr> </table></div> 8000000 0.05 500000 1100000 500000 0.25 2500000 833333 1 1 1 1 P30D P60D P1Y 6400000 750000 750000 43409 650000 650000 145396 504666 16354 435 39803 40238 6500 200105 206605 7500 870000 877500 1454 143942 145396 5046 499619 504665 0.08 0.08 1 0.5 1 1 Precision Therapeutics Inc. is filing this Form 10-K/A (Amendment No. 1) to our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 1, 2019. This amendment modifies Item 8 for the purpose of including the report of the Registrant’s former auditor, Olsen Thielen & Co., on the financial statements for the year ended December 31, 2017, which was inadvertently omitted from Item 8. Such Olsen report on the 2017 financial statements is identical to the Olsen report that was filed on April 2, 2018 with the Registrant’s Form 10-K for the year ended December 31, 2017, except that the version of such report to be included in the 2018 10-K is dated as of a later date (April 1, 2019) as to Note 12. This Amendment No. 1 also reflect exhibits filed with this Amendment No. 1. Except as described above, this Form 10-K/A does not modify or update other disclosures in the Form 10-K, including the nature and character of such disclosure to reflect events occurring after the filing date of the original Form 10-K. The filing of this Form 10-K/A is not an admission that the original 10-K, when filed, was not complete. true --12-31 FY 2018 2018-12-31 10-K/A 0001446159 15792586 Yes true false Non-accelerated Filer 13584316 Precision Therapeutics Inc. false true No No aipt

445689

140462

232602

137499

232602

1279114

785215

358765

273770

63019708

55636680

2298680

1124928

183187

68757

43548

37060

1124928

2298680

385111

62633

12689

7295921

4716240

79246

5773

2945

2828

2000

300

1250

3708999

3624254

1451527

2371182

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Nature of Operations and Continuance of Operations</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company was originally incorporated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 23, 2002 </div>in Minnesota as BioDrain Medical, Inc. Effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 6, 2013, </div>the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 16, 2013, </div>the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 31, 2015, </div>the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 1, 2018, </div>the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change the Company’s corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 1, 2018. </div>Because of this change, the Company’s common stock began trading under the new ticker symbol “AIPT,” effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2, 2018. </div>Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the registrant had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,091,748</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$.01</div> per share, outstanding. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of its proprietary cleaning fluid and filters to users of the STREAMWAY systems. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2009, </div>the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company acquired <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> and in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2018 </div>the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the Company and Helomics entered into a definitive merger agreement – see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div> The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">149,000</div> tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis, formed during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter, is presented as part of the consolidated financial statements (“financial statements”).</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$63,107,945.</div> The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect to generate sufficient operating revenue to sustain its operations in the near-term. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company incurred negative operating cash flows of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$441,000</div> per month. Although the Company has attempted to curtail expenses, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> guarantee that the Company will be able to reduce these expenses significantly, and expenses <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0">The Company had cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$162,152</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and needs to raise significant additional capital to meet its operating needs, pay debt obligations coming due, and the continued operating needs of Helomics, therefore there is substantial doubt about the Company’s ability to continue as a going concern for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that the financial statements are issued. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> with which the Company has raised approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.1</div> million in net proceeds in early <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>raise up to approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.7</div> million in additional gross proceeds in the next calendar year using the shelf registration statement. This amount of available financing will increase to approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.4</div> million in additional gross proceeds, once the Helomics acquisition is completed.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0">Since inception to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company raised approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$36,490,000</div> in equity and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,870,000</div> in debt financing. Equity raises include: a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>public offering of units with gross proceeds to the Company of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,937,500;</div> a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017 </div>private placement with gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000;</div> and, a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2018 </div>public offering with gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,755,000.</div> Included in debt financing were raises in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2018 </div>on senior secured promissory notes with net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,815,000,</div> and in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>the Company received a loan from the CEO for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$370,000.</div> Subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> commitments or contingencies.</div></div></div></div></div></div></div></div></div></div></div>

1327942

7500000

1100000

0.25

162152

766189

1764090

162152

-604037

-997901

244971

2.25

0.01

1.26

0.01

1.155

0.836

0.704

1.188

1.125

243.75

609.38

243.75

1.07

2.25

0.84

1.3125

609.38

0.5

35000

606910

18700000

5000000

995000

597000

1071776

1336805

221292

742188

138889

692500

69250

739375

73938

6455

94151

252333

1082946

2190758

3626643

221292

1063935

697946

1071776

86086

385000

94084

2529

2850

222

862

3626643

0.01

50000000

8000000

24000000

50000000

100000000

14091748

6943283

140917

69432

23065

6663

6479

5659

6479

566000

647819

1250269

1.167

415764

148045

71046

44475

2297727

2865909

1620000

7870000

0.08

1837

216891

3972

4068

57276

2020

11369608

8375590

6991

6950

481652

4488

3251

60905

50436

77777

64732

11152717

8375590

0.04

84995

58872

147628

71562

645008

272745

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><div style="display: inline; font-size: 10pt">Year</div></td> <td> </td> <td colspan="3" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Shares</div></td> <td> </td> <td colspan="5" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%"><div style="display: inline; font-size: 10pt">2011</div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">173</div></div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">281.25</div></div></td> <td style="width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2012</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,841</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">131.25</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">150.00</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2013</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,553</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">148.13</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">596.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2014</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">836</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">162.50</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">431.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2015</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4,088</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">65.75</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">86.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2016</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">100,294</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2.25</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5.13</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2017</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2,461,634</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.01</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2.10</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2018</div></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,098,858</div></div></td> <td style="border-bottom: black 1pt solid"> </td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">0.62</div></div></td> <td style="border-bottom: Black 1pt solid; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.35</div></div></td> <td style="border-bottom: Black 1pt solid"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">Total</div></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,669,277</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">$0.62</div></div></td> <td style="border-bottom: black 2.25pt double; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: black 2.25pt double"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">596.25</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><div style="display: inline; font-size: 10pt">Year</div></td> <td> </td> <td colspan="3" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Shares</div></td> <td> </td> <td colspan="5" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%"><div style="display: inline; font-size: 10pt">2014</div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6,455</div></div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">243.75</div></div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="width: 5%; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">609.38</div></div></td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2015</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">94,151</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">0.00</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">243.75</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2016</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">252,333</div></div></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"></div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.00</div></td> <td style="text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2017</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,082,946</div></div></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.07</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2018</div></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2,190,758</div></div></td> <td style="border-bottom: black 1pt solid"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">0.84</div></div></td> <td style="border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: black 1pt solid; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.3125</div></div></td> <td style="border-bottom: black 1pt solid"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">Total</div></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,626,643</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">$0.00</div></div></td> <td style="border-bottom: black 2.25pt double; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: black 2.25pt double; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">609.38</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> </tr> </table></div>

1320000

-0.79

-0.94

0.34

0.21

P1Y240D

741922

0.8

0.75

2465613

419266

12247174

214426

-5056725

-9452835

12247174

-7159255

2046347

31000

523546

-372263

182559

168676

48750

231309

168676

602580

72383

318304

264032

877500

1195804

264032

964495

135745

95356

828750

95356

-2150097

4626997

4050307

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Intangible Assets</div></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><div style="display: inline; font-size: 10pt">The components of intangible assets all of which are finite-lived were as follows:</div></div> <div style=" font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><div style="display: inline; font-size: 10pt"></div></div> <div style=" font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></div> <div style=" margin: 0"> </div> <div> <table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">12/31/2018</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">12/31/2017</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center; white-space: nowrap"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Gross Carrying <br /> Costs</td> <td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated<br /> Amortization</td> <td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Carrying<br /> Amount</td> <td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Gross Carrying <br /> Costs</td> <td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Accumulated<br /> Amortization</td> <td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Net Carrying<br /> Amount</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-size: 10pt; text-align: left">Patents & Trademarks</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">318,304</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(182,559</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135,745</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">264,032</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(168,676</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95,356</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Licensing Fees</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">877,500</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(48,750</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">828,750</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,195,804</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(231,309</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">964,495</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">264,032</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(168,676</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95,356</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" margin: 0"> </div> <div style=" font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></div> <div style=" font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><div style="display: inline; font-size: 10pt">The following table outlines the estimated future amortization expense related to intangible assets held as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018</div></div></div> <div style=" margin: 0"> </div> <div> <table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">Year ending</td> <td style="font-size: 10pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center">Expense</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; font-size: 10pt; text-align: left">2019</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 20%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2022</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; text-indent: 10pt">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">602,580</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Total</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">964,495</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Intangible assets consist of trademarks, patent costs and licensing fees. Amortization expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$62,633</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,689</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.</div></div></div></div></div></div></div></div></div></div></div>

995891

506791

-2293580

-2777127

2568515

-4974121

-94373

2118160

2633841

-118905

-757149

47868

-8336

66117

76922

22532

305227

-79650

95103

98580

493899

-870540

16402

-1335

-23979

-7163

1123619

1737512

-139895

141329

964495

95356

29215

58701

62932

241066

265045

127003

141028

55362

61085

69013

66122

P3Y

3655527

932340

3708999

3624254

3655527

932340

5794570

5114939

-1110651

-1653090

-5287956

-4459750

-10086477

-6003017

-10086477

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Recent Accounting Developments</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;">Accounting Policies and Estimates</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0"> </div> <div style=" font-size: 10pt; margin: 0">The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div></div> <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div></div>-<div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div></div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>), </div>which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>using the modified retrospective method applied to those contracts which were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> completed as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div>Results for reporting periods beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> are presented under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> while prior-period amounts have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been retrospectively adjusted and continue to be reported in accordance with Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605,</div> <div style="display: inline; font-style: italic;">Revenue Recognition</div>. Based upon the Company’s contracts which were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> completed as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> required to make an adjustment to the opening balance of retained earnings as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>and there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> material impact. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> for further discussion.</div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0; color: #252525"> </div>  <div style=" font-size: 10pt; margin: 0pt 0; color: #252525"></div> <div style=" font-size: 10pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01,</div> <div style="display: inline; font-style: italic;">Financial Instruments-Overall (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">825</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01”</div>). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> result in consolidation and are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018. </div>As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> material impact on the Company’s financial statements and disclosures.</div> <div style=" font-size: 10pt; margin: 0pt 0; color: #252525"> </div> <div style=" font-size: 10pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> “<div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>)</div>” (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02”</div>), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Early adoption is permitted. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The adoption resulted in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> material impact to the Company’s balance sheet, results of operations, equity or cash flows.</div> <div style=" font-size: 10pt; margin: 0pt 0; color: #252525"> </div> <div style=" font-size: 10pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>): Classification of Certain Cash Receipts and Cash Payments, </div>to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017, </div>and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company adopted the standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018. </div>As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> material impact on the Company’s financial statements and disclosures.</div></div></div></div></div></div></div></div></div></div></div>

497276

667512

1112524

1070000

7600000

306972

1165013

1890013

413683

1070000

1112524

163468

2014 2015 2016 2017 2018

1861121

1414774

406522

7861379

6053523

80320

40320

43320

82320

161280

34529255

12261799

40094472

12940458

421782

8129778

245812

9603237

1416758

132722

-1

-1501

441772

3228

510254

53734

189285

54271

10179

600000

67512

60000

907500

30000

305000

420000

177732

45093

3084971

0.01

20000000

79246

647819

792

6479

318431

289966

2185000

1815000

50000

2959509

3814938

1300000

1300001

2100000

3937500

1300000

2755000

3937500

358312

1100000

1250000

1180000

500000

370000

1300000

370000

950000

300000

1300000

284665

650061

10682

6209

204903

183528

140114

25635

108955

85246

43368

539218

361486

180453

87716

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Property and Equipment</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation is shown in the financial statements under fixed assets, net on the balance sheet, and amortization is shown under intangibles, net on the balance sheet. Estimated useful asset life by classification is as follows:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div> <table style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="5" style="white-space: nowrap; text-align: center"><div style="display: inline; font-size: 10pt">Years</div></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Computers and office equipment</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3 </div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">- </div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%"><div style="display: inline; font-size: 10pt">Leasehold improvements</div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5</div></div></td> <td style="width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Manufacturing Tooling</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3 </div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">- </div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td><div style="display: inline; font-size: 10pt">Demo Equipment</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company’s investment in fixed assets consists of the following:</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Computers and office equipment</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204,903</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">183,528</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Leasehold Improvements</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140,114</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,635</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Manufacturing Tooling</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,955</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,955</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Demo Equipment</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85,246</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,368</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 10pt">Total</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">539,218</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">361,486</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Accumulated Depreciation</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">358,765</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273,770</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total Fixed Assets, Net</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">180,453</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87,716</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Depreciation expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$84,995</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$58,872</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div></div></div></div></div></div></div></div></div></div>

P3Y

P7Y

P5Y

P3Y

P7Y

P3Y

2150097

406522

767000

526000

289000

-63107945

406522

-2150097

-53021469

1411655

654836

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred tax assets:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-indent: -10pt; padding-left: 10pt">Noncurrent:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-indent: -10pt; padding-left: 20pt">Depreciation </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,488</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,251</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt">Inventory </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,991</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,950</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt">Compensation accruals </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60,905</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,436</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Accruals and reserves </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77,777</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64,732</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Charitable contribution carryover </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,972</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,068</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt">Derivatives </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,276</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Related party investments </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">481,652</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt">Intangibles </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,020</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">NQSO compensation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,019,139</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">766,648</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">NOL and credits </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,655,388</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,479,505</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Total deferred tax assets </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,369,608</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,375,590</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred tax liabilities:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-indent: -10pt; padding-left: 10pt">Noncurrent:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Original issue discount </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(216,891</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Total deferred tax liabilities </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(216,891</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Net deferred tax assets </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,152,717</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,375,590</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Less: valuation allowance </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,152,717</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,375,590</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt; text-indent: -10pt; padding-left: 10pt">Total </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-size: 10pt; text-align: left">2019</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80,320</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,320</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,320</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2022</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,320</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,320</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><div style=" margin: 0">Thereafter</div> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" margin: 0">161,280</div></div> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Stock Options</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Warrants</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Number of<br /> Shares</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Average <br /> Exercise <br /> Price</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Number of<br /> Shares</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Average <br /> Exercise <br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Outstanding at December 31, 2016</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">165,643</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.22</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">871,101</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52.22</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Issued</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,612,070</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.45</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,082,946</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.49</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Expired</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(12,730</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.39</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,790</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">281.46</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Exercised</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Outstanding at December 31, 2017</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,764,983</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,951,257</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23.74</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Issued</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,098,858</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,336,154</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.07</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Expired</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(194,564</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,706</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">199.55</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Exercised</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(650,062</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.00</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Outstanding at December 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,669,277</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.70</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,626,643</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.17</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center">Year ending</td> <td style="font-size: 10pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center">Expense</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; font-size: 10pt; text-align: left">2019</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 20%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">2022</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,383</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; text-indent: 10pt">Thereafter</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">602,580</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Total</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">964,495</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> </table></div>

2369152

1095232

1124928

2298680

P3Y

281.46

199.55

1.49

1.07

52.22

23.74

4.17

0.59

0.66

0.59

0.66

0.0192

0.024

0.0233

0.0307

650062

2790

10706

1082946

2336154

871101

1951257

3626643

5000000

12730

194564

50000

111112

2500000

2612070

1098858

0.6541

1.5489

0.3816

1.0044

1.45

1.01

173

1841

1553

836

4088

100294

2461634

1098858

3669277

165643

2764983

3669277

201908

60000

10000

3000

191753

149110

23585

86958

195931

21740

66451

30000

41668

30000

111112

17200

2305790

14286

293

20640

57145

4000

3636

7147

3529

3902

190

1157

2323

187

232

928

1760

123

121

130

529

306

188

3669277

281.25

131.25

150

148.13

596.25

162.50

431.25

65.75

86.25

2.25

5.13

1.01

2.10

0.62

1.35

0.62

596.25

11.22

1.70

2946488

1.79

1900000

10.39

0.97

1.35

0.95

P3Y

P10Y

P5Y

P10Y

P5Y

P10Y

P9Y332D

P9Y109D

P9Y138D

P9Y7D

P9Y43D

P9Y277D

P9Y167D

P9Y200D

P9Y215D

P9Y222D

P9Y215D

P9Y222D

P9Y73D

P8Y273D

P8Y175D

P8Y91D

P7Y237D

P7Y233D

P8Y3D

P7Y182D

P7Y273D

P7Y262D

P7Y91D

P7Y251D

P6Y295D

P7Y3D

P6Y182D

P6Y273D

P6Y91D

P3Y251D

P4Y76D

P3Y229D

P6Y3D

P5Y273D

P4Y197D

P4Y14D

P4Y127D

P5Y91D

P5Y69D

P5Y

P4Y273D

P8Y313D

2.25

1.071

0.9497

1.18

1.17

0.64

0.90

0.80

1.18

0.9497

1.18

1.17

79246

4564428

647819

79246

6943283

79246

14091748

877500

1100000

660522

589747

250000

100000

43333

150000

100000

1750000

175000

1213819

2900000

215247

1100000

78125

1385000

1478750

1750000

175000

50000

1213819

2900000

215247

11000

1031250

1042250

6604

85236

86182

5897

582

1000

219000

220000

433

63699

64132

1500

175500

177000

1000

117000

118000

17500

3403688

3421188

1750

392000

393750

500

78500

79000

12138

1201681

1213819

29000

2726087

2755087

2153

202268

204422

142466

53472

2691914

792

45644

47894196

-47018451

1501

923682

7271

69432

55636680

-53021469

792

140917

63019708

-63107945

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> – STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Firm Commitment Public Offering</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 19, 2017, </div>the Company closed a firm commitment public offering for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,750,000</div> Units at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.25</div> per Unit. The Units comprised <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.2</div> Series D Warrants with each whole Series D Warrant purchasing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of the Company’s common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.25</div> per share. The Company received gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,937,500.</div> Subsequently the underwriter exercised over-allotment for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">175,000</div> shares of common stock and for Series D warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,000</div> shares of common stock at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> per warrant. The Company received net proceeds from the over-allotment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$358,312.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Private Placement</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 30, 2017, </div>the Company closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York based Family Office. Pursuant to the Securities Purchase Agreement, the investor purchased <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,213,819</div> shares of Series C stock at a purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.071</div> per Series C Share, together with a warrant to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,910</div> shares of common stock. The warrant has an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.26</div> per share, subject to adjustment, has a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-half-year term and is exercisable commencing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months following the date of issuance. Total gross proceeds to the Company were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000</div> before deducting expenses and will be used for general working capital. In connection with the offering and pursuant to a registration rights agreement, the Company has agreed to file a “resale” registration statement covering all of the shares of common stock issuable upon conversion of the warrant. Pursuant to the Securities Purchase agreement, and as of this filing date, all the Preferred Series C shares were converted at a conversion rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.167</div> to a maximum of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,250,269</div> shares of common stock. The remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">142,466</div> shares of Preferred Series C stock were cancelled with a redemption payment to the holder for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$189,285.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Firm Commitment Public Offering</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2018, </div>the Company completed a firm commitment underwritten public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,900,000</div> Units at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.95</div> per Unit, with each Unit consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of the Company’s common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.3</div> of a Series E Warrant, with each whole Series E Warrant purchasing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per whole share. The shares of common stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,755,000,</div> before deducting expenses. The Company granted the underwriter a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div>-day option to purchase an additional (i) up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290,000</div> additional shares of common stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87,000</div> additional shares of common stock at a purchase price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per Series E Warrant to cover over-allotments, if any. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2018, </div>the underwriter exercised on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">215,247</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01,</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.9497</div> per share as described in the Underwriting Agreement. The Company received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$188,066</div> after deductions of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,354</div> representing the underwriter’s discount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> of the purchase price of the shares.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Share Exchange Agreement with Helomics</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 11, 2018, </div>the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement, Helomics issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,500,000</div> shares of its Series A Preferred Stock in exchange for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,100,000</div> shares of common stock. Under the share exchange agreement, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018 </div>the Company converted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div> in secured notes into another <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of Helomics’ outstanding shares, which resulted in the Company owning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div> to Helomics. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,100,000</div> shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Company’s shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Company shares will be released to Helomics following a determination that Helomics’ revenues in any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>-month period have been equal or greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8,000,000.</div> The Helomics Preferred Stock issued to the Company is convertible into an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div> of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"></div>   <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Merger Agreement with Helomics</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 28, 2018, </div>the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 26, 2018, </div>the Merger Agreement was amended and restated. The Merger Agreement contemplated a reverse triangular merger with Helomics surviving the merger and becoming a wholly-owned operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> already held by the Company were to be converted into the right to receive a proportionate share of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.5</div> million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.1</div> million shares of the Company’s common stock already issued to Helomics for the Company’s initial <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div> ownership in Helomics. Additionally, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">860,000</div> shares of the merger consideration were to be held in escrow for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months to satisfy indemnification claims. Helomics currently has outstanding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.6</div> million in promissory notes and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.7</div> million shares at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share of Helomics common stock held by the investors in the promissory notes. As a result of the Merger, the holders of said promissory notes and warrants would be entitled to additional warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0</div> million additional shares of Helomics common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share. Helomics agreed to use commercially reasonable efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.6</div> million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.6</div> Precision warrants for each Helomics warrant, with an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23.7</div> million shares of the Company’s common stock and warrants to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.2</div> million shares of the Company’s common stock at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share. In addition, Helomics currently has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">995,000</div> warrants held by other parties at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">597,000</div> shares of Precision common stock at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> per share.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"></div></div> <div style=" font-size: 10pt; margin: 0pt 0">At a special meeting of stockholders on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 22, 2019, </div>the Company’s stockholders approved the Merger Agreement.</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 10 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01,</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.18</div> per share for consulting fees pursuant to the TumorGenesis license fees contract, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">750,000</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01,</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.17</div> per share, in escrow, for TumorGenesis license fees pursuant to the TumorGenesis license fees contract.</div> <div style=" font-size: 10pt; margin: 0pt 0"></div>  <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Increases in Authorized Shares</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">At a special meeting of the stockholders on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 29, 2017, </div>the stockholders approved a proposal to increase the number of authorized shares of common stock from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,000,000</div> shares to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,000,000</div> shares of common stock under the Company’s certificate of incorporation.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">At the annual meeting on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 28, 2017, </div>the stockholders approved a proposal to increase the number of authorized shares of common stock from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,000,000</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000,000</div> shares of common stock, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> par value. The amendment to the certificate of incorporation to affect this increase was filed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2, 2018.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0">At the special meeting of stockholders on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 22, 2019, </div>the stockholders approved a proposal to increase the number of authorized shares of common stock from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000,000</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000,000</div> shares of common stock, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> par value. The amendment to the certificate of incorporation to affect this increase was filed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 22, 2019.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Equity Incentive Plan</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years. Options under this plan have terms ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Accounting for share-based payment</div></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0"></div> <div style=" font-size: 10pt; margin: 0pt 0">ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> – <div style="display: inline; font-style: italic;">Compensation – Stock Compensation, (“ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718”</div>)</div> requires that a company that issues equity as compensation needs to record compensation expense on its statements of comprehensive loss that corresponds to the estimated cost of those equity grants. ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.</div> <div style=" font-size: 10pt; margin: 0"> </div> <div style=" font-size: 10pt; margin: 0">Since the Company's common stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> significant public trading history, and the Company has experienced <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> significant option exercises in its history, the Company policy is to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company has been on the NASDAQ Capital Market since <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and has had a volatile stock including reverse stock splits. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.</div> <div style=" font-size: 10pt; margin: 0"> </div> <div style=" margin: 0">When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.</div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"></div>  <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 19, 2017, </div>the Company terminated the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC and thereby received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400,000</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01,</div> from escrow.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">For grants of stock options and warrants in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> the Company used a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.92%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.40%</div> risk free interest rate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div> dividend rate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66%</div> volatility and estimated terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> years. Value computed using these assumptions ranged from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6541</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.5489</div> per share.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 15, 2018, </div>the Company issued inducement stock options in accordance with NASDAQ listing rule for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.97</div> per share to the Company’s newly hired International Vice President of Sales. The options will vest in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> equal increments: on the first, second, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarters of the hiring date anniversary.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 12, 2018, </div>the Company issued inducement stock options in accordance with NASDAQ rule for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111,112</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.35</div> per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> equal increments: on the first, second, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarters of the hiring date anniversary.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">For grants of stock option and warrants in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> the Company used <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.33%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.07%</div> risk free interest rate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div> dividend rate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66%</div> volatility and estimated terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> years. Value computed using these assumptions ranged from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.3816</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0044</div> per share.</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The following summarizes transactions for stock options and warrants for the periods indicated: </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Stock Options</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Warrants</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Number of<br /> Shares</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Average <br /> Exercise <br /> Price</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Number of<br /> Shares</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Average <br /> Exercise <br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Outstanding at December 31, 2016</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">165,643</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.22</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">871,101</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52.22</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Issued</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,612,070</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.45</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,082,946</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.49</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Expired</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(12,730</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.39</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,790</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">281.46</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Exercised</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Outstanding at December 31, 2017</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,764,983</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,951,257</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23.74</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Issued</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,098,858</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,336,154</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.07</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Expired</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(194,564</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,706</div></td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">199.55</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Exercised</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(650,062</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.00</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Outstanding at December 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,669,277</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.70</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,626,643</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.17</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,946,488</div> stock options are fully vested and currently exercisable with a weighted average exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.79</div> and a weighted average remaining term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.86</div> years. There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,247,489</div> warrants that are fully vested and exercisable. Stock-based compensation recognized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,124,928</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,298,680,</div> respectively. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$741,922</div> of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> months.</div> <div style=" font-size: 10pt; margin: 0pt 0"></div>  <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The following summarizes the status of options and warrants outstanding at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018:</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Range of Exercise Prices</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Shares</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Weighted <br /> Average <br /> Remaining <br /> Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Options:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-size: 10pt; text-align: left">$0.619</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">201,908</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.00</div></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$0.82</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.91</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$0.91</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.30</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$0.965</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.38</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$0.97</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191,753</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.02</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.01</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">149,110</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.12</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.06</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,585</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.76</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.10</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86,958</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.46</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.13</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">195,931</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.55</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.15</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,740</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.16</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66,451</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.18</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.61</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.20</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,668</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.21</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.61</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.35</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111,112</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.20</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.454</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,200</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.47</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,305,790</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.48</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$2.10</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,286</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$2.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.65</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$2.42</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,640</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.64</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$2.80</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,145</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$3.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.50</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$4.125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,636</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$4.1975</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,147</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.72</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$4.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,529</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$5.125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,902</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.69</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$65.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.81</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$73.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,157</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$77.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.50</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$80.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">187</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$86.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">232</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$131.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.69</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$148.125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">928</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.21</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$150.00</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,760</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.63</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$162.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.01</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$206.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$248.4375</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.54</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$262.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.54</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$281.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.04</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$318.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.35</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$346.875</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.25</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$431.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">306</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.19</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$506.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">188</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.00</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">$596.25</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-align: left">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,669,277</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Warrants:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$0.836</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">221,292</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.92</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.00</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,063,935</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.76</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.07</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">697,946</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.85</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$1.155</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,071,776</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$1.3125</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86,086</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.75</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$2.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385,000</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.06</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$123.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94,084</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.67</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$243.75</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,529</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.59</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$309.375</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,850</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.61</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">$309.50</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.85</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">$506.25</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.12</div></td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">$609.375</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">862</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.09</div></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-align: left">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,626,643</div></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Stock options and warrants expire on various dates from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2019 </div>to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2028.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"></div>  <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The Company’s board of directors had determined that the Company would require additional authorized shares for anticipated equity financings, future equity offerings, strategic acquisition opportunities, and the continued issuance of equity awards under our stock incentive plan to recruit and retain key employees, and for other proper corporate purposes. As a result, the board of directors called a special meeting of the stockholders that took place on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 29, 2017. </div>The vote, a proposal to increase the number of authorized shares of common stock from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,000,000</div> shares to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,000,000</div> shares of common stock under the Company’s certificate of incorporation passed. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 28, 2017, </div>the Company held its annual meeting. Pursuant to the meeting on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2, 2018, </div>the Certificate of Incorporation of the Company was amended to increase the number of authorized shares of common stock from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,000,000</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000,000</div> shares of common stock, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.01</div> par value. Additionally, the stockholders approved an amendment to the Company’s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012</div> Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,000,000,</div> (ii) to increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. Pursuant to the annual meeting and the aforementioned approvals, and as explained in the Company’s definitive proxy statement filed with the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 4, 2017, </div>amendments to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012</div> Plan were considered at the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> annual meeting but were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> approved by the required vote. For options to purchase approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.5</div> million shares granted after the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> annual meeting, the grantees agreed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to exercise the options prior to further stockholder approval of an increase in the reserve under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012</div> Plan. As a result of the stockholder approval of the amendments at the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> annual meeting, these restrictions on exercise were removed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 28, 2017. </div>Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Stock Options and Warrants Granted by the Company</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The following table is the listing of outstanding stock options and warrants as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>by year of grant:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Stock Options:</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><div style="display: inline; font-size: 10pt">Year</div></td> <td> </td> <td colspan="3" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Shares</div></td> <td> </td> <td colspan="5" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%"><div style="display: inline; font-size: 10pt">2011</div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">173</div></div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">281.25</div></div></td> <td style="width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2012</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,841</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">131.25</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">150.00</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2013</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,553</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">148.13</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">596.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2014</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">836</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">162.50</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">431.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2015</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">4,088</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">65.75</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">86.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2016</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">100,294</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2.25</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5.13</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2017</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2,461,634</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.01</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2.10</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2018</div></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,098,858</div></div></td> <td style="border-bottom: black 1pt solid"> </td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">0.62</div></div></td> <td style="border-bottom: Black 1pt solid; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.35</div></div></td> <td style="border-bottom: Black 1pt solid"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">Total</div></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,669,277</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">$0.62</div></div></td> <td style="border-bottom: black 2.25pt double; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: black 2.25pt double"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">596.25</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Warrants:</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><div style="display: inline; font-size: 10pt">Year</div></td> <td> </td> <td colspan="3" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Shares</div></td> <td> </td> <td colspan="5" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Price</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%"><div style="display: inline; font-size: 10pt">2014</div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">6,455</div></div></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">243.75</div></div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="width: 5%; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">609.38</div></div></td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2015</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">94,151</div></div></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">0.00</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">243.75</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2016</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">252,333</div></div></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"></div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.00</div></td> <td style="text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">2017</div></td> <td> </td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1,082,946</div></div></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.07</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2.25</div></div></td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><div style="display: inline; font-size: 10pt">2018</div></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">2,190,758</div></div></td> <td style="border-bottom: black 1pt solid"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">0.84</div></div></td> <td style="border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: black 1pt solid; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">1.3125</div></div></td> <td style="border-bottom: black 1pt solid"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td><div style="display: inline; font-size: 10pt">Total</div></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3,626,643</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">$0.00</div></div></td> <td style="border-bottom: black 2.25pt double; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">–</div></div></td> <td style="border-bottom: black 2.25pt double; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">609.38</div></div></td> <td style="border-bottom: black 2.25pt double"> </td> </tr> </table> </div></div>

36490000

1542250

574631

0.0294

0.59

P5Y182D

P5Y

12816289

6362989

12816289

6362989

3294087

12816289

6362989

The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the twelve-month period at the current equity investment percentage owned by the Company. The number of shares underlying options and warrants outstanding as of December 31, 2018 and December 31, 2017 are 7,295,921 and 4,716,240, respectively. The number of shares underlying the preferred stock as of December 31, 2018 is 79,246 for Series B Convertible. The number of shares underlying the convertible debt is 3,294,087. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. xbrli:shares xbrli:pure utr:sqft iso4217:USD iso4217:USD xbrli:shares utr:Y iso4217:EUR 0001446159 2002-03-01 2018-12-31 0001446159 us-gaap:IPOMember 2017-01-01 2017-01-31 0001446159 2017-01-01 2017-12-31 0001446159 aipt:OptionsAndWarrantsMember 2017-01-01 2017-12-31 0001446159 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementOneMember us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:ConsultingAgreementTwoMember us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001446159 aipt:LicensingFeeForTumorgenesisMember 2017-01-01 2017-12-31 0001446159 aipt:StockIncentivePlan2012Member 2017-01-01 2017-12-31 0001446159 aipt:OverstatementOfInvestorsStockCompensationExpenseAndAdditionalPaidinCapitalMember 2017-01-01 2017-12-31 0001446159 aipt:UnderstatementOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0001446159 aipt:UnderstatementOfEmployeeStockCompensationExpensesAndAdditionalPaidinCapitalMember 2017-01-01 2017-12-31 0001446159 aipt:UnderstatementOfEmployeeStockCompensationExpensesAndAdditionalPaidinCapitalMember srt:RestatementAdjustmentMember 2017-01-01 2017-12-31 0001446159 srt:MaximumMember 2017-01-01 2017-12-31 0001446159 srt:MinimumMember 2017-01-01 2017-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001446159 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001446159 us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001446159 us-gaap:RetainedEarningsMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:RetainedEarningsMember us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001446159 us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001446159 us-gaap:PrivatePlacementMember 2017-01-01 2017-12-31 0001446159 aipt:SeriesDWarrantsMember aipt:The2017PublicOfferingMember 2017-01-19 2017-01-19 0001446159 us-gaap:OverAllotmentOptionMember 2017-01-19 2017-01-19 0001446159 aipt:The2017PublicOfferingMember 2017-01-19 2017-01-19 0001446159 2017-04-19 2017-04-19 0001446159 aipt:AdvanceToHelomicsMember 2017-10-01 2017-10-31 0001446159 2017-10-01 2017-12-31 0001446159 aipt:OverstatementOfInvestorsStockCompensationExpenseAndAdditionalPaidinCapitalMember srt:RestatementAdjustmentMember 2017-10-01 2017-12-31 0001446159 aipt:SeriesCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2017-11-01 2017-11-30 0001446159 aipt:The2017PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2017-11-30 2017-11-30 0001446159 aipt:SeriesCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2017-11-30 2017-11-30 0001446159 us-gaap:PrivatePlacementMember 2017-11-30 2017-11-30 0001446159 aipt:AdvancesToDeLageLandenMember 2017-12-01 2017-12-31 0001446159 aipt:SeriesEWarrantsMember aipt:The2018PublicOfferingMember 2018-01-01 2018-01-31 0001446159 us-gaap:OverAllotmentOptionMember 2018-01-01 2018-01-31 0001446159 aipt:The2018PublicOfferingMember 2018-01-01 2018-01-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001446159 2018-01-01 2018-12-31 0001446159 aipt:OptionsAndWarrantsMember 2018-01-01 2018-12-31 0001446159 aipt:PreferredStock1Member 2018-01-01 2018-12-31 0001446159 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:BridgeLoanWarrantsMember 2018-01-01 2018-12-31 0001446159 aipt:BridgeLoanWarrantsMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:BridgeLoanWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:BridgeLoanWarrantsMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:BridgeLoanWarrantsMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:BridgeLoanWarrantsMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:NotePayableWarrantsMember 2018-01-01 2018-12-31 0001446159 aipt:NotePayableWarrantsMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:NotePayableWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:NotePayableWarrantsMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:NotePayableWarrantsMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:NotePayableWarrantsMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:RePricedWarrantsMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantEightMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantElevenMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantFiveMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantFourMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantNineMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantOneMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantSevenMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantSixMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantTenMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantThirteenMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantThreeMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantTwelveMember 2018-01-01 2018-12-31 0001446159 aipt:WarrantTwoMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-01-01 2018-12-31 0001446159 aipt:LicensingFeeForTumorgenesisMember 2018-01-01 2018-12-31 0001446159 aipt:EquityIncentivePlanMember srt:MaximumMember 2018-01-01 2018-12-31 0001446159 aipt:EquityIncentivePlanMember srt:MinimumMember 2018-01-01 2018-12-31 0001446159 aipt:ContractResearchOrganizationAndDchipArtificialIntelligenceProductsMember aipt:HelomicsHoldingCorpMember 2018-01-01 2018-12-31 0001446159 us-gaap:MaintenanceMember 2018-01-01 2018-12-31 0001446159 aipt:DemoEquipmentMember 2018-01-01 2018-12-31 0001446159 us-gaap:LeaseholdImprovementsMember 2018-01-01 2018-12-31 0001446159 aipt:ManufacturingToolingMember srt:MaximumMember 2018-01-01 2018-12-31 0001446159 aipt:ManufacturingToolingMember srt:MinimumMember 2018-01-01 2018-12-31 0001446159 us-gaap:OfficeEquipmentMember srt:MaximumMember 2018-01-01 2018-12-31 0001446159 us-gaap:OfficeEquipmentMember srt:MinimumMember 2018-01-01 2018-12-31 0001446159 srt:MaximumMember 2018-01-01 2018-12-31 0001446159 srt:MinimumMember 2018-01-01 2018-12-31 0001446159 us-gaap:DirectorMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsEightMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsEighteenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsElevenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFifteenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFiveMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFortyMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFortyfiveMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFortyfourMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFortyoneMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFortythreeMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFortytwoMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFourMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsFourteenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsNineMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsNineteenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsOneMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsSevenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsSeventeenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsSixMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsSixteenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirteenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtyMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtyeightMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtyfiveMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtyfourMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtynineMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtyoneMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtysevenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtysixMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtythreeMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThirtytwoMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsThreeMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwelveMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyEightMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyFiveMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyFourMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyNineMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyOneMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentySevenMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentySixMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyThreeMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwentyTwoMember 2018-01-01 2018-12-31 0001446159 aipt:StockOptionsTwoMember 2018-01-01 2018-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001446159 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001446159 us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001446159 us-gaap:RetainedEarningsMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001446159 us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-01-11 2018-01-11 0001446159 aipt:VicePresidentOfSalesMember 2018-01-15 2018-01-15 0001446159 us-gaap:OverAllotmentOptionMember 2018-02-21 2018-02-21 0001446159 aipt:PromissoryNotesReceivableMember aipt:CytoBioscienceMember 2018-03-01 2018-03-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-03-01 2018-03-31 0001446159 aipt:VicePresidentOfSalesAndMarketingMember 2018-03-12 2018-03-12 0001446159 aipt:SkylineMedicalEuropesOfficesLeaseMember 2018-06-15 2018-06-15 0001446159 2018-07-10 2018-07-10 0001446159 2018-07-11 2018-07-11 0001446159 aipt:PromissoryNotesReceivableMember aipt:CytoBioscienceMember 2018-08-01 2018-12-31 0001446159 aipt:AdvancesToDeLageLandenMember 2018-09-01 2018-09-30 0001446159 aipt:ConvertiblePromissoryNoteMember 2018-09-01 2018-09-30 0001446159 aipt:HelomicsHoldingCorpMember 2018-10-01 2018-10-31 0001446159 2018-10-03 2018-10-03 0001446159 aipt:SecuritiesPurchaseAgreementsMember aipt:ConvertiblePromissoryNoteMember 2018-10-03 2018-10-03 0001446159 aipt:HelomicsHoldingCorpMember 2018-10-26 2018-10-26 0001446159 aipt:HelomicsHoldingCorpMember aipt:PrecisionWarrantsMember 2018-10-26 2018-10-26 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:CommonStockMember 2018-10-26 2018-10-26 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember 2018-10-26 2018-10-26 0001446159 us-gaap:ChiefExecutiveOfficerMember 2018-11-01 2018-11-30 0001446159 aipt:ConversionFromSeriesCConvertiblePreferredStockToCommonStockMember 2018-12-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-12-01 2018-12-31 0001446159 us-gaap:ChiefExecutiveOfficerMember 2018-12-01 2018-12-31 0001446159 aipt:SeriesCConvertiblePreferredStockMember 2018-12-01 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:SubsequentEventMember 2019-01-01 2019-02-28 0001446159 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-01-01 2019-03-31 0001446159 us-gaap:SubsequentEventMember aipt:ShelfRegistrationMember 2019-01-01 2019-03-31 0001446159 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-01-08 2019-01-08 0001446159 aipt:SchwartzWarrantMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-01 0001446159 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-02-06 2019-02-06 0001446159 us-gaap:SubsequentEventMember aipt:The2019OfferingMember 2019-03-01 2019-03-01 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:SubsequentEventMember aipt:ShelfRegistrationMember 2019-03-01 2019-03-31 0001446159 us-gaap:SubsequentEventMember aipt:ShelfRegistrationMember 2019-03-01 2019-03-31 0001446159 aipt:PeakOneMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2019-03-12 2019-03-12 0001446159 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-03-12 2019-03-12 0001446159 us-gaap:SubsequentEventMember aipt:PlacementAgencyAgreementMember 2019-03-26 2019-03-26 0001446159 aipt:SecuritiesPurchaseAgreementsMember aipt:ConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2019-03-31 2019-03-31 0001446159 2016-10-27 0001446159 2016-12-31 0001446159 us-gaap:EmployeeStockOptionMember 2016-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2016-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001446159 us-gaap:CommonStockMember 2016-12-31 0001446159 us-gaap:PreferredStockMember 2016-12-31 0001446159 us-gaap:RetainedEarningsMember 2016-12-31 0001446159 us-gaap:WarrantMember 2016-12-31 0001446159 aipt:SeriesDWarrantsMember aipt:The2017PublicOfferingMember 2017-01-19 0001446159 us-gaap:OverAllotmentOptionMember 2017-01-19 0001446159 aipt:The2017PublicOfferingMember 2017-01-19 0001446159 2017-01-29 0001446159 2017-04-19 0001446159 aipt:PromissoryNotesReceivableMember aipt:CytoBioscienceMember 2017-07-31 0001446159 aipt:The2017PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2017-11-30 0001446159 aipt:SeriesCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2017-11-30 0001446159 2017-12-28 0001446159 2017-12-31 0001446159 aipt:PromissoryNotesReceivableMember aipt:CytoBioscienceMember 2017-12-31 0001446159 us-gaap:EmployeeStockOptionMember 2017-12-31 0001446159 aipt:InvestorRelationsConsultantMember 2017-12-31 0001446159 us-gaap:LicensingAgreementsMember 2017-12-31 0001446159 aipt:PatentsAndTrademarksMember 2017-12-31 0001446159 us-gaap:DomesticCountryMember 2017-12-31 0001446159 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0001446159 aipt:DemoEquipmentMember 2017-12-31 0001446159 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001446159 aipt:ManufacturingToolingMember 2017-12-31 0001446159 us-gaap:OfficeEquipmentMember 2017-12-31 0001446159 aipt:OverstatementOfInvestorsStockCompensationExpenseAndAdditionalPaidinCapitalMember srt:RestatementAdjustmentMember 2017-12-31 0001446159 aipt:UnderstatementOfEmployeeStockCompensationExpensesAndAdditionalPaidinCapitalMember srt:RestatementAdjustmentMember 2017-12-31 0001446159 aipt:SeriesBConvertiblePreferredStockMember 2017-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-12-31 0001446159 aipt:SeriesCConvertiblePreferredStockMember 2017-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2017-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001446159 us-gaap:CommonStockMember 2017-12-31 0001446159 us-gaap:PreferredStockMember 2017-12-31 0001446159 us-gaap:RetainedEarningsMember 2017-12-31 0001446159 us-gaap:WarrantMember 2017-12-31 0001446159 aipt:StockIncentivePlan2012Member 2018-01-02 0001446159 aipt:HelomicsHoldingCorpMember 2018-01-11 0001446159 aipt:VicePresidentOfSalesMember 2018-01-15 0001446159 aipt:SeriesEWarrantsMember aipt:The2018PublicOfferingMember 2018-01-31 0001446159 us-gaap:OverAllotmentOptionMember 2018-01-31 0001446159 aipt:The2018PublicOfferingMember 2018-01-31 0001446159 aipt:CorporateOfficeMinnesotaMember 2018-02-01 0001446159 aipt:CorporateOfficeMinnesotaMember us-gaap:ManufacturingFacilityMember 2018-02-01 0001446159 aipt:CorporateOfficeMinnesotaMember aipt:OfficeSpaceMember 2018-02-01 0001446159 2018-02-21 0001446159 us-gaap:OverAllotmentOptionMember 2018-02-21 0001446159 aipt:HelomicsHoldingCorpMember 2018-02-27 0001446159 aipt:VicePresidentOfSalesAndMarketingMember 2018-03-12 0001446159 aipt:PromissoryNotesReceivableMember aipt:CytoBioscienceMember 2018-03-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-03-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-03-31 0001446159 aipt:SkylineMedicalEuropesOfficesLeaseMember 2018-06-15 0001446159 aipt:SkylineMedicalEuropesOfficesLeaseMember aipt:OfficeSpaceMember 2018-06-15 0001446159 aipt:SkylineMedicalEuropesOfficesLeaseMember aipt:StorageSpaceMember 2018-06-15 0001446159 2018-06-30 0001446159 2018-07-10 0001446159 2018-07-11 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember 2018-09-28 0001446159 aipt:SecuritiesPurchaseAgreementsMember aipt:ConvertiblePromissoryNoteMember 2018-09-28 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember 2018-09-30 0001446159 aipt:HelomicsHoldingCorpMember 2018-09-30 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember 2018-10-03 0001446159 aipt:SecuritiesPurchaseAgreementsMember srt:MaximumMember aipt:ConvertiblePromissoryNoteMember 2018-10-03 0001446159 aipt:SecuritiesPurchaseAgreementsMember aipt:ConvertiblePromissoryNoteMember 2018-10-03 0001446159 aipt:HelomicsHoldingCorpMember 2018-10-26 0001446159 aipt:HelomicsHoldingCorpMember aipt:HelomicsWarrantsHeldByInvestorsMember 2018-10-26 0001446159 aipt:HelomicsHoldingCorpMember aipt:PrecisionWarrantsMember 2018-10-26 0001446159 aipt:HelomicsWarrantsHeldByInvestorsMember aipt:HelomicsHoldingCorpMember 2018-10-26 0001446159 aipt:HelomicsWarrantsHeldByOtherPartiesMember 2018-10-26 0001446159 aipt:HelomicsWarrantsHeldByOtherPartiesMember aipt:HelomicsHoldingCorpMember 2018-10-26 0001446159 aipt:HelomicsHoldingCorpMember 2018-10-26 0001446159 aipt:SchwartzWarrantFirstTrancheMember 2018-11-30 0001446159 2018-12-31 0001446159 aipt:StockOptions2011Member 2018-12-31 0001446159 aipt:StockOptions2012Member 2018-12-31 0001446159 aipt:StockOptions2012Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2012Member srt:MinimumMember 2018-12-31 0001446159 aipt:StockOptions2013Member 2018-12-31 0001446159 aipt:StockOptions2013Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2013Member srt:MinimumMember 2018-12-31 0001446159 aipt:StockOptions2014Member 2018-12-31 0001446159 aipt:StockOptions2014Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2014Member srt:MinimumMember 2018-12-31 0001446159 aipt:StockOptions2015Member 2018-12-31 0001446159 aipt:StockOptions2015Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2015Member srt:MinimumMember 2018-12-31 0001446159 aipt:StockOptions2016Member 2018-12-31 0001446159 aipt:StockOptions2016Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2016Member srt:MinimumMember 2018-12-31 0001446159 aipt:StockOptions2017Member 2018-12-31 0001446159 aipt:StockOptions2017Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2017Member srt:MinimumMember 2018-12-31 0001446159 aipt:StockOptions2018Member 2018-12-31 0001446159 aipt:StockOptions2018Member srt:MaximumMember 2018-12-31 0001446159 aipt:StockOptions2018Member srt:MinimumMember 2018-12-31 0001446159 us-gaap:EmployeeStockOptionMember 2018-12-31 0001446159 aipt:SeriesEWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001446159 aipt:WarrantEightMember 2018-12-31 0001446159 aipt:WarrantElevenMember 2018-12-31 0001446159 aipt:WarrantFiveMember 2018-12-31 0001446159 aipt:WarrantFourMember 2018-12-31 0001446159 aipt:WarrantNineMember 2018-12-31 0001446159 aipt:WarrantOneMember 2018-12-31 0001446159 aipt:WarrantSevenMember 2018-12-31 0001446159 aipt:WarrantSixMember 2018-12-31 0001446159 aipt:WarrantTenMember 2018-12-31 0001446159 aipt:WarrantThirteenMember 2018-12-31 0001446159 aipt:WarrantThreeMember 2018-12-31 0001446159 aipt:WarrantTwelveMember 2018-12-31 0001446159 aipt:WarrantTwoMember 2018-12-31 0001446159 aipt:Warrants2014Member 2018-12-31 0001446159 aipt:Warrants2014Member srt:MaximumMember 2018-12-31 0001446159 aipt:Warrants2014Member srt:MinimumMember 2018-12-31 0001446159 aipt:Warrants2015Member 2018-12-31 0001446159 aipt:Warrants2015Member srt:MaximumMember 2018-12-31 0001446159 aipt:Warrants2015Member srt:MinimumMember 2018-12-31 0001446159 aipt:Warrants2016Member 2018-12-31 0001446159 aipt:Warrants2017Member 2018-12-31 0001446159 aipt:Warrants2017Member srt:MaximumMember 2018-12-31 0001446159 aipt:Warrants2017Member srt:MinimumMember 2018-12-31 0001446159 aipt:Warrants2018Member 2018-12-31 0001446159 aipt:Warrants2018Member srt:MaximumMember 2018-12-31 0001446159 aipt:Warrants2018Member srt:MinimumMember 2018-12-31 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember 2018-12-31 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2018-12-31 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2018-12-31 0001446159 aipt:ConversionFromSeriesCConvertiblePreferredStockToCommonStockMember 2018-12-31 0001446159 aipt:ConsultantContractOneMember us-gaap:CommonStockMember 2018-12-31 0001446159 aipt:ConsultantContractTwoMember us-gaap:CommonStockMember 2018-12-31 0001446159 aipt:ContractWithTumorgenesisMember us-gaap:CommonStockMember 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-12-31 0001446159 us-gaap:LicensingAgreementsMember 2018-12-31 0001446159 aipt:PatentsAndTrademarksMember 2018-12-31 0001446159 us-gaap:DomesticCountryMember 2018-12-31 0001446159 us-gaap:ForeignCountryMember 2018-12-31 0001446159 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001446159 aipt:TumorgenesisMember 2018-12-31 0001446159 aipt:DemoEquipmentMember 2018-12-31 0001446159 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001446159 aipt:ManufacturingToolingMember 2018-12-31 0001446159 us-gaap:OfficeEquipmentMember 2018-12-31 0001446159 srt:MaximumMember 2018-12-31 0001446159 srt:MinimumMember 2018-12-31 0001446159 aipt:HelomicsHoldingCorpMember 2018-12-31 0001446159 aipt:StockOptionsEightMember 2018-12-31 0001446159 aipt:StockOptionsEighteenMember 2018-12-31 0001446159 aipt:StockOptionsElevenMember 2018-12-31 0001446159 aipt:StockOptionsFifteenMember 2018-12-31 0001446159 aipt:StockOptionsFiveMember 2018-12-31 0001446159 aipt:StockOptionsFortyMember 2018-12-31 0001446159 aipt:StockOptionsFortyfiveMember 2018-12-31 0001446159 aipt:StockOptionsFortyfourMember 2018-12-31 0001446159 aipt:StockOptionsFortyoneMember 2018-12-31 0001446159 aipt:StockOptionsFortythreeMember 2018-12-31 0001446159 aipt:StockOptionsFortytwoMember 2018-12-31 0001446159 aipt:StockOptionsFourMember 2018-12-31 0001446159 aipt:StockOptionsFourteenMember 2018-12-31 0001446159 aipt:StockOptionsNineMember 2018-12-31 0001446159 aipt:StockOptionsNineteenMember 2018-12-31 0001446159 aipt:StockOptionsOneMember 2018-12-31 0001446159 aipt:StockOptionsSevenMember 2018-12-31 0001446159 aipt:StockOptionsSeventeenMember 2018-12-31 0001446159 aipt:StockOptionsSixMember 2018-12-31 0001446159 aipt:StockOptionsSixteenMember 2018-12-31 0001446159 aipt:StockOptionsTenMember 2018-12-31 0001446159 aipt:StockOptionsThirteenMember 2018-12-31 0001446159 aipt:StockOptionsThirtyMember 2018-12-31 0001446159 aipt:StockOptionsThirtyeightMember 2018-12-31 0001446159 aipt:StockOptionsThirtyfiveMember 2018-12-31 0001446159 aipt:StockOptionsThirtyfourMember 2018-12-31 0001446159 aipt:StockOptionsThirtynineMember 2018-12-31 0001446159 aipt:StockOptionsThirtyoneMember 2018-12-31 0001446159 aipt:StockOptionsThirtysevenMember 2018-12-31 0001446159 aipt:StockOptionsThirtysixMember 2018-12-31 0001446159 aipt:StockOptionsThirtythreeMember 2018-12-31 0001446159 aipt:StockOptionsThirtytwoMember 2018-12-31 0001446159 aipt:StockOptionsThreeMember 2018-12-31 0001446159 aipt:StockOptionsTwelveMember 2018-12-31 0001446159 aipt:StockOptionsTwentyEightMember 2018-12-31 0001446159 aipt:StockOptionsTwentyFiveMember 2018-12-31 0001446159 aipt:StockOptionsTwentyFourMember 2018-12-31 0001446159 aipt:StockOptionsTwentyMember 2018-12-31 0001446159 aipt:StockOptionsTwentyNineMember 2018-12-31 0001446159 aipt:StockOptionsTwentyOneMember 2018-12-31 0001446159 aipt:StockOptionsTwentySevenMember 2018-12-31 0001446159 aipt:StockOptionsTwentySixMember 2018-12-31 0001446159 aipt:StockOptionsTwentyThreeMember 2018-12-31 0001446159 aipt:StockOptionsTwentyTwoMember 2018-12-31 0001446159 aipt:StockOptionsTwoMember 2018-12-31 0001446159 aipt:SeriesBConvertiblePreferredStockMember 2018-12-31 0001446159 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001446159 aipt:SeriesCConvertiblePreferredStockMember 2018-12-31 0001446159 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001446159 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001446159 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001446159 us-gaap:CommonStockMember 2018-12-31 0001446159 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2018-12-31 0001446159 us-gaap:PreferredStockMember 2018-12-31 0001446159 us-gaap:RetainedEarningsMember 2018-12-31 0001446159 us-gaap:WarrantMember 2018-12-31 0001446159 2019-01-07 0001446159 aipt:SchwartzWarrantSecondTrancheMember us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-01-08 0001446159 aipt:SchwartzWarrantSecondTrancheMember us-gaap:SubsequentEventMember 2019-01-08 0001446159 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-01-08 0001446159 aipt:SchwartzWarrantMember us-gaap:SubsequentEventMember 2019-02-06 0001446159 aipt:SchwartzWarrantThirdTrancheMember us-gaap:SubsequentEventMember 2019-02-06 0001446159 aipt:SchwartzNoteMember us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-02-06 0001446159 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-02-06 0001446159 aipt:RightToPurchaseUnitsMember us-gaap:SubsequentEventMember 2019-03-01 0001446159 aipt:The2019OfferingWarrantsMember us-gaap:SubsequentEventMember aipt:The2018PublicOfferingMember 2019-03-01 0001446159 aipt:The2019OfferingWarrantsMember us-gaap:SubsequentEventMember aipt:The2019OfferingMember 2019-03-01 0001446159 us-gaap:SubsequentEventMember aipt:The2019OfferingMember 2019-03-01 0001446159 us-gaap:SubsequentEventMember 2019-03-22 0001446159 2019-03-26 0001446159 aipt:WarrantsIssuedWithPlacementAgencyAgreementMember us-gaap:SubsequentEventMember aipt:PlacementAgencyAgreementMember 2019-03-26 0001446159 us-gaap:SubsequentEventMember aipt:PlacementAgencyAgreementMember 2019-03-26 0001446159 aipt:WarrantsInConnectionWithConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2019-03-31 0001446159 aipt:HelomicsHoldingCorpMember us-gaap:SubsequentEventMember 2019-03-31 0001446159 aipt:SecuritiesPurchaseAgreementsMember aipt:ConvertiblePromissoryNoteMember us-gaap:SubsequentEventMember 2019-03-31 0001446159 us-gaap:SubsequentEventMember aipt:ShelfRegistrationMember 2019-03-31

EX-101.SCH 7 aipt-20181231.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Equity Method Investment link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Notes Receivable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Convertible Debt and Derivative Liability link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Rent Obligation link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Retirement Savings Plans link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Equity Method Investment (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Rent Obligation (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Equity Method Investment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 3 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 5 - Notes Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 6 - Convertible Debt and Derivative Liability (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 8 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 8 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 9 - Rent Obligation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 9 - Rent Obligation - Rent Obligation (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 11 - Retirement Savings Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 13 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 aipt-20181231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 aipt-20181231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 aipt-20181231_lab.xml XBRL LABEL FILE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Summary of Significant Accounting Policies Statutory federal income tax benefit us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Note 2 - Equity Method Investment Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants Note 7 - Loss Per Share Note 8 - Income Taxes Note 9 - Rent Obligation Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details) Income Tax Disclosure [Text Block] Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) Unrealized (loss) from marketable securities Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) us-gaap_LiabilitiesCurrent Total Current Liabilities Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Note 8 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) us-gaap_ProceedsFromCollectionOfNotesReceivable Proceeds from Collection of Notes Receivable aipt_LeaseToPurchaseEquipmentDownPaymentPercentage Lease to Purchase Equipment, Down Payment, Percentage Represents the percentage down payment to purchase equipment. Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) Note 9 - Rent Obligation - Rent Obligation (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Share-based Compensation, Activity [Table Text Block] Average Exercise Price Issued (in dollars per share) Derivative Liability Proceeds from sale of marketable securities us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Average Exercise Price Expired (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Average Exercise Price Outstanding (in dollars per share) Average Exercise Price Outstanding (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Warrants 2016 [Member] represents warrants 2016. us-gaap_ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Notes Payable – Net of Discount us-gaap_PaymentsToAcquireNotesReceivable Payments to Acquire Notes Receivable Weighted average remaining life, options (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit Purchase of certificates of deposit Price, options (in dollars per share) Average Exercise Price Outstanding (in dollars per share) Average Exercise Price Outstanding (in dollars per share) Deferred Revenue Contract with Customer, Liability, Current Average Exercise Price Expired (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Number of Shares Outstanding (in shares) Number of Shares Outstanding (in shares) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Average Exercise Price Exercised (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Accrued Expenses us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Number of Shares Exercised (in shares) Accounts Payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Number of Shares Expired (in shares) Shares, options (in shares) Number of Shares Outstanding (in shares) Number of Shares Outstanding (in shares) Number of Shares Issued (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Number of Shares Expired (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Stock issued for fees Licensing Agreements [Member] Equity method investment – Helomics us-gaap_PaymentsToAcquireIntangibleAssets Purchase of intangibles Stock Options Twenty Nine [Member] Represents information pertaining to the 29th stock options. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of fixed assets Non-cash transactions in investing and financing activities us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period aipt_NotesReceivableTerm Notes Receivable, Term The period of time for the notes receivable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable Weighted Average Number of Shares, Contingently Issuable LIABILITIES AND STOCKHOLDERS' EQUITY us-gaap_Assets Total Assets Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Net loss Net loss available to common shareholders Nature of Error [Axis] Nature of Error [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsAmount Quantifying Misstatement in Current Year Financial Statements, Amount Equity Interest Type [Axis] Equity Interest Issued or Issuable, Type [Domain] Equity Award [Domain] Award Date [Axis] Award Date [Domain] Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated Amortization Net Carrying Amount Total Intangibles, net The 2017 Public Offering [Member] Represents information about the 2017 public offering. Gross Carrying Costs aipt_SaleOfStockUnderwriterOptionTerm Sale of Stock, Underwriter Option Term Represents information about term of underwriter option. Series D Warrants [Member] Represents information about series D warrants. aipt_SaleOfStockUnderwriterOptionNumberOfSecuritiesCalledByMaximumAdditionalWarrantsAvailableForPurchase Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase Represents mumber of securities called by maximum additional warrants available for purchase under underwriter option. aipt_SaleOfStockUnderwriterOptionExercisePriceOfAdditionalWarrantsAvailableForPurchase Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase Represents the exercise price of additional warrants available for purchase. aipt_SaleOfStockUnderwriterOptionMaximumAdditionalSharesOfCommonStockAvailableForPurchase Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase Represents additional shares of common stock available for purchase under underwriter option. Employee Stock Option [Member] Warrant [Member] Antidilutive Securities [Axis] aipt_ClassOfWarrantOrRightIssuedPerUnit Class of Warrant or Right, Issued per Unit Represents warrants issued per unit. Antidilutive Securities, Name [Domain] Financing Receivables [Text Block] Less: Accumulated Depreciation us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment us-gaap_PropertyPlantAndEquipmentNet Total Fixed Assets, Net Fixed Assets, net Property, Plant, and Equipment Gross us-gaap_PropertyPlantAndEquipmentGross Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage us-gaap_NotesReceivableGross Financing Receivable, Gross Leases of Lessee Disclosure [Text Block] Cash flow from investing activities: Bridge Loan [Member] Earnings Per Share [Text Block] aipt_ClassOfWarrantOrRightVestingPeriod Class of Warrant or Right, Vesting Period The period in which a warrant vests. aipt_ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, warrants and other types of equity, net of issuance costs. Loss on equity method investment Loss on equity method investment us-gaap_EquityMethodInvestments Equity Method Investments Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Total income tax benefit (expense) Accrued expenses Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Accounts payable us-gaap_OperatingExpenses Operating Expenses, Total Total operating loss us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount General and administrative expense General and Administrative Expense, Total Property Plant and Equipment Useful Life [Table Text Block] Represents the schedule of property, plant and equipment useful life. us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Demo Equipment [Member] Tangible personal property used in the demo process. us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match Manufacturing Tooling [Member] Tools commonly used in the manufacturing of goods. us-gaap_LeaseAndRentalExpense Operating Leases, Rent Expense, Total Warrants in Connection with Convertible Promissory Note [Member] Represents information about warrants in connection with convertible promissory note. Cash & cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet Debt Instrument, Increase (Decrease), Net, Total us-gaap_DebtInstrumentConvertibleThresholdTradingDays Debt Instrument, Convertible, Threshold Trading Days aipt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue Average Exercise Price Exercised (in dollars per share) Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were exercised during the current period. us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense, Total Certificates of deposit aipt_ConversionSharesSumOfNumberOfConversionSharesPlusInducementShares Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares Represents information about sum of number of conversion shares plus inducement Shares. Amendment Description aipt_DebtInstrumentConvertibleConversionPricePercentageOfLowersVolumeweightedAveragePriceOfCommonStock Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock Represents the percentage of lowers volume-weighted average price of common stock considered as conversion price. Amendment Flag Series C Convertible Preferred Stock [Member] Outstanding nonredeemable series C preferred stock that is convertible and may be exchanged into common shares or other types of securities at the owner's option. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer. New Accounting Pronouncements, Policy [Policy Text Block] aipt_RelatedPartyTransactionMonthlyCashPayment Related Party Transaction, Monthly Cash Payment The amount of monthly cash payment made to a related party. us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding, Ending Balance Preferred stock, shares outstanding (in shares) Stock Options Thirty-One [Member] Represents information pertaining to the 31st stock options. us-gaap_StockholdersEquityPeriodIncreaseDecrease Stockholders' Equity, Period Increase (Decrease), Total Vice President of Sales and Marketing [Member] Represents the information pertaining to the vice president of sales and marketing. Current Fiscal Year End Date us-gaap_NotesReceivableNet Financing Receivable, Net, Total us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Lease Arrangement, Type [Axis] Stock Options Thirty-Three [Member] Represents information pertaining to the 33rd stock options. Lease Arrangement, Type [Domain] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expense and other assets Stock Options Thirty-Two [Member] Represents information pertaining to the 32nd stock options. us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Gain from sale of marketable securities us-gaap_InterestReceivable Interest Receivable Document Fiscal Period Focus Warrants 2018 [Member] Represents warrants 2018. Document Fiscal Year Focus Stock Options 2018 [Member] Represents the stock options in 2018. Document Period End Date Investor Relations Consultant [Member] Represents information pertaining to an investor relations consultant. CytoBioscience [Member] Information pertaining to CytoBioscience, Inc. Entity Ex Transition Period Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_AreaOfRealEstateProperty Area of Real Estate Property Entity Public Float EX-101.PRE 11 aipt-20181231_pre.xml XBRL PRESENTATION FILE GRAPHIC 12 dthdr.jpg GRAPHIC begin 644 dthdr.jpg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dtsign.jpg GRAPHIC begin 644 dtsign.jpg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end GRAPHIC 14 olsen.jpg GRAPHIC begin 644 olsen.jpg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end GRAPHIC 15 olsensign.jpg GRAPHIC begin 644 olsensign.jpg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end GRAPHIC 16 olsen-logo.jpg GRAPHIC begin 644 olsen-logo.jpg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

GRAPHIC 17 olsen-sig.jpg GRAPHIC begin 644 olsen-sig.jpg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ⅅ<,KJ"#^!IT8PN !VQ0 HZ" 7EHHH **** #%)@>E+10 F!12T4 ?_]D! end GRAPHIC 18 olsen-ftr.jpg GRAPHIC begin 644 olsen-ftr.jpg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end XML 19 R1.htm IDEA: XBRL DOCUMENT v3.19.1

Document And Entity Information - USD ($)
12 Months Ended

Dec. 31, 2018

Mar. 26, 2019

Jun. 30, 2018

Document Information [Line Items]

Entity Registrant Name Precision Therapeutics Inc.

Entity Central Index Key 0001446159

Trading Symbol aipt

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Small Business true

Entity Common Stock, Shares Outstanding (in shares) 15,792,586

Entity Public Float $ 13,584,316

Entity Shell Company false

Document Type 10-K/A

Document Period End Date Dec. 31, 2018

Document Fiscal Year Focus 2018

Document Fiscal Period Focus FY

Amendment Flag true

Amendment Description Precision Therapeutics Inc. is filing this Form 10-K/A (Amendment No. 1) to our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 1, 2019. This amendment modifies Item 8 for the purpose of including the report of the Registrant’s former auditor, Olsen Thielen & Co., on the financial statements for the year ended December 31, 2017, which was inadvertently omitted from Item 8. Such Olsen report on the 2017 financial statements is identical to the Olsen report that was filed on April 2, 2018 with the Registrant’s Form 10-K for the year ended December 31, 2017, except that the version of such report to be included in the 2018 10-K is dated as of a later date (April 1, 2019) as to Note 12. This Amendment No. 1 also reflect exhibits filed with this Amendment No. 1. Except as described above, this Form 10-K/A does not modify or update other disclosures in the Form 10-K, including the nature and character of such disclosure to reflect events occurring after the filing date of the original Form 10-K. The filing of this Form 10-K/A is not an admission that the original 10-K, when filed, was not complete.

X

- Definition
Description of changes contained within amended document.
+ References
No definition available.
+ Details

Name: dei_AmendmentDescription

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Balance Sheets - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Current Assets:

Cash & cash equivalents $ 162,152 $ 766,189

Certificates of deposit 244,971

Accounts Receivable 232,602 137,499

Notes Receivable (inclusive of $452,775 in advances to Helomics) 497,276 667,512

Inventories 241,066 265,045

Prepaid Expense and other assets 318,431 289,966

Total Current Assets 1,451,527 2,371,182

Notes Receivable 1,112,524 1,070,000

Fixed Assets, net 180,453 87,716

Intangibles, net 964,495 95,356

Total Assets 3,708,999 3,624,254

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts Payable 445,689 140,462

Notes Payable – Bridge Loan Net of Discount 1,327,942

Notes Payable – Net of Discount 306,972

Accrued Expenses 1,279,114 785,215

Derivative Liability 272,745

Deferred Revenue 23,065 6,663

Total Current Liabilities 3,655,527 932,340

Total Liabilities 3,655,527 932,340

Stockholders’ Equity:

Common Stock, $.01 par value, 50,000,000 authorized, 14,091,748 and 6,943,283 outstanding 140,917 69,432

Additional paid-in capital (63,019,708) (55,636,680)

Accumulated deficit 63,107,945 53,021,469

Total Stockholders' Equity 53,472 2,691,914

Total Liabilities and Stockholders' Equity 3,708,999 3,624,254

Series B Convertible Preferred Stock [Member]

Stockholders’ Equity:

Preferred stock 792 792

Series C Convertible Preferred Stock [Member]

Stockholders’ Equity:

Preferred stock $ 6,479

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_BridgeLoan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CertificatesOfDepositAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Company (holder) a definite sum of money within one year from the balance sheet date (or the normal operating cycle, whichever is longer), net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82891408&loc=d3e4531-111522

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesAndLoansReceivableNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aipt_SeriesBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aipt_SeriesCConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R3.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Balance Sheets (Parentheticals) - $ / shares

Dec. 31, 2018

Dec. 31, 2017

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized (in shares) 50,000,000 50,000,000

Common stock, shares outstanding (in shares) 14,091,748 6,943,283

Series B Convertible Preferred Stock [Member]

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized (in shares) 20,000,000 20,000,000

Preferred stock, shares outstanding (in shares) 79,246 79,246

Series C Convertible Preferred Stock [Member]

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized (in shares) 20,000,000 20,000,000

Preferred stock, shares outstanding (in shares) 0 647,819

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aipt_SeriesBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aipt_SeriesCConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R4.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Revenue $ 1,411,655 $ 654,836

Cost of goods sold 415,764 148,045

Gross margin 995,891 506,791

General and administrative expense 4,626,997 4,050,307

Operations expense 1,861,121 1,414,774

Sales and marketing expense 2,369,152 1,095,232

Total operating loss 7,861,379 6,053,523

Other income 510,254 53,734

Other expense 441,772 3,228

Loss on equity method investment (2,293,580)

Net loss available to common shareholders $ (10,086,477) $ (6,003,017)

Loss per common share - basic and diluted (in dollars per share) $ (0.79) $ (0.94)

Weighted average shares used in computation - basic and diluted (in shares) 12,816,289 6,362,989

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R5.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Statements of Stockholders' Equity - USD ($)

Over-Allotment Option [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Over-Allotment Option [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Over-Allotment Option [Member]

Preferred Stock [Member]

Over-Allotment Option [Member]

Common Stock [Member]

Over-Allotment Option [Member]

Additional Paid-in Capital [Member]

Over-Allotment Option [Member]

Retained Earnings [Member]

Over-Allotment Option [Member]

AOCI Attributable to Parent [Member]

Over-Allotment Option [Member]

Private Placement [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Private Placement [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Private Placement [Member]

Preferred Stock [Member]

Private Placement [Member]

Common Stock [Member]

Private Placement [Member]

Additional Paid-in Capital [Member]

Private Placement [Member]

Retained Earnings [Member]

Private Placement [Member]

AOCI Attributable to Parent [Member]

Private Placement [Member]

Consulting Agreement One [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Consulting Agreement One [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Consulting Agreement One [Member]

Preferred Stock [Member]

Consulting Agreement One [Member]

Common Stock [Member]

Consulting Agreement One [Member]

Additional Paid-in Capital [Member]

Consulting Agreement One [Member]

Retained Earnings [Member]

Consulting Agreement One [Member]

AOCI Attributable to Parent [Member]

Consulting Agreement One [Member]

Consulting Agreement Two [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Consulting Agreement Two [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Consulting Agreement Two [Member]

Preferred Stock [Member]

Consulting Agreement Two [Member]

Common Stock [Member]

Consulting Agreement Two [Member]

Additional Paid-in Capital [Member]

Consulting Agreement Two [Member]

Retained Earnings [Member]

Consulting Agreement Two [Member]

AOCI Attributable to Parent [Member]

Consulting Agreement Two [Member]

Investor Relations Consultant [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Investor Relations Consultant [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Investor Relations Consultant [Member]

Preferred Stock [Member]

Investor Relations Consultant [Member]

Common Stock [Member]

Investor Relations Consultant [Member]

Additional Paid-in Capital [Member]

Investor Relations Consultant [Member]

Retained Earnings [Member]

Investor Relations Consultant [Member]

AOCI Attributable to Parent [Member]

Investor Relations Consultant [Member]

Consultant Contract One [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Consultant Contract One [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Consultant Contract One [Member]

Preferred Stock [Member]

Consultant Contract One [Member]

Common Stock [Member]

Consultant Contract One [Member]

Additional Paid-in Capital [Member]

Consultant Contract One [Member]

Retained Earnings [Member]

Consultant Contract One [Member]

AOCI Attributable to Parent [Member]

Consultant Contract One [Member]

Consultant Contract Two [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Consultant Contract Two [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Consultant Contract Two [Member]

Preferred Stock [Member]

Consultant Contract Two [Member]

Common Stock [Member]

Consultant Contract Two [Member]

Additional Paid-in Capital [Member]

Consultant Contract Two [Member]

Retained Earnings [Member]

Consultant Contract Two [Member]

AOCI Attributable to Parent [Member]

Consultant Contract Two [Member]

Contract with TumorGenesis [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Contract with TumorGenesis [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Contract with TumorGenesis [Member]

Preferred Stock [Member]

Contract with TumorGenesis [Member]

Common Stock [Member]

Contract with TumorGenesis [Member]

Additional Paid-in Capital [Member]

Contract with TumorGenesis [Member]

Retained Earnings [Member]

Contract with TumorGenesis [Member]

AOCI Attributable to Parent [Member]

Contract with TumorGenesis [Member]

Helomics Holding Corp. [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Helomics Holding Corp. [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Helomics Holding Corp. [Member]

Preferred Stock [Member]

Helomics Holding Corp. [Member]

Common Stock [Member]

Helomics Holding Corp. [Member]

Additional Paid-in Capital [Member]

Helomics Holding Corp. [Member]

Retained Earnings [Member]

Helomics Holding Corp. [Member]

AOCI Attributable to Parent [Member]

Helomics Holding Corp. [Member]

Series E Warrants [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Series E Warrants [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Series E Warrants [Member]

Preferred Stock [Member]

Series E Warrants [Member]

Common Stock [Member]

Series E Warrants [Member]

Additional Paid-in Capital [Member]

Series E Warrants [Member]

Retained Earnings [Member]

Series E Warrants [Member]

AOCI Attributable to Parent [Member]

Series E Warrants [Member]

Re-priced Warrants [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Re-priced Warrants [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Re-priced Warrants [Member]

Preferred Stock [Member]

Re-priced Warrants [Member]

Common Stock [Member]

Re-priced Warrants [Member]

Additional Paid-in Capital [Member]

Re-priced Warrants [Member]

Retained Earnings [Member]

Re-priced Warrants [Member]

AOCI Attributable to Parent [Member]

Re-priced Warrants [Member]

Bridge Loan Warrants [Member]

Preferred Stock [Member]

Bridge Loan Warrants [Member]

Common Stock [Member]

Bridge Loan Warrants [Member]

Additional Paid-in Capital [Member]

Bridge Loan Warrants [Member]

Retained Earnings [Member]

Bridge Loan Warrants [Member]

AOCI Attributable to Parent [Member]

Bridge Loan Warrants [Member]

Note Payable Warrants [Member]

Preferred Stock [Member]

Note Payable Warrants [Member]

Common Stock [Member]

Note Payable Warrants [Member]

Additional Paid-in Capital [Member]

Note Payable Warrants [Member]

Retained Earnings [Member]

Note Payable Warrants [Member]

AOCI Attributable to Parent [Member]

Note Payable Warrants [Member]

Preferred Stock [Member]

Series C Preferred Stock [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

AOCI Attributable to Parent [Member]

Total

Balance at Dec. 31, 2016 $ 792 $ 45,644 $ 47,894,196 $ (47,018,451) $ 1,501 $ 923,682

Balance (in shares) at Dec. 31, 2016 79,246 4,564,428

Shares issued pursuant to the public offering $ 1,750 $ 392,000 $ 393,750 $ 12,138 $ 1,201,681 $ 1,213,819 $ 500 $ 78,500 $ 79,000 $ 17,500 3,403,688 3,421,188

Shares issued pursuant to the public offering (in shares) 175,000 1,213,819 50,000 1,750,000

Vesting Expense 2,298,680 2,298,680

Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement $ (4,000) (4,000)

Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares) (400,000)

Shares issued for services $ 1,000 $ 219,000 $ 220,000 $ 433 $ 63,699 $ 64,132

Shares issued for services (in shares) 100,000 43,333

Unrealized (loss) from marketable securities (1) (1,501) (1,501)

Preferred conversion to common shares pursuant to a private placement agreement (5,659)

Preferred conversion to common shares pursuant to a private placement agreement (in shares) (566,000)

Preferred conversion to common shares pursuant to a private placement agreement (in shares) 660,522

Preferred conversion to common shares pursuant to a private placement agreement $ 6,604 85,236 86,182

Net loss (6,003,017) (6,003,017)

Balance at Dec. 31, 2017 7,271 $ 69,432 55,636,680 (53,021,469) 2,691,914

Balance (in shares) at Dec. 31, 2017 647,819 79,246 6,943,283

Shares issued pursuant to the public offering $ 2,153 $ 202,268 $ 1 $ 204,422 $ 29,000 2,726,087 2,755,087

Shares issued pursuant to the public offering (in shares) 215,247 2,900,000

Vesting Expense 1,124,928 1,124,928

Shares issued for services $ 1,500 $ 175,500 $ 177,000 $ 1,000 $ 117,000 $ 118,000

Shares issued for services (in shares) 150,000 100,000

Preferred conversion to common shares pursuant to a private placement agreement (6,479) (6,479)

Preferred conversion to common shares pursuant to a private placement agreement (in shares) (647,819)

Preferred conversion to common shares pursuant to a private placement agreement (in shares) 589,747

Preferred conversion to common shares pursuant to a private placement agreement $ 5,897 582

Net loss (10,086,477) (10,086,477)

Balance at Dec. 31, 2018 792 $ 140,917 63,019,708 (63,107,945) 53,472

Balance (in shares) at Dec. 31, 2018 79,246 14,091,748

Investment in Subsidiary pursuant to Helomics 20% acquisition $ 11,000 $ 1,031,250 $ 1,042,250

Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares) 1,100,000

Warrant exercises $ 1,454 $ 143,942 $ 145,396 $ 5,046 $ 499,619 $ 504,665

Warrant exercises (in shares) 145,396 504,666

Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share $ 7,500 $ 870,000 $ 877,500

Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share (in shares) 750,000

Debt Discount on Warrants $ 183,187 $ 183,187 $ 68,757 $ 68,757

Shares issued as inducement for Bridge Loan $ 6,500 200,105 206,605

Shares issued as inducement for Bridge Loan (in shares) 650,000

Shares issued to employee in lieu of bonus $ 435 $ 39,803 $ 40,238

Shares issued to employee in lieu of bonus (in shares) 43,409

X

- Definition
Represents the number of reverse shares issued for escrow during the period, pursuant to the termination of an agreement.
+ References
No definition available.
+ Details

Name: aipt_ReverseSharesIssuedForEscrowPursuantToTerminationOfAgreementShares

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the value of reverse shares issued for escrow under the termination of an agreement.
+ References
No definition available.
+ Details

Name: aipt_ReverseSharesIssuedForEscrowUnderTerminationOfAgreementValue

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of stock issued in escrow pursuant to a contract.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodShareIssuedInEscrow

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period in lieu of bonus.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodSharesInLieuOfBonus

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period as inducement for bridge loan.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodSharesInducementForBridgeLoan

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued as a result of the exercise of warrants.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodSharesWarrantsExercised

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of bonus.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodValueInLieuOfBonus

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as inducement for Bridge loan.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodValueInducementForBridgeLoan

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in escrow pursuant to a contract.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodValueIssuedInEscrow

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of warrants.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodValueWarrantsExercised

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 24 R6.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Statements of Stockholders' Equity (Parentheticals) - $ / shares

Dec. 31, 2018

Dec. 31, 2017

Investor Relations Consultant [Member]

Price of shares issued (in dollars per share) $ 1.18

Consultant Contract One [Member] | Common Stock [Member]

Price of shares issued (in dollars per share) $ 1.18

Consultant Contract Two [Member] | Common Stock [Member]

Price of shares issued (in dollars per share) 1.18

Contract with TumorGenesis [Member] | Common Stock [Member]

Price of shares issued (in dollars per share) 1.17

Series E Warrants [Member] | Common Stock [Member]

Warrant exercises, exercise price per share (in dollars per share) 1

Common Stock [Member] | Over-Allotment Option [Member]

Price of shares issued (in dollars per share) $ 0.9497

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_CounterpartyNameAxis=aipt_InvestorRelationsConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_ConsultantContractOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_ConsultantContractTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_ContractWithTumorgenesisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SeriesEWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 25 R7.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Statements of Cash Flows - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Cash flow from operating activities:

Net loss $ (10,086,477) $ (6,003,017)

Adjustments to reconcile net loss to net cash used in operating activities:

Loss on equity method investment 2,293,580

Depreciation and amortization 147,628 71,562

Vesting expense for stock options and warrants 1,124,928 2,298,680

Equity instruments issued for management and consulting 335,238 359,133

Amortization of debt discount 385,111

Gain from sale of marketable securities (1,837)

Gain on valuation of equity-linked instruments (372,263)

Changes in assets and liabilities:

Accounts receivable (95,103) (98,580)

Inventories 23,979 7,163

Prepaid expense and other assets 139,895 (141,329)

Accounts payable 305,227 (79,650)

Accrued expenses 493,899 (870,540)

Deferred revenue 16,402 (1,335)

Net cash used in operating activities (5,287,956) (4,459,750)

Cash flow from investing activities:

Proceeds from sale of marketable securities 284,665

Purchase of certificates of deposit (3,084,971)

Redemption of certificates of deposit 244,971 2,940,000

Advances on notes receivable (1,123,619) (1,737,512)

Purchase of fixed assets (177,732) (45,093)

Purchase of intangibles (54,271) (10,179)

Net cash used in investing activities (1,110,651) (1,653,090)

Cash flow from financing activities:

Proceeds from exercise of warrants into common stock 650,061

Proceeds from debt issuance 2,185,000

Net proceeds from issuance of preferred stock 1,300,001

Proceeds from Issuance of Common Stock 2,959,509 3,814,938

Net cash provided by financing activities 5,794,570 5,114,939

Net decrease in cash (604,037) (997,901)

Cash at beginning of period 766,189 1,764,090

Cash at end of period 162,152 766,189

Non-cash transactions in investing and financing activities

Conversion of preferred stock to common stock 6,479

Equity method investment – Helomics 1,542,250

Licensing Fee for Tumorgenesis [Member]

Non-cash transactions in investing and financing activities

Stock issued for fees $ 877,500

X

- Definition
Represents the cash flow effect during the period of equity instruments issued for management and consulting.
+ References
No definition available.
+ Details

Name: aipt_EquityInstrumentsIssuedForManagementAndConsulting

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the redemption of certificates of deposits.
+ References
No definition available.
+ Details

Name: aipt_ProceedsFromRedemptionOfCertificatesOfDeposits

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInNotesReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of investments transferred to the entity's investments in noncash transactions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_TransferToInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis=aipt_LicensingFeeForTumorgenesisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R8.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]
NOTE
1
— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

The Company was originally incorporated on
April 23, 2002
in Minnesota as BioDrain Medical, Inc. Effective
August 6, 2013,
the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective
December 16, 2013,
the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On
August 31, 2015,
the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On
February 1, 2018,
the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change the Company’s corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective
February 1, 2018.
Because of this change, the Company’s common stock began trading under the new ticker symbol “AIPT,” effective
February 2, 2018.
Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of
December 31, 2018,
the registrant had
14,091,748
shares of common stock, par value
$.01
per share, outstanding. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of its proprietary cleaning fluid and filters to users of the STREAMWAY systems. In
April 2009,
the Company received
510
(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired
25%
of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the
first
quarter of
2018,
and in
April 2018
the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In
June 2018,
the Company and Helomics entered into a definitive merger agreement – see Note
4.
The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over
149,000
tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis, formed during the
first
quarter, is presented as part of the consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of
$63,107,945.
The Company does
not
expect to generate sufficient operating revenue to sustain its operations in the near-term. In
2018,
the Company incurred negative operating cash flows of approximately
$441,000
per month. Although the Company has attempted to curtail expenses, there is
no
guarantee that the Company will be able to reduce these expenses significantly, and expenses
may
need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of
$162,152
as of
December 31, 2018
and needs to raise significant additional capital to meet its operating needs, pay debt obligations coming due, and the continued operating needs of Helomics, therefore there is substantial doubt about the Company’s ability to continue as a going concern for
one
year after the date that the financial statements are issued. The financial statements do
not
include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-
3,
with which the Company has raised approximately
$2.1
million in net proceeds in early
2019.
The Company
may
raise up to approximately
$1.7
million in additional gross proceeds in the next calendar year using the shelf registration statement. This amount of available financing will increase to approximately
$6.4
million in additional gross proceeds, once the Helomics acquisition is completed.



Since inception to
December 31, 2018,
the Company raised approximately
$36,490,000
in equity and
$7,870,000
in debt financing. Equity raises include: a
January 2017
public offering of units with gross proceeds to the Company of
$3,937,500;
a
November 2017
private placement with gross proceeds of
$1,300,000;
and, a
January 2018
public offering with gross proceeds of
$2,755,000.
Included in debt financing were raises in
September 2018
on senior secured promissory notes with net proceeds of
$1,815,000,
and in
November 2018
the Company received a loan from the CEO for
$370,000.
Subsequent to
December 31, 2018,
the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional
$1,300,000.

The Company has
no
commitments or contingencies.

Recent Accounting Developments

Accounting Policies and Estimates

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

In
May 2014,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.

2014
-
09,

Revenue from Contracts with Customers (Topic
606
),
which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on
January 1, 2018
using the modified retrospective method applied to those contracts which were
not
completed as of
December 31, 2017.
Results for reporting periods beginning
January
1,

2018
are presented under Topic
606,
while prior-period amounts have
not
been retrospectively adjusted and continue to be reported in accordance with Topic
605,

Revenue Recognition
. Based upon the Company’s contracts which were
not
completed as of
December 31, 2017,
the Company was
not
required to make an adjustment to the opening balance of retained earnings as of
January 1, 2018,
and there was
no
material impact. See Note
3
for further discussion.

In
January 2016,
the FASB issued ASU
No.

2016
-
01,

Financial Instruments-Overall (Subtopic
825
-
10
): Recognition and Measurement of Financial Assets and Financial Liabilities
(“ASU
2016
-
01”
). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do
not
result in consolidation and are
not
accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of
January 1, 2018.
As of
December 31, 2018,
there is
no
material impact on the Company’s financial statements and disclosures.

In
February 2016,
the FASB issued ASU
No.

2016
-
02,
“
Leases (Topic
842
)
” (“ASU
2016
-
02”
), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after
December 15, 2018.
Early adoption is permitted. The Company adopted ASU
2016
-
02
on
January 1, 2019,
using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The adoption resulted in
no
material impact to the Company’s balance sheet, results of operations, equity or cash flows.

In
August 2016,
the FASB issued ASU
No.

2016
-
15,

Statement of Cash Flows (Topic
230
): Classification of Certain Cash Receipts and Cash Payments,
to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for public business entities for fiscal years beginning after
December 15, 2017,
and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company adopted the standard as of
January 1, 2018.
As of
December 31, 2018,
there is
no
material impact on the Company’s financial statements and disclosures.

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment in accordance with ASC
360
— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount
may
not
be recoverable. The Company’s intangible assets are definite lived and currently solely the costs of obtaining licensing fees, trademarks, and patents. Events or changes in circumstances that indicate the carrying amount
may
not
be recoverable include, but are
not
limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were
$43,548
in
2018
and
$37,060
in
2017.

Research and Development

Research and development costs are charged to operations as incurred.  Research and development costs were approximately
$526,000
and
$289,000
for
2018
and
2017,
respectively.

Revenue Recognition

The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases.

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses.

Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company
may,
at its discretion, negotiate different shipping terms with customers which
may
affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally
30
to
60
days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers
may
also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of
one
year subsequent to the
one
-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the
one
-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do
not
contain any features that create variability in the amount or timing of revenue to be earned.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of
three
months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than
one
year but greater than
three
months when purchased. Certificates with maturity dates beyond
one
year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s
Accounting Standards Certification
(ASC)
820,
fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC
820
establishes a
three
-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level
1
– Observable inputs such as quoted prices in active markets;

Level
2
– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level
3
– Unobservable inputs where there is little or
no
market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities, which in
2018
are cash equivalents only, were determined based on Level
1
inputs.

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts. Changes to the valuation allowance have
not
been material to the financial statements.

Inventories

Inventories are stated at the net realizable value, with cost determined on a
first
-in,
first
-out basis. Inventory balances are as follows:

December 31,
2018 December 31,
2017

Finished goods $
58,701
$
62,932

Raw materials
127,003

141,028

Work-In-Process
55,362

61,085

Total $
241,066
$
265,045

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation is shown in the financial statements under fixed assets, net on the balance sheet, and amortization is shown under intangibles, net on the balance sheet. Estimated useful asset life by classification is as follows:

Years

Computers and office equipment

3

-

7

Leasehold improvements

5

Manufacturing Tooling

3

-

7

Demo Equipment

3

The Company’s investment in fixed assets consists of the following:

December 31,
2018 December 31,
2017

Computers and office equipment $
204,903
$
183,528

Leasehold Improvements
140,114

25,635

Manufacturing Tooling
108,955

108,955

Demo Equipment
85,246

43,368

Total
539,218

361,486

Less: Accumulated Depreciation
358,765

273,770

Total Fixed Assets, Net $
180,453
$
87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was
$84,995
in
2018
and
$58,872
in
2017.

Intangible Assets

The components of intangible assets all of which are finite-lived were as follows:

12/31/2018 12/31/2017

Gross Carrying
Costs Accumulated
Amortization Net Carrying
Amount Gross Carrying
Costs Accumulated
Amortization Net Carrying
Amount

Patents & Trademarks $
318,304
$
(182,559
) $
135,745
$
264,032
$
(168,676
) $
95,356

Licensing Fees
877,500

(48,750
)
828,750

-

-

-

Total $
1,195,804
$
(231,309
) $
964,495
$
264,032
$
(168,676
) $
95,356

The following table outlines the estimated future amortization expense related to intangible assets held as of
December 31, 2018

Year ending Expense

2019
72,383

2020
72,383

2021
72,383

2022
72,383

2023
72,383

Thereafter
602,580

Total
964,495

Intangible assets consist of trademarks, patent costs and licensing fees. Amortization expense was
$62,633
in
2018
and
$12,689
in
2017.
The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

On
December 22, 2017,
the Tax Cuts and Jobs Act of
2017
(Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate income tax rates from
34%
to
21%.
As a result of the enacted law, the Company was required to value its deferred tax assets and liabilities at the new enacted rate. There was
no
income tax impact from the re-measurement due to the
100%
valuation allowance on the Company’s deferred tax assets.

The Company accounts for income taxes in accordance with ASC
740
-
Income Taxes
(“ASC
740”
). Under ASC
740,
deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than
not
that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified
no
income tax uncertainties.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any
one
financial institution. The Company has
no
credit risk concentration because there are
no
funds in excess of insurance limits in a single bank.

Product Warranty Costs

In
2018
and in
2017,
the Company incurred approximately
$10,682
and
$6,209,
respectively in warranty costs.

Segments

The Company operates in
two
segments for the sale of its medical device and consumable products. These segments are its domestic operations and international operations. Substantially all the Company’s assets, revenues, and expenses for the years ended
December 31, 2018
and
2017
were located at or derived from operations in the United States. In
2018
and
2017,
business activity within the Company’s international segment was immaterial.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but
not
limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R9.htm IDEA: XBRL DOCUMENT v3.19.1

Note 2 - Equity Method Investment
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]
NOTE
2
– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. Summarized financial information for Helomics is presented below:

Helomics Holdings Corporation

December 31, 2018

Current assets $
419,266

Non-current assets $
2,046,347

Total assets $
2,465,613

Current liabilities $
12,247,174

Total liabilities $
12,247,174

For the Year-ended Ended

December 31, 2018

Revenue $
523,546

Gross margin $
214,426

Net loss on operations $
(5,056,725

)

Net loss $
(9,452,835

)

Net Loss to investee $
(7,159,255

)
1

1
The loss to investee was calculated at
80%
for the initial period of ownership,
January 11, 2018 –
February 27, 2018,
and then at
75%
for the remainder of the
twelve
-month period at the current equity investment percentage owned by the Company.

Helomics’
first
year predominantly included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have generated approximately
$31,000
of revenue in the year-to-date.

The Helomics loss reduces the equity method investment asset on the balance sheet. The recorded investor losses have exceeded the equity method investment originally recorded total. As such, the equity method investment recorded to the balance sheet has been reduced to
zero
, and all subsequent losses reduced the note receivable due from Helomics. The note receivable on the balance sheet includes
$413,683,

not
including interest, for Helomics. The actual note due to the Company as of
December 31, 2018
is
$1,165,013.
The amount exceeding the original equity method investment and thus reducing the note receivable balance is
$751,330.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-URI http://asc.fasb.org/topic&trid=2196965
+ Details

Name: us-gaap_EquityMethodInvestmentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R10.htm IDEA: XBRL DOCUMENT v3.19.1

Note 3 - Revenue Recognition
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]
NOTE
3
– REVENUE RECOGNITION

Revenue from Product Sales

The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases.

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses.

Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company
may,
at its discretion, negotiate different shipping terms with customers which
may
affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally
30
to
60
days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers
may
also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of
one
year subsequent to the
one
-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the
one
-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do
not
contain any features that create variability in the amount or timing of revenue to be earned.

Warranty

The Company generally provides
one
-year warranties against defects in materials and workmanship and will either repair the products or provide replacements at
no
charge to customers. As they are considered assurance-type warranties, the Company does
not
account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of
December 31, 2018,
and
December 31, 2017,
accounts receivable totaled
$232,602
and
$137,499,
respectively.

The Company deferred revenues related primarily to maintenance plans of
$23,065
and
$6,663
as of
December 31, 2018
and
December 31, 2017,
respectively.

Practical Expedients

The Company has elected the practical expedient
not
to determine whether contracts with customers contain significant financing components.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v3.19.1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]
NOTE
4
– STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS

2017
Firm Commitment Public Offering

On
January 19, 2017,
the Company closed a firm commitment public offering for
1,750,000
Units at
$2.25
per Unit. The Units comprised
one
share of common stock and
0.2
Series D Warrants with each whole Series D Warrant purchasing
one
share of the Company’s common stock at an exercise price of
$2.25
per share. The Company received gross proceeds of
$3,937,500.
Subsequently the underwriter exercised over-allotment for
175,000
shares of common stock and for Series D warrants to purchase
35,000
shares of common stock at
$0.01
per warrant. The Company received net proceeds from the over-allotment of
$358,312.

2017
Private Placement

On
November 30, 2017,
the Company closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York based Family Office. Pursuant to the Securities Purchase Agreement, the investor purchased
1,213,819
shares of Series C stock at a purchase price of
$1.071
per Series C Share, together with a warrant to purchase up to
606,910
shares of common stock. The warrant has an exercise price of
$1.26
per share, subject to adjustment, has a
five
- and
one
-half-year term and is exercisable commencing
six
months following the date of issuance. Total gross proceeds to the Company were
$1,300,000
before deducting expenses and will be used for general working capital. In connection with the offering and pursuant to a registration rights agreement, the Company has agreed to file a “resale” registration statement covering all of the shares of common stock issuable upon conversion of the warrant. Pursuant to the Securities Purchase agreement, and as of this filing date, all the Preferred Series C shares were converted at a conversion rate of
1.167
to a maximum of
1,250,269
shares of common stock. The remaining
142,466
shares of Preferred Series C stock were cancelled with a redemption payment to the holder for
$189,285.

2018
Firm Commitment Public Offering

In
January 2018,
the Company completed a firm commitment underwritten public offering of
2,900,000
Units at an offering price of
$0.95
per Unit, with each Unit consisting of
one
share of the Company’s common stock and
0.3
of a Series E Warrant, with each whole Series E Warrant purchasing
one
share of common stock at an exercise price of
$1.00
per whole share. The shares of common stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately
$2,755,000,
before deducting expenses. The Company granted the underwriter a
45
-day option to purchase an additional (i) up to
290,000
additional shares of common stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to
87,000
additional shares of common stock at a purchase price of
$0.001
per Series E Warrant to cover over-allotments, if any. On
February 21, 2018,
the underwriter exercised on
215,247
shares of common stock, par value
$0.01,
at
$0.9497
per share as described in the Underwriting Agreement. The Company received net proceeds of
$188,066
after deductions of
$16,354
representing the underwriter’s discount of
8%
of the purchase price of the shares.

Share Exchange Agreement with Helomics

On
January 11, 2018,
the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement, Helomics issued
2,500,000
shares of its Series A Preferred Stock in exchange for
1,100,000
shares of common stock. Under the share exchange agreement, in
March 2018
the Company converted
$500,000
in secured notes into another
5%
of Helomics’ outstanding shares, which resulted in the Company owning
25%
of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of
$500,000
to Helomics. The
1,100,000
shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Company’s shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Company shares will be released to Helomics following a determination that Helomics’ revenues in any
12
-month period have been equal or greater than
$8,000,000.
The Helomics Preferred Stock issued to the Company is convertible into an aggregate of
20%
of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics
may
take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.

Merger Agreement with Helomics

On
June 28, 2018,
the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. On
October 26, 2018,
the Merger Agreement was amended and restated. The Merger Agreement contemplated a reverse triangular merger with Helomics surviving the merger and becoming a wholly-owned operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock
not
already held by the Company were to be converted into the right to receive a proportionate share of
7.5
million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the
1.1
million shares of the Company’s common stock already issued to Helomics for the Company’s initial
20%
ownership in Helomics. Additionally,
860,000
shares of the merger consideration were to be held in escrow for
18
months to satisfy indemnification claims. Helomics currently has outstanding
$7.6
million in promissory notes and warrants to purchase
18.7
million shares at an exercise price of
$1.00
per share of Helomics common stock held by the investors in the promissory notes. As a result of the Merger, the holders of said promissory notes and warrants would be entitled to additional warrants to purchase up to
5.0
million additional shares of Helomics common stock at an exercise price of
$1.00
per share. Helomics agreed to use commercially reasonable efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least
75%
of the
$7.6
million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of
0.6
Precision warrants for each Helomics warrant, with an exercise price of
$1.00
per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated
23.7
million shares of the Company’s common stock and warrants to purchase an additional
14.2
million shares of the Company’s common stock at
$1.00
per share. In addition, Helomics currently has
995,000
warrants held by other parties at an exercise price of
$0.01
per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase
597,000
shares of Precision common stock at
$0.01
per share.

Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.

At a special meeting of stockholders on
March 22, 2019,
the Company’s stockholders approved the Merger Agreement.

On
July 10
and
11,

2018,
the Company issued
250,000
shares of common stock, par value
$0.01,
at
$1.18
per share for consulting fees pursuant to the TumorGenesis license fees contract, and
750,000
shares of common stock, par value
$0.01,
at
$1.17
per share, in escrow, for TumorGenesis license fees pursuant to the TumorGenesis license fees contract.

Increases in Authorized Shares

At a special meeting of the stockholders on
January 29, 2017,
the stockholders approved a proposal to increase the number of authorized shares of common stock from
8,000,000
shares to
24,000,000
shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on
December 28, 2017,
the stockholders approved a proposal to increase the number of authorized shares of common stock from
24,000,000
to
50,000,000
shares of common stock,
$0.01
par value. The amendment to the certificate of incorporation to affect this increase was filed on
January 2, 2018.

At the special meeting of stockholders on
March 22, 2019,
the stockholders approved a proposal to increase the number of authorized shares of common stock from
50,000,000
to
100,000,000
shares of common stock,
$0.01
par value. The amendment to the certificate of incorporation to affect this increase was filed on
March 22, 2019.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to
three
years. Options under this plan have terms ranging from
three
to
ten
years.

Accounting for share-based payment

ASC
718
–
Compensation – Stock Compensation, (“ASC
718”
)
requires that a company that issues equity as compensation needs to record compensation expense on its statements of comprehensive loss that corresponds to the estimated cost of those equity grants. ASC
718
requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has
no
significant public trading history, and the Company has experienced
no
significant option exercises in its history, the Company policy is to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company has been on the NASDAQ Capital Market since
2015
and has had a volatile stock including reverse stock splits. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

On
April 19, 2017,
the Company terminated the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC and thereby received
400,000
shares of common stock, par value
$0.01,
from escrow.

For grants of stock options and warrants in
2017
the Company used a
1.92%
to
2.40%
risk free interest rate,
0%
dividend rate,
59%
to
66%
volatility and estimated terms of
5
to
10
years. Value computed using these assumptions ranged from
$0.6541
to
$1.5489
per share.

On
January 15, 2018,
the Company issued inducement stock options in accordance with NASDAQ listing rule for
50,000
shares of common stock, par value
$0.01
at
$0.97
per share to the Company’s newly hired International Vice President of Sales. The options will vest in
four
equal increments: on the first, second,
third
and
fourth
quarters of the hiring date anniversary.

On
March 12, 2018,
the Company issued inducement stock options in accordance with NASDAQ rule for
111,112
shares of common stock, par value
$0.01
at
$1.35
per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in
four
equal increments: on the first, second,
third
and
fourth
quarters of the hiring date anniversary.

For grants of stock option and warrants in
2018
the Company used
2.33%
to
3.07%
risk free interest rate,
0%
dividend rate,
59%
to
66%
volatility and estimated terms of
5
to
10
years. Value computed using these assumptions ranged from
$0.3816
to
$1.0044
per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

Stock Options Warrants

Number of
Shares Average
Exercise
Price Number of
Shares Average
Exercise
Price

Outstanding at December 31, 2016
165,643
$
11.22

871,101
$
52.22

Issued
2,612,070

1.45

1,082,946

1.49

Expired
(12,730
)
10.39

(2,790
)
281.46

Exercised
-

-

-

-

Outstanding at December 31, 2017
2,764,983
$
2.00

1,951,257
$
23.74

Issued
1,098,858

1.01

2,336,154

1.07

Expired
(194,564
)
2.00

(10,706
)
199.55

Exercised
-

-

(650,062
)
1.00

Outstanding at December 31, 2018
3,669,277
$
1.70

3,626,643
$
4.17

At
December 31, 2018,
2,946,488
stock options are fully vested and currently exercisable with a weighted average exercise price of
$1.79
and a weighted average remaining term of
8.86
years. There are
2,247,489
warrants that are fully vested and exercisable. Stock-based compensation recognized in
2018
and
2017
was
$1,124,928
and
$2,298,680,
respectively. The Company has
$741,922
of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next
20
months.

The following summarizes the status of options and warrants outstanding at
December 31, 2018:

Range of Exercise Prices Shares Weighted
Average
Remaining
Life

Options:

$0.619
201,908

10.00

$0.82
60,000

9.91

$0.91
10,000

9.30

$0.965
3,000

9.38

$0.97
191,753

9.02

$1.01
149,110

9.12

$1.06
23,585

9.76

$1.10
86,958

9.46

$1.13
195,931

9.55

$1.15
21,740

9.59

$1.16
66,451

9.59

$1.18
30,000

9.61

$1.20
41,668

9.59

$1.21
30,000

9.61

$1.35
111,112

9.20

$1.454
17,200

8.75

$1.47
2,305,790

8.48

$2.10
14,286

8.25

$2.25
293

7.65

$2.42
20,640

7.64

$2.80
57,145

8.01

$3.75
4,000

7.50

$4.125
3,636

7.75

$4.1975
7,147

7.72

$4.25
3,529

7.25

$5.125
3,902

7.69

$65.75
190

6.81

$73.50
1,157

7.01

$77.50
2,323

6.50

$80.25
187

6.75

$86.25
232

6.25

$131.25
81

3.69

$148.125
928

4.21

$150.00
1,760

3.63

$162.50
123

6.01

$206.25
121

5.75

$248.4375
121

4.54

$262.50
130

4.54

$281.25
529

4.04

$318.75
3

4.35

$346.875
72

5.25

$431.25
306

5.19

$506.25
188

5.00

$596.25
42

4.75

Total
3,669,277

Warrants:

$0.836
221,292

4.92

$1.00
1,063,935

3.76

$1.07
697,946

3.85

$1.155
1,071,776

4.75

$1.3125
86,086

4.75

$2.25
385,000

3.06

$123.75
94,084

1.67

$243.75
2,529

0.59

$309.375
2,850

0.61

$309.50
222

0.85

$506.25
59

0.12

$609.375
862

0.09

Total
3,626,643

Stock options and warrants expire on various dates from
January 2019
to
December 2028.

The Company’s board of directors had determined that the Company would require additional authorized shares for anticipated equity financings, future equity offerings, strategic acquisition opportunities, and the continued issuance of equity awards under our stock incentive plan to recruit and retain key employees, and for other proper corporate purposes. As a result, the board of directors called a special meeting of the stockholders that took place on
January 29, 2017.
The vote, a proposal to increase the number of authorized shares of common stock from
8,000,000
shares to
24,000,000
shares of common stock under the Company’s certificate of incorporation passed. On
December 28, 2017,
the Company held its annual meeting. Pursuant to the meeting on
January 2, 2018,
the Certificate of Incorporation of the Company was amended to increase the number of authorized shares of common stock from
24,000,000
to
50,000,000
shares of common stock,
$0.01
par value. Additionally, the stockholders approved an amendment to the Company’s
2012
Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to
5,000,000,
(ii) to increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. Pursuant to the annual meeting and the aforementioned approvals, and as explained in the Company’s definitive proxy statement filed with the SEC on
December 4, 2017,
amendments to the
2012
Plan were considered at the
2016
annual meeting but were
not
approved by the required vote. For options to purchase approximately
2.5
million shares granted after the
2016
annual meeting, the grantees agreed
not
to exercise the options prior to further stockholder approval of an increase in the reserve under the
2012
Plan. As a result of the stockholder approval of the amendments at the
2017
annual meeting, these restrictions on exercise were removed on
December 28, 2017.
Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately
$1.9
million in the
fourth
quarter of
2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of outstanding stock options and warrants as of
December 31, 2018
by year of grant:

Stock Options:

Year

Shares

Price

2011

173

281.25

2012

1,841

131.25

–

150.00

2013

1,553

148.13

–

596.25

2014

836

162.50

–

431.25

2015

4,088

65.75

–

86.25

2016

100,294

2.25

–

5.13

2017

2,461,634

1.01

–

2.10

2018

1,098,858

0.62

–

1.35

Total

3,669,277

$0.62

–

596.25

Warrants:

Year

Shares

Price

2014

6,455

243.75

–

609.38

2015

94,151

0.00

–

243.75

2016

252,333

1.00

2017

1,082,946

1.07

–

2.25

2018

2,190,758

0.84

–

1.3125

Total

3,626,643

$0.00

–

609.38

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v3.19.1

Note 5 - Notes Receivable
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Financing Receivables [Text Block]
NOTE
5–
NOTES RECEIVABLE

In
July 2017,
the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at
8%
and were due in full on
December 31, 2017.
All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled
$1,070,000
as of
December 31, 2017.
In
March 2018,
the Company executed a new note replacing all previous CytoBioscience notes for
$1,112,524,
plus interest paid monthly at the per annum rate of (
8%
) on the principal amount. The secured note has a term of
two
years with the unpaid principal and unpaid accrued interest due and payable on
February 28, 2020.
CytoBioscience was current in its payments to the Company through and including
July 2018.
The Company had
not
received the scheduled interest payments from CytoBioscience for
August
through yearend. On
September 27
and
28,

2018
CytoBioscience, through its parent company (WestMountain; now named InventaBioTech, OTC symbol INVB), made public filings indicating that their notes payable was in default. In
October 2018,
CytoBioscience communicated to the Company that CytoBioscience is raising capital that it believes will allow it to resume debt service payments, and that CytoBioscience wishes to negotiate an extension to the note. The Company has reached agreement with CytoBioscience on repayment and in
February
and
March 2019
received payments towards the interest due and a portion of the principal. As of
December 31, 2018,
the Company does
not
believe a reserve is needed.

In
October 2017,
the Company advanced
$600,000
for working capital for Helomics’ business. Additionally, in
December 2017,
the Company advanced
$67,512
to De Lage Landen, a vendor of Helomics, as a
fifty
percent (
50%
) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In
March 2018,
the Company converted
$500,000
of the note receivable into
833,333
shares of common stock for an additional
5%
interest in Helomics. The Company now has an equity stake in Helomics totaling
25%.

In
September 2018,
the Company advanced an additional
$60,000
for working capital for Helomics’ business. The balance due to the Company is
$163,468,
plus interest as of
September 30, 2018.
Subsequently in
October 2018,
the Company advanced
$907,500
for working capital for Helomics’ business. In
December 2018,
the Company advanced
$30,000
to Helomics under the same note. The balance due to the Company at
December 31, 2018,
is
$1,165,013
in principal, plus interest of
$29,215.
On the balance sheet there is a reduction to the loan of
$751,330
due to the equity method accounting losses incurred from Helomics ownership; see Note
2.
In
January
and
February 2019,
the Company also advanced Helomics
$305,000.
In
March 2019,
the Company advanced an additional
$420,000
to Helomics from the Form S-
3
public offering that netted the Company approximately
$1.1M.
The balance to date owed by Helomics is
$1,890,013
plus interest. The Company expects that additional advances will be required before the merger is complete. All additional advances are covered by the security interest in certain equipment of Helomics. In addition, Helomics pledged all of its assets as security for the Company’s convertible secured note financing. Upon completion of the merger with Helomics all intercompany notes would be eliminated in their entirety.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for financing receivables. Examples of financing receivables include, but are not limited to, loans, trade accounts receivables, notes receivable, credit cards, and receivables relating to a lessor's right(s) to payment(s) from a lease other than an operating lease that is recognized as assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-URI http://asc.fasb.org/topic&trid=2196771
+ Details

Name: us-gaap_FinancingReceivablesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R13.htm IDEA: XBRL DOCUMENT v3.19.1

Note 6 - Convertible Debt and Derivative Liability
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Convertible Debt and Derivative Liability [Text Block]
NOTE
6
– CONVERTIBLE DEBT AND DERIVATIVE LIABILITY

Effective
September 28, 2018 (
the “Effective Date”), the Company issued convertible secured promissory notes to
two
private investors in the original principal amount of an aggregate
$2,297,727
(the “bridge loan”). The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a
second
investment of an aggregate of
$500,000
by the investors at the consummation of the Merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become
$2,865,909.
As additional consideration for the investment, the Company issued an aggregate
650,000
shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate
1,071,776
shares of the Company’s common stock at an exercise price of
$1.155
per share. Upon the closing of the
second
tranche investment, the warrants would be increased to cover an aggregate total of
1,336,805
shares. Each warrant is exercisable by the investor beginning on the
sixth
month anniversary of the effective date through the
fifth
-year anniversary thereof.

The notes accrue interest at a rate of
8%
per annum (with
twelve
months of interest guaranteed). The maturity date of the notes is
twelve
months from the Effective Date. Upon the earlier to occur of an event of default (as defined in the notes) or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i)
$1.00
and (ii)
70%
of the lowest volume-weighted average price (the “VWAP”) of the Company’s common stock during the
20
-trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that
may
be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate
2,678,328
shares.

Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using
70%
of the VWAP for the
20
trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required.

The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of
2.94%
over
five
years with a
59%
volatility rate pursuant to the Company’s established warrant volatility and a calculated value per warrant of
.5361
resulting in a fair value of
$574,631.
Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements. In
December 2018,
the derivative liability was adjusted for the change in the
70%
of the VWAP for the
20
days preceding the balance sheet date and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The derivative liability recorded in
September 2018
was
$645,008.
The fair value of the derivative liability as of
December 31, 2018
is
$272,745.
An unrealized gain for the corresponding change in fair value was recorded to other income in
2018.

The value of the embedded derivative was based upon level
3
inputs – see the Fair Value Caption in Note
1.

X

- Definition
The entire disclosure for information about convertible debt and derivative liability.
+ References
No definition available.
+ Details

Name: aipt_ConvertibleDebtAndDerivativeLiabilityTextBlock

Namespace Prefix: aipt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R14.htm IDEA: XBRL DOCUMENT v3.19.1

Note 7 - Loss Per Share
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]
NOTE
7
- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

Year Ended
December 31,

2018 2017

Numerator:

Net loss available in basic and diluted $
(10,086,477
) $
(6,003,017
)

Denominator:

Weighted average common shares outstanding-basic
12,816,289

6,362,989

Effect of dilutive stock options warrants and preferred stock (1)
-

-

Weighted average common shares outstanding-diluted
12,816,289

6,362,989

Loss per common share-basic and diluted $
(0.79
) $
(0.94
)

(
1
) The number of shares underlying options and warrants outstanding as of
December 31, 2018
and
December 31, 2017
are
7,295,921
and
4,716,240,
respectively. The number of shares underlying the preferred stock as of
December 31, 2018
is
79,246
for Series B Convertible. The number of shares underlying the convertible debt is
3,294,087.
The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R15.htm IDEA: XBRL DOCUMENT v3.19.1

Note 8 - Income Taxes
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]
NOTE
8–
INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Tax Reform Act was enacted
December 22, 2017.
Effective
January 1, 2018
the Tax Reform Act reduced corporate income tax rates from
34%
to
21%.
Other changes effect operating loss carry-forwards and carrybacks, as well as a repeal of the corporate alternative minimum tax. As a result of the Tax Reform Act, deferred tax assets and liabilities were re-measured to account for the lower tax rates. There was
no
income tax impact from the re-measurement due to the
100%
valuation allowance on the Company’s deferred tax assets.

There is
no

federal or state income tax provision in the accompanying statements of comprehensive loss due to the cumulative operating losses incurred and
100%
valuation allowance for the deferred tax assets.

Actual income tax benefit (expense) differs from statutory federal income tax benefit (expense) as follows for the years ended
December 31:

2018 2017

Statutory federal income tax benefit $
2,118,160
$
2,633,841

State tax benefit, net of federal taxes
66,117

76,922

Foreign tax benefit
132,931

-

Foreign operations tax rate differential
(94,373
)
-

State rate adjustment
15,355

(77,556
)

R&D tax credit
22,532

-

Nondeductible/nontaxable items
(118,905
)
(757,149
)

State NOL adjustment
746,479

-

OID and derivatives
(159,037
)
-

NQSO adjustment
-

537,884

New federal rate adjustment
-

(4,974,121
)

Other
47,868

(8,336
)

Valuation allowance decrease (increase)
(2,777,127
)
2,568,515

Total income tax benefit (expense) $
-
$
-

Deferred taxes consist of the following as of
December 31:

2018 2017

Deferred tax assets:

Noncurrent:

Depreciation $
4,488
$
3,251

Inventory
6,991

6,950

Compensation accruals
60,905

50,436

Accruals and reserves
77,777

64,732

Charitable contribution carryover
3,972

4,068

Derivatives
57,276

-

Related party investments
481,652

-

Intangibles
2,020

-

NQSO compensation
1,019,139

766,648

NOL and credits
9,655,388

7,479,505

Total deferred tax assets
11,369,608

8,375,590

Deferred tax liabilities:

Noncurrent:

Original issue discount
(216,891
)
-

Total deferred tax liabilities
(216,891
)
-

Net deferred tax assets
11,152,717

8,375,590

Less: valuation allowance
(11,152,717
)
(8,375,590
)

Total $
-
$
-

The Company has determined, based upon its history, that it is probable that future taxable income
may
be insufficient to fully realize the benefits of the net operating loss carryforwards and other deferred tax assets. As such, the Company has determined that a full valuation allowance is warranted. Future events and changes in circumstances could cause this valuation allowance to change.

During
December 2013,
the Company experienced an "ownership change" as defined in Section
382
of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The Company
may
have experienced additional “ownership change(s)” since
December 2013,
but a formal study has
not
yet been performed. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

At
December 31, 2017,
the Company had approximately
$34,529,255
of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in
2018,
subject to the Section
382
limitation described above. The federal NOLs will expire beginning in
2022
if unused. The Company also had approximately
$12,261,799
of gross NOLs to reduce future state taxable income at
December 31, 2017.
The state NOL’s will expire beginning in
2022
if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At
December 31, 2017,
the federal and state valuation allowances were
$8,129,778
and
$245,812,
respectively.

At
December 31, 2018,
the Company had approximately
$40,094,472
of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in
2019,
subject to the Section
382
limitation described above. The federal NOLs will expire beginning in
2022
if unused. The Company also had approximately
$12,940,458
of gross NOLs to reduce future state taxable income at
December 31, 2018.
The state NOL’s will expire beginning in
2022
if unused. The Company also had approximately
$421,782
in gross foreign NOLs to reduce future Belgian taxable income at
December 31, 2018.
The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At
December 31, 2018,
the federal, state and foreign valuation allowances were
$9,603,237,

$1,416,758
and
$132,722,
respectively.

Tax years subsequent to
2014
remain open to examination by federal and state tax authorities. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than
not
that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified
no
income tax uncertainties.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At
December 31, 2018
and
2017,
the Company recorded
no

accrued interest or penalties related to uncertain tax positions.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R16.htm IDEA: XBRL DOCUMENT v3.19.1

Note 9 - Rent Obligation
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Leases of Lessee Disclosure [Text Block]
NOTE
9–
RENT OBLIGATION

Precision’s corporate offices are located at
2915
Commers Drive, Suite
900,
Eagan, Minnesota
55121.
   On
November 22, 2017,
the Company signed a
second
amendment to its lease last amended on
January 28, 2013.
The lease as amended has a
three
-year term effective
February 1, 2018
ending
January 31, 2021.
The Company leases
5,773
square feet at this location, of which
2,945
square feet is used for office space and
2,828
is used for manufacturing. The Company expects that this space will be adequate for our current office and manufacturing needs.

Skyline Medical Europe’s offices are located at
9
Chemin de la Fraite –
1380
Ohain, Belgium. The lease agreement was signed
April 24, 2018
and started on
June 15, 2018.
The Company leases around
2,000
square feet at this location,
300
of which is used for storage and
1,250
for office space. The lease is effective through
June 14, 2027.
We expect that this space will be adequate for our current office and storage needs. Rent expense is
3,000
Euros Per month.

Rent expense was
$69,013
and
$66,122
for
2018
and
2017,
respectively.

The Company’s rent obligation for the next
five
years are as follows:

2019 $
80,320

2020
82,320

2021
43,320

2022
40,320

2023
40,320

Thereafter

161,280

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.19.1

Note 10 - Related Party Transactions
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]
NOTE
10
- RELATED PARTY TRANSACTIONS

The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company
may
be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements.

One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been
no
revenue or expenses generated by this partnership to date.

Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis the
100%
wholly-owned subsidiary of the Company. Mr. Gabriel receives
$12,000
per month pursuant to a renewable
six
-month contract. The contract extends to
March 31, 2019.

On
November 30, 2018,
our CEO, Carl Schwartz, made an investment of
$370,000
in the Company and received a note and a common stock purchase warrant for
221,292
warrant shares at
$0.836
per share. Effective as of
January 8, 2019,
Dr. Schwartz made an additional investment of
$950,000
and received an amended and restated note in the original principal amount of
$1,320,000
and an amended and restated warrant, which added a
second
tranche of
742,188
warrant shares at an exercise price of
$0.704.
Each tranche is exercisable beginning on the
sixth
month anniversary of the date of the related investment through the
fifth
-year anniversary of the date of the related investment. On
January 8, 2019,
Dr. Schwartz also purchased
78,125
shares of the Company’s common stock in a private investment for
$50,000,
representing a price of
$0.64
per share, pursuant to a subscription agreement. On
February 6, 2019,
Dr. Schwartz made an additional investment of
$300,000
in the Company and received an amended and restated note in the original principal amount of
$1,620,000
and an amended and restated warrant, which added a
third
tranche of
138,889
warrant shares at an exercise price of
$1.188
per share. On
February 1, 2019
and the
first
day of each calendar month thereafter while the note and the warrant remain outstanding, a number of additional shares will be added to the
second
tranche and the
third
tranche equal to (
1
)
one
-half percent (
1/2%
) of the outstanding principal balance of the Note on such date, divided by (
2
) the closing price of the Company’s common stock on that date. The number of warrant shares will be subject to a share limit such that the total of (a) the
78,128
shares of common stock purchased by Dr. Schwartz on
January 8, 2019,
and (b) the total number of warrant shares (
1,108,596
warrant shares as of
February 6, 2019)
may
not
exceed
2,818,350
shares (equal to
19.9%
of the outstanding shares of common stock on
January 8, 2019).
If the
second
tranche and/or
third
tranche cannot be increased as required herein due to the share limit, then in lieu of any such increase, the Company shall pay to Dr. Schwartz a cash amount equal to
one
-half percent (
1/2%
) of the principal balance of the Schwartz note in lieu of such increase.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R18.htm IDEA: XBRL DOCUMENT v3.19.1

Note 11 - Retirement Savings Plans
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Pension and Other Postretirement Benefits Disclosure [Text Block]
NOTE
11
– RETIREMENT SAVINGS PLANS

The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section
401
(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal
2017,
and again in
2018,
the Company matched
100
%,
of the employee’s contribution up to
4.0
%
of their earnings. The employer contribution was
$51,647
and
$29,952
in
2018
and
2017,
respectively. There were
no

discretionary contributions to the plan in
2018
and
2017.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R19.htm IDEA: XBRL DOCUMENT v3.19.1

Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Accounting Changes and Error Corrections [Text Block]
NOTE
12
– CORRECTION OF IMMATERIAL MISSTATEMENT TO PRIOR PERIOD FINANCIAL STATEMENTS

During fiscal
2018,
the Company identified certain warrants issued in
2016
and
2017,
which were incorrectly recognized as expense in
2017
when the warrants vested. As a result, investors stock compensation expense and additional paid-in capital were overstated by
$2,150,097
for the year ended
December 31, 2017.

Also during fiscal
2018,
the Company identified that employee stock compensation expense was incorrectly recognized in
2017.
As a result, employee stock compensation expenses and additional paid-in capital were understated by
$406,522
for the year ended
December 31, 2017.

Lastly during fiscal
2018,
the Company identified that certain nonqualified stock options were excluded from the Company’s tax provision calculation in
2017.
As a result, deferred tax assets and the valuation allowance on these assets were understated by
$767,000
as of
December 31, 2017.

Based on an analysis of Accounting Standards Codification (“ASC”)
250
– “Accounting Changes and Error Corrections” (ASC
250”
), Staff Accounting Bulletin
99
– “Materiality” (“SAB
99”
) and Staff Accounting Bulletin
108
– Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (“SAB
108”
), the Company determined that these costs were immaterial to the previously-issued financial statements. The Company analyzed and considered all relevant quantitative and qualitative factors and determined that the prior fiscal year financial statements should be corrected, even though such revision previously was and continues to be immaterial to the prior year financial statements. Management also determined that such correction to prior fiscal year financial statement for immaterial misstatements would
not
require previously filed reports to be amended and that such corrections
may
be made the next time the Company files the prior year financial statements.

Accordingly, the Company restated its presentation of general and administrative, sales and marketing, and operating expenses as well as retained earnings and additional paid-in capital in the consolidated financial statements for the year ended
December 31, 2018
to reflect such corrections as if they had been recorded in the appropriate fiscal period as of
December 31, 2017.
Specifically, the adjustments were reflected and corrected in the last quarter of
2017
for the period ended
December 31, 2017,
by reducing investors stock compensation expense under general and administrative expenses and reducing additional paid-in capital by
$
2,150,097
;
and, by increasing employee stock compensation expenses under general and administrative, selling and operating expense and increasing additional paid-in capital by a total of
$
406,522

on the comparative balance sheet for the period ended
December 31, 2017.
In addition, the Company restated Note
4
– Stockholders’ Equity (Deficit), Stock Options and Warrants, and Note
8
– Income Taxes, to reflect the impact of these restatements on the footnote disclosures as of and for the year ended
December 31, 2017.

X

- Definition
The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.19.1

Note 13 - Subsequent Events
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Subsequent Events [Text Block]
NOTE
13
– SUBSEQUENT EVENTS

Registered Offering of Common Stock and Warrants

On
February 27, 2019,
Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold
1,385,000
shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to
692,500
shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of
one
share of Common Stock and a warrant to purchase
0.5
of a share of the Company’s Common Stock at an exercise price of
$1.00
per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the
fifth
anniversary of issuance.

The Units were sold at a price of
$0.90
per Unit, resulting in gross proceeds to the Company of approximately
$1.25
million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately
$1.08
million.

The closing of the Offering occurred on
March 1, 2019.

Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to
8%
of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to
$30,000,
and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of
$5,000.
The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature.

Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of
March 1, 2019 (
the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of
69,250
Units (which represents
5%
of the Units sold to investors in the offering) at an exercise price equal to
125%
of the public offering price of the Units in the offering, or
$1.125
per Unit. The Unit Purchase Options shall expire on
February 27, 2024.

On
March 12, 2019,
Peak One,
one
of the noteholders from the bridge loan, converted
71,046
shares of stock reducing the principal of the loan by
$44,475.
The value was computed, pursuant to the agreement, by calculating the average VWAP for the prior
20
days and multiplying that average by
70%.

Dr. Carl Schwartz, the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional
$1,300,000,
see Note
10
– Related party Transactions.

The Company entered into a forbearance agreement with
L2
Capital, LLC and Peak One Opportunity Fund, LP. AS part of the agreement the Company added
15%
to the principal of the note and issued inducement shares of common stock. The Company accrued approximately
$503,000
in penalty expenses as a result as of
December 31, 2018.
This penalty expense is recorded in accrued expenses on the balance sheet.

On
March 26, 2019,
Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold
1,478,750
shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to
739,375
shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of
one
share of Common Stock and a warrant to purchase
0.5
of a share of the Company’s Common Stock at an exercise price of
$1.00
per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the
fifth
anniversary of issuance.

The Units were sold at a price of
$0.80
per Unit, resulting in gross proceeds to the Company of approximately
$1.18
million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately
$1.05
million.

The closing of the Offering occurred on
March 29, 2019.

Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to
8%
of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to
$30,000,
and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of
$5,000.
The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature.

Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of
March 29, 2019 (
the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of
73,938
Units (which represents
5%
of the Units sold to investors in the offering) at an exercise price equal to
125%
of the public offering price of the Units in the offering, or
$1.00
per Unit. The Unit Purchase Options shall expire on
March 29, 2024.

The securities in the Offerings were offered and sold pursuant to the Company’s “shelf” registration statement (File
No.

333
-
213766
), which was declared effective by the United States Securities and Exchange Commission on
October 4, 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v3.19.1

Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]
Nature of Operations and Continuance of Operations

The Company was originally incorporated on
April 23, 2002
in Minnesota as BioDrain Medical, Inc. Effective
August 6, 2013,
the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective
December 16, 2013,
the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On
August 31, 2015,
the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On
February 1, 2018,
the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change the Company’s corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective
February 1, 2018.
Because of this change, the Company’s common stock began trading under the new ticker symbol “AIPT,” effective
February 2, 2018.
Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of
December 31, 2018,
the registrant had
14,091,748
shares of common stock, par value
$.01
per share, outstanding. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of its proprietary cleaning fluid and filters to users of the STREAMWAY systems. In
April 2009,
the Company received
510
(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired
25%
of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the
first
quarter of
2018,
and in
April 2018
the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In
June 2018,
the Company and Helomics entered into a definitive merger agreement – see Note
4.
The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over
149,000
tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis, formed during the
first
quarter, is presented as part of the consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of
$63,107,945.
The Company does
not
expect to generate sufficient operating revenue to sustain its operations in the near-term. In
2018,
the Company incurred negative operating cash flows of approximately
$441,000
per month. Although the Company has attempted to curtail expenses, there is
no
guarantee that the Company will be able to reduce these expenses significantly, and expenses
may
need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of
$162,152
as of
December 31, 2018
and needs to raise significant additional capital to meet its operating needs, pay debt obligations coming due, and the continued operating needs of Helomics, therefore there is substantial doubt about the Company’s ability to continue as a going concern for
one
year after the date that the financial statements are issued. The financial statements do
not
include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-
3,
with which the Company has raised approximately
$2.1
million in net proceeds in early
2019.
The Company
may
raise up to approximately
$1.7
million in additional gross proceeds in the next calendar year using the shelf registration statement. This amount of available financing will increase to approximately
$6.4
million in additional gross proceeds, once the Helomics acquisition is completed.



Since inception to
December 31, 2018,
the Company raised approximately
$36,490,000
in equity and
$7,870,000
in debt financing. Equity raises include: a
January 2017
public offering of units with gross proceeds to the Company of
$3,937,500;
a
November 2017
private placement with gross proceeds of
$1,300,000;
and, a
January 2018
public offering with gross proceeds of
$2,755,000.
Included in debt financing were raises in
September 2018
on senior secured promissory notes with net proceeds of
$1,815,000,
and in
November 2018
the Company received a loan from the CEO for
$370,000.
Subsequent to
December 31, 2018,
the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional
$1,300,000.

The Company has
no
commitments or contingencies.

New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Developments

Accounting Policies and Estimates

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

In
May 2014,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.

2014
-
09,

Revenue from Contracts with Customers (Topic
606
),
which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on
January 1, 2018
using the modified retrospective method applied to those contracts which were
not
completed as of
December 31, 2017.
Results for reporting periods beginning
January
1,

2018
are presented under Topic
606,
while prior-period amounts have
not
been retrospectively adjusted and continue to be reported in accordance with Topic
605,

Revenue Recognition
. Based upon the Company’s contracts which were
not
completed as of
December 31, 2017,
the Company was
not
required to make an adjustment to the opening balance of retained earnings as of
January 1, 2018,
and there was
no
material impact. See Note
3
for further discussion.

In
January 2016,
the FASB issued ASU
No.

2016
-
01,

Financial Instruments-Overall (Subtopic
825
-
10
): Recognition and Measurement of Financial Assets and Financial Liabilities
(“ASU
2016
-
01”
). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do
not
result in consolidation and are
not
accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of
January 1, 2018.
As of
December 31, 2018,
there is
no
material impact on the Company’s financial statements and disclosures.

In
February 2016,
the FASB issued ASU
No.

2016
-
02,
“
Leases (Topic
842
)
” (“ASU
2016
-
02”
), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after
December 15, 2018.
Early adoption is permitted. The Company adopted ASU
2016
-
02
on
January 1, 2019,
using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The adoption resulted in
no
material impact to the Company’s balance sheet, results of operations, equity or cash flows.

In
August 2016,
the FASB issued ASU
No.

2016
-
15,

Statement of Cash Flows (Topic
230
): Classification of Certain Cash Receipts and Cash Payments,
to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for public business entities for fiscal years beginning after
December 15, 2017,
and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company adopted the standard as of
January 1, 2018.
As of
December 31, 2018,
there is
no
material impact on the Company’s financial statements and disclosures.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]
Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment in accordance with ASC
360
— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount
may
not
be recoverable. The Company’s intangible assets are definite lived and currently solely the costs of obtaining licensing fees, trademarks, and patents. Events or changes in circumstances that indicate the carrying amount
may
not
be recoverable include, but are
not
limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Advertising Costs, Policy [Policy Text Block]
Advertising

Advertising costs are expensed as incurred. Advertising expenses were
$43,548
in
2018
and
$37,060
in
2017.

Research and Development Expense, Policy [Policy Text Block]
Research and Development

Research and development costs are charged to operations as incurred.  Research and development costs were approximately
$526,000
and
$289,000
for
2018
and
2017,
respectively.

Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition

The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases.

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses.

Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company
may,
at its discretion, negotiate different shipping terms with customers which
may
affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally
30
to
60
days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers
may
also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of
one
year subsequent to the
one
-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the
one
-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do
not
contain any features that create variability in the amount or timing of revenue to be earned.

Cash and Cash Equivalents, Policy [Policy Text Block]
Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of
three
months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit Policy [Policy Text Block]
Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than
one
year but greater than
three
months when purchased. Certificates with maturity dates beyond
one
year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s
Accounting Standards Certification
(ASC)
820,
fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC
820
establishes a
three
-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level
1
– Observable inputs such as quoted prices in active markets;

Level
2
– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level
3
– Unobservable inputs where there is little or
no
market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities, which in
2018
are cash equivalents only, were determined based on Level
1
inputs.

Receivables, Policy [Policy Text Block]
Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts. Changes to the valuation allowance have
not
been material to the financial statements.

Inventory, Policy [Policy Text Block]
Inventories

Inventories are stated at the net realizable value, with cost determined on a
first
-in,
first
-out basis. Inventory balances are as follows:

December 31,
2018 December 31,
2017

Finished goods $
58,701
$
62,932

Raw materials
127,003

141,028

Work-In-Process
55,362

61,085

Total $
241,066
$
265,045

Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation is shown in the financial statements under fixed assets, net on the balance sheet, and amortization is shown under intangibles, net on the balance sheet. Estimated useful asset life by classification is as follows:

Years

Computers and office equipment

3

-

7

Leasehold improvements

5

Manufacturing Tooling

3

-

7

Demo Equipment

3

The Company’s investment in fixed assets consists of the following:

December 31,
2018 December 31,
2017

Computers and office equipment $
204,903
$
183,528

Leasehold Improvements
140,114

25,635

Manufacturing Tooling
108,955

108,955

Demo Equipment
85,246

43,368

Total
539,218

361,486

Less: Accumulated Depreciation
358,765

273,770

Total Fixed Assets, Net $
180,453
$
87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was
$84,995
in
2018
and
$58,872
in
2017.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Intangible Assets

The components of intangible assets all of which are finite-lived were as follows:

12/31/2018 12/31/2017

Gross Carrying
Costs Accumulated
Amortization Net Carrying
Amount Gross Carrying
Costs Accumulated
Amortization Net Carrying
Amount

Patents & Trademarks $
318,304
$
(182,559
) $
135,745
$
264,032
$
(168,676
) $
95,356

Licensing Fees
877,500

(48,750
)
828,750

-

-

-

Total $
1,195,804
$
(231,309
) $
964,495
$
264,032
$
(168,676
) $
95,356

The following table outlines the estimated future amortization expense related to intangible assets held as of
December 31, 2018

Year ending Expense

2019
72,383

2020
72,383

2021
72,383

2022
72,383

2023
72,383

Thereafter
602,580

Total
964,495

Intangible assets consist of trademarks, patent costs and licensing fees. Amortization expense was
$62,633
in
2018
and
$12,689
in
2017.
The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Tax, Policy [Policy Text Block]
Income Taxes

On
December 22, 2017,
the Tax Cuts and Jobs Act of
2017
(Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate income tax rates from
34%
to
21%.
As a result of the enacted law, the Company was required to value its deferred tax assets and liabilities at the new enacted rate. There was
no
income tax impact from the re-measurement due to the
100%
valuation allowance on the Company’s deferred tax assets.

The Company accounts for income taxes in accordance with ASC
740
-
Income Taxes
(“ASC
740”
). Under ASC
740,
deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than
not
that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified
no
income tax uncertainties.

Offering Costs [Policy Text Block]
Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Concentration Risk, Credit Risk, Policy [Policy Text Block]
Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any
one
financial institution. The Company has
no
credit risk concentration because there are
no
funds in excess of insurance limits in a single bank.

Standard Product Warranty, Policy [Policy Text Block]
Product Warranty Costs

In
2018
and in
2017,
the Company incurred approximately
$10,682
and
$6,209,
respectively in warranty costs.

Segment Reporting, Policy [Policy Text Block]
Segments

The Company operates in
two
segments for the sale of its medical device and consumable products. These segments are its domestic operations and international operations. Substantially all the Company’s assets, revenues, and expenses for the years ended
December 31, 2018
and
2017
were located at or derived from operations in the United States. In
2018
and
2017,
business activity within the Company’s international segment was immaterial.

Risks and Uncertainties Policy [Policy Text Block]
Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but
not
limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

X

- Definition
Disclosure of accounting policy for certificates of deposit common to companies in the medical device industry.
+ References
No definition available.
+ Details

Name: aipt_CertificatesOfDepositPolicyPolicyTextBlock

Namespace Prefix: aipt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The accounting policy of offering costs related to securities financing transactions.
+ References
No definition available.
+ Details

Name: aipt_OfferingCostsPolicyTextBlock

Namespace Prefix: aipt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for risks and uncertainties common to companies in the medical device industry.
+ References
No definition available.
+ Details

Name: aipt_RisksAndUncertaintiesPolicyPolicyTextBlock

Namespace Prefix: aipt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84159346&loc=d3e8275-108329

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 20
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68054294&loc=d3e8384-108330
+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
No definition available.
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e4975-111524

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_StandardProductWarrantyPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R22.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

December 31,
2018 December 31,
2017

Finished goods $
58,701
$
62,932

Raw materials
127,003

141,028

Work-In-Process
55,362

61,085

Total $
241,066
$
265,045

Property Plant and Equipment Useful Life [Table Text Block]

Years

Computers and office equipment

3

-

7

Leasehold improvements

5

Manufacturing Tooling

3

-

7

Demo Equipment

3

Property, Plant and Equipment [Table Text Block]

December 31,
2018 December 31,
2017

Computers and office equipment $
204,903
$
183,528

Leasehold Improvements
140,114

25,635

Manufacturing Tooling
108,955

108,955

Demo Equipment
85,246

43,368

Total
539,218

361,486

Less: Accumulated Depreciation
358,765

273,770

Total Fixed Assets, Net $
180,453
$
87,716

Schedule of Finite-Lived Intangible Assets [Table Text Block]

12/31/2018 12/31/2017

Gross Carrying
Costs Accumulated
Amortization Net Carrying
Amount Gross Carrying
Costs Accumulated
Amortization Net Carrying
Amount

Patents & Trademarks $
318,304
$
(182,559
) $
135,745
$
264,032
$
(168,676
) $
95,356

Licensing Fees
877,500

(48,750
)
828,750

-

-

-

Total $
1,195,804
$
(231,309
) $
964,495
$
264,032
$
(168,676
) $
95,356

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year ending Expense

2019
72,383

2020
72,383

2021
72,383

2022
72,383

2023
72,383

Thereafter
602,580

Total
964,495

X

- Definition
Represents the schedule of property, plant and equipment useful life.
+ References
No definition available.
+ Details

Name: aipt_PropertyPlantAndEquipmentUsefulLifeTableTextBlock

Namespace Prefix: aipt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R23.htm IDEA: XBRL DOCUMENT v3.19.1

Note 2 - Equity Method Investment (Tables)
12 Months Ended

Dec. 31, 2018

Notes Tables

Equity Method Investments [Table Text Block]

December 31, 2018

Current assets $
419,266

Non-current assets $
2,046,347

Total assets $
2,465,613

Current liabilities $
12,247,174

Total liabilities $
12,247,174

For the Year-ended Ended

December 31, 2018

Revenue $
523,546

Gross margin $
214,426

Net loss on operations $
(5,056,725

)

Net loss $
(9,452,835

)

Net Loss to investee $
(7,159,255

)
1

X

- Definition
Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R24.htm IDEA: XBRL DOCUMENT v3.19.1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)
12 Months Ended

Dec. 31, 2018

Notes Tables

Share-based Compensation, Activity [Table Text Block]

Stock Options Warrants

Number of
Shares Average
Exercise
Price Number of
Shares Average
Exercise
Price

Outstanding at December 31, 2016
165,643
$
11.22

871,101
$
52.22

Issued
2,612,070

1.45

1,082,946

1.49

Expired
(12,730
)
10.39

(2,790
)
281.46

Exercised
-

-

-

-

Outstanding at December 31, 2017
2,764,983
$
2.00

1,951,257
$
23.74

Issued
1,098,858

1.01

2,336,154

1.07

Expired
(194,564
)
2.00

(10,706
)
199.55

Exercised
-

-

(650,062
)
1.00

Outstanding at December 31, 2018
3,669,277
$
1.70

3,626,643
$
4.17

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Exercise Prices Shares Weighted
Average
Remaining
Life

Options:

$0.619
201,908

10.00

$0.82
60,000

9.91

$0.91
10,000

9.30

$0.965
3,000

9.38

$0.97
191,753

9.02

$1.01
149,110

9.12

$1.06
23,585

9.76

$1.10
86,958

9.46

$1.13
195,931

9.55

$1.15
21,740

9.59

$1.16
66,451

9.59

$1.18
30,000

9.61

$1.20
41,668

9.59

$1.21
30,000

9.61

$1.35
111,112

9.20

$1.454
17,200

8.75

$1.47
2,305,790

8.48

$2.10
14,286

8.25

$2.25
293

7.65

$2.42
20,640

7.64

$2.80
57,145

8.01

$3.75
4,000

7.50

$4.125
3,636

7.75

$4.1975
7,147

7.72

$4.25
3,529

7.25

$5.125
3,902

7.69

$65.75
190

6.81

$73.50
1,157

7.01

$77.50
2,323

6.50

$80.25
187

6.75

$86.25
232

6.25

$131.25
81

3.69

$148.125
928

4.21

$150.00
1,760

3.63

$162.50
123

6.01

$206.25
121

5.75

$248.4375
121

4.54

$262.50
130

4.54

$281.25
529

4.04

$318.75
3

4.35

$346.875
72

5.25

$431.25
306

5.19

$506.25
188

5.00

$596.25
42

4.75

Total
3,669,277

Warrants:

$0.836
221,292

4.92

$1.00
1,063,935

3.76

$1.07
697,946

3.85

$1.155
1,071,776

4.75

$1.3125
86,086

4.75

$2.25
385,000

3.06

$123.75
94,084

1.67

$243.75
2,529

0.59

$309.375
2,850

0.61

$309.50
222

0.85

$506.25
59

0.12

$609.375
862

0.09

Total
3,626,643

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Year

Shares

Price

2011

173

281.25

2012

1,841

131.25

–

150.00

2013

1,553

148.13

–

596.25

2014

836

162.50

–

431.25

2015

4,088

65.75

–

86.25

2016

100,294

2.25

–

5.13

2017

2,461,634

1.01

–

2.10

2018

1,098,858

0.62

–

1.35

Total

3,669,277

$0.62

–

596.25

Year

Shares

Price

2014

6,455

243.75

–

609.38

2015

94,151

0.00

–

243.75

2016

252,333

1.00

2017

1,082,946

1.07

–

2.25

2018

2,190,758

0.84

–

1.3125

Total

3,626,643

$0.00

–

609.38

X

- Definition
Tabular disclosure of option and warrant exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
No definition available.
+ Details

Name: aipt_ScheduleOfSharebasedCompensationSharesAuthorizedUnderStockOptionAndWarrantPlansByExercisePriceRangeTableTextBlock

Namespace Prefix: aipt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R25.htm IDEA: XBRL DOCUMENT v3.19.1

Note 7 - Loss Per Share (Tables)
12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Year Ended
December 31,

2018 2017

Numerator:

Net loss available in basic and diluted $
(10,086,477
) $
(6,003,017
)

Denominator:

Weighted average common shares outstanding-basic
12,816,289

6,362,989

Effect of dilutive stock options warrants and preferred stock (1)
-

-

Weighted average common shares outstanding-diluted
12,816,289

6,362,989

Loss per common share-basic and diluted $
(0.79
) $
(0.94
)

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R26.htm IDEA: XBRL DOCUMENT v3.19.1

Note 8 - Income Taxes (Tables)
12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

2018 2017

Statutory federal income tax benefit $
2,118,160
$
2,633,841

State tax benefit, net of federal taxes
66,117

76,922

Foreign tax benefit
132,931

-

Foreign operations tax rate differential
(94,373
)
-

State rate adjustment
15,355

(77,556
)

R&D tax credit
22,532

-

Nondeductible/nontaxable items
(118,905
)
(757,149
)

State NOL adjustment
746,479

-

OID and derivatives
(159,037
)
-

NQSO adjustment
-

537,884

New federal rate adjustment
-

(4,974,121
)

Other
47,868

(8,336
)

Valuation allowance decrease (increase)
(2,777,127
)
2,568,515

Total income tax benefit (expense) $
-
$
-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

2018 2017

Deferred tax assets:

Noncurrent:

Depreciation $
4,488
$
3,251

Inventory
6,991

6,950

Compensation accruals
60,905

50,436

Accruals and reserves
77,777

64,732

Charitable contribution carryover
3,972

4,068

Derivatives
57,276

-

Related party investments
481,652

-

Intangibles
2,020

-

NQSO compensation
1,019,139

766,648

NOL and credits
9,655,388

7,479,505

Total deferred tax assets
11,369,608

8,375,590

Deferred tax liabilities:

Noncurrent:

Original issue discount
(216,891
)
-

Total deferred tax liabilities
(216,891
)
-

Net deferred tax assets
11,152,717

8,375,590

Less: valuation allowance
(11,152,717
)
(8,375,590
)

Total $
-
$
-

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R27.htm IDEA: XBRL DOCUMENT v3.19.1

Note 9 - Rent Obligation (Tables)
12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Rent Expense [Table Text Block]

2019 $
80,320

2020
82,320

2021
43,320

2022
40,320

2023
40,320

Thereafter

161,280

X

- Definition
Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_ScheduleOfRentExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R28.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies (Details Textual)
1 Months Ended 3 Months Ended 12 Months Ended 202 Months Ended

Mar. 12, 2019

USD ($)

Feb. 06, 2019

USD ($)

Jan. 08, 2019

USD ($)

Mar. 31, 2019

USD ($)

Dec. 31, 2018

USD ($)

$ / shares

shares

Nov. 30, 2018

USD ($)

Sep. 30, 2018

USD ($)

Jan. 31, 2018

USD ($)

Nov. 30, 2017

USD ($)

Jan. 31, 2017

USD ($)

Mar. 31, 2019

USD ($)

Dec. 31, 2018

USD ($)

$ / shares

shares

Dec. 31, 2017

USD ($)

$ / shares

shares

Dec. 31, 2018

USD ($)

$ / shares

shares

Mar. 22, 2019

$ / shares

Jul. 11, 2018

$ / shares

Jul. 10, 2018

$ / shares

Mar. 31, 2018

Feb. 21, 2018

$ / shares

Dec. 28, 2017

$ / shares

Apr. 19, 2017

$ / shares

Common Stock, Shares, Outstanding, Ending Balance | shares 14,091,748 14,091,748 6,943,283 14,091,748

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01

Retained Earnings (Accumulated Deficit), Ending Balance $ (63,107,945) $ (63,107,945) $ (53,021,469) $ (63,107,945)

Net Cash Provided by (Used in) Operating Activities, Per Month 441,000

Cash and Cash Equivalents, at Carrying Value, Ending Balance 162,152 162,152 766,189 162,152

Stockholders' Equity, Period Increase (Decrease), Total 36,490,000

Debt Instrument, Increase (Decrease), Net, Total 7,870,000

Advertising Expense 43,548 37,060

Research and Development Expense, Total $ 526,000 289,000

Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice 1 year

Depreciation, Total $ 84,995 58,872

Amortization of Intangible Assets, Total 62,633 12,689

Unrecognized Tax Benefits, Ending Balance 0 0 0

Cash, Uninsured Amount 0 0 $ 0

Product Warranty Expense $ 10,682 $ 6,209

Number of Operating Segments 2

Maintenance [Member]

Revenue, Performance Obligation, Timing 1 year

Minimum [Member]

Standard Payment Term for Customers 30 days

Maximum [Member]

Standard Payment Term for Customers 60 days

Chief Executive Officer [Member]

Proceeds from Related Party Debt $ 370,000 $ 370,000

Convertible Promissory Note [Member]

Proceeds from Debt, Net of Issuance Costs $ 1,815,000

Subsequent Event [Member]

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.01

Subsequent Event [Member] | Chief Executive Officer [Member]

Proceeds from Related Party Debt $ 1,300,000 $ 300,000 $ 950,000 $ 1,300,000

Shelf Registration [Member] | Subsequent Event [Member]

Proceeds from Issuance or Sale of Equity, Total $ 1,100,000 2,100,000

Additional Gross Proceeds From Sale of Equity, Available to Raise $ 1,700,000 1,700,000

Stock Issuance Plan, Additional Available Amount $ 6,400,000

IPO [Member]

Proceeds from Issuance or Sale of Equity, Total $ 3,937,500

Private Placement [Member] | Series C Convertible Preferred Stock [Member]

Proceeds from Issuance or Sale of Equity, Total $ 1,300,000

The 2018 Public Offering [Member]

Proceeds from Issuance or Sale of Equity, Total $ 2,755,000

Helomics Holding Corp. [Member]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage 25.00%

X

- Definition
The remaining amount of gross proceeds from sale of equity available to raise.
+ References
No definition available.
+ Details

Name: aipt_AdditionalGrossProceedsFromSaleOfEquityAvailableToRaise

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the service requirement under the company's maintenance plan, expressed as a period of time subsequent to the one-year anniversary of the invoice.
+ References
No definition available.
+ Details

Name: aipt_MaintenancePlanServiceRequirementPeriodSubsequentToOneYearAnniversaryOfInvoice

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities per month, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
No definition available.
+ Details

Name: aipt_NetCashProvidedByUsedInOperatingActivitiesPerMonth

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of recognition for revenue performance obligation.
+ References
No definition available.
+ Details

Name: aipt_RevenuePerformanceObligationTiming

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the standard payment term for customers, in general.
+ References
No definition available.
+ Details

Name: aipt_StandardPaymentTermForCustomers

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The additional amount available for purchase in the stock issuance plan of the company.
+ References
No definition available.
+ Details

Name: aipt_StockIssuancePlanAdditionalAvailableAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Net increase or decrease in the carrying amount of the debt instrument for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph ((c)(3,4))
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249
+ Details

Name: us-gaap_ProductWarrantyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The increase (decrease) in stockholders' equity during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockholdersEquityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_MaintenanceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=aipt_ConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_ShelfRegistrationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=aipt_SeriesCConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_The2018PublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R29.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Finished goods $ 58,701 $ 62,932

Raw materials 127,003 141,028

Work-In-Process 55,362 61,085

Total $ 241,066 $ 265,045

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 48 R30.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)
12 Months Ended

Dec. 31, 2018

Leasehold Improvements [Member]

Property, plant, and equipment, useful life (Year) 5 years

Demo Equipment [Member]

Property, plant, and equipment, useful life (Year) 3 years

Minimum [Member] | Office Equipment [Member]

Property, plant, and equipment, useful life (Year) 3 years

Minimum [Member] | Manufacturing Tooling [Member]

Property, plant, and equipment, useful life (Year) 3 years

Maximum [Member] | Office Equipment [Member]

Property, plant, and equipment, useful life (Year) 7 years

Maximum [Member] | Manufacturing Tooling [Member]

Property, plant, and equipment, useful life (Year) 7 years

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aipt_DemoEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aipt_ManufacturingToolingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R31.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Property, Plant, and Equipment Gross $ 539,218 $ 361,486

Less: Accumulated Depreciation 358,765 273,770

Total Fixed Assets, Net 180,453 87,716

Office Equipment [Member]

Property, Plant, and Equipment Gross 204,903 183,528

Leasehold Improvements [Member]

Property, Plant, and Equipment Gross 140,114 25,635

Manufacturing Tooling [Member]

Property, Plant, and Equipment Gross 108,955 108,955

Demo Equipment [Member]

Property, Plant, and Equipment Gross $ 85,246 $ 43,368

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aipt_ManufacturingToolingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aipt_DemoEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R32.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Gross Carrying Costs $ 1,195,804 $ 264,032

Accumulated Amortization (231,309) (168,676)

Net Carrying Amount 964,495 95,356

Patents and Trademarks [Member]

Gross Carrying Costs 318,304 264,032

Accumulated Amortization (182,559) (168,676)

Net Carrying Amount 135,745 95,356

Licensing Agreements [Member]

Gross Carrying Costs 877,500

Accumulated Amortization (48,750)

Net Carrying Amount $ 828,750

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aipt_PatentsAndTrademarksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R33.htm IDEA: XBRL DOCUMENT v3.19.1

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

2019 $ 72,383

2020 72,383

2021 72,383

2022 72,383

2023 72,383

Thereafter 602,580

Total $ 964,495 $ 95,356

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 52 R34.htm IDEA: XBRL DOCUMENT v3.19.1

Note 2 - Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($)
12 Months Ended

Dec. 31, 2018

Feb. 27, 2018

Equity Method Investment, Ownership Percentage 75.00% 80.00%

Equity Method Investment, Summarized Financial Information, Revenue $ 523,546

Financing Receivable, Net, Total 413,683

Financing Receivable, Gross 1,165,013

Fair Value Adjustment of Notes Receivable (751,330)

Equity Method Investments 0

Contract Research Organization and D-CHIP Artificial Intelligence Products [Member]

Equity Method Investment, Summarized Financial Information, Revenue $ 31,000

X

- Definition
the amount of fair value adjustment of notes receivable.
+ References
No definition available.
+ Details

Name: aipt_FairValueAdjustmentOfNotesReceivable

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of revenue from sale of goods and services reduced by sales returns, allowances, and discounts reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. Excludes amounts related to receivables held-for-sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesReceivableGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=aipt_ContractResearchOrganizationAndDchipArtificialIntelligenceProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R35.htm IDEA: XBRL DOCUMENT v3.19.1

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details)
12 Months Ended

Dec. 31, 2018

USD ($)

Gross margin $ (5,056,725)

Net loss (9,452,835)

Helomics Holding Corp. [Member]

Current assets 419,266

Non-current assets 2,046,347

Total assets 2,465,613

Current liabilities 12,247,174

Total liabilities 12,247,174

Revenue 523,546

Gross margin 214,426

Net Loss to investee $ (7,159,255) ^[1]

[1] The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the twelve-month period at the current equity investment percentage owned by the Company.

X

- Definition
The amount of assets reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current assets reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current liabilities reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of gross profit (loss) reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations reported by an equity method investee.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of liabilities reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of net income (loss) reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of noncurrent assets reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of revenue from sale of goods and services reduced by sales returns, allowances, and discounts reported by an equity method investment of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R36.htm IDEA: XBRL DOCUMENT v3.19.1

Note 3 - Revenue Recognition (Details Textual) - USD ($)
12 Months Ended

Dec. 31, 2018

Jan. 07, 2019

Dec. 31, 2017

Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice 1 year

Standard Product Warranty, Term 1 year

Accounts Receivable, Net, Current, Total $ 232,602 $ 232,602 $ 137,499

Contract with Customer, Liability, Current $ 23,065 $ 6,663

Maintenance [Member]

Revenue, Performance Obligation, Timing 1 year

Minimum [Member]

Standard Payment Term for Customers 30 days

Maximum [Member]

Standard Payment Term for Customers 60 days

X

- Definition
Represents the service requirement under the company's maintenance plan, expressed as a period of time subsequent to the one-year anniversary of the invoice.
+ References
No definition available.
+ Details

Name: aipt_MaintenancePlanServiceRequirementPeriodSubsequentToOneYearAnniversaryOfInvoice

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of recognition for revenue performance obligation.
+ References
No definition available.
+ Details

Name: aipt_RevenuePerformanceObligationTiming

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the standard payment term for customers, in general.
+ References
No definition available.
+ Details

Name: aipt_StandardPaymentTermForCustomers

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the term of the standard product warranty.
+ References
No definition available.
+ Details

Name: aipt_StandardProductWarrantyTerm

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_MaintenanceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R37.htm IDEA: XBRL DOCUMENT v3.19.1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual)
1 Months Ended 3 Months Ended 12 Months Ended

Oct. 26, 2018

USD ($)

$ / shares

shares

Jul. 11, 2018

$ / shares

shares

Jul. 10, 2018

$ / shares

shares

Mar. 12, 2018

$ / shares

shares

Feb. 21, 2018

USD ($)

$ / shares

shares

Jan. 15, 2018

$ / shares

shares

Jan. 11, 2018

USD ($)

shares

Nov. 30, 2017

USD ($)

$ / shares

shares

Apr. 19, 2017

$ / shares

shares

Jan. 19, 2017

USD ($)

$ / shares

shares

Dec. 31, 2018

USD ($)

$ / shares

shares

Jan. 31, 2018

USD ($)

$ / shares

shares

Mar. 31, 2018

USD ($)

shares

Dec. 31, 2017

USD ($)

$ / shares

shares

Dec. 31, 2018

USD ($)

$ / shares

shares

Dec. 31, 2017

USD ($)

$ / shares

shares

Mar. 22, 2019

$ / shares

shares

Jan. 02, 2018

shares

Dec. 28, 2017

$ / shares

shares

Jan. 29, 2017

shares

Oct. 27, 2016

shares

Shares Issued, Price Per Share | $ / shares $ 1.17 $ 1.18

Proceeds from Issuance of Convertible Preferred Stock | $ $ 1,300,001

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01

Stock Issued During Period, Shares, Issued for Services 250,000

Stock Issued During Period, Share, Issued in Escrow 750,000

Common Stock, Shares Authorized 50,000,000 50,000,000 50,000,000 50,000,000 50,000,000 24,000,000 8,000,000

Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares 400,000

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 2,946,488 2,946,488

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares $ 1.79 $ 1.79

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 8 years 313 days

Class of Warrant or Right Number of Warrants Vested and Exercisable 2,247,489 2,247,489

Allocated Share-based Compensation Expense, Total | $ $ 1,124,928 $ 2,298,680

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ $ 741,922 $ 741,922

Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $ $ 1,900,000

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 1.01 $ 1.45

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,098,858 2,612,070

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 1 year 240 days

Vice President of Sales [Member]

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.01

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 50,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares $ 0.97

Number of Equal Installments Options are Expected to Vest 4

Vice President of Sales and Marketing [Member]

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.01

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 111,112

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares $ 1.35

Number of Equal Installments Options are Expected to Vest 4

Maximum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 609.38 $ 609.38

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3.07% 2.40%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 66.00% 66.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 10 years 10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 1.0044 $ 1.5489

Minimum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0 $ 0

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 2.33% 1.92%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 59.00% 59.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 5 years 5 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 0.3816 $ 0.6541

Equity Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 3 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years

Equity Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 3 years

Stock Incentive Plan 2012 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 2,500,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 5,000,000

Subsequent Event [Member]

Common Stock, Par or Stated Value Per Share | $ / shares $ 0.01

Common Stock, Shares Authorized 100,000,000

Helomics Holding Corp. [Member]

Notes Payable, Total | $ $ 7,600,000

Helomics Holding Corp. [Member]

Convertible Preferred Stock Held, Conversion Feature, Percent 20.00%

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow 860,000

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period 1 year 180 days

Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger 75.00%

Business Acquisition, Warrant Exchange Ratio 0.6

Helomics Holding Corp. [Member] | Common Stock [Member]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 7,500,000 1,100,000

Helomics Holding Corp. [Member]

Stock Issued During Period, Shares, New Issues 1,100,000

Share Exchange Agreement, Shares Received 2,500,000

Share Exchange Agreement, Convertible Notes Receivable | $ $ 500,000

Share Exchange Agreement, Convertible Notes, Percent of Stock 5.00%

Share Exchange Agreement, Potential Interest 25.00%

Share Exchange Agreement, Number of Shares Held in Escrow 1,100,000

Share Exchange Agreement, Contingent Revenue, Minimum | $ $ 8,000,000

Convertible Preferred Stock Held, Conversion Feature, Percent 20.00%

Conversion from Series C Convertible Preferred Stock to Common Stock [Member]

Convertible Preferred Stock, Shares Issued upon Conversion 1.167 1.167

Conversion of Stock, Shares Issued 1,250,269

Series C Convertible Preferred Stock [Member]

Stock Redeemed or Called During Period, Shares 142,466

Payments for Repurchase of Convertible Preferred Stock | $ $ 189,285

Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 18,700,000

Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,000,000

Precision Warrants [Member] | Helomics Holding Corp. [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1

Business Acquisition, Warrant Issued or Issuable, Exercise Price | $ / shares $ 1

Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants 23,700,000

Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights 14,200,000

Helomics Warrants Held by Other Parties [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.01

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 597,000

Helomics Warrants Held by Other Parties [Member] | Helomics Holding Corp. [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.01

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 995,000

The 2017 Public Offering [Member]

Stock Issued During Period, Shares, New Issues 1,750,000

Shares Issued, Price Per Share | $ / shares $ 2.25

Share Per Each Unit 1

Proceeds from Issuance or Sale of Equity, Total | $ $ 3,937,500

The 2017 Public Offering [Member] | Series D Warrants [Member]

Class of Warrant or Right, Issued per Unit 0.2

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right 1

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 2.25

Over-Allotment Option [Member]

Stock Issued During Period, Shares, New Issues 215,247 175,000

Shares Issued, Price Per Share | $ / shares $ 0.9497

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.01

Proceeds from Issuance or Sale of Equity, Total | $ $ 358,312

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 35,000

Sale of Stock, Underwriter Option Term 45 days

Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase 290,000

Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase 87,000

Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares $ 0.001

Proceeds from Underwriter Shares Exercised, Net | $ $ 188,066

Stock Issued During Period, Underwriter Discount | $ $ 16,354

Underwriter Discount Percentage 8.00%

Private Placement [Member]

Proceeds from Issuance of Convertible Preferred Stock | $ $ 1,300,000

Private Placement [Member] | Series C Convertible Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues 1,213,819

Shares Issued, Price Per Share | $ / shares $ 1.071

Private Placement [Member] | The 2017 Private Placement Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.26

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 606,910

Warrants and Rights Outstanding, Term 5 years 182 days

Class of Warrant or Right, Vesting Period 180 days

The 2018 Public Offering [Member]

Stock Issued During Period, Shares, New Issues 2,900,000

Share Per Each Unit 1

Proceeds from Issuance or Sale of Equity, Total | $ $ 2,755,000

Share Price | $ / shares $ 0.95

The 2018 Public Offering [Member] | Series E Warrants [Member]

Class of Warrant or Right, Issued per Unit 0.3

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right 1

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1

X

- Definition
Number of shares of equity interests issued or issuable from exchange of acquiree's warrants.
+ References
No definition available.
+ Details

Name: aipt_BusinessAcquisitionEquityInterestIssuedOrIssuableFromExchangeOfWarrants

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity being held in escrow.
+ References
No definition available.
+ Details

Name: aipt_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesHeldInEscrow

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the period for number of shares of equity interests issued or issuable to acquire entity to be held in escrow.
+ References
No definition available.
+ Details

Name: aipt_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesHeldInEscrowPeriod

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Ratio applied to the exchange of acquiree's warrant for acquirer's warrant in a business acquisition.
+ References
No definition available.
+ Details

Name: aipt_BusinessAcquisitionWarrantExchangeRatio

Namespace Prefix: aipt_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price of warrant issued or issuable to acquire entity.
+ References
No definition available.
+ Details

Name: aipt_BusinessAcquisitionWarrantIssuedOrIssuableExercisePrice

Namespace Prefix: aipt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Additional number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightAdditionalNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents warrants issued per unit.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightIssuedPerUnit

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of warrants that are fully vested and exercisable at the balance sheet date.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightNumberOfWarrantsVestedAndExercisable

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The period in which a warrant vests.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightVestingPeriod

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of capital stock interests, upon the conversion of convertible preferred stock held by the company.
+ References
No definition available.
+ Details

Name: aipt_ConvertiblePreferredStockHeldConversionFeaturePercent

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equal installments in which options are expected to vest.
+ References
No definition available.
+ Details

Name: aipt_NumberOfEqualInstallmentsOptionsAreExpectedToVest

Namespace Prefix: aipt_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the minimum percentage of holders of acquiree's promissory note agreeing to the merger.
+ References
No definition available.
+ Details

Name: aipt_PercentageOfHoldersOfAcquireesPromissoryNoteAgreeingToMerger

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the exercise of underwriter shares, net of deductions.
+ References
No definition available.
+ Details

Name: aipt_ProceedsFromUnderwriterSharesExercisedNet

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the number of reverse shares issued for escrow during the period, pursuant to the termination of an agreement.
+ References
No definition available.
+ Details

Name: aipt_ReverseSharesIssuedForEscrowPursuantToTerminationOfAgreementShares

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the exercise price of additional warrants available for purchase.
+ References
No definition available.
+ Details

Name: aipt_SaleOfStockUnderwriterOptionExercisePriceOfAdditionalWarrantsAvailableForPurchase

Namespace Prefix: aipt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents additional shares of common stock available for purchase under underwriter option.
+ References
No definition available.
+ Details

Name: aipt_SaleOfStockUnderwriterOptionMaximumAdditionalSharesOfCommonStockAvailableForPurchase

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents mumber of securities called by maximum additional warrants available for purchase under underwriter option.
+ References
No definition available.
+ Details

Name: aipt_SaleOfStockUnderwriterOptionNumberOfSecuritiesCalledByMaximumAdditionalWarrantsAvailableForPurchase

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents information about term of underwriter option.
+ References
No definition available.
+ Details

Name: aipt_SaleOfStockUnderwriterOptionTerm

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum amount of revenue to be achieved by the counterparty of the share exchange agreement, in order for the issuance of common stock to be fulfilled.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementContingentRevenueMinimum

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the percentage of outstanding common stock to be received upon the conversion of outstanding notes receivable.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementConvertibleNotesPercentOfStock

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the amount of outstanding notes receivable that are electable to be converted into outstanding shares of the holders common stock.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementConvertibleNotesReceivable

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the number of shares held in escrow under a share exchange agreement.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementNumberOfSharesHeldInEscrow

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the potential holding interest of outstanding common stock, upon the election of converting outstanding notes receivable into common stock.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementPotentialInterest

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the number of shares received in a share exchange agreement.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementSharesReceived

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the shares per each unit.
+ References
No definition available.
+ Details

Name: aipt_SharePerEachUnit

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of stock issued in escrow pursuant to a contract.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodShareIssuedInEscrow

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the discount on underwriter shares exercised.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodUnderwriterDiscount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the discount on underwriter shares exercised.
+ References
No definition available.
+ Details

Name: aipt_UnderwriterDiscountPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
An excess of the fair value of the modified award over the fair value of the award immediately before the modification.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of stock bought back by the entity at the exercise price or redemption price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=aipt_VicePresidentOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=aipt_VicePresidentOfSalesAndMarketingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=aipt_EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=aipt_StockIncentivePlan2012Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=aipt_ConversionFromSeriesCConvertiblePreferredStockToCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aipt_SeriesCConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_HelomicsWarrantsHeldByInvestorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_PrecisionWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_HelomicsWarrantsHeldByOtherPartiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_The2017PublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SeriesDWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_The2017PrivatePlacementWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_The2018PublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SeriesEWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R38.htm IDEA: XBRL DOCUMENT v3.19.1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Number of Shares Outstanding (in shares) 3,669,277

Warrant [Member]

Number of Shares Outstanding (in shares) 1,951,257 871,101

Average Exercise Price Outstanding (in dollars per share) $ 23.74 $ 52.22

Number of Shares Issued (in shares) 2,336,154 1,082,946

Average Exercise Price Issued (in dollars per share) $ 1.07 $ 1.49

Number of Shares Expired (in shares) (10,706) (2,790)

Average Exercise Price Expired (in dollars per share) $ 199.55 $ 281.46

Number of Shares Exercised (in shares) (650,062)

Average Exercise Price Exercised (in dollars per share) $ 1

Number of Shares Outstanding (in shares) 3,626,643 1,951,257

Average Exercise Price Outstanding (in dollars per share) $ 4.17 $ 23.74

Employee Stock Option [Member]

Number of Shares Outstanding (in shares) 2,764,983 165,643

Average Exercise Price Outstanding (in dollars per share) $ 2 $ 11.22

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,098,858 2,612,070

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 1.01 $ 1.45

Number of Shares Expired (in shares) (194,564) (12,730)

Average Exercise Price Expired (in dollars per share) $ 2 $ 10.39

Number of Shares Exercised (in shares)

Average Exercise Price Exercised (in dollars per share)

Number of Shares Outstanding (in shares) 3,669,277 2,764,983

Average Exercise Price Outstanding (in dollars per share) $ 1.70 $ 2

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were exercised during the current period.
+ References
No definition available.
+ Details

Name: aipt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue

Namespace Prefix: aipt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-option equity instruments exercised by participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of non-option equity instruments granted to participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R39.htm IDEA: XBRL DOCUMENT v3.19.1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)
12 Months Ended

Dec. 31, 2018

shares

Shares, options (in shares) 3,669,277

Shares, warrants (in shares) 3,626,643

Warrant One [Member]

Shares, warrants (in shares) 221,292

Weighted average remaining life, warrants (Year) 4 years 335 days

Warrant Two [Member]

Shares, warrants (in shares) 1,063,935

Weighted average remaining life, warrants (Year) 3 years 277 days

Warrant Three [Member]

Shares, warrants (in shares) 697,946

Weighted average remaining life, warrants (Year) 3 years 310 days

Warrant Four [Member]

Shares, warrants (in shares) 1,071,776

Weighted average remaining life, warrants (Year) 4 years 273 days

Warrant Five [Member]

Shares, warrants (in shares) 86,086

Weighted average remaining life, warrants (Year) 4 years 273 days

Warrant Six [Member]

Shares, warrants (in shares) 385,000

Weighted average remaining life, warrants (Year) 3 years 21 days

Warrant Seven [Member]

Shares, warrants (in shares) 94,084

Weighted average remaining life, warrants (Year) 1 year 244 days

Warrant Eight [Member]

Shares, warrants (in shares) 2,529

Weighted average remaining life, warrants (Year) 215 days

Warrant Nine [Member]

Shares, warrants (in shares) 2,850

Weighted average remaining life, warrants (Year) 222 days

Warrant Ten [Member]

Shares, warrants (in shares) 222

Weighted average remaining life, warrants (Year) 310 days

Warrant Eleven [Member]

Shares, warrants (in shares) 59

Weighted average remaining life, warrants (Year) 43 days

Warrant Twelve [Member]

Shares, warrants (in shares) 862

Weighted average remaining life, warrants (Year) 32 days

Warrant Thirteen [Member]

Shares, warrants (in shares) 3,626,643

Weighted average remaining life, warrants (Year)

Stock Options One [Member]

Shares, options (in shares) 201,908

Weighted average remaining life, options (Year) 10 years

Stock Options Two [Member]

Shares, options (in shares) 60,000

Weighted average remaining life, options (Year) 9 years 332 days

Stock Options Three [Member]

Shares, options (in shares) 10,000

Weighted average remaining life, options (Year) 9 years 109 days

Stock Options Four [Member]

Shares, options (in shares) 3,000

Weighted average remaining life, options (Year) 9 years 138 days

Stock Options Five [Member]

Shares, options (in shares) 191,753

Weighted average remaining life, options (Year) 9 years 7 days

Stock Options Six [Member]

Shares, options (in shares) 149,110

Weighted average remaining life, options (Year) 9 years 43 days

Stock Options Seven [Member]

Shares, options (in shares) 23,585

Weighted average remaining life, options (Year) 9 years 277 days

Stock Options Eight [Member]

Shares, options (in shares) 86,958

Weighted average remaining life, options (Year) 9 years 167 days

Stock Options Nine [Member]

Shares, options (in shares) 195,931

Weighted average remaining life, options (Year) 9 years 200 days

Stock Options Ten [Member]

Shares, options (in shares) 21,740

Weighted average remaining life, options (Year) 9 years 215 days

Stock Options Eleven [Member]

Shares, options (in shares) 66,451

Weighted average remaining life, options (Year) 9 years 215 days

Stock Options Twelve [Member]

Shares, options (in shares) 30,000

Weighted average remaining life, options (Year) 9 years 222 days

Stock Options Thirteen [Member]

Shares, options (in shares) 41,668

Weighted average remaining life, options (Year) 9 years 215 days

Stock Options Fourteen [Member]

Shares, options (in shares) 30,000

Weighted average remaining life, options (Year) 9 years 222 days

Stock Options Fifteen [Member]

Shares, options (in shares) 111,112

Weighted average remaining life, options (Year) 9 years 73 days

Stock Options Sixteen [Member]

Shares, options (in shares) 17,200

Weighted average remaining life, options (Year) 8 years 273 days

Stock Options Seventeen [Member]

Shares, options (in shares) 2,305,790

Weighted average remaining life, options (Year) 8 years 175 days

Stock Options Eighteen [Member]

Shares, options (in shares) 14,286

Weighted average remaining life, options (Year) 8 years 91 days

Stock Options Nineteen [Member]

Shares, options (in shares) 293

Weighted average remaining life, options (Year) 7 years 237 days

Stock Options Twenty [Member]

Shares, options (in shares) 20,640

Weighted average remaining life, options (Year) 7 years 233 days

Stock Options Twenty One [Member]

Shares, options (in shares) 57,145

Weighted average remaining life, options (Year) 8 years 3 days

Stock Options Twenty Two [Member]

Shares, options (in shares) 4,000

Weighted average remaining life, options (Year) 7 years 182 days

Stock Options Twenty Three [Member]

Shares, options (in shares) 3,636

Weighted average remaining life, options (Year) 7 years 273 days

Stock Options Twenty Four [Member]

Shares, options (in shares) 7,147

Weighted average remaining life, options (Year) 7 years 262 days

Stock Options Twenty Five [Member]

Shares, options (in shares) 3,529

Weighted average remaining life, options (Year) 7 years 91 days

Stock Options Twenty Six [Member]

Shares, options (in shares) 3,902

Weighted average remaining life, options (Year) 7 years 251 days

Stock Options Twenty Seven [Member]

Shares, options (in shares) 190

Weighted average remaining life, options (Year) 6 years 295 days

Stock Options Twenty Eight [Member]

Shares, options (in shares) 1,157

Weighted average remaining life, options (Year) 7 years 3 days

Stock Options Twenty Nine [Member]

Shares, options (in shares) 2,323

Weighted average remaining life, options (Year) 6 years 182 days

Stock Options Thirty [Member]

Shares, options (in shares) 187

Weighted average remaining life, options (Year) 6 years 273 days

Stock Options Thirty-One [Member]

Shares, options (in shares) 232

Weighted average remaining life, options (Year) 6 years 91 days

Stock Options Thirty-Two [Member]

Shares, options (in shares) 81

Weighted average remaining life, options (Year) 3 years 251 days

Stock Options Thirty-Three [Member]

Shares, options (in shares) 928

Weighted average remaining life, options (Year) 4 years 76 days

Stock Options Thirty-Four [Member]

Shares, options (in shares) 1,760

Weighted average remaining life, options (Year) 3 years 229 days

Stock Options Thirty-Five [Member]

Shares, options (in shares) 123

Weighted average remaining life, options (Year) 6 years 3 days

Stock Options Thirty-Six [Member]

Shares, options (in shares) 121

Weighted average remaining life, options (Year) 5 years 273 days

Stock Options Thirty-Seven [Member]

Shares, options (in shares) 121

Weighted average remaining life, options (Year) 4 years 197 days

Stock Options Thirty-Eight [Member]

Shares, options (in shares) 130

Weighted average remaining life, options (Year) 4 years 197 days

Stock Options Thirty-Nine [Member]

Shares, options (in shares) 529

Weighted average remaining life, options (Year) 4 years 14 days

Stock Options Forty [Member]

Shares, options (in shares) 3

Weighted average remaining life, options (Year) 4 years 127 days

Stock Options Forty-One [Member]

Shares, options (in shares) 72

Weighted average remaining life, options (Year) 5 years 91 days

Stock Options Forty-Two [Member]

Shares, options (in shares) 306

Weighted average remaining life, options (Year) 5 years 69 days

Stock Options Forty-Three [Member]

Shares, options (in shares) 188

Weighted average remaining life, options (Year) 5 years

Stock Options Forty-Four [Member]

Shares, options (in shares) 42

Weighted average remaining life, options (Year) 4 years 273 days

Stock Options Forty-Five [Member]

Shares, options (in shares) 3,669,277

Weighted average remaining life, options (Year)

X

- Definition
Weighted average remaining contractual term for warrants outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantEightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantNineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantTenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantElevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantTwelveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantThirteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsEightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsNineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsElevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwelveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFourteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFifteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsSixteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsSeventeenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsEighteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsNineteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentySixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentySevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyEightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsTwentyNineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtyoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtytwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtythreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtyfourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtyfiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtysixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtysevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtyeightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsThirtynineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFortyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFortyoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFortytwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFortythreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFortyfourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aipt_StockOptionsFortyfiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R40.htm IDEA: XBRL DOCUMENT v3.19.1

Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)

Dec. 31, 2018

$ / shares

shares

Shares, options (in shares) | shares 3,669,277

Shares, warrants (in shares) | shares 3,626,643

Minimum [Member]

Price, options (in dollars per share) $ 0.62

Warrant exercises, exercise price per share (in dollars per share) 0

Maximum [Member]

Price, options (in dollars per share) 596.25

Warrant exercises, exercise price per share (in dollars per share) $ 609.38

Warrants 2014 [Member]

Shares, warrants (in shares) | shares 6,455

Warrants 2014 [Member] | Minimum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 243.75

Warrants 2014 [Member] | Maximum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 609.38

Warrants 2015 [Member]

Shares, warrants (in shares) | shares 94,151

Warrants 2015 [Member] | Minimum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 0

Warrants 2015 [Member] | Maximum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 243.75

Warrants 2016 [Member]

Shares, warrants (in shares) | shares 252,333

Warrant exercises, exercise price per share (in dollars per share) $ 1

Warrants 2017 [Member]

Shares, warrants (in shares) | shares 1,082,946

Warrants 2017 [Member] | Minimum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 1.07

Warrants 2017 [Member] | Maximum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 2.25

Warrants 2018 [Member]

Shares, warrants (in shares) | shares 2,190,758

Warrants 2018 [Member] | Minimum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 0.84

Warrants 2018 [Member] | Maximum [Member]

Warrant exercises, exercise price per share (in dollars per share) $ 1.3125

Stock Options 2011 [Member]

Shares, options (in shares) | shares 173

Price, options (in dollars per share) $ 281.25

Stock Options 2012 [Member]

Shares, options (in shares) | shares 1,841

Stock Options 2012 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 131.25

Stock Options 2012 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 150

Stock Options 2013 [Member]

Shares, options (in shares) | shares 1,553

Stock Options 2013 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 148.13

Stock Options 2013 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 596.25

Stock Options 2014 [Member]

Shares, options (in shares) | shares 836

Stock Options 2014 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 162.50

Stock Options 2014 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 431.25

Stock Options 2015 [Member]

Shares, options (in shares) | shares 4,088

Stock Options 2015 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 65.75

Stock Options 2015 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 86.25

Stock Options 2016 [Member]

Shares, options (in shares) | shares 100,294

Stock Options 2016 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 2.25

Stock Options 2016 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 5.13

Stock Options 2017 [Member]

Shares, options (in shares) | shares 2,461,634

Stock Options 2017 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 1.01

Stock Options 2017 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 2.10

Stock Options 2018 [Member]

Shares, options (in shares) | shares 1,098,858

Stock Options 2018 [Member] | Minimum [Member]

Price, options (in dollars per share) $ 0.62

Stock Options 2018 [Member] | Maximum [Member]

Price, options (in dollars per share) $ 1.35

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_Warrants2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_Warrants2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_Warrants2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_Warrants2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_Warrants2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2011Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2012Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2013Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=aipt_StockOptions2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R41.htm IDEA: XBRL DOCUMENT v3.19.1

Note 5 - Notes Receivable (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 5 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Oct. 31, 2018

Sep. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Oct. 31, 2017

Feb. 28, 2019

Mar. 31, 2019

Dec. 31, 2018

Dec. 31, 2018

Jul. 31, 2017

Subsequent Event [Member] | Shelf Registration [Member]

Proceeds from Issuance or Sale of Equity, Total $ 1,100,000 $ 2,100,000

Advance to Helomics [Member]

Payments to Acquire Notes Receivable $ 600,000

Advances to De Lage Landen [Member]

Payments to Acquire Notes Receivable $ 60,000 $ 67,512

Lease to Purchase Equipment, Down Payment, Percentage 50.00%

CytoBioscience [Member] | Promissory Notes Receivable [Member]

Notes Receivable, Interest Rate, Stated Percentage 8.00% 8.00%

Financing Receivable, Net, Total $ 1,112,524 $ 1,070,000

Notes Receivable, Term 2 years

Proceeds from Collection of Notes Receivable $ 0

Helomics Holding Corp. [Member]

Financing Receivable, Net, Total $ 163,468

Payments to Acquire Notes Receivable $ 30,000 $ 907,500

Share Exchange Agreement, Outstanding Receivables, Amount Converted $ 500,000

Share Exchange Agreement, Shares Received Upon Conversion of Receivables 833,333

Share Exchange Agreement, Convertible Notes, Percent of Stock 5.00%

Investment, Ownership Percent 25.00%

Financing Receivable, Gross 1,165,013 1,165,013 $ 1,165,013

Interest Receivable $ 29,215 $ 29,215 29,215

Fair Value Adjustment of Notes Receivable $ (751,330)

Helomics Holding Corp. [Member] | Subsequent Event [Member]

Payments to Acquire Notes Receivable $ 305,000

Financing Receivable, Gross 1,890,013 $ 1,890,013

Helomics Holding Corp. [Member] | Subsequent Event [Member] | Shelf Registration [Member]

Payments to Acquire Notes Receivable $ 420,000

X

- Definition
the amount of fair value adjustment of notes receivable.
+ References
No definition available.
+ Details

Name: aipt_FairValueAdjustmentOfNotesReceivable

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the percent of ownership in investment interest.
+ References
No definition available.
+ Details

Name: aipt_InvestmentOwnershipPercent

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage down payment to purchase equipment.
+ References
No definition available.
+ Details

Name: aipt_LeaseToPurchaseEquipmentDownPaymentPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the simple interest rate for notes receivable.
+ References
No definition available.
+ Details

Name: aipt_NotesReceivableInterestRateStatedPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The period of time for the notes receivable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: aipt_NotesReceivableTerm

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of outstanding common stock to be received upon the conversion of outstanding notes receivable.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementConvertibleNotesPercentOfStock

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the amount of outstanding notes receivable that have been converted into common stock.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementOutstandingReceivablesAmountConverted

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the number of shares received upon the conversion of outstanding notes receivables.
+ References
No definition available.
+ Details

Name: aipt_ShareExchangeAgreementSharesReceivedUponConversionOfReceivables

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. Excludes amounts related to receivables held-for-sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesReceivableGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_ShelfRegistrationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aipt_AdvanceToHelomicsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aipt_AdvancesToDeLageLandenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_CytoBioscienceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aipt_PromissoryNotesReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_HelomicsHoldingCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R42.htm IDEA: XBRL DOCUMENT v3.19.1

Note 6 - Convertible Debt and Derivative Liability (Details Textual)

Mar. 31, 2019

USD ($)

shares

Oct. 26, 2018

Oct. 03, 2018

$ / shares

shares

Dec. 31, 2018

USD ($)

yr

$ / shares

Sep. 30, 2018

USD ($)

Sep. 28, 2018

USD ($)

Stock Issued During Period, Shares, Inducement for Bridge Loan | shares 650,000

Maximum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 609.38

Warrants in Connection with Convertible Promissory Note [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 1,071,776

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.155

Class of Warrant or Right, Vesting Period 180 days

Warrants and Rights Outstanding, Term 5 years

Class of Warrant or Right, Fair Value per Warrant | $ / shares $ 0.5361

Warrants and Rights Outstanding $ 574,631

Derivative Liability, Total $ 272,745 $ 645,008

Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Discount Rate [Member]

Warrants and Rights Outstanding, Measurement Input 0.0294

Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Expected Term [Member]

Warrants and Rights Outstanding, Measurement Input | yr 5

Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Price Volatility [Member]

Warrants and Rights Outstanding, Measurement Input 0.59

Subsequent Event [Member] | Warrants in Connection with Convertible Promissory Note [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 1,336,805

Securities Purchase Agreements [Member] | Convertible Promissory Note [Member]

Debt Instrument, Face Amount $ 2,297,727

Debt Instrument, Interest Rate, Stated Percentage 8.00%

Interest Guaranteed Period 1 year

Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock 70.00%

Debt Instrument, Convertible, Threshold Trading Days 20

Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares | shares 2,678,328

Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Maximum [Member]

Debt Instrument, Convertible, Conversion Price | $ / shares $ 1

Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount $ 2,865,909

Proceeds from Notes Payable, Total $ 500,000

X

- Definition
Represents the fair value per warrant.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightFairValuePerWarrant

Namespace Prefix: aipt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The period in which a warrant vests.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightVestingPeriod

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents information about sum of number of conversion shares plus inducement Shares.
+ References
No definition available.
+ Details

Name: aipt_ConversionSharesSumOfNumberOfConversionSharesPlusInducementShares

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of lowers volume-weighted average price of common stock considered as conversion price.
+ References
No definition available.
+ Details

Name: aipt_DebtInstrumentConvertibleConversionPricePercentageOfLowersVolumeweightedAveragePriceOfCommonStock

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period withing which interest is guaranteed.
+ References
No definition available.
+ Details

Name: aipt_InterestGuaranteedPeriod

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period as inducement for bridge loan.
+ References
No definition available.
+ Details

Name: aipt_StockIssuedDuringPeriodSharesInducementForBridgeLoan

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantsInConnectionWithConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=aipt_SecuritiesPurchaseAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=aipt_ConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R43.htm IDEA: XBRL DOCUMENT v3.19.1

Note 7 - Loss Per Share (Details Textual) - shares
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Weighted Average Number of Shares, Contingently Issuable 3,294,087

Options and Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,295,921 4,716,240

Preferred Stock 1 [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 79,246

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aipt_OptionsAndWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aipt_PreferredStock1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R44.htm IDEA: XBRL DOCUMENT v3.19.1

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Net loss $ (10,086,477) $ (6,003,017)

Weighted average common shares outstanding-basic (in shares) 12,816,289 6,362,989

Effect of dilutive stock options warrants and preferred stock (1) (in shares) ^[1]

Weighted average common shares outstanding-diluted (in shares) 12,816,289 6,362,989

Loss per common share - basic and diluted (in dollars per share) $ (0.79) $ (0.94)

[1] The number of shares underlying options and warrants outstanding as of December 31, 2018 and December 31, 2017 are 7,295,921 and 4,716,240, respectively. The number of shares underlying the preferred stock as of December 31, 2018 is 79,246 for Series B Convertible. The number of shares underlying the convertible debt is 3,294,087. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 63 R45.htm IDEA: XBRL DOCUMENT v3.19.1

Note 8 - Income Taxes (Details Textual) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 34.00%

Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability $ 0

Valuation Allowance Percentage 100.00% 100.00%

Federal Income Tax Expense (Benefit), Continuing Operations, Total $ 0

Open Tax Year 2014 2015 2016 2017 2018

Unrecognized Tax Benefits, Ending Balance $ 0

Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total 0 $ 0

State and Local Income Tax Expense (Benefit), Continuing Operations, Total 0

Domestic Tax Authority [Member]

Operating Loss Carryforwards, Total 40,094,472 34,529,255

Operating Loss Carryforwards, Valuation Allowance, Total 9,603,237 8,129,778

State and Local Jurisdiction [Member]

Operating Loss Carryforwards, Total 12,940,458 12,261,799

Operating Loss Carryforwards, Valuation Allowance, Total 1,416,758 $ 245,812

Foreign Tax Authority [Member]

Operating Loss Carryforwards, Total 421,782

Operating Loss Carryforwards, Valuation Allowance, Total $ 132,722

X

- Definition
Percentage valuation allowance that is appropriate for deferred tax assets and state income taxes.
+ References
No definition available.
+ Details

Name: aipt_ValuationAllowancePercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319
+ Details

Name: us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Tax year that remains open to examination under enacted tax laws, in CCYY format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_OpenTaxYear

Namespace Prefix: us-gaap_

Data Type: us-types:gYearListItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 30
-Paragraph 5
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109238119&loc=d3e30536-109315

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_OperatingLossCarryforwardsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)-(b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R46.htm IDEA: XBRL DOCUMENT v3.19.1

Note 8 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Statutory federal income tax benefit $ 2,118,160 $ 2,633,841

State tax benefit, net of federal taxes 66,117 76,922

Foreign tax benefit 132,931

Foreign operations tax rate differential (94,373)

State rate adjustment 15,355 (77,556)

R&D tax credit 22,532

Nondeductible/nontaxable items (118,905) (757,149)

State NOL adjustment 746,479

OID and derivatives (159,037)

NQSO adjustment 537,884

New federal rate adjustment (4,974,121)

Other 47,868 (8,336)

Valuation allowance decrease (increase) (2,777,127) 2,568,515

Total income tax benefit (expense)

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax benefit.
+ References
No definition available.
+ Details

Name: aipt_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxBenefitAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the NQSO Adjustment.
+ References
No definition available.
+ Details

Name: aipt_EffectiveIncomeTaxRateReconciliationNQSOAdjustmentAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the OID and derivatives.
+ References
No definition available.
+ Details

Name: aipt_EffectiveIncomeTaxRateReconciliationOIDAndDerivativesAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) state net operating loss adjustment.
+ References
No definition available.
+ Details

Name: aipt_EffectiveIncomeTaxRateReconciliationStateNetOperatingLossAdjustmentAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the state income tax rates.
+ References
No definition available.
+ Details

Name: aipt_EffectiveIncomeTaxRateReconciliationStateTaxRateAdjustmentAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32059-109318

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationTaxCreditsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 65 R47.htm IDEA: XBRL DOCUMENT v3.19.1

Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Deferred tax assets:

Depreciation $ 4,488 $ 3,251

Inventory 6,991 6,950

Compensation accruals 60,905 50,436

Accruals and reserves 77,777 64,732

Charitable contribution carryover 3,972 4,068

Derivatives 57,276

Related party investments 481,652

Intangibles 2,020

NQSO compensation 1,019,139 766,648

NOL and credits 9,655,388 7,479,505

Total deferred tax assets 11,369,608 8,375,590

Deferred tax liabilities:

Original issue discount (216,891)

Total deferred tax liabilities (216,891)

Net deferred tax assets 11,152,717 8,375,590

Less: valuation allowance (11,152,717) (8,375,590)

Total

X

- Definition
Amount, after deferred tax liability, of deferred tax asset attributable to taxable differences without jurisdictional netting, before valuation allowance.
+ References
No definition available.
+ Details

Name: aipt_DeferredTaxAssetsLiabilitiesGross

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from NQSO compensation.
+ References
No definition available.
+ Details

Name: aipt_DeferredTaxAssetsNQSOCompensation

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards and tax credits.
+ References
No definition available.
+ Details

Name: aipt_DeferredTaxAssetsOperatingLossCarryforwardsAndCredits

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from original issue discounts.
+ References
No definition available.
+ Details

Name: aipt_DeferredTaxLiabilitiesOriginalIssueDiscount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsDerivativeInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGrossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R48.htm IDEA: XBRL DOCUMENT v3.19.1

Note 9 - Rent Obligation (Details Textual)
12 Months Ended

Jun. 15, 2018

EUR (€)

ft²

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Feb. 01, 2018

ft²

Operating Leases, Rent Expense, Total | $ $ 69,013 $ 66,122

Corporate Office, Minnesota [Member]

Lessee, Operating Lease, Term of Contract 3 years

Area of Real Estate Property 5,773

Corporate Office, Minnesota [Member] | Office Space [Member]

Area of Real Estate Property 2,945

Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]

Area of Real Estate Property 2,828

Skyline Medical Europe’s Offices Lease [Member]

Area of Real Estate Property 2,000

Lessee, Operating Lease, Monthly Rent | € € 3,000

Skyline Medical Europe’s Offices Lease [Member] | Office Space [Member]

Area of Real Estate Property 1,250

Skyline Medical Europe’s Offices Lease [Member] | Storage Space [Member]

Area of Real Estate Property 300

X

- Definition
Amount of monthly rent.
+ References
No definition available.
+ Details

Name: aipt_LesseeOperatingLeaseMonthlyRent

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Area of a real estate property.
+ References
No definition available.
+ Details

Name: us-gaap_AreaOfRealEstateProperty

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=aipt_CorporateOfficeMinnesotaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aipt_OfficeSpaceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=aipt_SkylineMedicalEuropesOfficesLeaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aipt_StorageSpaceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R49.htm IDEA: XBRL DOCUMENT v3.19.1

Note 9 - Rent Obligation - Rent Obligation (Details)

Dec. 31, 2018

USD ($)

2019 $ 80,320

2020 82,320

2021 43,320

2022 40,320

2023 40,320

Thereafter $ 161,280

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 68 R50.htm IDEA: XBRL DOCUMENT v3.19.1

Note 10 - Related Party Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

Mar. 12, 2019

Feb. 06, 2019

Feb. 01, 2019

Jan. 08, 2019

Dec. 31, 2018

Nov. 30, 2018

Mar. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Jul. 11, 2018

Jul. 10, 2018

Proceeds from Issuance of Common Stock $ 2,959,509 $ 3,814,938

Shares Issued, Price Per Share $ 1.17 $ 1.18

Schwartz Warrant First Tranche [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 221,292

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.836

Schwartz Warrant Second Tranche [Member] | Subsequent Event [Member]

Class of Warrant or Right, Share Limit 78,128

Schwartz Warrant Third Tranche [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 138,889

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.188

Class of Warrant or Right, Share Limit 1,108,596

Schwartz Warrant [Member] | Subsequent Event [Member]

Class of Warrant or Right, Additional Shares Increase, Percentage 0.50%

Class of Warrant or Right, Share Limit 2,818,350

Class of Warrant or Right, Share Limit Percentage 19.90%

Director [Member]

Related Party Transaction, Monthly Cash Payment $ 12,000

Related Party Transaction, Contract Term 180 days

Chief Executive Officer [Member]

Proceeds from Related Party Debt $ 370,000 $ 370,000

Chief Executive Officer [Member] | Subsequent Event [Member]

Proceeds from Related Party Debt $ 1,300,000 $ 300,000 $ 950,000 $ 1,300,000

Due to Related Parties, Total $ 1,320,000

Stock Issued During Period, Shares, New Issues 78,125

Proceeds from Issuance of Common Stock $ 50,000

Shares Issued, Price Per Share $ 0.64

Cash Payment In Lieu of Share Increase As Percentage of Principal Balance of Note 0.50%

Chief Executive Officer [Member] | Subsequent Event [Member] | Schwartz Note [Member]

Debt Instrument, Face Amount $ 1,620,000

Chief Executive Officer [Member] | Schwartz Warrant Second Tranche [Member] | Subsequent Event [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 742,188

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.704

TumorGenesis [Member]

Ownership Percentage 100.00% 100.00%

X

- Definition
Cash payment to warrant holder if warrants cannot be increased as required herein due to the share limit.
+ References
No definition available.
+ Details

Name: aipt_CashPaymentInLieuOfShareIncreaseAsPercentageOfPrincipalBalanceOfNote

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Monthly increase in warrants held .
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightAdditionalSharesIncreasePercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares limits for warrants outstanding.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightShareLimit

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share limit fro warrants expressed as percentage of total common stock outstanding.
+ References
No definition available.
+ Details

Name: aipt_ClassOfWarrantOrRightShareLimitPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of ownership held.
+ References
No definition available.
+ Details

Name: aipt_OwnershipPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents term of a renewable contract with related party.
+ References
No definition available.
+ Details

Name: aipt_RelatedPartyTransactionContractTerm

Namespace Prefix: aipt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of monthly cash payment made to a related party.
+ References
No definition available.
+ Details

Name: aipt_RelatedPartyTransactionMonthlyCashPayment

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SchwartzWarrantFirstTrancheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SchwartzWarrantSecondTrancheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SchwartzWarrantThirdTrancheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_SchwartzWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=aipt_SchwartzNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=aipt_TumorgenesisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R51.htm IDEA: XBRL DOCUMENT v3.19.1

Note 11 - Retirement Savings Plans (Details Textual) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Defined Contribution Plan, Employer Matching Contribution, Percent of Match 100.00% 100.00%

Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 4.00% 4.00%

Defined Contribution Plan, Employer Contribution Amount $ 51,647 $ 29,952

Defined Contribution Plan, Employer Discretionary Contribution Amount $ 0 $ 0

X

- Definition
Amount of contributions made by an employer to a defined contribution plan.
+ References
No definition available.
+ Details

Name: aipt_DefinedContributionPlanEmployerContributionAmount

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of discretionary contributions made by an employer to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage employer matches of the employee's percentage contribution matched.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 70 R52.htm IDEA: XBRL DOCUMENT v3.19.1

Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements (Details Textual) - USD ($)
3 Months Ended 12 Months Ended

Dec. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

General and Administrative Expense, Total $ 4,626,997 $ 4,050,307

Retained Earnings (Accumulated Deficit), Ending Balance $ (53,021,469) (63,107,945) (53,021,469)

Operating Expenses, Total $ 7,861,379 6,053,523

Overstatement of Investors Stock Compensation Expense and Additional Paid-in Capital [Member]

Quantifying Misstatement in Current Year Financial Statements, Amount 2,150,097

Overstatement of Investors Stock Compensation Expense and Additional Paid-in Capital [Member] | Restatement Adjustment [Member]

General and Administrative Expense, Total (2,150,097)

Retained Earnings (Accumulated Deficit), Ending Balance (2,150,097) (2,150,097)

Understatement of Employee Stock Compensation Expenses and Additional Paid-in Capital [Member]

Quantifying Misstatement in Current Year Financial Statements, Amount 406,522

Understatement of Employee Stock Compensation Expenses and Additional Paid-in Capital [Member] | Restatement Adjustment [Member]

Retained Earnings (Accumulated Deficit), Ending Balance $ 406,522 406,522

Operating Expenses, Total 406,522

Understatement of Deferred Tax Assets [Member]

Quantifying Misstatement in Current Year Financial Statements, Amount $ 767,000

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of each individual error being corrected in the correcting adjustment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 1.N)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e30840-122693
+ Details

Name: us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis=aipt_OverstatementOfInvestorsStockCompensationExpenseAndAdditionalPaidinCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RestatementAxis=srt_RestatementAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis=aipt_UnderstatementOfEmployeeStockCompensationExpensesAndAdditionalPaidinCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis=aipt_UnderstatementOfDeferredTaxAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R53.htm IDEA: XBRL DOCUMENT v3.19.1

Note 13 - Subsequent Events (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

Mar. 26, 2019

Mar. 12, 2019

Mar. 01, 2019

Feb. 06, 2019

Jan. 08, 2019

Dec. 31, 2018

Nov. 30, 2018

Jan. 31, 2018

Mar. 31, 2019

Dec. 31, 2018

Jul. 11, 2018

Jul. 10, 2018

Shares Issued, Price Per Share $ 1.17 $ 1.18

Debt Instrument, Penalty Expenses $ 503,000

Chief Executive Officer [Member]

Proceeds from Related Party Debt $ 370,000 $ 370,000

The 2018 Public Offering [Member]

Stock Issued During Period, Shares, New Issues 2,900,000

Share Per Each Unit 1

Proceeds from Issuance or Sale of Equity, Total $ 2,755,000

Subsequent Event [Member] | Chief Executive Officer [Member]

Stock Issued During Period, Shares, New Issues 78,125

Shares Issued, Price Per Share $ 0.64

Proceeds from Related Party Debt $ 1,300,000 $ 300,000 $ 950,000 $ 1,300,000

Subsequent Event [Member] | Peak One [Member] | Bridge Loan [Member]

Debt Conversion, Converted Instrument, Shares Issued 71,046

Debt Conversion, Original Debt, Amount $ 44,475

Subsequent Event [Member] | Right to Purchase Units [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 69,250

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.125

Right to Purchase Units, Percentage 5.00%

Right to Purchase Units, Exercise Price Percentage 125.00%

Subsequent Event [Member] | The 2019 Offering [Member]

Stock Issued During Period, Shares, New Issues 1,385,000

Share Per Each Unit 1

Shares Issued, Price Per Share $ 0.90

Proceeds from Issuance or Sale of Equity, Total $ 1,250,000

Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs $ 1,080,000

Underwriter Discount Percentage 8.00%

Placement Agent Offering Fees $ 30,000

Placement Agent Blue Sky Fees $ 5,000

Subsequent Event [Member] | The 2019 Offering [Member] | The 2019 Offering Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 692,500

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right 0.5

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1

Subsequent Event [Member] | The 2018 Public Offering [Member] | The 2019 Offering Warrants [Member]

Warrants and Rights Outstanding, Term 5 years

Subsequent Event [Member] | Placement Agency Agreement [Member]

Stock Issued During Period, Shares, New Issues 1,478,750

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 73,938

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1

Shares Issued, Price Per Share $ 0.80

Proceeds from Issuance or Sale of Equity, Total $ 1,180,000

Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs 1,050,000

Placement Agent Offering Fees 30,000

Placement Agent Blue Sky Fees $ 5,000

Right to Purchase Units, Percentage 5.00%

Right to Purchase Units, Exercise Price Percentage 125.00%

Unit Agreement Number of Shares of Common Stock Included in Each Unit 1

Unit Agreement Number of Warrants Included in Each Unit 0.5

Placement Fee, Percent of Gross Proceeds 8.00%

Subsequent Event [Member] | Placement Agency Agreement [Member] | Warrants Issued With Placement Agency Agreement [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 739,375

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1

X

- Definition
The amount of penalty expenses incurred from a debt instrument.
+ References
No definition available.
+ Details

Name: aipt_DebtInstrumentPenaltyExpenses

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of "blue sky" fees entity reimburses to placement agent.
+ References
No definition available.
+ Details

Name: aipt_PlacementAgentBlueSkyFees

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of fees entity reimburses to placement agent for offering fees.
+ References
No definition available.
+ Details

Name: aipt_PlacementAgentOfferingFees

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The percentage amount of placement fee as a percent of gross proceeds.
+ References
No definition available.
+ Details

Name: aipt_PlacementFeePercentOfGrossProceeds

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, warrants and other types of equity, net of issuance costs.
+ References
No definition available.
+ Details

Name: aipt_ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts

Namespace Prefix: aipt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price of unit expressed as a percentage of public offering price of the unit.
+ References
No definition available.
+ Details

Name: aipt_RightToPurchaseUnitsExercisePricePercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Right to purchase units expressed as a percentage of units sold in offering.
+ References
No definition available.
+ Details

Name: aipt_RightToPurchaseUnitsPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the shares per each unit.
+ References
No definition available.
+ Details

Name: aipt_SharePerEachUnit

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the discount on underwriter shares exercised.
+ References
No definition available.
+ Details

Name: aipt_UnderwriterDiscountPercentage

Namespace Prefix: aipt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of shares of common stock that are included in each unit pursuant to a unit agreement.
+ References
No definition available.
+ Details

Name: aipt_UnitAgreementNumberOfSharesOfCommonStockIncludedInEachUnit

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the number of warrants that are included in each unit pursuant to a unit agreement.
+ References
No definition available.
+ Details

Name: aipt_UnitAgreementNumberOfWarrantsIncludedInEachUnit

Namespace Prefix: aipt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_The2018PublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=aipt_PeakOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_RightToPurchaseUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_The2019OfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_The2019OfferingWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=aipt_PlacementAgencyAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aipt_WarrantsIssuedWithPlacementAgencyAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 498 383 1 true 165 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.precisiontherapeutics.com/20181231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.precisiontherapeutics.com/20181231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.precisiontherapeutics.com/20181231/role/statement-consolidated-statements-of-comprehensive-loss Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.precisiontherapeutics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals Consolidated Statements of Stockholders' Equity (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.precisiontherapeutics.com/20181231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Summary of Significant Accounting Policies Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies Note 1 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Equity Method Investment Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-2-equity-method-investment Note 2 - Equity Method Investment Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Revenue Recognition Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-3-revenue-recognition Note 3 - Revenue Recognition Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Notes Receivable Notes http://www.precisiontherapeutics.com/20181231/role/statement-note-5-notes-receivable Note 5 - Notes Receivable Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Convertible Debt and Derivative Liability Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-6-convertible-debt-and-derivative-liability- Note 6 - Convertible Debt and Derivative Liability Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Loss Per Share Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-7-loss-per-share Note 7 - Loss Per Share Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Income Taxes Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes Note 8 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Rent Obligation Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-9-rent-obligation Note 9 - Rent Obligation Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Retirement Savings Plans Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-11-retirement-savings-plans Note 11 - Retirement Savings Plans Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-12-correction-of-immaterial-misstatement-to-prior-period-financial-statements Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Subsequent Events Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-13-subsequent-events Note 13 - Subsequent Events Notes 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies 21 false false R22.htm 021 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-tables Note 1 - Summary of Significant Accounting Policies (Tables) Tables http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Note 2 - Equity Method Investment (Tables) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-2-equity-method-investment-tables Note 2 - Equity Method Investment (Tables) Tables http://www.precisiontherapeutics.com/20181231/role/statement-note-2-equity-method-investment 23 false false R24.htm 023 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-tables Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables) Tables http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants 24 false false R25.htm 024 - Disclosure - Note 7 - Loss Per Share (Tables) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-7-loss-per-share-tables Note 7 - Loss Per Share (Tables) Tables http://www.precisiontherapeutics.com/20181231/role/statement-note-7-loss-per-share 25 false false R26.htm 025 - Disclosure - Note 8 - Income Taxes (Tables) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes-tables Note 8 - Income Taxes (Tables) Tables http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes 26 false false R27.htm 026 - Disclosure - Note 9 - Rent Obligation (Tables) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-9-rent-obligation-tables Note 9 - Rent Obligation (Tables) Tables http://www.precisiontherapeutics.com/20181231/role/statement-note-9-rent-obligation 27 false false R28.htm 027 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual Note 1 - Summary of Significant Accounting Policies (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-tables 28 false false R29.htm 028 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-schedule-of-inventory-details Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) Details 29 false false R30.htm 029 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-life-details Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details) Details 30 false false R31.htm 030 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-details Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) Details 31 false false R32.htm 031 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-components-of-intangible-assets-details Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) Details 32 false false R33.htm 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-1-summary-of-significant-accounting-policies-estimated-future-amortization-expense-details Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) Details 33 false false R34.htm 033 - Disclosure - Note 2 - Equity Method Investment (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-2-equity-method-investment-details-textual Note 2 - Equity Method Investment (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-2-equity-method-investment-tables 34 false false R35.htm 034 - Disclosure - Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-2-equity-method-investment-summary-of-equity-method-investments-details Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) Details 35 false false R36.htm 035 - Disclosure - Note 3 - Revenue Recognition (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-3-revenue-recognition-details-textual Note 3 - Revenue Recognition (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-3-revenue-recognition 36 false false R37.htm 036 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-details-textual Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-tables 37 false false R38.htm 037 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-summary-of-transactions-for-stock-options-and-warrants-details Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-tables 38 false false R39.htm 038 - Disclosure - Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-summary-of-status-of-options-and-warrants-outstanding-details Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-tables 39 false false R40.htm 039 - Disclosure - Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-schedule-of-listing-of-stock-options-and-warrants-details Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-4-stockholders-equity-deficit-stock-options-and-warrants-tables 40 false false R41.htm 040 - Disclosure - Note 5 - Notes Receivable (Details Textual) Notes http://www.precisiontherapeutics.com/20181231/role/statement-note-5-notes-receivable-details-textual Note 5 - Notes Receivable (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-5-notes-receivable 41 false false R42.htm 041 - Disclosure - Note 6 - Convertible Debt and Derivative Liability (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-6-convertible-debt-and-derivative-liability-details-textual Note 6 - Convertible Debt and Derivative Liability (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-6-convertible-debt-and-derivative-liability- 42 false false R43.htm 042 - Disclosure - Note 7 - Loss Per Share (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-7-loss-per-share-details-textual Note 7 - Loss Per Share (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-7-loss-per-share-tables 43 false false R44.htm 043 - Disclosure - Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-7-loss-per-share-shares-used-in-basic-and-diluted-loss-per-common-share-computations-details Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) Details 44 false false R45.htm 044 - Disclosure - Note 8 - Income Taxes (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes-details-textual Note 8 - Income Taxes (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes-tables 45 false false R46.htm 045 - Disclosure - Note 8 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-benefit-expense-details Note 8 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) Details 46 false false R47.htm 046 - Disclosure - Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-8-income-taxes-components-of-deferred-income-taxes-details Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) Details 47 false false R48.htm 047 - Disclosure - Note 9 - Rent Obligation (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-9-rent-obligation-details-textual Note 9 - Rent Obligation (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-9-rent-obligation-tables 48 false false R49.htm 048 - Disclosure - Note 9 - Rent Obligation - Rent Obligation (Details) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-9-rent-obligation-rent-obligation-details Note 9 - Rent Obligation - Rent Obligation (Details) Details 49 false false R50.htm 049 - Disclosure - Note 10 - Related Party Transactions (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-10-related-party-transactions-details-textual Note 10 - Related Party Transactions (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-10-related-party-transactions 50 false false R51.htm 050 - Disclosure - Note 11 - Retirement Savings Plans (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-11-retirement-savings-plans-details-textual Note 11 - Retirement Savings Plans (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-11-retirement-savings-plans 51 false false R52.htm 051 - Disclosure - Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-12-correction-of-immaterial-misstatement-to-prior-period-financial-statements-details-textual Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-12-correction-of-immaterial-misstatement-to-prior-period-financial-statements 52 false false R53.htm 052 - Disclosure - Note 13 - Subsequent Events (Details Textual) Sheet http://www.precisiontherapeutics.com/20181231/role/statement-note-13-subsequent-events-details-textual Note 13 - Subsequent Events (Details Textual) Details http://www.precisiontherapeutics.com/20181231/role/statement-note-13-subsequent-events 53 false false All Reports Book All Reports aipt-20181231.xml aipt-20181231.xsd aipt-20181231_cal.xml aipt-20181231_def.xml aipt-20181231_lab.xml aipt-20181231_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 77 0001171843-19-002172-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-19-002172-xbrl.zip M4$L#!!0 ( $)P@DY\D#!R _^7 M,VD@G@G$MP/']9]_.?OUH7_^<'ES4[EA?XY)A+XC*!TV\^R+\^G@IR*(T[(MJ M7Y3[_8__>'L*/?<#_BL !'Y$/[J_G(WC>/KA_?O7U]%X#-!/21*[=C2P@PF\+YF2K$C9JW:0^'$X MR]^F$T7$'CP'+^_3'_$EHR]*_<)K21@"%7GOI;]6O.@0M_H=^($"5WZ"D*5%DRZBC.GLA>\%S_KYJG\> M_-4PT9\0)*D,DA_X?C*IGL.)P_?Q;$K>PT-]>(J$KIV]%[EV]43P0\4T43BG MU3J+^LV5- MEZ%)?ZB *(E#[B(,W\.O9P7)0NTD"#\ V?]$-&?[LE(H%!\&(=D],L9 MBGX_$^K!6^2// ;WEAL1P09M0M[B>YS5_9/I.@56X\^' MY"DB?R?$CZ]?X)]'F/C\S8WZ"]]_(9,G$M*G7<>UPAF;[2$.[+_8\V/BC>[) MLQO%H'$!0O;&F>" ,IM8'I#[YNNG,\%U?CFS54TS51,E,O'=%"@FH_T$B/!1 M,D3\WS_>;X-S@6H72>3Z)(K.;7@RHH.Q=VZ *B&HE9LH2HAS&^)_<0@<^QIT ME.4_P_B_6V%H^7%4HJ+S)^5I2>S+>O%CQ5R40/\B7C !=?&OP$/K=1F$TY2H MEYX51?DLM^&]^SR.Z3MWF27((%A%5$T2M0)1J='J1V,+<#S[*"LELNZ(*-N0 M^6N"Z ;40B!0LZ-?QW98?"Z'U+7$$XWLXYWTAV2*5[NG#<.BGD(I"V8\>8]ZIW7&D41EB7&F20C:7QSH?+I4P=X( MVT427K^1$)0$N0,_HD+/'XM:4JMU?7]*PGY9VJ251*LE08&(EU8TOK-F$[!? M-_YGER0IH]WX=DC PSN/@,ML^-5"A09O^[8[M;P+RT/S?3OZ&L35EE/NB_J? M]\3#K<6=%<:S1P KLFR$,;J8%7^A!+L-?L@N#[X2.1G M801C]D?6Q/7@R]B=D$CPR:L 5LKRTU\C]]_D@R")T_CL/Y_CG[L1NQ&_JQ$7 MG_E9F%CAL^M_$. /06P.Q"M![?]!> (S\3-]K2C\0C 24O''T=[#<-G(V6>A M/0=<# FW!$<->MPS)!$-;D? Z)KX 1@H\H(@X Z'$ M447BS02'?O=$9H'O'(ITN+ V^D0 (W$$"V0Q\%FP+(:_(A)' ^%Q3&#E%_D! M".Z #*,5?$$DP6<18G!5P1P+%F"$ST0Q#51:,3P5Q<+42^!=VP[!T\D9K@<2YF&6.:/K*:>S4=>Z&4U+EXDY]9V1I3FJV(27^IW(NAHUM#GVS!;OS+ MP/<)W5#\#IKPRF6HHC7=>XD!3=*F.4!5HKJ(,VZS! M\[\"$,OL0T\8I&'Q8PW[@-HFT559QFJ"DJ"-<=R[Y DT#FR["%KKU:$@5>1* MICB0Z^A30G9+RI1V2#1TOI(RUVM2QER7,CH_NB@.E)U1)M-H&3J_@>TCSKGO MI#M]W/1SQ:M.YQI\G2O+JJ&:PSHT=ULL'=>K5)N?;(J$# WZZB@TI/?&15_4X(<8U?5!$"]:0L?2]6\ZM; MZ3VHJ"5E6?Y.J/!8*1,:JLCOQV!>>QS=H%%7\GNQ$X^OQ*NTF!IU);\;D1B[ M84RJ^0&V6F_1!]_U?CF+PZ2M!#Z,;TP)7:&SD,?B13$DUMJ!\A079. MA"$_M&!*)MB)71.!$Y4]##D6LA&6(VA9*%8:UL98JM!;11*,PX"&XR4^&7U) MZBMB\2.?+%G(,'1?K)C<>99-\!RG<6!M\<6*O"F-YDV9]1Y#":BAY_AP2.G"^[G@(C.837\^%8XOHO,Y7G;)NF,K)/#K[>-U"V?, M>CDA 7,6_N,-JQM^%BYOO_YV??]X<_'Y6KBZOG@4SK]>P8?[F]_.'V]^NQ8^ MWYQ?W'R^>?SCFTVVN!Z-4/.\D!860G@@TY@*JB";/:P#,H5W103B,2FLCUT M[@HT_?P7Y^>?>@(^?!E,II8_$UQZYE$Z]8]0Q\!WTUQ/ "QXBA\';:1BO :E ME9DR8Y7F*P1A!)\H!D'HPHI8'C[!<@ %:X+U1)C$8OF"]0R:\1E?W3_0/\@] M>6CT#-DHP?YN<5F>0M2I:(D=+)#=/$#WR9+:T0DBG+L,P&HNO+@(AR"Y/GO0 I M,QO#F1,+%[)25[4L MV[JVO*K,_T'ZNC219S(!\"-TL)=E?N[D",S+*4D^2F6901@14&Q'(_!R:/X4 MS;1ZS4I\X!4+\X% DI,I_:M=BD@]T9!ZAJ%S:%)8LSFNPY\7" 6\#'"3-"\> MN==N2U"E@:1I92L#>$U2#P' MQ!J>8/E U$C8 5CS,EO$ <#4#GVEGJ+H/5/4*OAC(%RC 4OA!Y'..(#F2RQH M2\ +3+Q/%\%O:Q'P=OUR*CH^]9XTYMXT(^Y;6))I'/7!76# M$+9FNC%47Y6 C"8FH\IS8E$_D#BIPUC*/2Y;>Q"L M0X(]@KT#A::\$2EH5V!6ST5O)Q "&US.U&?#DQOJOSED9"5>++RS(OP,$#N9 MYT\Q_"DUE,*(EGKC*S;L8"QX)BR4^+*<9>J[]ICOG"L7ZA!1]QJ'"1%G9I1F M=+O/Q,<:Q0S(=(<$WJZ',^-34RN,,Q^ UF'!2@4;V<%T=(R.I(:0N7FH'O]. M0&^G7@+FYA,DU0?AG?M3.Z9RP?7!S 5I>$E\)()24=# MMY =)J7T6W+#?OO]_*[L>35>(2>A%13MZ'6Y1.X^L#&>F(&$SU O8>R4T#,T MM(C$11YE1+$B/'' 8GPT1<6WX*4P8Z "GZ'.Z&5"M/"]\*Y(NGGHKLJ#9:K( MIV$^I.G2TUC$$;<1))D MD7BH5?$M@P@1U'R]#^@B5)WF:0UK8)M3>$G>\R M1%+ M@S1>&?]1/]D?E,=>M0Y?_?$'I\_N.3W(Q0>GAHP'ZUEIUWNZ8;94V2S MRBG;.C"W,Y_@B^6#$%.JC2T:)K>]Q$&*E;ET1-#VX0+3Y02B._B4DP>)V8+" MSR&A6R5*<^"()W>4A#:K8P%5%A'0XO"7AX)"(D+#+!8&5+PLRISYGD^LQ!1H M1DC,N+YBWK(>H34OX.VB#<.Z+&K&$KJM.)C^1$V8[[7;5FA%U10AR6WB9,JU M1.!4/]'2(Q#B"3Y46'^Z)A9["M=K,N>;)P*.Q0M*/5W_:1@\T$@I M]/E$-U P]GRX\GJ2MRDH$>99T/$*P0SP40!\A#,;.F.](Y*O4IS1IOV7 .., M&_)M)6S$*$MG2W/A6?9?>!X;@ N2-TC9TZTL,BWZ*6$+NAIV!ZRP%4"<%QBV%>LU MU)ZN2&7)+ABOHN%*U4XN7$C59>\ _7QW-*.R2&A'DKR4TZ8*AYF<:=I::+[% M*APJ"*^P9<$M2L LW!.!+1KQ"\:3Z3G4@+T<(*9EW3E$Z18FUX9T?X0-(]"N MEDG-PC5 -?!?0KQV%YK BVX?)=@?U@QV*B9/9*WA]"5G 'YN8B7!K*@=I3N7=D7J+5.KE9#7#[(A]PQ56SC5\H7$#PD,^&_@ MFV<,0N6*)0A!ETX#MFF?JYD";7&9!C=U;L^/:IKA0F1EMS*_,,[K"46 MK-KK(069HD@POHCYWUX+9%,6SI^G"5CW4II,1%AT$8N2!5J5+%Q:4ZJK8&%I MT+"%\YA&31=*25Q-$Z^J,[;N0C(BP/8.S3G$EFGSJ,DGMG%/,R>K*F2QPEKZ M\Y)N34*,L=<\T^0F>LK+2#>'?1^X[Z-I(+_WVZ[0+R-?J-!W"R&F]8#T&.[VX:W-' MP"V*9]?@,_E1=1KJ&W+Z^F'FOZ3)AC1?EA73;P>JT0!4C0>JJ1CPL[@+2+_^]\,M!@. M^LQKWH2HILPE*KCEDC+D0;HX^W:0-J"IR6DNPK9Z!^P?;:R<"^WD)3[KQ9KQK:GQ2-B:2KA:4]'I@ M[18E8X[2:F;7#6[[<'DXU.0=H)3G5]S0[2(PS+T5DWO,)+-I]B#Z;4$(#H.? M/W%!?)@QWLFJ:2I7#B1%'BJ9'&P-YWYQKEK6(I+KBT\3(-'$G--()/58UUB/ M FP:ST2T =M:X@#_XTJX8IBFN@:O5(&W)H:W-U>EW6VT&X'0N)Y17P*KH1AK M8,D!<5^(KI "C>=);<=I#YBA]97$)0._F5C4K I731DJ&)?A&HO2"-YV:+!J MP?:CMBBPZ2^[7B>5OUG3%$U;=YDX4.X5X?5THLK5B7T#MGSZ'C!.KSO(]N,1 MZWL'%G-^?HDN-5:HL"/6K=94-20NBHJBR4JVAUD;KMWBM,ZR 4Y<9U4!9UM1 M=H!3WLAROI:LO7T$RTY ER]V&.2UR, [?YQD?@O-%Q*/ ^<$#^^@QN"*?8<;/EN^0BINN%JC!;X:1$6,M/$OTB2)"YHX-#O,%JP0\ )_C M,.C@*A<_TI?.,5N%J>'E)Q&9:V11%JO(X M2!*")I]'L%<@44#WBX7U&KA6V&##?R#A"P!SS](.4B*!%,R;E3P&MS[Y@UCA M^;QTYW8$K!S7B(#MR ETCKX* MTS18:!:7-8BYQ@1(=%LLSZ-^R2W-DXC.0W)-4[R(\QA@ M0QZ.)LDM!OWXZ,;H\-[DJ8D4\-_P4!66 E0#^E_8&*G!+0C+1-K#)Q%ZB\'V?V(04-4S'Q#B4GN]HH)((##K0=IXGS-G.F69VNA?U<4LSJ M2DP+C7;H@.F1+QT2=ECA,W[&5-*(I4CGB?_IH-DD/5#(],XN6L9H4X#9@ !4 M5O4&H[C//BTE\&EG((:)C=U]8+ 9?8.PC!Q:_Y:A?$SW-=79AZ(96=BK<]Q- MMM?.'V:=%9-) (3WP416^ 7E_I$RSX_.CCPKX"A 6(;"5.@!.XX0E%Y%&@B-TV)#@Z9N">M6Y."_@^536W(YKA>)>9P^.D22EH M8*C+C9>7@@:K42W2)?T*[[NG5TSCW<@46N7!>Y+TO% MCWQ6O7TAX;GG!>S C$*W^J28G_0IF::HZQ7(U^)0QGL*M)GAR0<>LN63QR/5C3'VP]WL*+\7L%)MX7C2U,(+[RQG84_Q[BI6MZ=_IG#_# M?CH$OWV;^OKA.//PB&*$[?TN)*.G>8#4P/?6W+ MRSK!/05Q'$P*3SK9D["3C$D?8:5E9Z^A-:W:A,=.X=U5OR,2,*+_RYEV5C-/ MN5D=6DQ@ML81B07:XZG7 @$][Z1- RA_UR&QFO8KUR8%M$AZVCQM#([@3K!K-DO":<:3Z?32CRLU[-9O:#^6M6NK(LYOV+\.R$4]W3WSCF_7#L@40AFW!/:@.\.\[ >YQ>$T-I0^-CXNDS. M.!$FA\U_H?&<*WK$'53EZ9OI]31[QHB?%"P/N6$I M>1Z2:XQ("?D7XB<8X1\A)V*P]0GDEQ;P/+I93[656 ,O.8D=WX9I3B_%KY#N MN[1HJFFJQ=3@U7 L !U&A(7;\A*6Z\@.@]>[M,_D8_!(&]RRDL-1'JGF77AG M]$6U+PT+'^O.HA7^U94T2"H6T-H.TOVCO1 <_O,A:U&?WD$X#ZG"XKHDNBPW MY0T*!CUO)-*]S^94B-Z@R]U8_?G'@D=#C8B_T6$[G.#IZ5&)6 M:/NS2J\!ELV/8%6+SWO#&*SE6\!I;767.$>QZO-%GP50L=# ME_.\]>>=Y3HW_J4U1<^P8LV5]4NC#XS;/6&]MJ^M$&]$BJJ0XK4>.%JDSFT[ MF;#>TK?8]1)_#LF8^%%>ZER%Y_J-"/:-9ZT 4J;^2F^1_\FY>KAM_V6NYRJDR%7Y*F5<[K,M= D.8),(FXMRE[(<_3, MHO/SJNJHL3L"' -+\!M\;D*$Z"^L"?K53R]WH*62--=ZVXH<2>TJ_C&X/.;@8OW>X44C?0*-WIU'SZ%A3;I]0X3UBX -"J& MSNC-%U$(E#BVJ>4K:N+/,#TH'&H7[P7H('?&"*;M 85:Z"3D(LXN' MIR1VV;7!(\I',;''?N %SQ1!U_>#%^HR1CC>E& O"+QFUQ?^(O1"N2CP?>+U ML+HH)G9V&S7\-0U=V'#@+:+9B#-V3PB]9,ZEET+0NVY"\HP./,Z1E29]NCIG MB4FTD?TS7LCCIP52%MHV=^'*L4-]SHUC4YM7,)0%ZUU(2&1ICR5G"YSU?%>: M.DG1^8OE>ACJ!Q<_L\F<5NC*[E,N.;O$/K!#OQP3 @]"S-)I=XYP0V)^L=[< M23*9C\FV2*5^UROIN>R?[(>TR^71&2GE82&\M@]\&Y(S*]">=P2ZM#P/.V4L M3=R86]NB[G(]6D9=TVA&W!UAWY#6#4[EMB!4@3+Z\.SCG:I=-:# PEG\FH7G)^EMVUBCRW/!6<#?R!W=DG2. P16#%X!U>IC9= MI;EC%HSFG[/5G']#US7B9R0T 3ZE>0ZIA,]MDD<^SQ-7S@Y%O?1*W(X@&7R_ M9SPI?>55'^\IY,P-W*;D/-O\9,B%VG(X7/3^]D4>W)BMF3->VG M1H)7)(M'1DQ_I)U,/C1>\L:IM\WFWWJD0D+3(8$Z/ 2'),NV_/S[BA1U0_RQ MH@*H$L@?Q($N#?FHYCF]''NZ3AIZ4YC6&51>-6J;&7S@Q?2&8NF6[0.1I5NN M)G>CX1:W]<4Z'F,&LF_*WX+*WCNGZ&)/;,HJWZ/-W/L"# =#J1WR[\TV-Y;) M%-..)59I[TXF#RR32DOD/RJ3.=2UCCV:7)#;B>>AQ;/A3N30XKD#DVET+-'$ M9 ZEGJ$MEV)U0MF>4(KR:0CE#FVF-! [E[:1?*K#GB1U1O.0\BF=B'QN:S1! M*/6.)9H$=96>9BYWZ^ADLCV9-/33D,F=VLS4#G3<4<\=IMX;:BUM=+H%J!1/ M]43$5#Q M')Z&>.[ 9G;;S$8I!GI/U3J3VI);1UQ=RM0*93R M]YW8HXF &CVY,YH'7 !S8)S(R,K?B=64,TP[EEAA-8==HZFF(Y_;VTNQ\V"8LH1D]2>WJ3 [IPXHG M+3+=Y)W\MFB?'XGW0S4+BK;U&1JP[8:1'7TKX[+GDA&^[864]>ZR$_3;@9=W.> =;$#\_N+RAI* M%NWJV&.%4CA/)4SDVT-IJEW$MFTQ6P7\SFD1'Z'(5E)D3KI;)@7UG7E.F! M_+L)R$JJV1V3-"VBE[NV/P=,ANJK ^U$2J1W:3([A[:Q=+9U^WA'_9.6SJU-IMF=E#3UH[K2DH.* MI'@B(KG+_@62V>6Q-PP+=K)Y0-E4OI,=IJ+J [.3R&;)TUW:SR&#/M]AVH_: MI?TTO[ZD:RUR2.F4OI.\'ZT[)6F>N=ZE_1Q2)-MJ@'84!O-G86HYCNL_]]E$ M\-PT$]GA6B++'ZG)^C\%H4/"_-4+#]#% 80H\%PG6ZY=<-I6,[6ZFVKH-[=' MNIVN>,6[NX1U_>';W2DW/8O="YG:\P86P9<'&A?>QP!HN07WT;&WTP-T",$) MDB>/[%WIK#%9R_T&]6%/-AK6S[5*QQWS (<[]Z>%FDS0YEHOX+"V-MH1P8[" M%?H&O>5# G5X" Y)E@/OMW^WPM#RX^A#MUP=%W\+>OD'<6"F79!/?-GV;M-E M6>K)P^[0Y9"[N[;(?^BPKM15BS6M%A-UI3=LZWR\6X.JC>W :.FPZXCL)DAH M=_]MH^*EH=$;JMUIZ"'ETSR17(7MS::D=8>A#>VF(?6,MA1WMP9;'58<6BYW M:C>5KD])P]9!>D_L[J7N!+2[E_IX6$(QM>XJOP-[LVVE5AZ3U92[JS:;=O=2 MP6JV5,K4+4#5UF*@M]0B^.!64^VDLG%7]ZZ\\Y#T%P?:B63$[[*\4QP.NG8E M3074;*OO?T?_2@'53Z3'U]8UGB"579>2ABD'7;K!(47R5,Y-=GG;9E=0UKBD MJ7-H#RF?"U131*:OZ=IV560[/YSIRLB^V3(R<2 VU.U'64:VD3O0593M M9+*6*\IDO:>K#7LS=15E.Y[@.Z\H>Q];P#0Y&"E(_WAON=/XPX,])D[BD=O1 MP]@*R9,5$>O/;Q?_\O0?@'FQO'OGZSQ_C4 M^7-(R(3X\26@#A2!3_?DA?@)^>+Z[B29"#;\ */I+4O'C M)>C7F(13*XQG7ZT).7]SH_Z_B!=,7#OZ5^ AK2^#"8XQ'9A[:)? MSFZ^?CH37.>7,UO5-%,33>-,2'R73>=&@2I+1C^)G+./IDC_EQ%P+22:8$\- M")#L:Q"3Z ZH"5_#\B#-2S1P4\25OK)3Q.4"XF]/H>?VITE(SCZ"M=56(5T# M^]JHWQ.;N"_(/*V@+?'66VNTW!S05V+]-4'(4O&+ '3GQK^.[#!X;05K;6FQ M(PK(V4=)6HTW'_B5>-\F<11;/H(ZIU9T/D'44G(2IU+F%9#UO5!#5;;A@48( MK23+'; /J [+NT&<2!2WP@4*5^3E>I%? GPN-UCB M,NQKHOKK-/ 9'T1@-V]'!29IF\V7-7Q&!5/!_ZU!A!JL%ND#YN#:LL>_PLS+ M3&W0M1[^^9 \1:[C6N'LP:)>"9H.BNKCF.!S=^ !N_;M: 1^F/^\>LD5_I)+ M13P+T*T%.&526)Y5@)OK JZK^P5\F+(8 D[^3F!EK\%3B1]G4\9:"]\S@%>B M.6R,H"'5V)Z&""ZYJ^?HBCY3/KV8S1^YLV;XU?FK%3K7?R=N/+OQHSA,\,OH M-@:?_A&8G'FT4>;!.K]3IY\XY\#=UC/Y)WJY5U9,/EEN^)OE)619;BD;,[DU M^I),&2.&5W B-C%"&_@X+Z5:ZCQGU)J31Y;,:F/4G\+FL$0NX2WZX+O>+V> M$3E[?_1$,N=$,CE9$5M2K,RBQV81,450Q<"1D]G>B3AY%,07B81[ Y! MQS8B)MUU4<*ENXXE[E)-4SS[>*>(5QD5ZJ?='X#6&P] "0#4MP$P#)S$CE/> MF>$;38 KZ6!9!R"D/Q9A6!ZY-#]HQ)LH2BS?)K@I/H<=/C*$Y9V_6*Z'MI%Y MAA01L;'M [3A$6=L]2^^/ GL1 M:HTK!H>DP/;B?0SBD'6VRS>7SD!3:XSH8]H$NIJ5SR;L@V MQT&K?8@8J.;3IM76PJBI7*?ZHZ1JRE!O(HQ+6!^*7/?LO-PY!CDTQ2/GK0V) MM1=!-'?MN+=-K.TEL2)A()-$302G>%^22%-17D,7]K57;F171]2 5G)?EHH? M^3&RVQ<2GGM>$-/SW&F3*)DF&MQ$$4E7-+4>^0H<5B-.8\:[WNBLWJJ)'#S7 M9O2]P+_>1HUS3H#[-*U^Q9:!/Q#"\R#KG>4Z-_ZE-<64M0;(:SSDE:$I*B>" M_CV)+=G2$/X=D3/S(?8')[&!"JI#B MJ9N6D*KE+.Z!@2K*BKDWSMK7[G#U3I>7,+3I8AS'/I>K('";VV@5-]SC[ID* M&ZM,C:=)/LJB*(G-3,9QTJ2!'M5VK7+VMKX;:52-I[5:1Z^6!8=\%@3?K 46 M/(93I]5G;3S/;L/%/ :DUSMJX]I@HZ'R7O.<[7CHM+%ZE[FR91JKX[HG3K4& M!D#9\=;O&-#>S%9P,\2/F1)UK%_*!5Y@_7TJC&.(-Z^.LBL[7>UCP'F]&#L_ MM*6NBFQ58WQ"E-K4FF@JUP)+JC)4Y6^<;JOMB:;R[.WIRM5&YD33=FM86R%$ M'>MSXR&-SN2.BO4W.C=9:5&,X^;\%@Z+>":5GA5]Z_RQL4TQ^0<6PZ$NK<@L M.WW"-3 J)B]J><*BM9E5,7=[[M$.)6JYG^N'T@/F)K&O.NZO.(1-2]>MY^KR MI7T?*9M+)^IY"7YVBE(+].;(#>>%IZT7",JE\D"YI@_!^D1P8T[1^NVH8+] MI+S$H9O9^KI)6=\96>X\BP5ESV'3;L]R,%<74*K7\82QA!@Q,IS ;1+:$U)$KMV M), B#00W$D:N!YI&B,?P^5,03@1)[/_?]^?"NWQNX6LP$*2?A#@0@B04SGT_ ML3SAGDR#,!9@V/PM812$,! 19L0*!7@;[. 5L2G'"8K4$Q! G!"^?W7C,7WV M@=A@B&+81 F6[PA9+;V DN=&%&[XO_-IZ'H"&V(X $P 6BL'JA@)(YCKP"3NO MX6+BTZ41XK$5T_G9$N5DE].5R]>,1["U. $P)F\VF:;SXM-IBP12KB ,Y.:(FFPR0,Q!_T\ T.%52T!O,*3? 1L7.> R;5_#6&7E[E/WP1?#;IQZ)R> ?[WF*L$)-?O*LYW7THS0\ M^XB._L(D.,Q\]$L@$7X)A+2\/X"AKWT':]/7F4@]^]AGW["I>&/.9[T*;%HS MSQYA;OHG^*YA!E**GWGV\=,?;$KN@+PY$:SU9S3PM%TRJ^;,!UR>D8&S 6$E MG5I<)SYZ->@8&&32O"TR;L!S??V?\EL+9L- M?I8H2JJJ2]J0S50YYM*4=_AL%K/,8X@>6OM3(E95$S MYM+$;X]@*R,:UF(\N1;;@0\W@@4JS[LTY.*DGT"?AI? ^,]!N!:6P.5? []O MV3:X.2&UJW2LXO2EP1=G9EU\/GF!5=T+2._C8?F<[\0<4V[@4U(T4U6D$M,5 MIEF$8.Z?X/'O6L2N]9>+TY?G6(0 6TEX&["8I%8L=G&PI8F AMY%$KD^B=93 MU-(R-Y<&6YSIM\!+8'L2LL5?:RX#6:HXT<)8BU/]#OC^7S]X]1^(%04^["0Q M8A6N,Z6Y."5GS/G4(%"HKQYFDZ? 6VPC;NG89*51V.!)U'^VK.F'^?JQ$+U]T& /P2Q>?_8K%"_OO M/5ONM"_,MR\*;.-N[^^O+Q]O;K\*MY^$FR]?SA^O[V_./PM?;AX>'N&/+]=? M'X7'6^'N_N;V7KB#'V^OA$\W7\^_7N)C^3,/2WUM\_E:HV=-D]TM@=G@??HN MBS>#GX^N8 M+C7+2*P&,6X],)[.=\,C%4#WLM"W88[VFX2O8NV!\'+==K4!9 MN@.4[N):F=8H$R>-/I"0[K291O)FL&&T@V02[?O [$R_&S3%^'8")BF*F2>=-RW(,D,Q6?M0H3"W7Z0-6 M-CMM9'0(,!X14P_H:=8"PC_(/4D3>^*PC'9%+&7_L"R':P8[4"0UJFGM4;94 M9><8Y'&.52?14 F93+U@1D@='[-P8:6\MB:D)D\KWUKV+8GBW*9O*X[Y2)^M"%GPN(4JL_9^X/^=P'3T%\:= 6M*R1B.O*7A M9AIV+XQ8#GG'UILP#8,7MF,$A&W,1<#/QR!^3IIK1<&THHC$3-IHL#T[@1*L M[ @J/4- \\B>/9#H&;JQ>#5]&ML_56G;VGO>C=&\P ZMN,H8EP==.XM<2M;Y MUE3(.GA&P.]XJF8S'GDW9WO[Y_.'R_F?SL\_M<'HY2M=RSNW$FQS5-)M-CM7 MQ(VV4-AI%Q$0W@%&+2%1F+:(T$\]I/RHM!07B>>1N!4],APVH^X7/%ES889X M5B9@\:&'\XMV0.;1DJ[X(_#_*$#K!'2@<_P13/M$&"L M">8OYL>$$49NH\P*N9-)RGO9V?4T)"]ND$3>K)_NV*N.O=E)938-57IT,^O3 M(#Q="/S3\\!H>N0%*"S\3>D,([@O;*-('87T[Y%ET[TE?E\!-$"%2Y@Z/]1/ MK#R,C\9!XCEXKIWZ[GCXB:>R,$B0/(^S _#4L9CC2CW^%'I@YH1$V?EX!8$0 M%"X, ^$+D(-U\&9GWHOX4!CL7&?BN(W0HWYR 9Y)F9S4#\7$SZ 3R),R(K3E!0L& R!E&R[ M"F*2]@G'_([(\E)' V;["ZW,H!-P)#.Y92(#=!J?+/ M X09LVSYQAM#Q?FZ)55((JGD]@H2XU"O'3?6B.UY0!4/G:- M]+6S^VUAR:OBS&6M"B3I(;ZN;X?$BJ@":Q++6T5T4)6@^RB=J[0C_;8P9_UB M6&"R\6,K;(\&B>*QH3$QZ,HRDKX MQL_9AF/=:?IG"P3F[P%IKM0X\#"R5@PH"JS&27AW1<",N#$-"Z"TI1?F4/G( M\NR9A]$2,C4;6E9E)3Q:;P1@*EAY)+X+M+>S5.N(9(O +&*6-!T$L8]H%+-> MTV1>P/ X?!E^'+!\9^Q&Z1Z5F2+1G37#BV&RK7V3,H2%NC!%XC8J4U5--X=+ M\"Y,NAE@%64;2X!Q^X5)JJCJ\F: S>_6^TIB+GCL#B&CKKZ,W^]&5F1=K "O M:NIM@%Q)0TWD-IWY*"F&.JQ8W%T#N9H#Y2&7 [>B9)@0Y[-K/;D>+1[91D9D M?DF^; PE22V!6#WQQO U$!69VX#&P$OPM$W RVIFK\@4\QVI%P>?,4!*;ZP^ MGV J[;_I]WUUE"EM;I4GA#F M%?TU"FAS]?NIH[UIKPR5;U%D>6@N",=^R7!R1%_=9T.5UVJ*=D*X;]1L0UVO MX>@QD:-6AOA^[?BQ$D2LH$EXK8$_B88:2-K MM%X/X&,C2>U-'?R#B].6#SR,3<^I=FMB])/@A4W1K[ ^\9&QN V MO-5-0_O^9*B!D3'VYM\? P$VLS+&27AP7)K42@C7#=NUA&"W/A^^Q_$%#BW=%LASU7"FK@ M. NT"P"FI556F*=!TRQZU\>&D+2E1N'9/+N79K"W47NO]#2UG''85CEU>=9V MNK'\H!@]411NB3XJ!G#2&J!Y0$GT&&E4]V(QJKL32FH2]TZ7B@AT(X!V@\0Z--B*/,5YO_Z03-QDLB4[&]SLGX\*8"=)!?!7@;(UY%64 M+X*Z63"P!,>-'UO^LPL;AG/6S&([\@U%;NJ>+NN*PJ/>(AC;@;R6EAA*_#"; M7,[]7@=D/W8=UTNP(&3>O/TZ;9?R"=PS9/4D3@?+=N-W)*3" %,E"\F3O-W@ MEC-=S*H'8)>.L'J*<[_Q'2N@\9?O&LBZXAKR4!O*11':!95:(7Q%$M#1$5[C M$AYTA2ZKXBD2OF6.+X>8I0947[[#(F?WH8PWD>V3YB&Q;D?WQ/*N:;U0EM]< MV5%81C)^)F!FSY&E6$N#_.J4RR"ND6CR0. M^]'?H_CLHV88177/@?1 ^/S)S02_F.5#L#WKH?4GCT^/AKQGN"K\0!\O/KQ,<*6*T MB>A+JQ&3I&K$Z/7>QXY8HQ4'U1=:STT9O]0%?TX/Y9LAQUIJH-2=?4X-2=;6 M)\>R=]NXGI&[)X>-KSDLU;Q5.:^" 3;$+?#NODF7!G6V/3@RS.SKI1NQ& MW/G1R>XZ_;/;JH*1<,NZ?V1M#2X#VM",-2(M_GJ.\8SGP@VN0FR!F_H0/787(&M#B%T^ MV@ W>4ZB6-!I9P6EW.BGV+*#70;(^G'Y>)=+' BI!Y2!SZ"_2\((V_;A Y8O MY'=34LY"'PA9Z@L)GTDHD#8QS=M(2"N1Q;N$LBOF6!\<1 9&\*Q7/*C+F H; M[N1W\45(%4::[/H^ES:,#( 3^\$K=A>+\FM">^Q%VGXK'_>R,*[%>LA%2?CB MOK!SPOF/Z75P%,YP(-RVP]F,5=(N'%H-KZ17QCE ,T 0_.%HE&!S(':9;M8T MT4Y=GV3JN1'M/0141F'^>OYP=?[?0E9U_(4V/O5)3W<,01*XBR.*"EGO)LA_+ M+:%#,@$;0]OX6'[9(L*8;G;/9PU''(^I/S]4>\$*-1#F]X[11HDM]/!5>^)0 MZAD+^1@L%(QT*?)^3YA:(6TMWTJ>R$"42D!-4;00L)X0S*\@++< 'M/[65^( M%TQI$T:!^"]N&/BH$ZGW%EDC,("S"&_:S5I/V6!-TR:XM/$OX!)$K/.2+D-@"^T*\:N MO!/K+R2T_QR@.F&=1G%>VJ(4^V$R]6][Q/+IQ0L(!6NT61AE M!OSA\?[Z_,OOYW^D:$8#$+@6O511'/+M6TB[_[32XTN32CDW[_[ZB5(QI%N0 M_-Z'3U?GU*M,XC'X^/\NM]V-@[3C*R4X]C:D"S.G\ -C)%@I)[$W[[Z[YPV, M9=/>R*U M[:B*EV1::8O9M,/J_C$KJ[ M 8\]I0Q\D?4.MZAF"S ID6TVBBM)A9'Q:WJ9.WH:]")JV.V$T=B=%OFG+=WV M7XE/5KCNN XY6R_0P2$C%PME7[+]E6#E>]A2M\6(D-8:6):UU2//^YWF3MP$ M_4-T%"-6!1R587=(Y#[3]O+4(@D6VWJXM+-UC(UAGPGJ7MHWEF[H\OH%M+EX MO($7DUM8?8QCN!.\>X>Q0>XMTYM0T2]!-4[--_B5LS(@-)'5LQ+?'AWP+4%6,T8A&'22^_F W(\XQS3 ?#>@ M#>L*3TT9WF;7BKLX7+J[)TXFV*LY#6QP5YW1!E8YA/W6DP=?N.#R( DLNBG( M"()[VA6-TS\=+6]RF[?/9^RGM M&,RX5AG)6=/5A.9%X_?D+RA2S^O& EXR#SAN>7"[#VS0R6E,8" M7EB"7ADCSR1PB,>ZS,\Y?D'@&'=@\]Y!KTJ[_+!T> MN"+.'925/?=+)*]ZHD3Z(_,$+=MF',?N;JM ;VQA!VALS \T0GE!$D7))%NY M/!CN>EY^.PG=_PMLZX+!-Q+ZR]NQK.H ?7_X@,]Z013EFJM\3C!F(05K7NU& MC:?MQBTU M>5GB0:O:&J<>VCX 2DC8M"%N\XP4H-FX;V4AG&4"Z>\E,9GK=; M#_&JF83:T"B)Z(5XJ,P*E$Z]91^T<1]OA6G)C5IV7DN7^66,XI-GMF>>HV1; MT1CVOL$KZQN-=T6\N7@%C=?.=9&JM&3W,!PQ@1?& ^'<2^_U6=3M%KB_DVG, M?"+ #M;"RPMNJ"G RX_:X:42\,\);H1C0N9W&Y4D'*_*02--^WW#WI:D#;[S M8B%T]6A@V8_Q-@P4W?RW%OSQQ2MT?,)H#'"/80PT5$&FR;+MN>!1!PO-VA.: M9@PGT7@+2 ->11(N2!:5'$J%5* :[.^9&A8>Z:GL5_(JW..I;(]]T1,> *W1 MENI^XRFVM4@[C$A@<).*-#VVP0_88.@%5L./6PK'_B#I>%-&^8:$@UTU4]Y1 M(U60HVEP+[3 T2W*6_'>C"RP@I$JO+6AH.=!:](QT,O#*]B>P$0\@3>>F@!P M"/ 1)TF=WM0+HG;=61RCN.5.U1:($9DK,'178[Q8#6!Q@@3FLIZ").;ONU@/ M:QIBJ_$FJ+#N?SD"GY38@-Y%8(WB]&@'O<*YGJQTGRQ*!BP>9PY0Y4-.< "G M :PJ)FH+-$11N*^(XC/!04O1;,00%H[>^9 =D"5^>J]N/%MV[ZP7L&E42Z8X M8ZAFFKD9.#<]GL5;1;Q1?L!!0SWS*^7@CT^X5WOH[Y] 2MD#H7M M@=?M-Y4 M\ISVO0UY4#[XF(!%=MFEPS[(.#UG0*&$OX%16X$)I9;O#Q_ X#.MF$QIO+#M M!9(&!F^!"KKY.81M3FFU\CVXC9;.L=*+_%B\@69FU @)BAX(H\4*3M +KI \ MZKRE5RR1@]!&'ZAKTZ:'\306Z,LCJ#0('-'GT<#D^1][\<'2Y@&NC_>)PW<# MS?47_;+C]] >7*0B_C/-0NG'<:R=G_X=2*$J>D\=BDL[.-2?[$:FECH!&#W3 MJ 2#>F>Y% ^RBZ(HO3(S"H-9K1QU6#Y+%1$EH[22TP3<1WN><@4J"#/%T]#O M@K;+\H_2E6_'I5=Z0\7H::*X<-U=&V3[&KPP,5BF6P@[&_ @84J;N3M5!&MI MT]-31,J!%1<"MLU=9BUW'8Y&5ET MET#$[S8IB7U9+WZLF(J6Q68;S#3Q#//.TJ+:,B2+@!0J:RL:VO*O<1Q*_$8+ MX*F6RJ]W0YZV2%XHU105;'!Q-"27N227I!9)?DES>F@8YR$F4^X4-_XYRWC# M>Q5LS%1^)I7%XYM1N:YM5$7SE2GXC&OB^$HCE*$@\6OM1_8#4O5N99?)!9C+YSI8 M$6-Y'DT'\6:"Y_Z-A3,T<./Z$3BG;#/!TE9A1&P4%+<4J(S'8!G+IR3PY)AN M;3Q,<'X=8R)>@JFR49[8LI@G,1 N%S,G\!B:'AC!KC>F78"SC7$AYBZ,+#OP<')'1M($(Z7OF+PI,WV?GT55KR]<\P2*;P!FUQF>9" M%!H9;P7BO8]?;0N68B*@W("+?IS-T51R*'14;](CEWT]>Y1F?(!'9M70W MZ?'W%6'_S>&Y?F.EWO>@!%E#C&V[[NK<;DE]751%Q=@12==&[+B(NE9C6T/G MWKW;'PYATR$=#U%_]<&7P#.6BC:@#:5R*',-Q()66YAL 9IYHX<(VS2#X+EQ M\^UT<2.ZT85,F\W?9%_,;TBFJD.CR P-0%@ NNI&FNLW$F)MT1TP#3NBX2WZ/+BS..X=/1.]38]$5P>^ M>%=5]D'9]LN!,+D4W]F($'NE)9\VMR\DQ!;L]#2 -1QN0!F.D%501AR4-,P1 M44:2^HI8PV49U[!CM+LLW: QURV^N)JL6G.&DP:R?HQDI0:_]G8J)KS7:PJO MN:[P\GS<*EH>)R'9P0N?D%F$.AL,_G8N9C?TM#<(,\)^)L^6=PUN8CS;-*ZM MB4..JWMJQ%S_2&5+\M?=D2%R;ASXGHF:MSAJW/!>XAU0G!H9U^4T>FWA'=:' MDUW*NB1R[I\Y(=N^.Y+6$8K77OG4""4J-83*!KGQ+P/?9VV=?G?C,?Q%+TMZ M\K!O=9H/AZTV5M^5H#5W'J6!I!VE7VVN]!X?[/$K<-*_TY\^82'](W9+&C?H M'ZYP-HV5K&4J1^D)#FF4PFQ.H@<"8S@E&OUY3VC1.LKD[+'0H.AB5OR%Y32, M73(",&UZM09KUQX6O$N6Z7?]4FH07_Z^P<(T=X3$@2&J1[HP>_?V*!18[9F%#7HN%CS-.1"E9ZS'EC@#-T$(7( ]LG&/FZ"QO M([UCKJZ?IFYAU.96]'C9&Q;E\)34.&<(IT+)U7>F_V M5Y P&P0>5C/W#4]\V/U1KN].DLE*5E-X!Q1507=5&1A'J4ZW)9;UUI!8S;=2 MNC@<*$?I/JU%+&T+SEK#=_\6Z=20J=0UXI+?B 3J#8ARXK[$6O0P-A8R55PG MN",:WR*I&LM9)M97?9.F/SQO,J[ORFXXO+<\CSL7LVK+'Y6>/.1.(7W6XRMJO M0X&]$_1XLC/X]V6?%$%/-_3+7P!QL,HFM+8$BRJGO02WY4+.C#R*5JIXW1*C MO9/G"+/<^,I4%_6A=#+$/:X4+8.O44UCH4S[-.AZ3-E:XG#(I2_K.W!RY#V: MA".32]GA\)24;4MI1R*?$8?&J9&K]>0COF&71$,RC%6Y-$=#OF':P&+GY-O9 MR;BJ\25;4A3=%#=W--OGU;WF>_%;K,BR) _E4Z'3MYGTQ7>M#%5>G91T3*MS M1)E?-0ZK8IJE4NYCI^J)Q@!4_D9L*&NGXTD<21X8W[6@Y#PI:GYSN6!\K]E0 MALK*0^RC6YW#DU3C.RU(TE:MXNW\!NO=9./4)I(H?$%75]8K%$!M%3&M 6)\ MDSQ4)6U59/Y0F#5)W^#''&5-5A3E2%$S&J!6MZ,UY:&Z:D=[*-S,!KCQ@VZR M-!0-;962V3UNM0>P?,6@Z+*NJ\?(9K?^Z@VJHM3(3Y,-ZB$0>WP-&B#&7S)) MU$'5'Z,Z?\2&9PUPJW-(C>-4#)^")&R 6L5$4[R"HN2]-%HVO\DQ=-(\1 ML0?W;35>-2D4BMD@RG\0Q/"BR@:H\77(4!57IJ,= K-K_*(!9GP- F[3J@C- M(1#[ZC8Q9S6Q)]EXB.1(,J!Q@S34? _FXUX"%<.6=G3Q(:U2@'V;%1+4O#>LP4(];]]*\:4G[ M\]&-,7I^ U;IQ742RZ/K]9MKDSN S<7K3F]'&&%OD,>S1K._ Z&L@*2M@?*Y M[WRQPK](W.3P4=(.P;/LDIGS)!X'H?OOA7MX&OL)_'./-!-0K(1VC?ZZ#(D#H\*G=6^',D6SNQVJ M&[$;\8AOAZ+"+5#IWNG-4,TOI%TQTB=VQ;;EE>]LHC<:38,8_H+?O)D0)4__ M@S=/%"\6C@-467-U1B^YMAG*8:K0(C?"2[!=F&-*!\)'K&@\$(H72M&+VR,! MK[JG=S#1.Z/P7JELN+]AEX&71XU*X+IQPN:EMZL_P3CT(J/L:F*/WDHUP5$1 M;(O=(#&'D;Q- [SN 1%!*/9_+57@ER^EJD2G3)K#7 9<7L3Y$@M/Q+:2B"!! M@7"X36P=N%'B._06>/)FXU5>L*#TV@Z@),G6&WZUA C<$H\(3Y;_U[%=P\7W M I;: Q+ MH-<#LC7<53<%%0'E\47]W32[@&-%:[V[D(P(K)W3K+N>:G(==DW76B7Y,JOL M%E6-U^5CU]S%-GV;KFIZI#?/,V:-)2ZKL-TQ+PQK"B1U?2%BL +IK6E4QPZ' MHY$F\0,KP$6F5,='&]&(E0I4$@BH4B;0TA 7LU]]]^^$7)'(#MUI7@@^?_ 3 M[ !2ZI6J&XM4>0S6NO:\KGA1UD197TVC%.DJ E7 5WSG5UC<^: U!_;'0:J: M,-U THU%0JV%_"+UHOAV],\@<;QGY\#_QD>F>#L>93X(G2=9_(YL/Q=5V@I-45 DEC,AUV/ M''6DO U=V(5;'G[++/#)4H_KUJJJ6BR@6DF 97K-"5O0$/,Q: >RFOM+RD.D MMC0K*\J*_O+2IJSR[[ZZQ=J?#^,@C!\7";M%TP'>O:;US4,;TZ4A.3%K/!J# MY#^&%KU/UII%E?:8DG1KZNZ>BLLMJZ9)2& 3*S8@6A7V=83[9-F$?PVI..S+ MYK$0AI>XAEF?0]CD&3SRS''-C:XB@$6[Q#^%(3L[=Q\ M?I1,94%Q-X=J$2.VT0(6#B;DT7K+XJ,PTB;Q9&W(CR=+NCDL^3#\J;!Y%)(XNP1-S8XOY67'H/M%S&GKM]2@(034[FQ&-E]I\]E$9 M&O(RR=8!:!\HK8[1:P;7#JBB;NX5I2M"^TZ"C;LI'&5NM"[@T4E M#+N!NXJ_#=ZF?SW^QEC J^MYYS[(6@Q;(#0,[*>-Z&?RO4^Q[)DW!V27*%21 MTN1M9=%9GG9S\!H03Z])'-/J*+<.>%&\A;;CTD\U)5VKLT.% MJ;BI+X'T-5>#V9>L&,A%=N M9(<$O[7"6?&AB@CGVF$0\.JX>JZ,TQ8@[A?==BO0Z<+2"^UF+SV'OOB$]# (DE:V^7_C(4 MN>%)^'%8\C3GDZX#SEIQ\2'O'DEP#$VS'"YM @Y\]DCJ&()^#&/WW[N@FB%Q M_5=)-739K(:3!\TNX%_O^(%W6R FQ&@ZA\Q-P<\BG2N.&\1A?6?]#:\QJ#O7 MXH92L8&K6 Z^56"Q(:)->V/N$E%NN$$7F:<+ZL RX8QZM,+H=T>2P"RM"75_8D^+J/K,#VXO9_)D[:T8/>?'8 MXQ&@N_ ">YWZ4)">?96&TB,:P2:>%TTM&WR17\[ 4<>_IY;C9'^G<_XL/ 6A M0\*^'7B>-8U@L.S3T@P_"Q/7[[-_7UTG'G\0#%&*[SLX",D"&/7@#(_*98L;S% M7>&E'0U>-!.N#JWW<=B8M0!R@/0YA'V4@]P[*F_53) M?HR3=?/'C?$ Z9;J5V=A,NG'JB+1';\A_5A>K!!MUAHX;E,0N D5)4.IK=$[ M.$'7?D,[Y I4%B"O#?+:$MXVU\BF-)"UC1E'6T?J#[ >*YEN6Q7Y.]J HE[< M0@G*VYFHIM)U4DJM9ZK+MF%O)/HF2:AL)N$GI<;HHOW'&PB14E^IOKS<1XF/ MI(D#4=P5X^_3#]Q"WRW[*YVP]C1M#3>NTW<5)%3-005K=?KNF/6=-M37,E*G MX]2IG9);I(JIZ)V*VTK%Z?) 6\,[Z%3<$>"CKNF'GZ1+MXS?=R^L:D\TS4[? M;4-"71L8W0[VM-2=^:TZ=,N^RW9"L1.D:_]S$ BN_1)N!6#\CC!,F31[:S"Z6A3DO-*#U= M'_9D8WF+L9EM6(^JW0)NO8 _[,10K"3#]V4LN QVE*BO>VZ_,ZDJFHWWM&2C M:O*5Z'35(6LL=E<=TE6''*0Z9$4.S;HYW]]C=8C>4[7-T_R[^I"=A,]49:-S M[%.M+=G.+^)@[9'1,:^Q+@X'R@;1KE.L5^F2?9:H,E1[DM85K&P9?ERG\N$[ M.ABJ0O7(U>&Z)F^_RF]/9^1=1M R532YIR@M5K*L(-(W1MX34H]2E38_*K76 ML++X=/RR+F>GZAS:E'M#M<7"D^]+(X&8;W".TSEMQXCH>IFH)^FR=1D_^\N. ME(9BSSB=C)]NT7#+;:Z1S;H)!;YQ[;X.*8Y<^TL#1=K9D6Y;64 [$SIZ;+>T]4-VC1TJ3_'L( _;!:D[5)_MB+'D5N.3<^^6D@&*G35W6W/VH6& MN EY# KWT\[;\)[[SM? MWD]>8>TT:UY=+?>*OQ;;Y7%6V^;X5XFV+45^J[_ MC%W?,T*[-CQ_Y7H)C+-EJW*%=^5&FKROWLR%$2ORYZSPV04M"7\(8G,EEJG$I\!SF.[[>OMX M+>Q?Q9;B94)?^'S[\"#<7=\+#_\ZO[_FJ=%%P!K1H3+$O5!P_O:03F!<::3 *?O81_ M3).8JN#HP_&@7/7^W(CEZ:#%],_%]-"RG:M*!N5D?6Z<]LGU55;XJ4OT6!*1 MU4/EN9#&6?-AN7X?)IT*U[Y#'!S^*13>T[FNB$V-EZ!(O6TVD^T2[V.I-%FK+J.M[XF$Q):,0S1F.R[(>?F1U-' M <[.@T8+R7B&^..2*\+9D.']I]2J6=DM]6C]EBT?GZ)Y F#-1K-I(FU3J']8 M/9:\:K V(Q7O)+$GFGI/K:@9VPU%?NH6:*L%TGNBJ/16IB#L;GT.I;/WHB2; M*,9Y#&C;D;;2^+L#ZO 0')(L>[-A552^(GX .XU=NQK?\OIT9&D]K:..X+]3 M2P2.E 5S6<^D%$&(A"")HQC\+;KY0.?K6UC.O5MM2>Z9DMZ3S6$SJ_T]RM3> M%T'O*;K<&[:U!JW:G6^+%3JK\QU9'0Z,UZ,1L6,A&+&=O?M"X'T\*@FF-'XM MO*;WFM+=_S1,;Z9/'WHGU>PS3V?%]ZX3^YT]^M9IW]FA8U:X'5F.QP[Q#E76 MV!*E4>@U"+/124YU6L]20\#=L<96,QWS3JL]$G8K?U3;NWU3L#.[QVQ?.K(< MC]E=A'%9,[),53K8YZK$IO[2,? 6:K@PV<;Z<2'#>.NCR*TG:?6($O,\MU#" M&Q&O^7:_6_%]K'C%W31MKWBFO-(_LB1UH0B8L$",FO1$;FIB@W=K4QM;?7]G M29KO6O#=BS#^)& FK)_0%,1@E*>]^L ^W@QS8[- (*K]/!A8V(P)5H0O[A_N M4JJD@,E])9Y#^ X A%$&(B0M &'TY*'6&\JEE13:(8#:,W#CIXJ]TN3 -%-B M8_S8FPU6\A1F4R_&DH^$C=RHC04< @5++3S@T5!X@+> 4!?"9>!3;Q!T:S-B MVO,7!(<\Q4(K:"AX65I/-(U!"14$F.3G"H5D^GALQ<)KD'B.\$0 Q"B!U4^F MX%^2-Q+:;D0HAHD]SK1.+U M3?^)V%8"@,3C(,H!QQ\ "+>?'9(,ELSP4GT6MPIEH5B%$@J& MO/'!UR:/UMN]%9-[ MC:KN>R0J[X$X'EMKR'V(J3. AGI8?7+S!<3KJZH6$)>YB,O2/A&?3+U@1@A(^XMKD^K: MO:_([!'P)ZW2BV@U=_'WRR"*OP;Q'R1&2)Y]<"H&*@UEN07Z%7%8(-O?B1O/OA!0>,X-'1B+0V]??1)&8W<*A,=J!!:/ M7T)=E/NR\>>#/29.XI';4?5@R]\2\M6:,&[[%_&"B6M'_PH\="C3]" MYX JQ"@B,5]86J#0@@R*DLB30?#$-%U25M&I"<+;$RZK-#XZ^HDFCWZHPG1] M._*5T-X9%3^[UA.8:*S@/B922EQS(,FR:DB&NA-B%K#?GJ+_#,%-O@N#D1O3 MV' 3K^( E%6Y0BZIJKPEDR[0X"!$K<6>V^.@KXF:;L@K;4'+^#,G&ZH>J]:3]ZOU=JKNOI)XOH3'JNPXW32 APU)&\K:ECQMI?+*XB4:12 M(Y\M"-ON"AU =R@\&FJRHJE;.DIK$/&XU !7HZ[DJD8R'//XA?+E^_-?ME7#S];?KA\2']PQX(XV$* M!O#UPYZ)^'$SI:-6=4=*'L@0'#A\WOH-B T;.29>JF$A )1,P]Y[' M2\?#5U7OSQ-)CK0;5.55E#M++5Q:Z-5#-;T&=/5<96&[P2+[A7XI.[ZN#3(5I&&/5E?<:]5+=^M3:(N M5_TP2=GK:XUCS=1NJBB^!G[?;J@L]KO4-6KA:%2!W!-5O:>H33LZ'2,[=1J@ MTP!%L&GJ1R?[#61?U;6>+BU?TW ZC-3)?B?[5=L$;W[NU:F VHIE635ZDM&P M@N8H&:K3 9T.6+;_G08X/0VPH^JY+C!\D,#P[CK#[S!:W*A=_*<@I,4P>!M! MG^!M!/,["4XEJ/Q-+(N[WV&I_>. M5+4IZESASA7>IRM,DY-3=Z;S@FM"89+:4^5M5$ZG9SH]\_WJF?R"'*PBS[/Y M.XW#E]-W6D_4])Y1<1?WZ2F=GSI=T^F:MG5-IUUJM,NPIVIRSU0Z[=)IETZ[ MK*E=:'E;'*1)Y*0FG--IFG=&3]*&N [?HJ:IFRZ-7PX4A4Q**)@839L&$6W' M JN!EZ:[+_#&$HM;$:%CL9.8)FKNM$Y(&KS?:&5W3>K]<]+R8J:?L7+%6] O MPJL5Y8VXL-5[O$C /4!HBC^6EFR4GH&XV$;(\K#YEQLXV!,LR'JA]%H 2_@O MRT^L<"9(>1^Z8IG2.@*Z V ^D:>00B,;#)I>"0+LM08T\]M9,4.K7K&03"P7 M.]]EC>7V#TK\2KP74H2F/X%'QQG7 #UH<[DT&R>MS2H494WG#8.0O1SA:4;? M2(NZ!OO4)LNNP*K(V8: 9,50+HVQA\49N6$4E^">X2WKTY X]'Y(/_9P M+=).@(YK/?M!!-H2&(E5YP9^UJX2RS"Q(!H[6=**:"$HE$337H-7_9$<- M"2QK8M,^DH1?!$FS83$ZAT\]69Z%:Q.-"8G90H?$QE/9[!W0+#@VC$J7A+S9 MA."OM7,$X'<">WFP5OEP,>;B#(3SB#:P[-4/4'AK&7I448%) &AIPA0H=F&C%8Y8-B;-(@I58G[0K-#'& @VG1S7HOZ6/%8U0IE MLMI&\](?5$GIZ:;2JV/)/!BT@!P2$\HEN8RZH%F2D#A4"(B M@5.^R2J#OZ?FN3](/4G7>N D+;>=M2:P?8Y3*3I'R=O;?( ML1FKMH.EH4D]11&YG6:+GU=V)ZAH/-"H8<$&;0KLOFSLJT7!+M//N$EH38(U M1Y#R=.CLIMUG+[5-U#U2L"M.[K*_NN+D[G3A.SY=Z(J3N^+D3@,<]Y)UQN=H1Y3:6*G SH=T!4G?^\:8)YYLPA0%];=9UCW="M9 MN]+B(UN0KK1XDR&^D>!R5UK<.;*=(]N5%G>EQ9V>Z?3,2>B9KK1X73GM2HL[ M7=/IFJZT>$_:I2LM[K1+IUVZTN+]:YJNM+C-TF+VN>I\8V4B/2=]_I/EAK]9 M7D+.G?])V*.WH]^M,+06KSA<^[)BU9"Y]X7W%4.6]<+5];5P; 6R,0?9**7[ MIS#R+N44WJ(/ONO]F/EO3W4;1\^)46G;-Z7:SZM&R;3&GAKFUC MQ1F6C$U#U[?=J0=$QG*\)$;TG:R6]M/YPT6Q.GJC&C(*R_E\RH?8\ATK="+A MDK"JY*7;)X5WYP^7/VTRV9IFWY3%.2%>,55'+O _:$]GK$EA-4,8$B0FT@HWBN;1(SK M'7P_F-**]RA*)E,:SA1>L8L$<@(KA9\O]GQE07Q&@><%K]'!+J&EOC.VFO"! M>.) <_VJT3]3$NU_<:0R\,4V(;=/$0E9?:KK3Y.8E9\C"?]. M105.@B*BTV M>M"I5$0'TZ['1=J:BZ)O&#T#T!>8V0*\NH*D/288V/\AF"\+<>D C@NJ#OM1 M *L#]NE?/V/M\5'8.?8O+D>K]%?X]/_5#Y:8&[1'B"8$_P6K NHBQEX"80N0 M^J7N")EQ >-A]0 L%X0NQ +S,&U0$9)I$%)3 HR.6@WL6*H2 8 (F\$4]>*F M_37V?.5X@MT>"LNP@#4V!'JQ7 ]_ZZ% 3*R_$.6"U2A8VF@@?*K^@*N,RJ0,="?(0XN.&X\>U@0AZMM^NW M*?$C<@'[D)$;7P;HJB8@);?Y:?%VL29-$S5>K$DL8+,V6 MH86LF]/_N\^8: MFW2:B"1)EX::V$*D9X_[X*^WC]#@88BTW#VOV*KGB3R#)PF&RG)>:#N94>([]*3DYD M2ITJUG&HI3Z,Y:9^V'2'V0[6<6R4 ,A!*\NTF!EM#$K+5:8=-7W!"T!*>_=9 MF4V>S@3%LMXA=U#-CC"E')- MVA8JC3EAG2WK?)0^14&D.Y5@XD91$,Z6&8'VZ%K@.=K$#-[;_QK\(/5$0UQJ M0G>P1E8++-".NOA"&PTN=]LLZ@OR!FM)0XW49J5-J0 4%D !SIB&Y,4-DFAQ M,=F*CUK9'&%3+DGN:;):#@).O22:RPF-Y]'VF1A#99&X*8;U?#^9"-@*$5?_ M7=NJZ*>L&=VB.#$ARX2)DAY[\UD".KOM,&K\6MYV8D_&B&D%A#CQ*4T+@(-" M2;\$?1,F-!:7DA\5+?X^M699"[X6F'S>6=9$29/%LJ0M,"UM$)Q6#X,FQ)TR M@,LVB0M-[^)Q&"3/8XK2O(M>BU;>+&-2W#>/K3:4Z&(OP7DP'=G6'A,G\8H, MD%.R2O>WHRB$\^0YB>(%=<<6$GF;^,Y N&V%,1_P"(?: -DHP8,,U<(>VVR[ M]>32KK[, ;U;"Y CX$H9Y)-CW M]/;Q4HAF$]C@"#=??[OXJ0?.N .J-7D"B(61"\@\1S0"BH=5M-4BLP1NF%JL M3#VA*J#G"",K\4 7MV.3;^TXH#RQ9)47Y 4H,X&MLDU]MR75!#@M/.^"]V6Y M4=&=9R&L&'QRSR4O!/4ZGH#AT0=^#8."V"83#*\\82PH?,$#M$R*>VG?RN6I M7MFY$;SOD^<@=M&PPJ8#=M6P3T>O,@47ZH0K.>0L!,R:FX6 MY@BP/6T*2JJ"6[4F[0OLW%T;EF;/M6[!4+W2HT/697[!^EH"#0QCDO^H['70 M[L$'ZN/*=T"=H)5^O(NV+)4)(!=VY Y?J #YM#GS$45U6]=)-9&%=&O8RNY- M%Y?W;KR 165S^$*DPG%HDA\F5O1:TB(Y^Q\118V>)I5/(T%+7Q'A,UX=\-G" M U/0^ )86R>@%R!D=.T)5CLY B-W%,_*VSMVN4$;6S9-7-BS.7B"EAD@Y#-+ M\(@5T=[8TP0T-7ZV28@."SVVF.*3A6;D;M0@KK,T0)'R;?DD3>($=N!C:FP[ MS*I5B']JS1:[9@,QV^A>;RI*3U'*I\G1V,+36 ,?34PN%&,!PR45WS!RO5. M&^'W-2GNWFND MM963O57;R9;O!5DPM?,-=F]!@[2B/GZ0ASU9^O_9>]?GQHTDR6.MH'R@+(!_L=(42UO&P! MF;I%J 5)M)1L)8T&$7$FRKACD&49OANC_69HVX4_/4VTD@2>DJY/#@]278[F M ?QH-H.GBK!]2-(TOVXJ,3CT*#OU5/V\/@FJD*R8=4OOE1^9FU_B^+0@.$629Y$L.+/(^V!4!+9RAR<981 ,F%#1:"]?4XSUW)@$ MF\OZ5G(BM^4TKJ4_^BGYA%<&'\/4"^]PCV<4/6>3239G MLW'/YGA+D(^?K.9$^I5$R+^VK/7NZ;/WKR@^QZSJLV]^#7[V^OA^Z/T-AHY!H]& MFJ[JRCB/]-8-V6,XBY6'\HSXLQGH&^R'_ &KQ/8AE;NT-=W1]]WD*FQ=]MF-BOI!]M<'_>@:41;OMR^N M;=!]7P!3UWW=8$WS?AOCMESIO#$*5.>=/4;[[4LYW+X>H\:[8AUUCVG4#88(PVTYY'(W-#2Y-WI/>U M-+<3;:L:YZHY577!6!G^6&V%UAK\/&!?O+W$-M?7="W#<,U&H,++>P%T"%'% M9R3=M(V!]CN@:.:RHFOJ9C/WY2CDW4\JT'_U8) MQXW%=&"K7UD3+.#PL^D.?"O?V9>F/JS)\#D9S]) M4C@TB,R/83XWD#DV-*#J!=?%QT"/+UZ:Q>1R=A''44Q)F%@&8"J.;X(=Q$-O_+\J1^>L\P$1LF_OI)R.?J"ZN]EI\1=3&[:"O=( MGV@JF!ZNO43_#I1VQ'^K9I.ZS?40#$NSW.' WM1P<@O87(/>4$Q%5_8&.XJF M>.,"WUX]&:N_LTX.;3M5.HHF.E6*%<6*'5=LE'3:!(CU#AW+@RZ=+:=9]Y4( M>]1$VI,T6M#5RC\4 ^5:$6Z%-'B?C;>L4 M41OD)*"55+0O!*<-X'CV.0Q4W%5+9FC ".7/;-9FOL2.69KU*9IK SE7!G8N M7[''4,>-Z.UE?N/NI8O/ VQ[]5U=!W:N M ;5IGN6&EO;[,\&&B9U[OF'#&,]&V]D^GI,/# MGG7MQ_%04=MS&T@\4I/,H M29L/;'G.6*A!6(0,^_8(953&1A^BIP((Z$.!+['XD!9QSK1N-1 MN7F8F/6[Q?])RW QGXKCG'OLC&GLL:XZLJX8:Y9Y/\CHAF%!I&+IHLFFZ M!Z+2]X(X'8BCZJ9L&TT'48D3=)Q1RY8A*[HFB#1F(KU5+4>V[*8#L868&Y(X MKBGKYJ%(<[BQC4TG;:X#MM'FIRN5M]K2!T(Z>E.-^6N7^=^?I.KTIB%9TK'7 M*NC'@#]!]@.K"<.1;7-0LF]1'8+:!S[DVN#4%H?\^&0_$007!!<$%P0_-.:. M,A=^E96T4W-MTM\R.P2[UG7@4[IX-_ZA2TC3*+L-UE,[VONW7=\Q:'A/5L'U M=9J&R'M#7R\B2I"^DZ.AZ:JL*PW#[KUAKXNS(0C>*<9E&;+A-@SEBY/^<@C? MZGI $/[E$+[=E8,0\<^>X&VN,08XZ%7OXP>::KS\M8\TY@-G5'=:=9\L>9;? M3MOIL8E<68H/L,DA)$EI&[VI-,NP[ V'DBW[Y)"\<*J8'IA&&[+L[TDP/=Y, M/6>-+YLDRX\LK5VBW/_SFTJJ]"$SH>EC6/\HD7":I[@UDJR'RM2CZ^:U<<<( M-A34LAO?OF(#03[:CG$WWF)131G3+;FMR;JCKQW=EWM+GC.0IO1X[EJ]N_-* M8V6/8_/$7H%-'GNH@CU>&'MT%QF:X(D7QA.]B@Q=L,<+8X_F(F-CM&VT]S#S9OZAPGX=]RC[M=>'?A2]16(,BS[X!&=^X) ) M?[[P_#B?5!UF;-(LG5F]_(!-+Y(E?P:?X,V)3%5J,%B2E')=+C/0DE M'[6T/_-7IA$?Z^=*>ZNV':M6&EYAM?55',W\M&LK,8O??LXU'5>MP+Q\:0MH MVG4(L[A=!TW%LAM!\['DELOX/?!TE'C!Y>Q3%-[1UGD%DB=!AHIQ,[;9O\O) M(&W;A=F.:!T'F%>.(>NP=5O,.E5/3#P]KD%6G M4C%MFI1:KYCLO&*QK>A:L 1P/& \I9.XZ#BFL^OS :P#W:K/45M.EC)^JI D MJ7U0*$YJ&%SB+$:9JGH"GI4$_Z*MS&*T"<([.N90FOCQ))LG*1NH!:0!_RME MD[@F1;L2CW:E&.+V=>[5)PX>_I5AE-;03*>2T9EBR!^UN6;UV5X;VL&!M34E MK >X MV$U'.GE-$+-.3'@>S1HB2[=92JDU/$0XH(UE.@!1I00\7Y!$$P]]04K+?&Z; M-"=(NP#XZ0'8 B7;WR0%X.!GY(7ZH]X4&PB3E26*6<32)* I&/AWUJJP.NJ0 M^03@3:$X^@97\ 33N!9T'^YF.@V7MEVFSYH[>@ZUP[?43 M37/UVNRC1@#ULH=-/D<%:'6O80P,EAOO&U!K GYH%I,]'(1$52W5-8T!_(,# M6D]?+F\N!I MSE(AZ75+Z>.7\\O/%]+-V?]W<;TF@L=KK>U\GCTJW5!R?P%R M?T5RR^P/LG0-^)KQS,!%'#WX"9JTU,*C["JEWC=2!NFH/L:9N4Q#TLF>[/-2 M@R^\)ZI)F RN+PG?I2N1?V>$*F&P!0@=(IU&1?8;"%L_FH(.?U]\5@.$!7TF M$8CV_^1A'Y35^<-K+_#2-/9!EU&0<$BLCX-MV6>W)'TDA&F"6=&&7BK;P*_: M W3OY!M@@?XM-VAH8-*[]0,_]0G[G0T5C4F"(UYQEAA"=>LE9/.FN$O%J..\ MA(Y$S:C50T)O0E4C/$554CY'EB'06RS0=(KPXT*9XSMR9?=$O#BI:K@(]"%L M=1'%.$FZBAE\=77EI9$ OP/& =XT6 F)]I7U:$T070 _&/P/ 4LPRSS,Z:X"DZYBB<^L)YAK&R#XI MJ?(SXTPZR'H ']#XKL8BP*T#A*75[^J\3_W(TM<@E')%+!G]%CJ\",7)":#P MT8NG[+C3/^'-'?HOB?1(T"V%CP"_"^(%Q:#C)9:]("5Q2.<88(ZK/\_FB/)3 MZ8P]E61!6CQ5)YE"A51:ESY4,9+/(P$YP&2J*0/Q5[ M ZV>N[ %%AED%ONP[O3@'%_]94:F..*$:N1T10@O#:]<_>,QIIR& JDTN8%58K?DI#@!=K;_"[\^]RDRU4QDCQ+(]#Q!=ML?78YE:%$*#,@"3@[PYI' MNMIY,,1PSM@RIX.:X*M5)JM5*/5Q>G;&BXS D&]#*78<\5)/B%S)5KMN(OSXQ!YGHTU5 M&U,-D2:KJB.K5L/LR8T\_8I:V(Z->):NRXZACH-XQVR?VE*JU$2(+(6$^M^% ME&$QR\9:Y#6GR5H6"!"[ _\=#">OF2JV);M:TP;DAZ#*2++@6TB%#U$,V T; MFA:"UY;>O:[)KMY%!0D1<+R.AZ,\_0,9 L61KV2/%_'Q\EXMQA3&ST3U?RUG^[UGV4A MV23%U.H?0EB[2+Y+R5R$_AJV,U4=V54.K_N%Q=],Y9NVK!I-YW:^/IW/C/PO MEY^$C=\VG&Q8LF$?GK.$RAYKO-@6D/M#$.*'G&^IYTY45_?"7 M?$+/O_13/Y"F__+/ZTNAY)\17PF";""(J=NRXS0,< !6*MS_D0)_JX)]J1=?T9 M7LWUW)EVO=URL_/_^X;BL2F9Q,1+B/36#]E/WS>7$*(?<^^C+&7;MD%E=0D9 M](/7+K//!!=TNR:634LH6$U5?Y+0]L.?I9,3!MKJ4S_@8\6G>\#VOM)] M@-2;W-<&0AYC:J,HIQ?E]**<_L67T^]G.K9PH-^O=UCY\24$;II4A(L@UW%Q M=7R'JW%^:-X;4QP-<32>Q='HIU5+LRC#>[*(R<1G8=@M>!(]/';?TP]0RBYX8&$Z ML 7M #H> :>."'G0S(]T;=%-861$,63EJ(FSH_3HWXO*R9;6I"UK]C&M24&5 M#51YS@64PVOYKR3P<++6PHO3)T#N5F^A*AG&#^N7EZM7.![MW[@ISX1!7/B%#V/4R0*YIX5N06N1JY@ M^OY(DP\&#R02@;-&N5#@9O?Z+TYS_-U M, \=8ZN8U4+H":$GA)X0>J.R]D2 3?@_8\35N$L%EY$!DG:[4QLQZ0\ND555 M5DU-ME51,#@RRO1Q$W5L"3"2CNZ?2)+\*#ULZ.LN3,&CN0.]2![A$3QW-AC/ MA?L1I]/LWY>]E'$L[M&!D46[[;$YMZ+UNN"%E]-ZO8>NW[7GV:/2C3\GB81C M^;Y& JYC2N(YT'TJ@PQ/P(?,%F C M8HKZO9]@?SE92N^]%/XB^8FTB*-;VI*"_FV6I5E,YV#0O^5C,0[/7["OIQJQ M;O'E23:;^1,?9Q&F$< 6!$]23&#]_Q#:7CX?U9$4[>9#\)RC!8G!*@[OI"!* M$M9;8Q;%CUX\9YENMAFG#(T>128C18XH!3>%7MA M2J:GT@>&3_) "X!IN<"]%]X!A?U0FOCQ))LG*3Z'K?.S #[VL@0W!\ML6AW0 MP!8X/3@_CN=D'.MDO<]BY*,!N+\<6J IJB[7#D*5%7$B3>SC>(^">+$ZM8KLXD!^Q>3Q>U7_%$Y#A3J9$ M BTQN<_Y?1&E<#1\#X]VX,]!)N%S['[K"=D]2_WRO.=XH*SWW]\ 5^Y/R89# M#U1^^^7R4_+]J505CD>08O?> ZE3#>P2) F:MN4N)C^M$O)M\OWR8S#X$[]P M[H_'B+<9E7OTVP!"-F6B\?! A5%:XZTG(/@M(:$$:$5P4,XBG>] &^ 86\I& M3'#&&99G4_%9D^D5OD+U@\#,X6UX89O6UF,ZLZ8+;)VF>!:F_ M")Z0]^C$DWR6;A"!^8E?1 5S0KZ1.8@5.F 7'N+R,HI\ &D.>_+ANW F;@EL MD7'_*I/L5@'["KX6LGWO5QQ9:9RE@QXG797Q2-E\V7[O@718@#7VS9\STA\> MOG_HAFQJ+H8R5Z4W>/Y)?C#@0("AE($ RJW#@L?K5B*SFN;>OZ(813>LP>2\ M%S,1.,&F*+ 66';>@^<']%%@;@D-'G\()86C6>3:1BMG'H$_GKZLR)DI22:Q M?XO*XC9Z($RV%2BG!'GTP?8$E/HQFL# V"%*GX%0J-4!]V=2%@(%IW5=ZP5) M=!R65C59LU39=MTV+ U&>+KF]GC'D1&G-1F!6&70 >1U;3%^/OA_F'FVP=F2 M<^D J ZR*5-P2!J9RHNJ+N:Z6N"OC46(%\<3'3Q&K WP L%(/(05]P]'5D&J MVW:M!) "-\#+-<.4'3B%M7?')$$-X#^ %.CNNH[&]3P. SHCLR(,159<0S;L M-1_PA5H1KK B7KX5X0);&Z;S3*T(YP59$4?D T,#4W+EE %J&!.@9^[?A1QF M>$>".]\+1\L.+]E$VZ A<]DGY\< C:&"?D>UU;!5@RYKNBUO,T8.(N-D0[5D MVSR*E:CJFFQKG:S$%QS=NH%#^$2\F$8E$SK2F9ZT0:P;8X4F6WJ/]YI.D+LAC\N"3QZ20A?C=1930B'BR:MZEWM_P M2C^L?CDF(%I#*FS+,"PJ#;S2(U0LX5LJ#V1PEN,4-K )EDET%P(9$OK-\BYQ M%D?SY7,K,$8AZ!UX(;L[G6-H-O#_1F64WGM#J,S58#B-2J-\J\-)E?HM2ND$ M=P%(!7JMT Z>H).YE\0J+HPQVDTF]R&F!4ES!*B\8BU?44'Q-#N_Y>$5&DI0>(3AD7D#KNH $65A^;5IG40_5$Q#8JSP. MWR4@.*>,?V?>0Q2S:WUX$+1Y&A#6A/K13^_KAPK/79@<3U?75/4PZH=&<5;. M49TZ\700-EY-JSG\VP8]EC7*X@0D>B^=[_UD$D0)F.$WY%OZ+H@F?__R?_]?DO1_UKYYP9C_ M'3M:="X+//&5S ]?R%WGB@J_#_[4=5.=/4-"+J?WTP,TW1,T]+> +P^>\!/ M(O 7[),LF;Z1OB4_AG[P\YL4-OWFASW?;B_?;F]ZN][CV\_AY7Z8@4JX9+?I M@/.SZ;\RUKW^1''AX>(/ MX"Y55M^4=WI22SRE?\*J"HR@P>_XD@4!6'+7:OD&L(D02@R$2."Q^?.,IA$Q MERL@=WX2Y/E--.(XI8__=GI]6EFCZC4CL,PO&.!.POBN;E@/$K50OZM[>F<) M16^2!6F!7C U:70!&*6>X(N<%)-_9W[,[,\\"2M--E;A(N6J#3AR]QOE6_$& MQ#>E54SHXL?TAGW8(QQ:2GR$,R8G<^*A98P&DC3-2'$T#@^EJBAUWMB4X1R% M_/2X34G;SSE,6+OCF- N5O16H4) EBF.'\93BA_TWZ6SZ_,!Z&4;M2(VZ62? M=VY5NM+;:A;L<+NJY-96P?G^5/HMG().' R2>A"BD;P!H5)-02T#=O?8"FT& M"Q!Z?W%+TD=,DJ5W'WX(O..#J@&-$\542^&Z-*CD8;XTR$C>^^#W#745R\D' M*R4668+?*43A4OT %Q. #F41,#A"A0%N_#.[95J%?_7"/Q=D]=NT4^GW37?[P'1(1@\"2)%S]5KNHV(3P7A]Z<'<>5J'1>?C)],7)'A.1% M2/YX(?EC_;PAL+02^N$$B+X"BX(H!0F)*&=^P\=P-\VT'%,UC[;Y"Z;I\'-TN]H&D$VK M4PAW/YC:X=ZTN9QGN+:A:FICY-]L%X(%VN>-JP.AV-5"'CA-\/TL_L.O_Z]1+,ZPLKL'?E3(Z[VC\ MHJFJHUJ;;@?Z@'M0E+0[BCKW*&J6KCO&[I-X0)1\BR M"D]/FVBIVOCT<'3=.LPF\(B1LW#Z*0);OOP.Z4P1G4L1RU+5W>8A#ZZ>-]52 MXG$I9%NNIAUV4_"'G89 M%#$!!_8]8?_]&)[E<,[G@.Z;3"/6MP,?$IT^5 MH&I7IN?Z+(:K.ZZ[ _X5:/J OR7KB>S-(?6VD'1'X!IIJZ[:I;CW0^VWD*B8+SY\6@(*ZOH!JJKFWEP7WVF'KA';KA[-,O)+WXANE#?GCW M:Q1-Z7U/=4=^,UKI"G<;KF48=5+M!J$/H'?C7E>Y=KAKZJ;5$6::,,XQ_ZIH M_>L<;3,2+[PX??KBSKW#:O@K8+/9//3!S^DU]&X2]SVY0R=L?AA17,T9!.7'PLTP8BJ10)W M # MQ+MYQ-T2H-#-,9*_Z1E[1'F.ZS)A-\VPJJM)IUJW,TALG M49)6D]PPNVN !):9'R>U5)X3/Y2/\MXH2S'OQT].I5*@PQ^"97J;ERSI-(LP M0$?ZT%=:<@B:Q0=WOD=! MV0J(9S4#4-5L65'T9HQRL/V_:@H8JJQHSC 4.,JX19Z1^4<4_WWR,3RYBB,L M!&JQ:S$BKU^-;LJZU5!9#(<^0?4#FP@@=QQS'%0_YB#$]3F(]9&''3B4+MZ- M<^@2!Y]Q-\H1=QIJ1LOJP*'[(*^G\8:"\!T(;YFR8G013?T2OBJ=.*,,C_7S MAAO('663^;? 5?I<>$H]7'WS$STT6ZFGG^X"H#O #6Z^^ M8AH+-6Z[H]C@9B=C8=:FNWH^ #U W 3'W*182P7+HP/$GS!%Z"RD(V=&=LGIZ0 MJ*JENJ8]0';" >]NOUS>7 QPL^@N.YWH]4NYKQ=?;J3+=Y\^_GIV\_'R"T_@ M'_<"^2H&[DS\**RW 5HVN8IP/FQ^(PIL5%PO#V SN&I]9-IY-)^3.)'>Q_X# MD:7K##R$(0BLK+20N?#NL /(9S\,20+^Q PF*:JJ?6N#DL.*'^2AFEK]R5Z MV-76KFB0D7>/&P)%"59C36N$\N8DG,[SON[8S2- &2D%'K:"QL]8WL, */M? M+\RP+8[F4(SIZZ,B&&A>4@*&O46&P%MZ'Q-2A>:$-@VB@4D%R/2'1P_4 3,#39J8?A:P"!B9+- MO$E*)U#7^_JPGDQ)T68(GF)@%_V%O"F!7:9L*E:4Q=(DKXS(-XG;JRT/5A&9 M)G56.J[>O_[["=$L?293VN_H(HNC!:D; 4=3_?6YDN?W9.[CN"V0W-*'V*-J MOV)T#=%647?J??HN[SU,7*,#B+)YT364BO [D*=4Z53:IPX@M\X6L1](FL%I M^)^D7IP.I^\R8"W5W#$7J9"@'HW\#B(0%$5I(4@/#Y&^ D\INJN2*@%/VKL; M2FJJLF;6@5H5WU5V!SB75@+8$E%V-X3>R3F,1=C/'#3 [#&&K.BC$ZD*["\Y_#,_8@&K]2P,TP_WG]8K@S2OV[P#S-8R[)D M=66J'C+2 /*K2 \==L/KHUQ&.FOVAM?5F!WNV\"_8WT@B_ZH(?DVA#TS T35 M]L8&C[$D$K:=UK:=_UNYAFN>/T%4/DB3IFX\PV9 #^59-(/-S- MO(XBZUI-$?6(C#$D$'#X)M^SR';;P1Y:<_8X-D_LE>S&8P]5L$<#]C#TY\,> MW46&)GBB"4^TT"C'YHE>188NV..%L4='D;%JY9=&?>'.Q,2;I21>,^@%$[6; MP[F"6=529C3-R2>7\Z*]F&; MDI84#1-"6+I)'&-'<0QEWSPM6)N7\R(MX)(&RLHK\*+72R6W13'?_'*E_UF% M?Q= *QO@-,-KVN.'WZI(MTS3K/:MY#:ZVPI#@W8C_-:9KJ[IU29\34 X"Z?7 M*1#Z/@K *4\N_IVM]J%KBAON3-5?=%MQW&I[PUWO[PIM RQR9[ ")35#,XT> MH-W4VZPQIW';!&WCM(VMRYI U !C_%YD6_AN(T!?2'KN)?=7J6.2B&Z=KF;MHTV0UKX?TI2I*S!\\/T B[B3"] M$)N9+U7&.R_Q)UT)I/ )I"J*8QFV7=M3&]AZWE@[6BE\6EF*HBOJB/?U%^U9 MCZ8M,POPTB@*<;P -7.OXKQ')5U\S;@U#)>G7[=V:A]^(Y65UW=A*CQ).+)= M?"5LFMN%%X=PL)-=G25A9]R.T<^>-\\FDVR>!9B,1?NFXL,Q*&W\C6DV>Y/(MJ9+LXFT[IW$,ON/)\4*[GW@+# M,9MV=!Q9TGI'K66)Y?([Z8]-@;>G[S["Q')YTG4'K1_SP0Z =[#:P@AG5M*9 M/JS L6L[54<1[53%BF+%CBMNS]S .5S^[*G'.CULZAVFTE(V2._) PFB!14- M6T/T1X1Z<[+5J"#<&Z[Z7KZ_0DPKV8M#Y!>P3.WIUI6S1VD,Y-?UP#>:N M*85E.B&HPP2+;FG:8#2KS'E/"LU*!Z^#LII%\1Q#W+2_KK?<_B+VX8E% BX M(R%.@ R>\'.RP(1\G\V/_PWT*?Q&U34=.WV&$Z@GGA034-P !!:4>.PZ!LO9 MYM[?= [PR7%K)/#8/'Y=E0>JS?R&>N;Y]&/RUOE_"+J(AA M(_AFWC/L+5-6,$I_WH@H?(X'3@RG/LQR /) ;#"\H,/)9=5Y TA?!?Z2WRV3@R4\?SJ[?+7^?_O3]E/; TT+WXEX@_'/X9@(]\P8/_9+Q@*ZY\.*Q_ M98*32;SB+CUA:J@8#Y9(;V^B!?B,A]^KI=0:/'W/.<:LS"G*4GPOECHG<.#H MW)F*"RK-HRD):+H^#NFFN@:47X8U.&%5Q^(W<@4B>;&?T+\A/B9U?$P*?+ : MIB0_WVO-#\A2:V.U#U.G(0/BB=41Q602W84@.,L7/P+4@#0)7A@F,T3Z D#P MDZ)+L82U7"1^H$65L(T2&+J9,%>&[&4QF05Y#2IM,Y+X4WJO 58(/,F0AQ_E M$)45JQ'6-]$_!LRX(-\F=#)\7O. ^G -F'KUJS>-J&625A D1YA M5!M!0%D](-0,0@MH4 073=CS.G=UI8;N:VY2L7-5M[L28#&P$,)A"_+Y#M>A MRR&WF4\#%'DM-^[%I3\"/).! 1A+ TKU.B+@Y 142D;Q">.+TIB_]P;I&+%Z MG&X)B-^: $ _BTX.QR,63G-'!B0U$Y.E%Y+KDGB*PS^8HA@.KV9G!JM9 5^9 M6D)-45WW5'KGH2+*%A%S.#?6R8U3, XA9=;D(;^IS3#UK:LXR>, T]+Y1X.! M,G<1$D 8(W";42[G@VR87\UN/"227WD,A]05+5Y':1X+B(WV.@ZR]#2QS!)XXQ& M,$\N'V@ 5WI[G=VF ]D(CF8.C$.U5AKQ_8]5JX):4I^)A]'A.6N:(57"<,L M\?*/E23C&FE6HVDOE2&K4<(:8NM1"(EYZF! 1X_+>,>93ZUJ^7EEHH^+#6;)M_FANW15T^CHQA= MZ ;G]SNT,[Y7'@'O**9Q'O/*.P,M"9:CK8AXI%4*(K3+:!6:L!4FJ7P/?L.) MD3[-^X"U Y*P^%.5&/_.8!NS)VG90N,1> \L*'_". J#47BWA3;,[KC2L6S1 M>KCC[%ANAK-F%L0#M1?:;@Y+V[Q$[M7>\MJP[55;)_-SE+9?VX)6JI@R524(U6E1>Y!^4BN$>L9'QYF9(0@RA-_ M[@?8,CO=2^O;Q(H&7N@VK@S>TI+[PXR$T5 MQ#-L=H$CLE,P7#9;,R_YW%4EZ;"-LIEUY-;UYO*^C]ZP,F\T)H%/9D7\DW,1 MZ"T6<>1-[N7"3',^8T?364=AZ H@4A-2ES2L_SR Z%#].A M_46NR^E?KG+MOL)\$4BA:8PN.OR%Q F+FM#841$JHHOTWY,_5 M0K]VU6PKM7!12AO4?(K@_%.)_X"'!%L:[-^'1G.Y%?F&:VMVM1/$KO=W!G=W M P&-6T3_BV79IJH= -PO43CIT.B'6T7]BZJJ8-\:34!>PM 'U V: ?$[4*B* MK< _G:$&"X4UE=Z 4^5$L_[Z1.Z\X(*FJM*ZT_\A033W)\G_1 $*?6PKMJL0 MUU1<[CYL2]FPCQPJ/KQ=>CZI_.YBB@6G;3,L?';=!9*]7O"J:[SN8MOK"*W_E9 O8$KL3^9MA\PR:W,; M-VVERV;/Z=5:O/#B]*G3)HPMXU,/M0GW1-';;^*OZ^PVH=DZZ<5#M=7?RM]W M;]G@:A_5<95N6P8!-"H6Y;8$,%3=67.!ANYYOPIC=[Y43+Q,9EK-POPA>)F3=,1,4[. M\>-'#%=2_5'4Q[^5U&.'C\,;[]B>&AMMUH3!-S8$W*JJ!SIA)@X8T MND!]LR4@E3>LO9I!=AXE*?+Q17$;U0T]NLUM>ZF626QEI3-[!64N! M\T ?Q7$4TT-'4Z+*%>"3^2*(G@BA35W0)P:H:"2G !"V4F^^X]>;[_SUE93+ MY8UMEK^7:>$[#[:M&U6VW3]!:,BC7U+$4 M4S-L!S^[&M1L#H^@L T\M+D)%[^&/2>I/J"T;/^W4:*;*E7>Z86JN9IJ; MMKD*Y\'V0^T$&F*;>,'_9K&?3/T)JOD&.^-*/U73+-5V-ZG$'G?F]$TI;@#8 M4!37,.Q-UL=P^^E *;X85#774 S3.>K./D0Q\>_"QH3:HG;A)Z=7,F&Q&+6$ MSW J(LU9.;S(X)J:#M#+MAM1:QWP ;?<1:IPC5D-^%1M1-S#[KUON<-7@ZX% M9I=NCW[+7403/Y)CJ);=3#(==?.MI1<_,*UK]D87M_V&.=U3?PO!/@K\_Y!I M'F[[U?-#7/TRO"83(!R=5,(:UKRGKSF#G0S0S-_9JYSKB'6_M MO6P8>_5N'_%V&S=I-@Q>?/ZY;KUU-V?#Y'H')]4(Z(&V_&P0VZ(Q]!9<;YD; M8RJO"MU;T;1E(,VQT/0E"J.5R&77>*[#/7F&H=HU7X\#P;YPM@ON.ERNU37- MZ0PE(UGGX#C7=395I381C0/ GE"VC)-S[X--W=;; EG$G<#^^TH663RY]Q)" MIP?2>9VW :F;.IMPK&J\_O@T+?MR1I]D-C:<$9*<3N&CC.,N';#+Z:AV>KZ/KB0= :\Y:PO/@7@ M>;<_P%=NO3?!K2I+N)7.:0MGTP?T0FZBXCJ_01+"EENK>G+&KNWU@ QMQ1SI M QD P7ORR;N#_V%SY 88X6>@UA-0#XT0FK!1'$>6NW$4A.CEQV06[D%P%1 9PVYS52'UN$TN=^O#$M-=RFP7)PQKSO&2%/FC9!5S:*3H M2Z0PKN?.3E!6"-D#CE@N!7GGK*D:3,'VZ M"KPPQ?0>^"L=#-+9I.$'!6W;UK?)?BY,_>VEG97#C6C]8IB*JQ]@*YAL%/N3 ME$RQ=I$5,^)L\O=D$25^0^)4=[#7/+3N8+7$,W]JMN(8[E9#> =H*QM#[SX* M@2#4,;J*X%F2^JS?VCL2DIF?)ALFP#?'>Z*JENI:0TS,:MJK M7 Q0V::JG)XR^D_2UXN;CU\O/E]\N9&NSW[_^.77:^GJT]F7:UX%V5Z=/'LK MF*]63X*+*7E88'J2>M^DQ NPF!$)/VPB"/@LI/DWJ,#6 "G8:7=V *G M[B9TU$PTDZX)?68 4AA*C19O__Z^J#S]B*HS] *I:(1\'DU)T2!F$F&%M$3R MK$ML>4=H#XBRJ5[@@[/'VJWDW63H^3V%=8M2WT$*[>UZW3MMZ'*'$ [28((6 MD-8 J#8^GGLIEEH, ,<0'2YK=?G?U7==5#/G_+*A239V0$26SQ98LOT2,&*< MUC&R 2%^7#:19I78.8+B.DZ&Z>?\#U.5+<->.RX#O%ES9=>LM\<9['@>8;_K M8BDFR^I_R@G8Q7N87O&KBO6Y'[N5LOGJ+UC]CG9?%*)JKAZQI.CU0]7R2^>] M1J7_%=M[3^MYQ0:O!=ROO/@RIG<%4]K-_(K$U_?8\81?E;CC8N'=WA<+AJYS MW&\G1NZP:Z;7:0\V^/9+.# MG'%C))L=Y!R; V[V,DMI_R@:$3C*H76XN[5=S;"V;[4"?L>]#G)FW7'L=9 C MRQ?&.]AW>)IVVB=?#H.+[JAN+YNEFOA(!Y0;^@>>Y6V.PKO'A@8YA=R+T -L MJ+^C5N6YO;H?]4J 3D>&FV8()X9[7C938.'Y1>.#PNME64M=.EPI_#Q(%1M@ MU4#1H0L@T^1!'\_,H"-B-Q^6L26J/LY+B\0SZ MU7"E0TUM-4+)-CR6I^<]N>U\I6]R*YLTU5E)[N!#T0'<3;?)5?AX*0<[!-82 M GPM3=K^F"09)GC1KB>-TLFNP1A.;TA,URB9J2:_JGRU4WXY_)I0U5'YV-Z\ M!?Z6BZ]A,FQ9U<-+,7*J/WXEM'SA"@_"#?;9]2A_)GBJEI\P--S[9';QC4PR M#&E?SF;^A,0]IQY9_.P!<]6;V;']SMAJ=Z[X:KN,#8NOPQS5 M<'6G=] ;YZ(#]"H>S,J/_!2MJQAD:4JN H_UF-V=>\X7AJJ^YCVWVDK/>-B1 M&63N5:W7 W5:I9GS^]Y19*N'1';,F(65<>U*OJ1YAD=+'#1 ,_!U=!.VK&VV M.W)J9(8?<^1LWN['J\L&:I$O<5Q]);EXD VJ%3YF4F9KX5\SQZ9'404HXS?+ M:"2J>D9932#MXHF;>X+?NZ*3#L!P()@LU6#+7/M:LTV^\7308Z"ZU1]W;=EN MMV53V9)Y?9R#T6++./07"_]I3[W+1:,<:86?8:R;CEZK+AE@OQO2S8^9/\ZW M3HZA!E:1H_2'''9:W,;GQ-[2*E9KXB@< C6:5?VQ+]24*N+LCH23I[.[F#0S M;K4^DP)#^[CF_97$\,O/ MS2U'D=]AO_JMJJ?-"_&H%?.?&BC]..Y;U2_7"M5M_I97-]-EVQNL\G'%*P!) M^WF0?6)I0WG&U^\'8BNF='4N4UK: MRFU"$P@W5[#N&/7#?>[=4RG+F,0K/]EI,KG<&[Y?-,5P%;VVM2U@=]NB?= M M8+;:A(NU@?1\%TX]SK%JLNEY;-\H_1X:BJL;X:+GG1K=<[X&= M9XZ/H)^],)N!U4([F=U$4= DY.KRKP)5Q7'-@?;9AIY[[I,?31]PGVWH^9[, MHQ82R.(&DAUS)7UT''1LNS]^;PU=MX85L%OAY 913-W5U($ ;6!N6-Q AFZI MAM,WQVR;5;<53+["<13#;&(\K W;:@=D US:_&$RMJTV065S&%\8#]6XJC3VN)RW,_SM8I-5A)V;H)"QWIX+6IY*%(35(I(*"H MO&4#91"GBQ@D*KT;91T]YE&<^O^A?SB5WE<_CF;86V73FWS4?O-%ABMFV,HW MGWL?>XC6$T2T-*=#3B7L=L(:6"1 <8\]0699( 7^ TF*]A;+*G[)HYG/*[# M&Y/[Z)$6F./W-XYI9SUA9OXWQ !=108&*^>]WWH!;?*?W!.2RFN[7[Z#K>.7 M;3>W+',J7:SNB[X9=C>#KSY)$TS79SV6\G=X"= 86_6?RT=B[AG7YX\NA/T_L?)5M1 M%M]^>B--2! D"P]SQG]^H[#?%]YTFO^^?&M*$Z\X,0+_+L03V*:1O/* M-Z?%-Q_O_92H,G+38XWEW8+3?!Y=*N1Y7*FHW"CLE51_MN[TV6L3?)KP3?FO%D_GKUNYT2 MMO,3YG=UZ3KH$=^H(UN#//I3:[:72N56QTV*G?PV(F5:"YY*>?14Z%"A0X4. M[56'[KLC#(IO^&F*[^4'Y@?KMRU]'$8^JM/*MMR?U MPP>2I"QD%-8",QA!3WRL&,X#0"PD HJQ95"DGP#(EO#'P-&.C5'0!@)E#3'K M<4XIA_&$O1V^V&3],E*BOVGSKG7!40:9BM>_"T"F(Q!2 B;1-)?%$WHKN01) M5VF_S]M8^H&"539_?/5HL/O6J/'=[5M-,61-=V3--+_?XJ#:RG<;(H/5W09D MUCB6M-W2YUP-M'%.F\+ZC]UK:;L6&U*=([5<95WO]8.-;B@65"H;?#NZ;&K. MX%3J*@_^X$6IF@&V#$1]7 U$-9'=^ZN^O9EY/!QC*+*J<XYF#[?\T4T$S9 MTM?C9P?9_A!ZNQF,_%"5X)==0QP^_;(AC-=O[7@Y1 MW7/F.#-]6IJ=WC0D(SJFK!E6,SX<#GV"Z@>>6:/+NM70QC\T^HYB4!3\A/!5 MM-%-!.@4"JP!!YFZ*VMJ0Q82)L0!**!;JFPX#47WL0_I(4R(3R1)?I3.*@FC MU2Q,H5R.QIBF(]M60]M6V!0OA>R:K?4_';(@JEY:Q *8IQ+C*1:;($K>W!V]28M9[94N(38VW- M/'J #V9Q-%^O8*'KY"4X64 G$=,AO_#" ,M<_00^F6%'?5@"_[X@K+5B41+'[QPPE.-9B>C@?9M5(CDG<6&6AT MK&/(KENS[%[T$,U_@"7KV,<96-ML>N>0/SS8OI"I6.]8;YYI)]>M]X^[1A MG_9SV>?663757;FP*_.Y[(H_L:41JYKJ\ M>_J"V 0+.P,K OWC! ME>>#P7'N+5##[IZBZ7('-VFJJ2BNO41Z)QP^8W+\AKWS*_2XF"^"Z(D0'CF2 M3O3@SR=2+%/3!#E6R?&>S @F7]]XWYAOU@#)W$F"MF77AJ+VB.2O9$+\!S02 MDXZS=VS7$K-WQ(IBQ8XK-JK(: +$^NR=RF%?\U9'41]2 3"OJ%E$<3YG!TMG M/";;TV4?5%I%,DD3+'_!]'7X&>?'Y)4WB11E*MG>EA4+WW@,9H-XCC&JMG*5;0G"_*3P%$.?P;1HC-(HB MD:52Y6O"58VY>9CZ>S^9!%$"=L$>*C1154O%^;.'UZ 'E"]?+F\N!N XM79K M()U(7R\^G=UNSK[>_"G=?#W[67YXL(K9HQ51>CA*0;[?:K5?-X"O#DTB]@'":CN=T_+*Q0(@HU($'<@:6(LQ(@WR)KCZKC+D!2R?F,O[RG M/$''6I:^^JAQIM*G4^E7[S;V22!CF2A]]-XG,^F2%7R&=Q(+(L:4M@F)<>(; M,(]7KH:O_/73K](5+#CWI+?+=TY^@K\O?YW^]/VI= 9"'5%=<$BQBBS=^'/I M_XVCR7WV-X4EG]669 #) S@M\1/( X09U2HL7%>Z"!U"05438X 0W*9[?R%Y M=S%A%;B/?GHO_0$HKD_8>H9W[#(XD644-3=8O2)#L.+[AA+,-;!(7J I-0# M(%(RN0^C(+KSF9*\S?Q@BM: !( FZ (#D:; .5-_@E/T@.-3>-6\?-_4]^[" M*/&9AD]CXJ6%FGZ,X*FTAW M)$0N@=W> E[N84=5O -NIO#AB Y(9R-R[=30:8!!$E%]''NTPMK;?HZ0#6ZR M>13_"MA+\D,WA&I3OJOM__$>[-&GD^@Q!)B3[#;Q@3&!O^L2Y%3Z'"]W&U-+ MA@Q25:UJLJ+4]3'@4IK#]^_QS"88JJ!"', "0X7*Y\/#E?C?JC"=,'@*\C.A M5/P&)R4EX92*B0%4X6;]1P90I]A"H3HQ X[2 =%MY6UDY+/6*UJ MQ_SL@GR"QU/6[<'#(;# P0 >.A5PJD# T<8)<8RG"V75 D[FBIK;KVA0 %! M @(7+8YT"$PJIXYNK4D<"L*I=#&;E>-MAZ&L]+]>F*%(=MB)KO/A>Y#+!?>5 MS.>57 MHM22+Y3@$*UT;$=6M7KGH/SD;//C:SH;Y*:'!^O!HT*TY(EA5/<_F,R75US% M!6P!@,#CY U\ZBUCLP*75WP&]'@FL;]@H>TB1# 43WX@MS%E2NM9J'9=:6EB M/@M-;ST739_>^_$1%;VJ.[+CN"-5].KIJA%2,=H'/LVYZUT[S$5,? C%'"?U M&[.I1W4Q0<-GX@7 TUX10<'H)O%F*> *V!DL((2Q= SQEX+$,9G3;H++^TX9 M?D4PY=SPZ >!A(%X>D+RB[JC&L3#$8%_5LF_,W9M^7: (UN%X/L! MMAV%I&82WGO!# \BMN\:9,,_:-_5]YQ;4!6VK6B:HG]F_J4OR/=H4N$%$%JM MLD1OQEED>P#PM3KL]+H^B)(YV:/4C=%Q#'-/1.HY'+D[HBM(MC"J;0 MOS"[@=E%^)D4^',_S>_#[O,4B916!<$R;[WO!SI,U#ZN"_>E?;PQ=$4)5K.? MHN,[&2A]WMY^7\$BER9#'!49FWZ8KK55H0\5XUJUA+^O8>X(%\C#Y[60;Q,R MB+NIR8[JR+JI;#I1;TO]- +NJ=N_39J@[3FG/2CG.?O3VL\\G$V"I/FAT%\ M?+Y%,_%"X&54(:!78T+%KY<4Z1%3"4U,L!RG&2F,P(IVH7VP\;H$?B49-23! MC:0JIUA-KGF8\"SHJX5'TU3J<1N )+DOW, M'5:3VAHGJZUFN24$+RK/PNE[\D""B!:RY+4$S?+:>)GNAF.;O$QW4[-JF>Y; MP>@$\7HYP%:(+6Y!BN,>!&*6@]@Z"=\12?AB1;%BUQ57OU,OPOY7EF#Y3:^9 M^4P4T!!(11B,,SND!NUT"2V=E]%X*L42G/*G'0L_8G(=S7?]YF.&>3!$[NH_ M0"=M#$ /\&I0+FNO'BC;XSA3*U ;KUY3)0N6T1$\C:YB8*?^7E7XJ0>(FE[D MQ2.59E3OR8:>KW!S!RSB.6V?J'G]Z? T*C.8D_AI,@PXC-&:VFH)7)'?TXW>*6 MA:N&JEIF3>RTANX VVOE].D6UTVU3,/1K>%VU[4TVW&$5RA6%"OV[A7VZ "R MPIVO9!+=A7[9DK0OWV\_J#:[C%V!N>%=D1;52Q,L=D2';Q&#:(Z!7C3VZ07+ ME+OKFZ\79Y__./M3NGY*P'B0T;=\)$& _ZU]LUH5-@F(1]-'9T'FL[RAF1_0 M 4[H5F685.^SM(NU-]0KV1([3,SS4EK%@RM@(>J"T&K4LFX%;+!3Z:HH M!J!]Y9(RZPD0W;6RE2DZ CK#LCN@6"Q1I M/B^]13KQ@B@D%*/+F_2B#(_>=][E19QU"M2W)$LW%&B$"%0H,T 36J/H25@\ M'V"O #+),$>L+/UA70 H$;YA^2@:=N"@8NTZUC1B]P%::(B7(O ^'O?5(2OV MF^0S1.>W@%2:P8C7)\OZ#4JR,NEE$_BTY(;":4I!OHTK-EI5\3>-: MO18Z%YB*F;3[#UF>_4=ZW91*Z%,D,SPD'M[58&TFNR&Y!5CS[@I/K P8.^T@ ME2@ZHJ!R\.<^7G;=1=$TH8-=L49UP@I"\>@66$4V"5E"8=Y?PDN+8:P%$1E) MV8LY_2> 4IA.FP8L[N5CJMV$]FG(V1GK5]> .96N*2>GWK>\ZX4_QTK7J51_ M4YWTC/OA+2&1S;.D19DTKZ-EFEQK8/^,;FL2DV,<2K((/$*"B MA'5$Q:E73-KG<.>*BIUKE.4@(CC,6B;H+.57R> I\GCDA_0@HV%21VCEE.3* MIGY:J-R.L.\'%60/5,#3$NMHPH*M/Y;90%4BE8<'.P/3O@FAKNI(JN54]"]_$:\5"65"%2PNM4=',2;HD36D@X'?HRZLSHC>>[HJ) M4*O4_W#Y+L_(KA;L%TJ_: VP45Z@IL6JZ/KNL=8_H;6Y.).Z?I,_)?@5#$$L MF;>D":K56T9!9O?0CS-:H,_(&-UB_()F\*=H-U#$H);*J7,+V)JAO$%4R"N8 MRG/9X"AP45@_(\.D(*TDC*54B\"[)CA '+M5A.0N@JVFV#]@!D>+=O*I\QLU M,)>"EY'N"!E4'JV4+/!,:ZIFI5R)EVY(#<\IH%I?>Q0H@ZSA?ICY]LK3L@+ /*"E0X;V%1^$8/^5_.AZB&MY&#[3Q&87^A- )\K35SB)+T1*ZC^A>LX2Y17/B8=X9/@DF M5H*=&@[;Q20J)L#)[5/%9_?R $),O.E3 =>Z,[)NR/A) 5C9!M #HPLT M\RP+X/L+?Y)6+. "&AJ%XOF0(Q*.9T%0NFZW?I#[HU[%>L-RU-SU6F8%EM6_ M*)&J$1[4#@&M*/)I_J>\C%$5%D-".R*2:1FX87YNP1YR$>9(EDXE]5!HFR2? MWH\P"SQ?[Q0HB%JJ"A+F/FZ$BVZ2_A$S3P(/W!=JT'L)31Q!LC%PDBB8CHA. M>YQK^MSO'K@8*K3JRZ*P55B85CK#K-/9O,XQGLKP?YD\0;*Q9 M:OD=\9DJ%^=QQW1+:":WR[C!(TZ@AFL(%TT[BX ;E'-&V_P G+$T8,]NMR;-A>FK2Y;]V[?:1BB M?6<3YZPN4LJ#I/\D?;WX_>++;Q?PW_/+7[]\Q!:>XY1J^TKNKU7)5\02:?QW MG/L45W7BJDYE!<#XKK07$]**X'Q?6@N!X4UX/B>E!<#XKKP6/325P/BNO! M9WD]V)(1V+]QQ-I(#M ?K,O>T_B/S-)K*C75D:R!O#,A#5C= 9>!7&7.!SV< MQ3Q(=H0?H_AOL)O8W"_\'5M<$I]>O8#J\/RX[M:S"9VX/?PX\"9%Y&6(>2,K M$[:8$4?'C2X#JF=4S#PQ!5,Q%A,P9= H.DF?%J2"HI5(2C0(V5;%01YX+53R MG%[';3=N8:O%V<"8$,Z9JXW9HP@HAYYZ1?!LLF'.:4E<5+HLZE%AH4ICVJN\! M7C;,2MTTS&J8WCMK4-@K4.3#AZODH'UR!^F*^@]-UV1+J<^?&J@-DZK;LN&Z M#1L3'=]IJ#U?N?K%F]^?I&L:IIG0-;2?I-^](,.?BROACA?&N^ZC.PH%E.[T M1JIT+,O9MF4""D815J(X QUD8%)9LR&+7I:F/QM?X-?KJU?^BW 4I=G$$.QCO*(L08#ED>NFJKUS(%4YT M];XYGVY/PP3S!;A'VZ;;-\YAY62O7D_NR30+R.7L?2X+;[QOV%@HQ9YGGW(' M'HSH&]30^_0,.M'U0R6RIM1JF) @6.! DO#NYS?*&_I[LO FQ>_Y.V_I9?H) M9JA@T/A'J?@)^,P/3]B_'_UI>O^C9"O*XELN"NB+XF*5!_ ;D,>*+*;;* 7T M5KXY+;[Y>.^GY 0!H1SS&'L+SD[JIR.=;EAL[6BLNPE2CH,3!A)\L ; :AF=V$W;!+_).58+V!Z!^[VWP@9.FK^M-X<\C7NW%Z%[(U;33%D37=DS32_W\2:;;<4D%F1O.?35-0? MI1/V8(%Y_$:%I0M9@KE6U-E.DQ\;DWC_0[$**@O2 6NUI;O M>H#^0* ZG9IF9^1+%.:1?'$TQ-%X%D>CB6XI+:CO>/!N/1[:4H4L8C+Q6:QM M"Y[8Z]3UMS5'-7<)#H+_L7LM;==B%6XXN(MBR$9]6F)+MFN-H&Y8%X0K,POA ME*GC(-QP6K6%C,#NT6$:Q4];!,3ST0H'9R=+=MTN[/0:5?401*G/9GN!-D&7 M,U[M"8^7S'&&]_Z"M1HEBT9'_S]5?V^,N#\W@.4LEL>O-/"S%VT M R9>'#_1B@7!>8W\2-<^)N,)HFR,RBA6EZC,L:7!03SZ]X"SA[S]B>"B)M:D M+6OV,:U)094-5#EYQN=Z>"W_M1D>4Y MRX #1>M3+[SS;P.AVQN.KY45[9BA84&4%W:LAU?M7_YY?4G36(L0ON"Q!CRF MRHKJRJKNBL,_+L+8EB5;QBORVFOG?D.:;3MA5(ZO6E(/G;!83!EO5-6T'!H%=QP8*DF&[8KFYVNB@^-UI&8/EU%X U6 MN"[+#I?I\4(8'L_:4F7= HFH"&DHV"']R9%UVY1-MXOG/79I>)#XSLOR)40] MP_AQ]?)JY8)EP:VH"A*GZ%F<(E$P]ZS(+7 U<@73O]=Y630K]I,DH\V[6:\V MX60$GA!Z0NB-RMH3 M 3;A_XP15^,N%5Q&!DC:[4YMQ*0_N$1655DU-=E61<'@R"C3QTW4L27 <2,@ M)0=](DGRH_3@!5G>2 !GF]%^OL(4/)H[T(OD$1[!#\5RXKW'!9W&+[PX!%Y+KDA\?>_%Y)V7^!-8Z+T?9"FNO7>G M4&3%L62C M<2>SMAC9XO0+ C4@D"4KBBXKC<,WG>ES+)G]LN+6QP3J^! <$RU#A9/H5]Z3 M, )'HV]3XR731Z!E+'= ]"M_4$V$DX_A73@U7"MK6JRHUJRYC1L+O$:S]3!B6#)NJ7)[E T&%3OO"Q6$%KG%6D= M#HP7,YP!C^-OJ6>/H\"3%$/3T8(-^LY'Q[-6Y8NXR$1B7WJK-K]<'C'%#RX3 M&UZ8O,;3]E)P+_30F 6N0,MX]!#O4J6%2Y1'H5L@1B0V'=73$BUD7@KE6[IW M8Z]K$6I7J-W7H79W)YY7\N(^X17P@L0U'7RR=@W<00R+)+RN5Y3*J=U%".^% MO"ZYY(+BW2GN&D>G^'[)E:WR(KG)E318Y3^0CR'()7+C??OJI>0KF43AQ _8 M/.T.&9;:J\RP;%):-/;IA$?8^5%R#%NEK[6J)[E.O32CT[5G M!':/[8.H2*$5MKIQR+L@7COB6;HN.T:7 M?B8]$N^9U.JC5*F)$!FL WJY5D@9^$Q,"&H8:+) @(BZ_9%1Q;9D5Q.#?MM( MA0]1#-@-&YH6@M>6EPRZ)KMZ%Q4D1,#(JC^/??H',@2*(Q\ML!Z*YM'@Z8_1 M/)CZLQG!3K]^FXKVU\QP;UU#UFW]X&PG^O$?7ODSEX >?&_ZKXP-_Q7' MOI'Z-V7=[#*W26C_0PACVY9-\_!3V8_8KZ;3@?]*J8G_>T]U/AL(*$Y\HZB3 M)INZ&/8],JH(A=_F_'^)L,5'-DEQ&/@/(:SM?6-E]"F9B]!?T^YYCNQVFMDH M+/X^5;YIRZIQ^(G-SU7G,R.?C@ 6-GZ[<+*!33#$+/"1D46H_#;'__+C>Y84 M"4A]\# _2>CYAGK>=&5%/_PEG]#S+_W4#]6-_Y_7ET+)/R.^$@390!!3MV7' M:9A*/,KC?@2_GCR663PBG"^DP/,GR%M#=FU#5K7#9U@G@#%QF)OP MC@$*Q'+$B1X757#BE]"59PMU[FM:W4NXET7!D]O*%,ZBWY MMB!A1\$HBH./Z%Z)^3R"%\8_GZ=]]3>OCOR#'\+./\%2TX]AZH5WF*O!9O[L M7SZNF:^R?+PW]VM-C^U>JBR-5M4^)O2HV@^Z^D/7,N_C@=VI1KNUSU74CV^0 M(OVI NK"[?6&MG-:FI7#\X'Y-<:6.>=>'#_!!B@4Y8RG\RA)DU>!A;/)))MG M@9>N3+DZFT? =/^A,OI5( +GZ!3,L(J)+$Q?!0[$D1!'8O\C,6"#$=UHW*/@ M"NB(W;#++'_I)O:F9.[%?V]AYW&VG'#&U'%"5QU95YK>2;^>OB"C(M);U=%D MTVR:K_GBAY:-BCBJ;LJVT30H*D[0<6+7EB$KC6NI0LP- M21P7RX(/19HQ7.@TNMBF*WWRP29/T+?Z0$A';TI<2.[/D@[61"L-&]V)5O@O MA>QO#4>VS4')+K(.CG?(M<&I+0[Y\\"Y5$%P07!!<$/R9E<2LI]ZLIX65 MWB?- .O IW3QKFD]0V3UC#*I1Y55<'V=IB'RWM#74TJ7('V7M&==E76EV[27 MH8>]"()WB'%9AFRX#4/YXJ2_',*WNAX0A'\YA&]WY2!$_+,G>)MKC $.^GXI MV8T3J7F9V!_#!_ QHOCI/(NQ)W:'].O7.;UKWUO"-7ZI<6^_XZJ:O*M]HAD% MY3V9D/DMB9<@@:6,D)3)9>.9VG5L-!PZ/7Q?WNL#F<=\-U>''#74TVIV&ET MA7D"@EFZBZ+ILTMF'-?\+-.1;:5I7XW7D^4S+B+A'/,CI&(=+Y.$/O35>Y3F M'F@6WPN:YXSL;U@\_[8:JF;+BM)P_LC!]O^J*6"HLJ(U[#=S[//9RT5,863^ M$<5_GWP,3Z[B:$(2D>-U/(T._KK5)3 G[H:?(=4MD#M.ESC\B"Z(F]L-XE;X MV801-=2,UGCBB(+P@]T4F;+2M-IGM 'D[?%?7M3X*WSS@C4=VC]@K!LO/F#< M,7;DF(V]74"O*X(17+XP].HJ,%61*(WI][\7DG9>0 MZ7DTQ^=H-ZLGH85S? U9186E1=#L4$O&SH#RGIW M1*IMX^(;B2=^LO+7J]B?D.>T-T&L(UCQN;HP-N2ET:]?9FF2>B&J)LE+I2*S M4=)5&9,8K7VB8H>+,K99=%3A1M4R9[9%R;%56 M1=+GR*ED:L6AKS?2>(_D.[W7+MF7(KO/">B=MR7D9#^I/FPXD>RY8?U:03:O74RCR6T2X M9_3H?ZLJLJWTFE\D^+Z1TG'=4W.@A'J1UR62 $:8!" (+@@N"'X8M6Z9BJP, M._:ARTA.0>ZN'FQ#(UHD=HW6Y!17!0(M BWC1\LHO*GE#)(=^5YM9LB.9-#) M$"\;4COKLF6YLF8W##*+83=W+V;8C7K:M&>%H/K+//F:U;Q=H>"!EW/RC5-U M//)^OZ[B;9J$;VXT'LUP-G=*/OD/9/HQ!#/ESH>GSI*$I,F'+,UBY/8B MUI8LAK]5V34"# M9UX"I7,N0#?<(F89- TU]!(E6PD_D;@[2[2M9X&/AW16< MB,D3^_<^<27#-!W#4;5#!9?$BF+%5[/BNF(J9V^"\E*: U&;+$8?R\]]LB;K MJG,[VX)2EW5=5CKR\V#A21C(]\(G*5J0V$N!=GZXNM0!5%#Z&-6 3W(ZP0.Q ME )8B1<0*9K!\HDT)U,T,*0I>? G1/)"#"F'23:G$?A%'$VS29J<2K"=A"R7 M\F)"'Y]&P))@HN1;Q.F5= T?H\PA_0,LOOSP5+K.;C&!(O6]('B2X%\4I!Q3 ME/S__0V#O3_!0E0GR5),'DB8$?@)ER9,(RVW\T2\.,'(.ID.@-WUE ^IBFV$ M\/! E)V%"AH_@CLA@9X%+IMB7@J@!LQ55/'2#(1%E3S @XBUW] (F$K7*3+F MJ?1Q",XL$V0*L(?#EEQ[[VV6P-H)L%A^O28]^NE]CIF-O%AGZ/P<2(\>?#*? M PICX.=3GB0<\N>*Q=?$+ELUY0) ^MU9./WLQ7\3?"HW )O9;U,R\0'MR<]O M/G[Y4#7G=-MX(V7 '-R]LU/ M3B[^G8&X^!CB/2J(5_SL,U4'?WW%]]/O?/:^^?-LSOY>086I:NZ;7Z[T/W=M M>+_-](2F8H=)&F=4V5^"4(QO[KTP'T_](8IGQ$=',?F#BF RS2?*_HJCH-^# M-/S@^?'O7I U.HE_41V$KV*O1GBC$-],L9E/F"ZPR>,S4^/QV0GHOI-OMW'@ MGR1T5B\P'FWSW@,9>D76\R#@AA/2$P%UI3$!63WG:R4@?7/R,60'?UR'L 4- M3PUW" JVQ-:S(>+A#J)FM2"B8K]B(GZ)P@=0PJ0E_7PDFM4OT93F1*/#;8>@ M6G/T/ >"]2PJ-:VYO8*]*@7!VA*L;_O$:4PPS$=^D?0JUSM+DFS.@$"'=P+O M?N\_^%,23K_">[LYC:9J5(UYAML%V&!O?MGI+?:XB:/CK$TTP%0MZW7@[/\!PNLM%KZK82A\VY3CP2Z-. MAY"$6Z+>VW#K:&XOM[P[=WP\S!Z0:]=U^#(A>7S,5AHZ?'7:?1Y.]:M;(KW&4\ Q_U:S^>..GV)+I M(PB8!W^:>0%%Y^_^A%P!(O"N*X5SY 4DV7VVS1UGNS]T;MCM<="I S=6?VR. MSFH>=0/4;F%5_*>/L,"H<+M!;O:C?[;8^F9?^F?LF.Q!=BI\AM0L%3Y^<7@\ MD [B!Z14Q74<*SU9;<+_NJ'V$#5\!^IMRO]T\UQ6G:Q@].AG/&_T'LE.: M9[*JIT8?=38O@A@',G::UZWA^. 70HP6(4OZ&(*R]''R1>!+ZDX$Z]O<1+N/ M."5O2^/$V&Y_4+>V1-*H\&V#/! MF+D;8S;?+S84IT>G^)F@S&J LBW"7U$TMT=+\YD@S=Z--(0/, M9SC-M@S7>5&(Z]$'U?FBZP6>U#(79N.KZ%\K^1&_A5,25[")UVK)NZ5917>4E*HV#8_[F,6J ^?6ZI +S5K]WGJ\(\?FO UPS]>Q8'0Z/5XMO1[47^!%30/4\W6L M8[DO,AAQ<-1_\9N8]"9?QZJNZ>HO\@+EX)9E(W'#5[*::AM"TN\C;H)FHM[B MJUG+,DS!]'OYL21H8EQ:?#6K"W]J7U?6CU/2B//YFM90+4MHVCV]V8;8W^[1 M"M[?RZ6=-43^%J^VYQ*,UX-]\&J;8=_>XMG:FF#]O1W;ANC?YMPJ9C^M,UX= M :A[VPS_6Z+(AN:\R!2B(3S[P'7X M:A>$C\C3V1_]C:YQ';[NU4VMQZK-UX;^1E>Y+E_UZJXB@@W[8[]9C-_EZUY5 M>+O[H[_AE:Z[Q>%5>^EJ]DKQW^Q>U]WB\>J:<'GWO61IX/*Z6^+,CF#\O3$? M->![7=F2HJP+I;LW\M,&[JZN\%6N(^[4]\=](V=75_@:M\%X98%^'OIGX.O. M=V-_2R*5;0E[[(L:Y9SI;$S=75[=$EP7:]T1[ M(Q]7XZM;6[BX^Z*^D8>K\56MWLMTG%>*^V8>KK9%T[[,ED*#8'_6Y#)7U_B* MUA!29V_<-_)NM2VZ]OGVO%AIXUA#V0%;+#9O+JTYZJEVF!RI;7M_3@C/.S3N MT>=8KQ4"[6@FJ@M"M"=$PX['NM6BJZMY&(?VI5!![W YV'YJI:$V1H38:FQ\%IKJA-8;@V:GF] MSVEP6CC4O4[G>!UD:'P:FBMI[?1 '=U>"AF<#J>AN8Y63JW#1+!?,!D:GX8V M\YOT5Z^B]V!TM[GV%8R^ST@XW6VN6%]W1*C/N0(M@M+JJ?9JV;K'D01:BM0VPQ[M'E,MN^VU)[QC'L?G:.K/_ E]Y&,XB>D# M7E!=Z3Q*TDVC4%6E/@IUJZKCR%U:J-Q36\ 6VVF)P&0'-0OB\*9W\AFU\U39 MZKB=QL)6^I;\&/K!SV_2."-O?A@7-KJ,=:VJGL8&[:&QL?!C^M 1N&/+;*86 M@33E5&\C^GK&R-CH<:"QPRW"_"^&%EM''C+\*;S]_'?) 6SIP%EFB!+NXW6V7W:YB;REC&.(:B50TYKYX\URB_COS MTR>PYV!)_X%00V]'T+S",+KRYI%H'HHL(H@%1"D*B/&4#GU M_BQ)LGFINICG1.*YVLAL:L(LA@VX,/M Q4Z8QXH;+I\83F]\,F+D;#AK31C' M &<*[&Z53GGT0?BV(R#3RI3=ZGQ%M",<\&X%G<9 I]6!O%5* MZ912JBTTU @HM3JYMTHHDQ+*506=CD^GU1F_53JA)6'_J>DB9#0"0M4' E?) MY.9D$AIJ-&3:G 'A,%M"T&DT=-J<".'H]$2ICG"AQD,I3CJ$8S+I)^SS\="* MDQ3AY/:$)8[5>$BU.37"83:%,-''0ZG-&1*NRLZ4*2@U'DIQKJ1<-"NL/S57 M!"A&0RM>NH3+S IA5(R&4IR4"??_9^]-F]M&DD71[S?B_@<M,J?$5)VMW@Y4Y48X9]$TY[*O,]/;@R:OC*&& XTPU9E^[4%46!:E& Z& M=+.T,_W:A*GR*,5P@.;$Z)_328>JMJ J.W4ZBZDIYRJ]NU[3'E25!BF& VY3 M=!9%:Q 5E,4HAII&EY,[VZ]-F"J/40RU(2DJ;=[E?%N#*U8>HQAJXPY7;<.5 M6QJE&&I3CJI1AZGF,96;OYU%TIPC2>_XJ2U8*@]1Z-R@Z$(4K<%3>81"'Q*> M)ITKU1H\5<0G]/&Q^@=U:#KRP/ LEK@5T3E2+<)4>6A"G]=H['L S';NX%T% MREIMMO+MM'CU-GB*1R3"XYVG!,[!51!$\%I$Y6= -GY6-N%@WK/7U;0]1/ )<+ MQ_%"/!RGWJ>/"#RS0SO4T49'WV.?$=OG;^MR6[^9.Z!$*\Y^.,%NM\Y1T';I MR:N=%+9SDIVS?WUA#C !2#I0$3<@! .04"CG?GG,?D,$=;FTV0+4C1EA\U00 M*_ "/\-F[,\(*.T]WGM*FGP7/G^2 ">C7?KQ3D8G!M$0URE%\$W M_AHY)>DU? 5Z*0@]G]@(.0HT51 Y8"0\>1-EM)X\ M%_X9<-G@K59@LM92O'LHIM%XA_F^,A33%L2G>(XMON2.S:Y W *0R:"^II9% M(C7!D5QE.28X]/IZHVEP$!#^L,/E3;3R?)!_++"#XT-DI,DP-C*.3_40P">M M^'+3?2LLRA[)GG\XUZHF@3WM\![G6+\<[5B56,X/I,QC=3K71Y,B6C,'._S< M!Q/I<%X]KFT$QN!(W^#40PXPE4Z/U0IM,*L\^60TG6G%44)2#BZ!8L>#N3R* MW3CWP10[U@;5>)N/AOJL.-3^H -L6%\2)>AD/CV5!*U[+ GT.)E7,^+1Z7%/ M8WKK]JO921L-YMITM(,(M>] Z.BM*!>7 MEY]^_WAS]?&ORN=/OUY=7KV_SJZ17V\/<.$6W-M@??A*>P+>"",PL+V%\@EL M5NY%*T"W"AK1MAL9KEGXMIW'OUDR!5G< Z(#O"TE])3K MKX^XCWC[?/>?(S\ T@GQ!X:K)*$GHBQ,JB%)_<; ,?,5)O.D[YA)TE[1GCSL M"K=G*0_@1-*V;14V/,> M7%@Q2*(V*G\PB,QENNYE9EUXG%:-_'O[GFN[]$L (7Y)^_3[RBT&1!L(@Y07\G::DN@2(O=,\=;HZIP%>;>V[[GHDPDZRTP%J M'P/PY>#-G'5-T*;,Y!K210H.UEY@H'*!71*7>E&@+)S(M@*NB $XD1-R<0C: M]([89NU[)K,B!!PN VN$/8_;N<#E)FP\OU?P#3V@QZ\(:/?.0W$2X-!8>B]H M>5@/[#XN_DV'&5B1PG=!ZX.J")D?H.0%:>8'L0*_OOGR_N*W/R[^*8X9]('A M)%JI@\&\6K^!0& #1FD/=8&V5V\_/J*H.B3"T*8PXU]>'=!5F5N4!?\#5Q'I.NLF9K3/_$OT2/[I#RV,-\HXA#Z&S&'!5!G#R MI9B+! '-BJQSF$#6/;!W[IUX ,;3!X$@4%.00P0],F12,#6 M#&U 2QY=]#(%G#;V#2NHN25DN(;S^!]F<1>.PSU9CPB-K%G\DC\O8,?WC+B* M0:[2>E& \@8_9]_"F$!SP,??J[C,O6T1SH(U4 8<6Q D.3J*[QG6REB3C#(L MRT;YEG,SR5S%35)8HS*J0T4'?^5%!]S;SFG([-<%+0E<)*QAX:-^"Y&D1.Q5 MC6$,/_+)*N/@67D6L\D@,%$"KY]@6N; @J^&P-MDK(ND3Y$%>]HLA M[0]_X&\=+P@2R97/$RQY2 $V'*TBAT<4&,J34(Y]]<-DJ&J#J3H?C2OUHV)Y MJ/M.OA?7RU,RH_L+R-2"AS&4BS6]Q,,"D"Z**="3$>G0( (&,ER8S:-%ZSI)40BLONN,^<'LDT@B7XOMX#*7]C#:+WFPV:@X%++X$H M1B-M0^]A.&(%#RS[RH4#WF-TM]R0[0:8OZMUR&TB.!W@PB$T@A()2!6 U6#+ MH:7U>"-._L/'*UF7PGP1Y? M&8\Y0]QE',:P[R6L@8K*BR59[)XK#AE8J-9N435C.(GB+< -GF_Q9S*<19Q# M4! ,5<._YV)8N:%T^$?VH'S!=+C*/U 5+)%8'"CN]W[%$3+"QXI(8'"36)K2 M-O@' Y?O'K"!NDB.H-!.\R;KTHK/:[C%O;L4,*L6VQ)HA93X\.SV4Y,G@$ MO:@8BU"D=M J3.5DJ?ED$!BP_)8;0*4_LKP&C ;0JDYDH=<-1KOU[X@[NR*. MO<)%<]%L/"$@#J@C39!%B L4AN'CIGEGW(-.(RDISHRAFG5L9N"[*3VK!$OF M+)($!X5Z$M"@R_P!?;7KWND!-,Q;(.0#SR<^5J"1$5Z@ MIUS@<P)N;;:'FY X7.I&*TI7B@;05I_6H6@C&R^\\'-R6$K M\<%-U'06"!F2-#S>0)496Y@$60^8T5AAD1]9P26<1\8;L)W/1!!-.FPF_='. ML%$QGL8#?4D$E8+ ?T>%4Q2_W$2&PP<$4!+SW8MAL\/^F/;+=IE[;?0KFV$ M(O[7.@ZEMR.MG63_&A*HPXDZF@\V/#B4GU3,2P:0A'U,U=FT=!MDG25U5QQ+K0V^94GG!)FE0'&:Q#Q";GE 8DV W-M<)P"#+C" MA@%^*W!./ [> =,,&S.E)1%?3.-(-M4!CO+I-5)[*1(Q5 _<(J)5!7F?6ZB-H%C0#(I__5(D%93XG6ZLL,TZC MXN^]$,O>XT">5=B#3"&;P]XYQPZ+3K_T>#7BVA:1"V! 'C+"Q+)=)RI[XLCF MOKDZ\CD .'>P&@9F[,7C$:_B? '>!0Y*;X4!-R>IV@.NW9QVU^6P;-4.]]Y7 MLH5#7I_!9WS-CV3H>S@G>E2'8C;G V_L^="L=")-1"8^N7I2&C %:0Z4<)-:([?P4.!?]'=B4!S--7@?.5[O^94I+(8E+R_!/+B(:%+4U*!B)%&>MO9\4C(4EN'9R2!@(7_4 ML7F<.T82(-ETO$!6P,>4$&3#M*X+;RYU;Z/T%EQI6;7^O$QMQO M!KE=([7\!$ *Z1C5VGLG[Y7%6S,_2 O"AU13HK)!8<5 MZFVIQ(]\61!V7->(JEW;S>I8_$5<3F3X-B4J"!YF'AYF# ^>( P$?V]<)F2I MUL:H/E>G+M^$*#T![]N[<_$J1OSB!]@U (V7B2\0Z#RB 3+ESO,L\@B2.EPJ MM(F1@X=QXY2)N+FSP+L^05+U9ULLO0Z9Y@'%CGC)52!*2^A#AQL7[)NX.\EO M$:$^W-A,X;Z/Y?%2H R %$^N#HC#;\*=+R>A-!\%9&(O;*K="WT/BUQ%#3L< MF.+XCLWK;C@ ,D1!@*2XF/R4=^:N,%I 4@%+R<0+$;K$M^C.'2D*>7 ='TQ@.2O@ M"U=+J"FRZ_85Z@*O1&MO:ZBRC8*QB0CRM#H[_" IL)B'B8@#6(GS3^'BN$XJ MCE9[X#:C7+XUG+B%#39FL/&J!C-\_"Z0!]2"%L^#5,0"@,!D 31?[P'NG$^W M?P"K9MA7KN5=:1OF=H(Z=A'Y" L*O$0!7F1I,EJ,'.AX_AOEO_4Q_K^GX@G_ MU>LI'VSF6&^4S\8=P[0?9G],6'T^?JO\ V_BPXN47H\>48H/O<:GXF^/L=5C M'SV[WGX1%,DYZ\FF^,+ AQ*'.*Y_E["A0JQ!CNV4G7[X:QJ9SJ&F&+Q[K@29#4KF )L/>HB&0F"O>P]I>&7%0:V(4NJX\BS- M=8NN(=P/2=80:8R%8<>=5W+)DFRR0+S!RC0ERCXF:@(IXH*]H\+0MV^C,+[F M S^'WWH/KF+"&C8H[M]SO8WN(IO,>#4]4GQ3*&="B6.6'(]>W4@-O"APY^DD M<<\S9@&C$4MOS./B663\&<$Q%H]*W ,'4;Q&%\4VXZL9[)LH)*T1QFK*],U'5UK4RJFA M>WT%ZUO9YI169A+3+.5!M16[6KNMM/W2SFF=\2=1U^H%XR]C8.QK"/Z*5R(D MYFMFH]S=PE<;L<>X$^!W8C[IE>937+R7E&2@QF(\E[..0F7E!2%\1NCC @UT M71R)"98,+56P9#+*D51I7.J0/"(T8K[ Q, "$!?O MLKVS%\<5.;NH@*A<@* M]EW BTFX*24VJSQ0D41&/_,=)Q9:JFK36YA)S(G_=,UG%XJJ$\5'R/9"KT?- M=- @3Y:@K^*,'7Y %H1#[1WRO^0K\SO^N4-@#Y6D!26%2D#J@R[ &TE!W*$6 M4+I*LA,8OR5S%%,]N5^G>0M^:5*F!L:FL9N6P'NZ%T>FBKA !*=8V6$87] L M6C//F>^RDE1.P^J\E5;H!YBF%RFAR[U1GSDV6\3AUHJ$UT<,LRE&KM)H@S, M$Q?IDGY"LBRGDU6;WU,0Q)G].! E]< >!22I#?$FRQ=(YVVVG-13DPHM ML'K3[AYJ[$5@H6S2-^.[M^1$J^G.CI,9@#I2$NXZO2F^4"Z1IC]0+QAIQIP^ M+(;2:/P);ZTM2E@O162']H?5U_9:Z'+Z1$PF#@K$Y^'E!!]==/B$^0&/FE#L M* X5$1/[V07ID]1\1"QP01CW#>>+Y0T#<3/K%N4V M[C.)_VQ8#2VP Z:;R;#:=LP&+((E&76W+"EUX;K+*.BEC!X3D1M *P-%)=Z9 M8J>O7"TVE9H34Q'8*=CUD(=A>'U6D'1B$!TF@IA@8#NWC]SZHR)*WEHNL_VT M,DD\^% \SCJ?TT]Z"&-; 19E,)!" M/R&'J51IRK"5*A;]B*MF:8S=M'TS6J&(,ND#B\_5X VN?9][W[S65(+(*'9$ M::(PC.(=F$HEU5#90GB3 MT+!Y+&3&8F1&C?1\PV+8JCW@S:S6!G:;!H7^_FD\4ABG0V8>F4*3@TV!@;5F M%Q7C(9XQ:B M?27[VR02+*GL\H?14!T7)JI("2P52YQE];493M7!9*.IC93S3G>[8_^=W@3G M;=>)'#*7P-O)Y;G=9KJ+9U@>A#<-TP,O.]L^.L/_97V[GEB8A(/TUE1C?;+1 M$$H2U^JSS6;^ 0*?C?W"]K3OJB4K& M9<9#%MZ0CZOAO*H@GB1&\ZD4RP8;']TKD)Q++Z#>P3Q$XU&9?&Q*+PPSKBKD M$4^V6CO>(\ZEH'W[+.W?<,_B=+'%P,ZRN$3E]UT\#*I^CG#D!\XSP2;;09SM M1T%^A_Z&RP.9?.5D+@Y/SN.P 8-ZI5-(*>F X%!*6X $:!'1@+6)?^*86#M\ MA-\O[?4ZG@PJ0N7\(0ZE]"G>7I+?!!5A2.\6KW"2(T012=#-'LV]<1R15T5]^9W%YXWOP>+PF22(92CK',J2]A)E MVQ=WOHSDUFWYS:<<-D_4+^)$H3!1T1%LW$<. &+!@OIT8&";TR(L+O/,-YR 4KXFGU.BDY^ O27JNI9>Y>?WKRA:_PW.@Q28N M1XJL.9 !7$NC$*(D/@6.FT]FS1DLU>%6999K@DGK:0XQ:2 MVX!E[X$$V7TZ<\8SN"P.]0PR"8Q7:5O0*R_M I/W5+^,QMH\NW@ M:TRS#]3J!".8V1EVV67C:Z2"GQ+EQ;686=24IN:*>#6ED1Z(L2.$F MC9)6+$Q1DQ@(^!MZ.5:F)VT/2Y,]J8F0[P/SZ1?8@ TTF:WW2_KS!5OD15)? MESO]J[YR$5#*%6M=\O.S+(8_H5N8"?$F.$&U*BXW<+N'YTIIL!I'(P\H9X<7 M8&K32<3S+4!K@?(&0:$6(,670U:H!&&_@2[IA?PW'PF!"3B?\9E?+KOSX*@A M$QV=D"\*])9OZ2%0UT 4/--H"^ L>@['$J'(F(,]<9=5K@3LD MY*P*4_1DW(LIQ.@LXS'(C+E(IMXF;58VK162[ 73I#C5F"IS@-HBWR6A9[&X MF@2/Y 7$E/ L4SNU_&H7JZSBD*J17HX[1'4!.O@ M<.E$(V"1,TU@)94/+]\$W$81=HXDO-@6+/4M%#'6E1>[2*F8*!W9$N3ZX^). MI6^DQV?'N"X5QQ4CV!8;$+3=>R^I--] 5MY#!3L.!UM1:4ZY)9<@ M=YVQ!% [8&Q& M16U"XBR)4:4=,+%3A[ARR7U%]'-C\DC&8 4LWW&'^M_8F>[O8KT^8!"U5'9+ M$4C0TGW1(>E#S%^DY9E&0.D'FO5+VPD\I\:,DW;%BDLJ=O]A^+QJZ#(;EFAG MQJGHR**SYF>;_UDXC@:R5"SBCN&6T(RPRRJ#1T\W MG"L$XL2=IK0542-7L?'U!D$*% \SPLB/2W!P9A%HM'LB''YC2GB[\<@CO\0+ M$( CQCY*!JXA_%&&E*?;1]" SF].$$HZ-OF0!)-( P993FEOAG6$=Z1B/=E[:.2 MY_*\UE=R%)4%'O?>T/Y_]*24*)1/(MTP&5W/C?4Y+Z@EQ1^P#7I MP-STR @ MJ1Y.Q$.3V;N;T@,R#0/X,X%97:< MQYPO<=TSK *P 8-0*1&0W>-"4"ZETU^I5 ='KDY(')Z\#(0'L" MI&K:2RY3+L7LD/=;%85FF&=SXW]1H6S$X 9/N7"12"!K["F;D8HNO[^ )JRZ":[UE96?:1F?9( TO)9#SCL\[M(EO6^I6938H?/-X6%N8#7-7 M5&Z*&DF%6ALY_.HJN%UDN=/,\*P@2U*&U+_#]VY)G$6N6(3?Q(T+)Y>^%]TM M168XX*TKXH[VF."@=K#!AK1)23^=H)?G;(/*].*V+;S$@P_+8E8N5F^ ( MM97',ALLQ+804=@6UV= !_\A?B#=I(IJ-PQ]9>0Z$IL$^EK8?I"C," "M9'W M@BQ!CK:!_6(@/J:2ACI&!RF>CN:QGI1RDK]YEVN3.JL7Z6ZL^)>%$Y8=*;2>?JZ,7Q5QTAY_._RPSOIP5("(^].+X8M= MWI6]H8%3AYD/HI*#,7[]+XYA?L5-*-2 F[82=[U)MS3D7?]O?>4U;2LQS;Y[ M,$R+VWP=^NF6FZ.]8P"SR7?GL487!)Y8=A? _X!WW=@8;E63W0O\N]N7^J# MD:H/9ZH^'K\J0TXB9'Y\6V$LB-JXS,/SS_:^_*[7WV/?"BZO/KGF9KWH&I,#F/J:<.>I-4C3Y6AY.:RD(> M^#JLG]A$ +DS&[<#Z_+LAB(1Z?WQ1H@Q44DW'D#V JEQ0^C'%I"L;SHUF%' M,%8/?8=, M51,TXF!U#H/L [BFCJ$'\0XB=C=3 Z1#0=%_&Q=!+_P'!I^MUW MGECY(S2=P#&,5K4'^/E&7$&RLM;DJ8VRN+]UI6/DV%]H9I M1JN(7PNT\!ZB:6=TD->6XO-LT_>'#CFM[2[NY\ M"Y>5>G8"X:7;\W\ M9 X[V+_$\AAIV52@)TFH;-*IF)02>TD2!V5IJ$V"/7)>Z@&-S1YND_36@V^L MGU3U3YH"22Q^_&++>\JR*#LHY7S Y9_8EF>;DCW4*O_OR\OW[S]\>%&$PQY[ MO>3L+6Z8>HL%EH^S2K&X$^SKFFE-F4/[P&NH5*F*>N?;F;1D'["WPP';>XKI MCH)Y3-M6@TZ&=#NUT MZ"$Z=-\3O6,K;XO/_[P8U8,MIE7;YJ_:D*['J,A1SLO-_SQC0Q^ID M6+,JHFD^W:M0M'2/U<&JCEZ>X-C!3)V/)1%,AX&F,="<:JWV7THB65VM;P.$ M.!NK^NB02LJNPOL,L3X:JL-)31N_[17>!]T\P?WM7=;]/2NP\7"NZIJDRTD= M!DHP,)QHZFA64W0WS:2G,"%^94'P1KG(U(QF"S$[Y=(88>(]\$E+[@]U:)<6 MA)@.U>ETT ZTMR)*47FG;)OUH7R@U..%J K_R YQCKK;1H>%P@?J:%PS8=%= M,WL^B)]-U:G6GNN%[:^J^'U-,\9PLC3O6^B+:7A\PG80BHF^W$RKON9#[1U7 MWGUVC&[N%DLR4YV/M<7 [QW.1<+6X%X0\,E["S&B&C]?BQ%:05_Y+3/ICF]G M;=ABA&D\WR_T,H_@!1B;3XQHTVRQW'4C,4A;>3!DS,O\8392Y_.<:==4KUDI M^TOR& 6D%^M0Y?U@,SOJ0F;)NCGJY1Z/1";TVK)1_$VB ) M4=0BF'Q8XX9$YPHD*^^CO,C<\XLKT\30;3%DQJ?;AG@US*%I&=1TN>(27WO. M*6=7E:LFQ- 5Y&VK#MNAZ$S3#JPZX\:W_GJHO3ZT@*ZY;9^Z\61YN=X^-U!W M"9#L^89=^TG6JSZLWLQ??30&+PW??T03$7>1%"/2]-GO @J9T&@. A>9N^3? M!2 ^@N,0$T,1$M&AV>/ M]EZ'\ [A'<([A#_+^N%N L795(AJJ@:N[ZQNB+PK#GX^J'^I#S5U.*@9=C\: M] YQ-CJ$'Q3CFHS4T;P]0T40R?BSQ[ANZ0QVGKA9Y=" MYA/75!^TZCYU\DE'5H579GM1B \$A7D^BRB,L"0^.TLGOD 37TX*O9(Z^R5S ML!LLUMJ?GAB5N*&F H:F4KSY4O6WS,)VHN2?7HBRY^;KW"NKL7&0C<)G&0W..YLW,GGH^SFDU;)\/ M<7?=R'"<1SZ?//,%-F+"2>3V K[!KRO[*STLF:O8J*;MA=VJ'DL;S_]7KZ=\ ML)ECO5$^&W< ^6OV9\1HU/Q=\>NJ%]%]BK M;8_IK9AR8WQCQ^W8^9&.#K/8GWE4OS*=DTGLD!:@)"P(I/4! @MWO3- M7WO YTP)82?X!TB$S.I""L#KJ6^;B5?1>[#=!\.W. 3I(S2Z BYA\"5K9CCQ M%+[T#89#NPSM>X:9!GL5K?"M?9)D#KNS X>K,-HEXPWD?N]?]S-KV)S.D\WR M_G.GQ]QP]&,.<0 :">2B_9B7M1TC>@/ F7/FRC O7 M*^C9!/>HQH!ID^:#/NNMF!%$HJ^A!2<5K''Z76J#09XV$-*B42*F.ZF1H>=F MD9,?:5F"CZ=5+!>TRHV] FQ]!#1]\5:&J_(/5%![OKTX4*#O^XK,[$[L(8E] M*@)NE20()*%$7_H6P>?!#I?*Q?6E!'Q-1SF_5NGM\\ZM2E=YF2+8?"OO5,E+ MK1QR7_65WUWPT.7!5\U!HY:\ :%B,= /H!C@E[=& /\MF,:R%[ &G&!A_\VV5A4;^10H.MVB'7:XFF MB\C=BD5AJGZ BAGL#F41$#CNZA%SV? Q;_97W#^>$STT,ZYAX((,%J2,/N>0 M/MFI!1$BG@W0E;6#)?8-1+/!&$0!GH)S+?MF , X =\^XA/$ MFU&X]'SB/S7#X=MJ^):;D4"2P/[ ;%Y\,D&:I59< MPK#(3,IA4B@BK&-@$.^!LM/8]DS$KH??X)2K0E0,B'3@*]B:"?K0@;"H6 M6;!*QAM,M(T)3(6+/29ZQ@UH/OH1^V/O1QSE*#PJSSR?8,XEMT"^V,%7I9U\ M]"$QO9">_8BF\ HB7'L8KK8QY@@T?/MOY*NL8PH4;'HN%MO%\47@ &%T^7CD M. R^!G8P[34MA#\Q@F5>%P PT2Y"I8%?>II<.#Q*4$&>RW((*SW. MIIJ4KAL+2$Q1#"++-"(NFX3Y)'USB\BUN+W^#2UFWJ@;\$CNI\ W^J0*6OH. MSC-PO[8LTKV'*/GL>QCQ4_X ;P94Q>,)E'.;%,)58ZDG:4F@O&^=%:R)66.L MP;CX1L7TC@SY](,V4"#X^F44SZ9$N=/TM? ML[MTZ'WK+(.FG\\J01[>UV+TM MYMR@V1.M* RTYE*;N[Z@-I.E4'-2"!]\4-#\9FX*#DDAD6+Q,!N4G:IS'=V" M@Q[;93B0HM*3,<1,,Y\GDT1>1W@3Z7$PT!7@K0TI;OCF;9N<:2Q'W&SD[VAT MA^.9?%X2#52R8(ED,%(&/2+A]CL._K"4ZQ )LZ\TI[":T%:W&$9%X\M ^8R6 M.9KL]I;<2)Z@!1]0^LE>H7[S@9[/7Z2CI\<9^/=L3*F=$CXK8>T@=?$\,ORQ MBFFUPKB>1V-Q#-=F"?$7I)[M6A%XC^!Y\0PU13]NH["!Z"8Y !1>47%WS/%H MX#U%+[,:Q>?>)OR3@>/E^>1'8):4PIB>X]W1 6W7]>XYX^-Z:Y22(@WXE8'# MR?S 493NX$L=.\V6^>PN'Y M&_8M_ 4DWM>?_^__493_29X!W6(9OB7\C=C=H*?0\G*Q?.\+6P R_X7BJ#?0 MX/_S/S6]-]1>*+;UTPMS-![/1C-M\.+G6C2P,%:V Q^&E"M //B8*WA;I./Z MS-FMV*WX7%;LX@I=7*&+*S005VCJ[XP.WZ:/-U1WR"YTG)C?!,W MX'_AR>I+#XV ".R 3ZE'4TNK6\P$@G&"GUYL<#T[35^=O'-#GI)?_$/C'WP_)MHY?F86 CLX#=R8*MA,II. MQU4PF<%W@QQ@TB/MMBIE,-F3S>I.)WR+7CCVLY/+T(_8B]>5Y[G7809 MTL_ NYYUO32 (R_,/R,[KD6H@]E?A N:>9!.\CV&?P-- F\X]+SU_P$ M_R(21"OZTC&"X-."]D//8"4*"RX_^R+72]\4GWH/[PD?+Y,)H?1DV2-94(V' M64+X=NL[=B^@ Y\WK'XY":PFYPVKTE-?DA>=.W*EV!@/IU40^%G3!OB?4L&Q M_=@[0 LD,+B: 3SU:<'_#O%>TW5:$E%'#C5!/*.Y=GSB.3(X#J:/T5ROI(_) M9##6]9KD\>3!3@ND$K8[(A-I\TH@C6?SZ6C: )#XYZ!9@0,P9%8.%*"80>;/ M+4:7IHTJ#ZF/=Q 4&QL[[J%*V.$2 U',7QM^^/C16#&!8!DXPYKI1\;:6S M^@ ["6..3^""2 ?8X8PYKA3H/X^&\)_6\F4C7#:O-*)D$TTCKNA@T+KCU^6 M["E.X!/5LV2+YOTVSC=P;.%UTFX9-X,EQP57H?[F]61AY^U M%KEB^T.M68-O,FC&L9 !KU-PY610Z8&<#[P.YLK)H#H*),T/^\@>Z*LJ3:_- MLW]B9:=MV8;_>&TX+$LL-TN&O_LPH$X\&V:/)T%\F4G*.!LW^Z M9_Z%XW@A>>R4L7KZY*/JZ!@_>5,'U[3><)#]\TF)FHD\E@N+2LA]]NU[6/PS M7J["-]0 VQ:>T;7A3)LW [><:($_T2Q^@EEFNS++I#JTKL]W$1C'/[O>T[7L MGT=FENFP^N3:6*\=+S\%TC4M^V>I/JE,S&T[\ZS2"T:) MDKG \N3'))+W-+"&6W3.:#H#;=V@D=*"0-PI(E''/?9)@M:G"%WM>>S#0\^# M:MNB>4.\&1K?SXC)PO0$L;IV\L7!H-+:(T+J\=)Q+5P P)8(7:/N8+T,V15X M@$'H^63OH>F7AE":3,1.*LT<661U(FB=1*%-3I"VE@NMP_7@I#(3_7.G!0^, MWHQ&LRU2KLGH33M59Q5\LP"M--O.3V_6.:Y<>;ZM"%1FTE<_0:'?<8]]DMRM M?H*LVI['/CP%JU<7W34=O&V*Q@_U&L;5 ?'GQA>'@ZH]DK,1!VM<;=R>/H5 M7_*-!N^_,=^TL55F'>UZ@2VADY#G^]7:\1X9RZRW@>HQG.;XJ*YY@A*T[W." MX5$C:S2(I?%+5D]?+)J\!M'DET 9#3:^1F3AGL'UAO _X>\-WX;F2>\#CT>#9<=6% M:4:KB/*J=)T:O_;9$B]'WS-^;[T,$-KY 6(;Y8_T:LH?Z2>F_/;=NJQL<#"9 M#$;U0'&KI2_2SAL[?9J%<9 P"KYTE*-4Q% MO!O:Q!O:/:L^3T>W2'>[WK;L>]J/WU-_>B:N!T'W^V2^A;/ MMFXT8+^+$2V"V-XV;J7;^[.NS;\?^-4P>X_O%[?CZ/L9QI5>==NAL949*IUC M7:^5>&LW,]2]F_9T%X:C&P7M./AN/1@J_:Q1C08,SX-2]E8[X\H8_F0XF3]= MW/,\P%=#ZXRKK)LS9[7]M,[DZ$%Z2=#86DE8Z6-/1MJPII=]6EXX?9>"I_M9 M5$F,4Z*^;=T9JE,957UXGQVA[!W*JLY\:-/Q=P.^&N&MRK3'>7/:?O&OXR<[ MY !C*R=4)36 $Z8M<7-.WX'CZ=XC1\_]M.+<.W4>T2K#0VT)KIT>8/MJG(E6 M:=AIVO?#9T]KG(G61#!) N'LHW$F6A/!E2, 8RLG5%92:-I,!B<<\ZK*4XIC M.#^ZS][<;>]M1G-=O.U6"7WT ^\=I!I44NT0 #.9S<[B^#6"3(.C&[E'Q=]> MH:+C6V\[G6DK755&CH?PIW8F='6:3@A'C_*8Q;2"+K=+VZ/"J M5$_#N5[;KFBE@#Z\4\;1PSB-"/7#X="TR7?&[8K=\/ M%-M(?UH9W9W6K_T[+S=DCU8TU2%P[$1S%D Z=G>5=IN6>WH@>Y!&Y61<#78[ MF6EG01P[^Q]U**39Z(L$YZ,.$*HLB\8]CSU(O?K2?'5V6@2A_H M^J01O^I( OKHH*J,4#7B8)Q."QPN@V1&J\K@<&3$5YMP@]%(KWDU8!OVOS + M;RI8G_Q+PW'*&KJ5G1L.NV,CR,OMDY^VC;<9;QNJH8\FQ3XL3Q^I! Y+S[&8 M'W#RS1W9KF<9#"NOIOP\'HZF153EWK?[?IXN,AA6WRK1)W-MKA5[_1RXH\D! M_E?U(>9; I1'!FF] ^SB@0VK^P=AE\E&$+"O0S6LK(/_>32=S4?:O,B&4HY3 MY2!M.4>EV=$;38'11^.B3I6#E_J.TI:S5=L)X\%ICK5U.Y4AH[D^G&RTCSF. M2#RN !I7EVI-]>F107K\\LUQ=07Z9#[:N%HH9?][AW2J:Z/&X\EP,ID50UI2 MCK.S!!I7URSUQL.!KHTFQ5BJ'+SL%:HYH,BHGLEU7'Z>5(O_HQL4QP_I3@?5 MJ@V^T:!?RB#LD?*-_' [+ME^$:Y!4B\ MI<<^?KIYK]1ZEKZ$SX!U;+.PGNT"_NPP_TO7\X$>^6M&^(K7\ [\A_(78[5^ M^]_? *+#M\KUS:?+__]OGWY]]_[+=?K%_*WR_G]_O[KYI_+RW?L/5Y=7-Z]4 M_E/ET^>;JT\?KY6+C^^4/RZ^?+GX>'.=73[_JCT@B9MP;X/UX2OM#M=]G]L1 M'ZAT"%F>"V]& M'6"X,O8RZ.NYO?! I )"S?!] [2D\F"'2X49YE)Y -W%-GX!=.6;2R- DFH0 M=AD6R KPH #4$."J,#%Q0P&4F_1T4V1(V^=T&/.OSTP&MH>EW/E>$, 6/9,Q M*Y"TRZ$Z'T[5\6#0SY-%,AS:>2101RY8,0^P%AR")0-,O'OF]XPX?B]+PDS' M&_*%A[Y+>0HWE=#P0TSEH1?3,9.PY6']'4L1D8/^0-N@30&;"NIT69C2Y@+, M2"*+ @%(HMGQ3!UJ>O^H]D%K[(LSLM]$O9R2%,Q]SQ;;1^ %=!R5X:"VR;86 M %S' $0.,M!1 [%K^@S=5"7@P@N^6<=A'2$L+!;8=R[]R @R#H[Y5@B\2R63 M8522J)!"GFGZ>^LMU_J&\A%G<,8Q4QDH2@SNFP:(W_//V6)X.).M?JJ#*N1^*]PB8;L\2T MOCXIM\14)8AN_\U,@J5A_3L*0DZZM%T)>UN ;LUNK2?)#2B8U;VEX2QZC\SP M%3#P5K0).XBQ9:#P0-0RUY1C]0?VMQS"@*C")9@='E@:#[@%%"T62DZ@(#M MH83RZ<:#MQ7M:"&K8MG[P'P9%M\/FCH<;/K!MPS,4=@ZLR(36V("B-?,#5A M('^P'0=^HD0H)M%NO6,N\^%(#R"2\=M8^"%; M43V:LC8>B98%N?& OB1?]P=M-E?UV?BXOL[WX:O,SC_6?"4UUHPPV^*TP/\Z M+"P--2?1H9"Y&W%G*:))5^@/R^/1:N9."O^&Y5* !I4 M&L .#:Q*BE8/KY .D= @ MY4*07(;W.,K)EIYE/"H>MUFRH0$@,R.I1E%> MVJ^D!0OT^:9(SFRE.@2.P"RJ$VD#O#)[WB3])J(PL^E^<&THS#4 @5,9 MYDIQ!: C?[&050A4Q0:Y[X*\D!/)_72?O M)4D_SV;JH.#(&@LD-:&,<&"XI*U,U.$X7T?ELS70&@ LCL-E>"%O,":R5,I> M9S\6346N18KR+@U!Y5/>9^E(4X9 >?\-SNC>99(OW"2.!\.WT[F57$A5*,JI!D'[2*CFBV+*$"5H<@I9]63:UNWF8XXDVI\ N2V%[GXS0/ 0Q6V)J,1A M90F2O SI (D @^>HYKP0X,E)'_[&;./I-S7>$-F)Q,K6Y'I1&(1@CR.;<<2# MR[^T ;SP9^2$J6:/(>L]2(HYZ]5'R&\[#8GG(8Y$ZC.J1R]DJO*Z%'3NO>U% M@>)XAC3M7T8SL,GXA/P\#8L !. M0Q@OF4.$@.:>]Z#(@\\;\NRA]]IBD[^X]49%AV6!&XM^WC]6K MWGJ&;R%"^:\]G[NG*\.%76T:IG%>2KP+:(=1544&+YD\J0$F(V9T;9=GYL(E MV.2E3 ;TQ=R(9 #Z6C+0FJM$[5&.%RUWV[.4I7&/:&4 X3\C<&DQ%TKE,"C< M#1D"_(<9A80&Q5L![&HIS(<(62!Z.!(=](2B/J@U$#. M2BF17A;Q@HPLHX1S'&'@R6*DJB!>I!H@//RBF'!X R@+/*D0D];W:)![]W9 MO@Q1I0^8MGFR-1"54%D@BG!<\B8)*GQE/.9UM_$U/8G!_3!5'!'!A]CGD:I\ MF1893L1SV,*V"/$4<+@9J@0 'VQ5RK;*S0XE"18#Y)3Z9+7PI@C]; O.JX!CB>C$CY S(GXD?H*ONV7@SG&[!?-1SF,/+'D,K()9 M8%# *4A:"1451 6REG E[V*4PSVR3=L.H:] O@F9&%&8%#2I2VT M [/23(+'-.U/2LF>V_TKH&(/Q+:(>V!50#.7L;19?[J-/=M6F9%(Z!3+62&1 MU0GQ;8L@EI=%N ,K!J2H,6Y65(!I=2.Q26#8UA.(>_ B?#GCIHW#950F$UV* M85E)\G%_4(KFTDQY.6Q;20H9=D^KM*- E.C#3E'* HJ- ,Z( 0>V /'%D6 : M^,-,&2L$VO1M]R;5_&EPM&G>FY\ M)5Y[$O5M6;)[:;SBMA<6S22! FZAQ+]%P7<+AHV+11N,7%23Q]5*-PYPXN&Q M@D6TQ:2 ?=R^BLO4,Z?*:];2T%E"Y56O37Z0U_R\-OVE^4JD4=.G,JY=CWFU3=%F5F[#IIA!%3B'_Q^.T9F3R:B_CX R.M+'C5J/.2(LD$!6I_!%:' 7\H7N-'20XG:SC8* MX:L%28NLPD1,9A"+& M9>/'H/.I7E)*^GBXW7K:J8*XU#[(URM*L ='A9X8>Y](2KG35IK,1NDKG(+3 M;W$^WVQWD& Z-E=Y2"P6<0T:6J6]$+;;W #H4&1UTO 7268X5, R]O&&2#8V MXT^E^I=$8D,.TGB^65Z:NT@EQ'=;&E=PXF]/P#LM0BD&3-7X%DW&M$UMK,Q= M9#,"J*XPRAE31V)V!9F,$SY/]?+WAE-83QA]0:8''?[B%OB.-F&XMO#F.">F MZU?$>AW[*WNPR@HOX=MD$_+B M)BY\NC#NO=0?VP*"PRE]S^13.8.7 M*ZY<;,$E+,B+*%QZ/KS'BA/-K2RVJ;)D-GT!N:T%*MO8EILNHDHA@$, 0=L" M$3PV%E&7-8PUIRBIN/)(?0HEI)OC4M$RH2;GINUHVQ:*8(D2![4\J(65JI1C MYOV57#-SMZ55I$[^K^M&65J70M?OF,F;_8F*LV=*V!5D)2=].]B!I&44E90$ MGV+SA(=,J' NVRIH&R-1IIQRI+PO54(*6(*'/;+6.!L4,H!)74!V!Y@JB6^UI=4M )2O MU*J!,H=N18?0?S#>8DM<-J+V(G2A;W/!7^)[>>^2$\()W*3A#QTWR:SZ_$HT MRM:D#9(<81[AW7P%U85)[C7BV"VFW'F_<+7I6'CM/T^CS3=N2Q[%#KR]EQ%@+L>+< M[*M]R0T%.7,#;H'DIVF1=,Y^K^9O:,@[=>;V1Q8"KW+@$-)?7#PU1#[\D?_3 MYG/-A?XT^*B@Y-QNW%,:=(+G6_DO18]@+=1]#U4Z?K+R+$95PKQ@ 7/TZY#2]2MF%._"1@'C MW=U^<0QX^[6)[0V#V(+ O7&4\47C;A()66#%\3HBT..(!3+$<=M &ZMUL0H# MK:WX^,+H 17K8_A;7&?'3['B)[&;>&603U,5%:S9W["RQ'UG81")8H^56J"/ M>\^!6%Q(J=29 .T M>!#)H8>DB=M%#-+HB'C+5EE M"V937P.^R;BH!39Y7V)@J?E76N**,6^>G=Y$#K[V%F ?8#$SPWN']'U?N:3* MJ:2*(XL"P(F"V_)YR7OB$K$\L!&57SX7DE>4 MFR1%.*)8R(DO#\'KTR83L/"_(^N.]YO(W!&AWGL+@]N_<2\=L5CNJ):-C1I9 MGDG4PMZY "N#?@Q>,[Y1DL%KNK2@@4441OM7?!W'FN#MM]!KVL9V<@HN72\? MYLA(+-%%,_0-$E7@! FQ#DUV4#MB2T:L(#8 >K!$JM[42"'3F2JILAD)B+*2E"$22I:P?=-25W\F/-$ M(*CT'L.FF7T#J2:#L3(T'[-J7D$AP*G!B="!'R^NWUW\KR+F!&-D!=W9@ A, M2M5'_FXN'ARWN#0P\"B Q)*;,['JBV]\BT87(%Q"WBR$0E@8DD)]$A?>E440 M\E=34B\\IS((%_QB)OGZMK7V0++!O\,'A"%^&&N>9( )?NBP.PR7PD>;NQ*; MR=;9)LU\/8J 9,(OST!RW-)GC<-!AN2$^N4*B MM0'92\^'!V7(M?Q#?V!<(S&X,A!!KHIA@I>R<$P5V;)&L,S+;W) F7\/5D8! M6A9C*X[E1.M1C)O_&," X0D.A"42>J6;'1X8C!'*DO_D#%@E9\#V ME0]T=9LZWG **+9PV6J[%LQAV(0 USKM[%*#GD]M\>9OHZ8%2FE9_#;C-W>( M%EC"^;LJS]\L3FK)1!?L PWEQD-';7J^[952[2_'O0 6=FI,QH[K[%G.U,W7 MNGPV_#!N68$\]_X;R#B*T'P!Y\MQ-ILM_?77ORJ?EP;L1U5^_?4RYE2Z#9UT MC3X]%$8[Y#<;+J,DHYB7,;8HZOZ!>@K&F:HM^D=*O]B-V:H%!]N2,E!"Z\_U M_*5J.=5K_5&ACPRJ/653[ @6M8QLTR)M=OKAT+R>7"G)V,AYI\F'T@]8?CV;Y$8!MO(4I MN;W\^*G.@^+JC(WW%;DYD=UX<0API@BR,=$ MSU&.";+P(C]W2-YZF8K+R&%]$\+):BVQ@/!8'PW0E"7@JHZ:<3@Q+%GZ9IJI;O3_Y=RS^M M/]P<8[F;_*N0>,3(/-D!;-3)OT[^273TF_'S\^4T&WZ^#'=[.&S QQSV!]/. MR^^\_,[+WTGA#V?:1#Z,J,W8:%2N]%LDW-%>2,?= )K@)_! D!N305;CE@AO MW$R;YRY1$UAT\<9Z<\34RM:5DK]Y0:/)'&>-N6KW[J<7@Q?T[V!MF/&_Q7MO MP4QF?L^$\QOK %X>_X4][-S>@VV%RS?*=#!8?Q-6.G^''R] ,VE,P^D!B=S! M=F^],/16+]+=6/$O"RBDX%1S>_>G%]$7]98%/V+
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
^^X8YTNL,G>!KZPYOLIK*E U\0J%'97\!37S%.EW;N29J5F!78) 7<% M05^JTI>JE$QQ[>L:< 6M'CA@16X'YTXA[L+3G[:@86F:3"/5"MA9)W;9,$97 M%N]0*,M'].J[H5]0]HP'+Z W$- P2YN^XD5N+5\5&:&NY*L/M8(E4]LT)+Z_ MAVNO9R*)OCI+;BYJB?P/YU13KES<-6[8,6FW PQ<$ &I'1I$6)<0Y&4?.%;5 M2#5TG0+A71%)=>WDUM0S5V1+#:!QL[\T5DL:OGBK:O"DTLKT"8(&ZD[U0[)[ ME+TK9U\O&SPX]<)Q&SP$A^.&"WUBWQR3 A5AVC>>UQ4=KA^"4Q[%[@1*-% M<:Q@FJU6J4^L7%>D$0DE*][=9^E9'!?\4:1[#M4?Y3JU0VFR^9/\.-3!9:7& MT*U^B#.*@C3[Q]W89&KK.J,D],$,D&;IC%;0!R=V NT!'INZM> 5>=Z2)EV] MH$G2J-?S.>TU7O5*0ME+'*+\$1\V M]4F>N'C"\$SL>H41'6$7[AZ'E<"3E&2Q,C@!SAJ>G5]12K9D0K,AHE6/3PY#^@%Y26:.LY.8LZW)LVJ.N8_+_H*7ACL-;C208J"J$DJ36D.D!+N/#$ M$WP%+?<*3_V.XL62B*;3%[)=%^AS24MYS.:5]#HK"Z*3I71)P\3??@]SKR*4 M2.CQQ:#>3S&H(0K)6&[E](5DY!P)O>4-YQ8.%RZH&4F?,=Q(&W,(-!QKR/O* M"Y&R:+VO0$>@OO^^?+E0I) MD@ 1SG/MBA 1$@H+$3F'J\,2NZ;W"6& &0I(^R=*\(J<#_\D6[Q22[,UFRKA8 4$U1(:SAY04LE]F-)>I>,)/*%O%Z;8NY'[CU9/:R>[[U(Y]VCIP^87!"^.A#/?8YN-G9+=)I6[_$$?:176[OK MFF%/UDYPWQ4#>8QN)KJ>+IS9FDGNL\3Y#^@=*I-G12-,AOS7:8@,^1,1=LNT M0-DZR(H-;:_4$GLO&C8,H0]H76;A,LC1_A(^):HUH:'3W.'#E*9A6*[*A%H! M*JOR93,[I+84MDH$G><;8#&*8BI&!C7V@GH]J2LS]$>"+4^9WB6+\H\ M3E&>5R6>\HK0;;4G?E][\#P[6&)WJA>,-I#7E01YODW+Y7X"]D!C1&\7]2Q[ MH-X #NK"\9:P /D O!DFT@+WKCONG<8<9X)D8#;Z&0N">1U-(YJXJG5)>:Y. MYQGEJG:ETTL=I^1^X^X/[MAWDHIFCEV6 /XES;8M8;9&_%UGF%G:Z"*3Q;0) M:5-/)(S/YNRL'=VO,P @V6_3),%UBY>JUBWW1!6.'YZ%X[IK7.IY0TT0'K\0 M+?(^"6H[D(!TWF 3J7 %6>,HVL6+<(GG#S:05A4D:'OQ4(L$V8.'+L;3;:& MN;J':.>-RYQN%X.*MZW<,^V"HN>FY3_#+E8[;MGVN898.Q)6>'P<#32JHO0@ MVZ224C[G<10'V:9A0N!)]Z+Q[E4XD1.DWTF]$P&/6'K%. .(D%TL;;5VKL;% MV6*!!9B-?8T(N=PU^X/GZXQ]:?2!A)$K-/9"X&!()--NQKY4.IVP$/?4V!<, M_"X&Q5N-_92%,KO;1L"T.N>*"#%7"3 ^S)5U(F87P].N7#EDX:! LAK'OG=D MI11Q3OK8ZV[U0*2OV&9IT2T91,#)Y:Z()O#C!%9G8NP'BCPNP%3VL9\K$G8E M>)R!*Y(*C.4C[4<4>C3V4[?#>N&'USBW5ICL'I6 !$:JN2+>=D '$([H'#K0 M3-GT2UZ^M&M>IE4>9.!42CHRT4=!N M9$2%;.# ."_+L_/PX2"Y+\>K0&G4,GS?,OQP^^I8(L.D80(UY(#C9+FSM.=R MXO6B@&,T:HF\5S<@.$9.B-X]R];#T1JUN*VF>PTE MQ>SI!(=HU-)XKU9I!XR&;C"I/$\#LEA.@G"D-H9 MJ8ZUQDDP M%D6*(%W0V)9)D.>(_'$ PX\D":,P 77BJ9[*/\AH!U4.N1>;3\&_<5;E]'(*X'=X@E5L_IKAO -O1].L8NB ^7FY M!SA_O*=8Q2[;%@N;-#PS=W%(;%\P=CL>;$I M"K";MJAAH]B?JZO .N+<[NH*V)D.:]C#\'&"ZI3%%2J6.*HB&.H _J92P1K3 MU:F@^*VF_ A:V.CE.A!V 6K:U($M@_0X#A1C!_(5:/E>WCTPD'L@SXJ&V8C\ MUREYM)9NG8#]J?IV=6;G5!UJP9[3VO(A5#UN>(-? M.ZV/U?ZDM6G(Y1JD81PDM^D<9ZM:@*CN5H9QL/L#3<:6=J'ZLLRH *,OW@U#Q\;/)625SE6&)&!O<>O;GB#?F42T>A9 VJ8*AE*X2YQB4*C"4+A[G&(8,*P@8/^ERAW%1_S;!ZVI=3((TFKQNZQTW M[6O%H95E/B%<\Z9U"_0R3*6IP# KV.X52-;>,FY*W[>H&+W8'(;V6JK;D-/RR"=U93O"V[_CFBC611-R:D1+-"OE)4K N--$&=' MK>>:L5TVT#7Y.$2 G.$U! JHLV*=^P"\$[*LR<^O-MX3>2TG$[UUC &/*[DB M\ :AJBYP?2)PTWN%XTTYC1D=X%O=P=QN\8-Z3.F1?2$^U2^D3_4;G,U17)2T MXX/D?6,7<=TN'=L_3\5G?IO6U;?M^T(=Z7/I$WW&M6_+PJ\#)^VTS;C_--:0 M=MH3;!2?AK!7,WH&Q%D_(560 UYIM"B1%L;6\=:V-22:^Y>ZAF>U^89'8H><8!VW$MTF#F9,=M5,\[K,XU+6E@6]W9%5: M#+#-*SAG\7CP+J31?1*DPN*J.E\U)N!.G**L.U7) E5*A-5WNIC3,W':#."= MR#"8:7?BS^*5O@;-\9F.)C,==1'+:?G:\..*3;C2#S*J$V_[;7/=V:UCWDLR MJNDH%I^\ZG[RJMSM:JWCW".'0=X"Z"K;&,%%]B>8%RNS,DQP@KD%?ZOD[054Z ML$%?LKJ-[1>&"F34E[KN%*IZDRPT)+/;WY%EB+ ],+"_O(O5K=5G"M=HX,JB MPZNX6_ ^'&1IO=$]N4-K[B+\2\ URA$L]_YN8SAPTMKA>)>PUO A..)P%7 $ M2W7()#4XQ./7!ZVM80+_"-(J8FUWND[=6NG02&\XL-):XGL!5B8L&0ZW='$S M-^'ND1('QUI:1703:XU9\PY4HZ./)!"3?[6.Q(?E:+ 877Z!;@WT]/" :UE75V$^++ B+,DB>4+;:4=0L;*;XT0K*P1WI M@?3E[/:M@J$ZB$&HO2H6<+1JDA):FA=(4,M8Q>3#TSY<"U&XS&2(.ANN@RB ;_C!^I9^L%'RULL9K(0LLQS*& M:R$JA]]OS EZ"(->*XSA6HB2D/N9$_00!I7\&<.5$R6!DW:$7E$"/CY;QJHG M)RTV$K8UY@0MA,&--JSQ>LB"7S6,\5K(DB%I '+@2B5KO!:RP-H<8[@6HB0T M.^8$/82!;[[VX5J(DCG161/T$ :^^=J'*R<*3(YZ0K9^),'=PAZED 2!:X0S M3!T1_*N,.4@A =Q+BSE('0'\^X Y2!T!W).?-4;=ZP5G/'N40A)XISEKC+K7 MW^Q1RDD0:"'<(:I)()S/['&*'B]UN)7W<-#FMQ; M2J+VAF[7OLEKYD0>K&4I\K6*3M8K'51_2:D';U\%]/W5PQ5(X[B#MNH*. M3ME&F,BD4!9PYGN(JT'JED:=J;>J=VF?^7D8UFUG2K4.#"?#-NE,V=>AX609 MO/55'G0;4)8W3U_-0#%>C,Z4$AX:3Y3K64!;P70#*C$IQ MIAS@P("RHCMTE/Q[%X RHB4T5O=S&T]V#)B.,GWO E)V"(G& GZ.0\J)3])1 MH^]=@,I+M-98E<]Q4-F5/306V7,;4TZVL,;Z>HYCRLM.UUA&SVU4>86/--;+ MH9+($X;AZG4HB_1D. MJ]>J))+=X;!ZQ0J>P@Q'U:M6,OGJ<%R]O)(I1P&-[O(8%K)L& MA]1K6/#27'!4O88%+TH%1]5K6#(5R."X>@U+HI8A'%:O84E4KH3#ZC4L>'E$ M.*I>PY*IA0G'U6M8,F5UX;AZ#4NBT"T8UA^\A@7K%0)'U"M8X!X><%"]?@5N M]P$'U:M7$HU=X+!Z[0K>6 B.JE>NX#VDX'%!EH,JS)(&UMYR!1!0D0- *4ZX M8\,Q/!S/-I;'P_5T86E$7,_WE0?$\81=:4 95&Q/FD M5?F;U_&L4_E-XW[:: =QU?F\SPXBJX+$3T/PK^K]?'FZ/^";3PC@G?L:E44/7MKEM( MC>I)3>"?)@37?+)&V22G>ZC^O_FD)&!/XG1"]E0<5C5^HS@I"7.'\>39*YQN MIY'_6)8-O14HC5#T MM=(V,D/0G]2'@GE"?$L8NUO"7 <9/5;S>Y3MA*@XG*;15?W%3TB7G#4\.Y]1 M<9N2]8CNR$J=OI"52&7L)WQ9K=?'1LGVBF0&>QV?XKL+F.PNH(?8$SFD5B"V MR[SV@3>$EFGT[S(O*-4,KGH^S1+V9W,6R3)LLY\R^=XZAL]HY!T?G9[Q7AIG M#")T^/88[Z<]QA 6Q;&8?KQ%$625Z27?.;=HN%#UN,O>EZ5/B6BGSP!8X")( M[L:"&UPV="6:"P:6E-X-L89N?Z'_AUK\R5_^?U!+ 0(4 Q0 ( $)P@DY< MO9\8 F@! *HA% 1 " 0 !A:7!T+3(P,3@Q,C,Q+GAM M;%!+ 0(4 Q0 ( $)P@DX+YIR#Y1L $EK 0 1 " 3%H M 0!A:7!T+3(P,3@Q,C,Q+GAS9%!+ 0(4 Q0 ( $)P@DYI171480P +^N M 5 " 46$ 0!A:7!T+3(P,3@Q,C,Q7V-A;"YX;6Q02P$" M% ,4 " !"<().JYG-4!UT !;? D %0 @ '9D $ 86EP M="TR,#$X,3(S,5]D968N>&UL4$L! A0#% @ 0G""3BV *#%F0 79H( M !4 ( !*04" &%I<'0M,C Q.#$R,S%?;&%B+GAM;%!+ 0(4 M Q0 ( $)P@D[.H[ ESW0 //<"0 5 " 2&? @!A:7!T G+3(P,3@Q,C,Q7W!R92YX;6Q02P4& 8 !@"* 0 (Q0# end

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2018	Mar. 26, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		15,792,586
Entity Public Float			$ 13,584,316
Entity Shell Company	false
Document Type	10-K/A
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	true
Amendment Description	Precision Therapeutics Inc. is filing this Form 10-K/A (Amendment No. 1) to our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 1, 2019. This amendment modifies Item 8 for the purpose of including the report of the Registrant’s former auditor, Olsen Thielen & Co., on the financial statements for the year ended December 31, 2017, which was inadvertently omitted from Item 8. Such Olsen report on the 2017 financial statements is identical to the Olsen report that was filed on April 2, 2018 with the Registrant’s Form 10-K for the year ended December 31, 2017, except that the version of such report to be included in the 2018 10-K is dated as of a later date (April 1, 2019) as to Note 12. This Amendment No. 1 also reflect exhibits filed with this Amendment No. 1. Except as described above, this Form 10-K/A does not modify or update other disclosures in the Form 10-K, including the nature and character of such disclosure to reflect events occurring after the filing date of the original Form 10-K. The filing of this Form 10-K/A is not an admission that the original 10-K, when filed, was not complete.

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash & cash equivalents	$ 162,152	$ 766,189
Certificates of deposit		244,971
Accounts Receivable	232,602	137,499
Notes Receivable (inclusive of $452,775 in advances to Helomics)	497,276	667,512
Inventories	241,066	265,045
Prepaid Expense and other assets	318,431	289,966
Total Current Assets	1,451,527	2,371,182
Notes Receivable	1,112,524	1,070,000
Fixed Assets, net	180,453	87,716
Intangibles, net	964,495	95,356
Total Assets	3,708,999	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	445,689	140,462
Notes Payable – Bridge Loan Net of Discount	1,327,942
Notes Payable – Net of Discount	306,972
Accrued Expenses	1,279,114	785,215
Derivative Liability	272,745
Deferred Revenue	23,065	6,663
Total Current Liabilities	3,655,527	932,340
Total Liabilities	3,655,527	932,340
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 14,091,748 and 6,943,283 outstanding	140,917	69,432
Additional paid-in capital	(63,019,708)	(55,636,680)
Accumulated deficit	63,107,945	53,021,469
Total Stockholders' Equity	53,472	2,691,914
Total Liabilities and Stockholders' Equity	3,708,999	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock		$ 6,479

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	14,091,748	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 1,411,655	$ 654,836
Cost of goods sold	415,764	148,045
Gross margin	995,891	506,791
General and administrative expense	4,626,997	4,050,307
Operations expense	1,861,121	1,414,774
Sales and marketing expense	2,369,152	1,095,232
Total operating loss	7,861,379	6,053,523
Other income	510,254	53,734
Other expense	441,772	3,228
Loss on equity method investment	(2,293,580)
Net loss available to common shareholders	$ (10,086,477)	$ (6,003,017)
Loss per common share - basic and diluted (in dollars per share)	$ (0.79)	$ (0.94)
Weighted average shares used in computation - basic and diluted (in shares)	12,816,289	6,362,989

Consolidated Statements of Stockholders' Equity - USD ($)	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member]	Private Placement [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Consultant Contract One [Member] Common Stock [Member]	Consultant Contract One [Member] Additional Paid-in Capital [Member]	Consultant Contract One [Member]	Consultant Contract Two [Member] Common Stock [Member]	Consultant Contract Two [Member] Additional Paid-in Capital [Member]	Consultant Contract Two [Member]	Contract with TumorGenesis [Member] Common Stock [Member]	Contract with TumorGenesis [Member] Additional Paid-in Capital [Member]	Contract with TumorGenesis [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member]	Re-priced Warrants [Member] Common Stock [Member]	Re-priced Warrants [Member] Additional Paid-in Capital [Member]	Re-priced Warrants [Member]	Bridge Loan Warrants [Member] Additional Paid-in Capital [Member]	Bridge Loan Warrants [Member]	Note Payable Warrants [Member] Additional Paid-in Capital [Member]	Note Payable Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2016																																										$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Balance (in shares) at Dec. 31, 2016																																									79,246		4,564,428
Shares issued pursuant to the public offering	$ 1,750	$ 392,000		$ 393,750		$ 12,138	$ 1,201,681	$ 1,213,819							$ 500	$ 78,500	$ 79,000																										$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)	175,000				1,213,819										50,000																												1,750,000
Vesting Expense																																												2,298,680			2,298,680
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																											$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																											(400,000)
Shares issued for services									$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132
Shares issued for services (in shares)									100,000			43,333
Unrealized (loss) from marketable securities																																													(1)	(1,501)	(1,501)
Preferred conversion to common shares pursuant to a private placement agreement																																										(5,659)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																								(566,000)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																											660,522
Preferred conversion to common shares pursuant to a private placement agreement																																											$ 6,604	85,236			86,182
Net loss																																													(6,003,017)		(6,003,017)
Balance at Dec. 31, 2017																																										7,271	$ 69,432	55,636,680	(53,021,469)		2,691,914
Balance (in shares) at Dec. 31, 2017																																								647,819	79,246		6,943,283
Shares issued pursuant to the public offering	$ 2,153	$ 202,268	$ 1	$ 204,422																																							$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)	215,247																																										2,900,000
Vesting Expense																																												1,124,928			1,124,928
Shares issued for services																		$ 1,500	$ 175,500	$ 177,000	$ 1,000	$ 117,000	$ 118,000
Shares issued for services (in shares)																		150,000			100,000
Preferred conversion to common shares pursuant to a private placement agreement																																										(6,479)					(6,479)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																								(647,819)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																											589,747
Preferred conversion to common shares pursuant to a private placement agreement																																											$ 5,897	582
Net loss																																													(10,086,477)		(10,086,477)
Balance at Dec. 31, 2018																																										792	$ 140,917	63,019,708	(63,107,945)		53,472
Balance (in shares) at Dec. 31, 2018																																									79,246		14,091,748
Investment in Subsidiary pursuant to Helomics 20% acquisition																											$ 11,000	$ 1,031,250	$ 1,042,250
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																											1,100,000
Warrant exercises																														$ 1,454	$ 143,942	$ 145,396	$ 5,046	$ 499,619	$ 504,665
Warrant exercises (in shares)																														145,396			504,666
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share																								$ 7,500	$ 870,000	$ 877,500
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share (in shares)																								750,000
Debt Discount on Warrants																																				$ 183,187	$ 183,187	$ 68,757	$ 68,757
Shares issued as inducement for Bridge Loan																																											$ 6,500	200,105			206,605
Shares issued as inducement for Bridge Loan (in shares)																																											650,000
Shares issued to employee in lieu of bonus																																											$ 435	$ 39,803			$ 40,238
Shares issued to employee in lieu of bonus (in shares)																																											43,409

Consolidated Statements of Stockholders' Equity (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)		$ 1.18
Consultant Contract One [Member] \| Common Stock [Member]
Price of shares issued (in dollars per share)	$ 1.18
Consultant Contract Two [Member] \| Common Stock [Member]
Price of shares issued (in dollars per share)	1.18
Contract with TumorGenesis [Member] \| Common Stock [Member]
Price of shares issued (in dollars per share)	1.17
Series E Warrants [Member] \| Common Stock [Member]
Warrant exercises, exercise price per share (in dollars per share)	1
Common Stock [Member] \| Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	$ 0.9497

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash flow from operating activities:
Net loss	$ (10,086,477)	$ (6,003,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	2,293,580
Depreciation and amortization	147,628	71,562
Vesting expense for stock options and warrants	1,124,928	2,298,680
Equity instruments issued for management and consulting	335,238	359,133
Amortization of debt discount	385,111
Gain from sale of marketable securities		(1,837)
Gain on valuation of equity-linked instruments	(372,263)
Changes in assets and liabilities:
Accounts receivable	(95,103)	(98,580)
Inventories	23,979	7,163
Prepaid expense and other assets	139,895	(141,329)
Accounts payable	305,227	(79,650)
Accrued expenses	493,899	(870,540)
Deferred revenue	16,402	(1,335)
Net cash used in operating activities	(5,287,956)	(4,459,750)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(3,084,971)
Redemption of certificates of deposit	244,971	2,940,000
Advances on notes receivable	(1,123,619)	(1,737,512)
Purchase of fixed assets	(177,732)	(45,093)
Purchase of intangibles	(54,271)	(10,179)
Net cash used in investing activities	(1,110,651)	(1,653,090)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	650,061
Proceeds from debt issuance	2,185,000
Net proceeds from issuance of preferred stock		1,300,001
Proceeds from Issuance of Common Stock	2,959,509	3,814,938
Net cash provided by financing activities	5,794,570	5,114,939
Net decrease in cash	(604,037)	(997,901)
Cash at beginning of period	766,189	1,764,090
Cash at end of period	162,152	766,189
Non-cash transactions in investing and financing activities
Conversion of preferred stock to common stock	6,479
Equity method investment – Helomics	1,542,250
Licensing Fee for Tumorgenesis [Member]
Non-cash transactions in investing and financing activities
Stock issued for fees	$ 877,500

Note 3 - Revenue Recognition	12 Months Ended
Note 3 - Revenue Recognition	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 – REVENUE RECOGNITION Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one -year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2018, and December 31, 2017, accounts receivable totaled $232,602 and $137,499, respectively. The Company deferred revenues related primarily to maintenance plans of $23,065 and $6,663 as of December 31, 2018 and December 31, 2017, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

Note 5 - Notes Receivable	12 Months Ended
Note 5 - Notes Receivable	Dec. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5– NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. CytoBioscience was current in its payments to the Company through and including July 2018. The Company had not received the scheduled interest payments from CytoBioscience for August through yearend. On September 27 and 28, 2018 CytoBioscience, through its parent company (WestMountain; now named InventaBioTech, OTC symbol INVB), made public filings indicating that their notes payable was in default. In October 2018, CytoBioscience communicated to the Company that CytoBioscience is raising capital that it believes will allow it to resume debt service payments, and that CytoBioscience wishes to negotiate an extension to the note. The Company has reached agreement with CytoBioscience on repayment and in February and March 2019 received payments towards the interest due and a portion of the principal. As of December 31, 2018, the Company does not believe a reserve is needed. In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. Additionally, in December 2017, the Company advanced $67,512 to De Lage Landen, a vendor of Helomics, as a fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics. The Company now has an equity stake in Helomics totaling 25%. In September 2018, the Company advanced an additional $60,000 for working capital for Helomics’ business. The balance due to the Company is $163,468, plus interest as of September 30, 2018. Subsequently in October 2018, the Company advanced $907,500 for working capital for Helomics’ business. In December 2018, the Company advanced $30,000 to Helomics under the same note. The balance due to the Company at December 31, 2018, is $1,165,013 in principal, plus interest of $29,215. On the balance sheet there is a reduction to the loan of $751,330 due to the equity method accounting losses incurred from Helomics ownership; see Note 2. In January and February 2019, the Company also advanced Helomics $305,000. In March 2019, the Company advanced an additional $420,000 to Helomics from the Form S- 3 public offering that netted the Company approximately $1.1M. The balance to date owed by Helomics is $1,890,013 plus interest. The Company expects that additional advances will be required before the merger is complete. All additional advances are covered by the security interest in certain equipment of Helomics. In addition, Helomics pledged all of its assets as security for the Company’s convertible secured note financing. Upon completion of the merger with Helomics all intercompany notes would be eliminated in their entirety.

Note 6 - Convertible Debt and Derivative Liability	12 Months Ended
Note 6 - Convertible Debt and Derivative Liability	Dec. 31, 2018
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 – CONVERTIBLE DEBT AND DERIVATIVE LIABILITY Effective September 28, 2018 ( the “Effective Date”), the Company issued convertible secured promissory notes to two private investors in the original principal amount of an aggregate $2,297,727 (the “bridge loan”). The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a second investment of an aggregate of $500,000 by the investors at the consummation of the Merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become $2,865,909. As additional consideration for the investment, the Company issued an aggregate 650,000 shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate 1,071,776 shares of the Company’s common stock at an exercise price of $1.155 per share. Upon the closing of the second tranche investment, the warrants would be increased to cover an aggregate total of 1,336,805 shares. Each warrant is exercisable by the investor beginning on the sixth month anniversary of the effective date through the fifth -year anniversary thereof. The notes accrue interest at a rate of 8% per annum (with twelve months of interest guaranteed). The maturity date of the notes is twelve months from the Effective Date. Upon the earlier to occur of an event of default (as defined in the notes) or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) $1.00 and (ii) 70% of the lowest volume-weighted average price (the “VWAP”) of the Company’s common stock during the 20 -trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that may be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate 2,678,328 shares. Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% of the VWAP for the 20 trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of 2.94% over five years with a 59% volatility rate pursuant to the Company’s established warrant volatility and a calculated value per warrant of .5361 resulting in a fair value of $574,631. Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements. In December 2018, the derivative liability was adjusted for the change in the 70% of the VWAP for the 20 days preceding the balance sheet date and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The derivative liability recorded in September 2018 was $645,008. The fair value of the derivative liability as of December 31, 2018 is $272,745. An unrealized gain for the corresponding change in fair value was recorded to other income in 2018. The value of the embedded derivative was based upon level 3 inputs – see the Fair Value Caption in Note 1.

Note 11 - Retirement Savings Plans	12 Months Ended
Note 11 - Retirement Savings Plans	Dec. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 11 – RETIREMENT SAVINGS PLANS The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 (k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2017, and again in 2018, the Company matched 100 %, of the employee’s contribution up to 4.0 % of their earnings. The employer contribution was $51,647 and $29,952 in 2018 and 2017, respectively. There were no discretionary contributions to the plan in 2018 and 2017.

Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	NOTE 12 – CORRECTION OF IMMATERIAL MISSTATEMENT TO PRIOR PERIOD FINANCIAL STATEMENTS During fiscal 2018, the Company identified certain warrants issued in 2016 and 2017, which were incorrectly recognized as expense in 2017 when the warrants vested. As a result, investors stock compensation expense and additional paid-in capital were overstated by $2,150,097 for the year ended December 31, 2017. Also during fiscal 2018, the Company identified that employee stock compensation expense was incorrectly recognized in 2017. As a result, employee stock compensation expenses and additional paid-in capital were understated by $406,522 for the year ended December 31, 2017. Lastly during fiscal 2018, the Company identified that certain nonqualified stock options were excluded from the Company’s tax provision calculation in 2017. As a result, deferred tax assets and the valuation allowance on these assets were understated by $767,000 as of December 31, 2017. Based on an analysis of Accounting Standards Codification (“ASC”) 250 – “Accounting Changes and Error Corrections” (ASC 250” ), Staff Accounting Bulletin 99 – “Materiality” (“SAB 99” ) and Staff Accounting Bulletin 108 – Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (“SAB 108” ), the Company determined that these costs were immaterial to the previously-issued financial statements. The Company analyzed and considered all relevant quantitative and qualitative factors and determined that the prior fiscal year financial statements should be corrected, even though such revision previously was and continues to be immaterial to the prior year financial statements. Management also determined that such correction to prior fiscal year financial statement for immaterial misstatements would not require previously filed reports to be amended and that such corrections may be made the next time the Company files the prior year financial statements. Accordingly, the Company restated its presentation of general and administrative, sales and marketing, and operating expenses as well as retained earnings and additional paid-in capital in the consolidated financial statements for the year ended December 31, 2018 to reflect such corrections as if they had been recorded in the appropriate fiscal period as of December 31, 2017. Specifically, the adjustments were reflected and corrected in the last quarter of 2017 for the period ended December 31, 2017, by reducing investors stock compensation expense under general and administrative expenses and reducing additional paid-in capital by $ 2,150,097 ; and, by increasing employee stock compensation expenses under general and administrative, selling and operating expense and increasing additional paid-in capital by a total of $ 406,522 on the comparative balance sheet for the period ended December 31, 2017. In addition, the Company restated Note 4 – Stockholders’ Equity (Deficit), Stock Options and Warrants, and Note 8 – Income Taxes, to reflect the impact of these restatements on the footnote disclosures as of and for the year ended December 31, 2017.

Note 13 - Subsequent Events	12 Months Ended
Note 13 - Subsequent Events	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS Registered Offering of Common Stock and Warrants On February 27, 2019, Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold 1,385,000 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 692,500 shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.5 of a share of the Company’s Common Stock at an exercise price of $1.00 per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the fifth anniversary of issuance. The Units were sold at a price of $0.90 per Unit, resulting in gross proceeds to the Company of approximately $1.25 million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately $1.08 million. The closing of the Offering occurred on March 1, 2019. Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 8% of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to $30,000, and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of $5,000. The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature. Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of March 1, 2019 ( the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of 69,250 Units (which represents 5% of the Units sold to investors in the offering) at an exercise price equal to 125% of the public offering price of the Units in the offering, or $1.125 per Unit. The Unit Purchase Options shall expire on February 27, 2024. On March 12, 2019, Peak One, one of the noteholders from the bridge loan, converted 71,046 shares of stock reducing the principal of the loan by $44,475. The value was computed, pursuant to the agreement, by calculating the average VWAP for the prior 20 days and multiplying that average by 70%. Dr. Carl Schwartz, the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional $1,300,000, see Note 10 – Related party Transactions. The Company entered into a forbearance agreement with L2 Capital, LLC and Peak One Opportunity Fund, LP. AS part of the agreement the Company added 15% to the principal of the note and issued inducement shares of common stock. The Company accrued approximately $503,000 in penalty expenses as a result as of December 31, 2018. This penalty expense is recorded in accrued expenses on the balance sheet. On March 26, 2019, Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold 1,478,750 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 739,375 shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.5 of a share of the Company’s Common Stock at an exercise price of $1.00 per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the fifth anniversary of issuance. The Units were sold at a price of $0.80 per Unit, resulting in gross proceeds to the Company of approximately $1.18 million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately $1.05 million. The closing of the Offering occurred on March 29, 2019. Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 8% of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to $30,000, and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of $5,000. The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature. Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of March 29, 2019 ( the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of 73,938 Units (which represents 5% of the Units sold to investors in the offering) at an exercise price equal to 125% of the public offering price of the Units in the offering, or $1.00 per Unit. The Unit Purchase Options shall expire on March 29, 2024. The securities in the Offerings were offered and sold pursuant to the Company’s “shelf” registration statement (File No. 333 - 213766 ), which was declared effective by the United States Securities and Exchange Commission on October 4, 2016.

Note 1 - Summary of Significant Accounting Policies (Details Textual)				1 Months Ended							3 Months Ended	12 Months Ended		202 Months Ended
	Mar. 12, 2019 USD ($)	Feb. 06, 2019 USD ($)	Jan. 08, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Nov. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jan. 31, 2018 USD ($)	Nov. 30, 2017 USD ($)	Jan. 31, 2017 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Mar. 22, 2019 $ / shares	Jul. 11, 2018 $ / shares	Jul. 10, 2018 $ / shares	Mar. 31, 2018	Feb. 21, 2018 $ / shares	Dec. 28, 2017 $ / shares	Apr. 19, 2017 $ / shares
Common Stock, Shares, Outstanding, Ending Balance \| shares					14,091,748							14,091,748	6,943,283	14,091,748
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.01							$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance					$ (63,107,945)							$ (63,107,945)	$ (53,021,469)	$ (63,107,945)
Net Cash Provided by (Used in) Operating Activities, Per Month												441,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance					162,152							162,152	766,189	162,152
Stockholders' Equity, Period Increase (Decrease), Total														36,490,000
Debt Instrument, Increase (Decrease), Net, Total														7,870,000
Advertising Expense												43,548	37,060
Research and Development Expense, Total												$ 526,000	289,000
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice												1 year
Depreciation, Total												$ 84,995	58,872
Amortization of Intangible Assets, Total												62,633	12,689
Unrecognized Tax Benefits, Ending Balance					0							0		0
Cash, Uninsured Amount					0							0		$ 0
Product Warranty Expense												$ 10,682	$ 6,209
Number of Operating Segments												2
Maintenance [Member]
Revenue, Performance Obligation, Timing												1 year
Minimum [Member]
Standard Payment Term for Customers												30 days
Maximum [Member]
Standard Payment Term for Customers												60 days
Chief Executive Officer [Member]
Proceeds from Related Party Debt					$ 370,000	$ 370,000
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs							$ 1,815,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares															$ 0.01
Subsequent Event [Member] \| Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 1,300,000	$ 300,000	$ 950,000								$ 1,300,000
Shelf Registration [Member] \| Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,100,000							2,100,000
Additional Gross Proceeds From Sale of Equity, Available to Raise				$ 1,700,000							1,700,000
Stock Issuance Plan, Additional Available Amount											$ 6,400,000
IPO [Member]
Proceeds from Issuance or Sale of Equity, Total										$ 3,937,500
Private Placement [Member] \| Series C Convertible Preferred Stock [Member]
Proceeds from Issuance or Sale of Equity, Total									$ 1,300,000
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total								$ 2,755,000
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage																		25.00%

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Finished goods	$ 58,701	$ 62,932
Raw materials	127,003	141,028
Work-In-Process	55,362	61,085
Total	$ 241,066	$ 265,045

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	12 Months Ended
	Dec. 31, 2018
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant, and Equipment Gross	$ 539,218	$ 361,486
Less: Accumulated Depreciation	358,765	273,770
Total Fixed Assets, Net	180,453	87,716
Office Equipment [Member]
Property, Plant, and Equipment Gross	204,903	183,528
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 85,246	$ 43,368

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Gross Carrying Costs	$ 1,195,804	$ 264,032
Accumulated Amortization	(231,309)	(168,676)
Net Carrying Amount	964,495	95,356
Patents and Trademarks [Member]
Gross Carrying Costs	318,304	264,032
Accumulated Amortization	(182,559)	(168,676)
Net Carrying Amount	135,745	95,356
Licensing Agreements [Member]
Gross Carrying Costs	877,500
Accumulated Amortization	(48,750)
Net Carrying Amount	$ 828,750

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
2019	$ 72,383
2020	72,383
2021	72,383
2022	72,383
2023	72,383
Thereafter	602,580
Total	$ 964,495	$ 95,356

Note 2 - Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 27, 2018
Equity Method Investment, Ownership Percentage	75.00%	80.00%
Equity Method Investment, Summarized Financial Information, Revenue	$ 523,546
Financing Receivable, Net, Total	413,683
Financing Receivable, Gross	1,165,013
Fair Value Adjustment of Notes Receivable	(751,330)
Equity Method Investments	0
Contract Research Organization and D-CHIP Artificial Intelligence Products [Member]
Equity Method Investment, Summarized Financial Information, Revenue	$ 31,000

Note 3 - Revenue Recognition (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Jan. 07, 2019	Dec. 31, 2017
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 232,602	$ 232,602	$ 137,499
Contract with Customer, Liability, Current	$ 23,065		$ 6,663
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual)											1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 26, 2018 USD ($) $ / shares shares	Jul. 11, 2018 $ / shares shares	Jul. 10, 2018 $ / shares shares	Mar. 12, 2018 $ / shares shares	Feb. 21, 2018 USD ($) $ / shares shares	Jan. 15, 2018 $ / shares shares	Jan. 11, 2018 USD ($) shares	Nov. 30, 2017 USD ($) $ / shares shares	Apr. 19, 2017 $ / shares shares	Jan. 19, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Jan. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 22, 2019 $ / shares shares	Jan. 02, 2018 shares	Dec. 28, 2017 $ / shares shares	Jan. 29, 2017 shares	Oct. 27, 2016 shares
Shares Issued, Price Per Share \| $ / shares		$ 1.17	$ 1.18
Proceeds from Issuance of Convertible Preferred Stock \| $																$ 1,300,001
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01	$ 0.01		$ 0.01				$ 0.01		$ 0.01			$ 0.01	$ 0.01	$ 0.01			$ 0.01
Stock Issued During Period, Shares, Issued for Services			250,000
Stock Issued During Period, Share, Issued in Escrow		750,000
Common Stock, Shares Authorized											50,000,000			50,000,000	50,000,000	50,000,000			50,000,000	24,000,000	8,000,000
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares									400,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number											2,946,488				2,946,488
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares											$ 1.79				$ 1.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term															8 years 313 days
Class of Warrant or Right Number of Warrants Vested and Exercisable											2,247,489				2,247,489
Allocated Share-based Compensation Expense, Total \| $															$ 1,124,928	$ 2,298,680
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $											$ 741,922				$ 741,922
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost \| $														$ 1,900,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares															$ 1.01	$ 1.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,098,858	2,612,070
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															1 year 240 days
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares						$ 0.97
Number of Equal Installments Options are Expected to Vest						4
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares				$ 1.35
Number of Equal Installments Options are Expected to Vest				4
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares											$ 609.38				$ 609.38
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate															3.07%	2.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate															66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term															10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares															$ 1.0044	$ 1.5489
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares											$ 0				$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate															2.33%	1.92%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate															59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term															5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares															$ 0.3816	$ 0.6541
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															3 years
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																		5,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares																	$ 0.01
Common Stock, Shares Authorized																	100,000,000
Helomics Holding Corp. [Member]
Notes Payable, Total \| $	$ 7,600,000
Helomics Holding Corp. [Member]
Convertible Preferred Stock Held, Conversion Feature, Percent	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow	860,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period	1 year 180 days
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger	75.00%
Business Acquisition, Warrant Exchange Ratio	0.6
Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000												1,100,000
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues							1,100,000
Share Exchange Agreement, Shares Received							2,500,000
Share Exchange Agreement, Convertible Notes Receivable \| $													$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock													5.00%
Share Exchange Agreement, Potential Interest													25.00%
Share Exchange Agreement, Number of Shares Held in Escrow													1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum \| $							$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent							20.00%
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion											1.167				1.167
Conversion of Stock, Shares Issued											1,250,269
Series C Convertible Preferred Stock [Member]
Stock Redeemed or Called During Period, Shares											142,466
Payments for Repurchase of Convertible Preferred Stock \| $											$ 189,285
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,700,000
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Precision Warrants [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Business Acquisition, Warrant Issued or Issuable, Exercise Price \| $ / shares	$ 1
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants	23,700,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	14,200,000
Helomics Warrants Held by Other Parties [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	597,000
Helomics Warrants Held by Other Parties [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	995,000
The 2017 Public Offering [Member]
Stock Issued During Period, Shares, New Issues										1,750,000
Shares Issued, Price Per Share \| $ / shares										$ 2.25
Share Per Each Unit										1
Proceeds from Issuance or Sale of Equity, Total \| $										$ 3,937,500
The 2017 Public Offering [Member] \| Series D Warrants [Member]
Class of Warrant or Right, Issued per Unit										0.2
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right										1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 2.25
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues					215,247					175,000
Shares Issued, Price Per Share \| $ / shares					$ 0.9497
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 0.01
Proceeds from Issuance or Sale of Equity, Total \| $										$ 358,312
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										35,000
Sale of Stock, Underwriter Option Term												45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase												290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase												87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares												$ 0.001
Proceeds from Underwriter Shares Exercised, Net \| $					$ 188,066
Stock Issued During Period, Underwriter Discount \| $					$ 16,354
Underwriter Discount Percentage					8.00%
Private Placement [Member]
Proceeds from Issuance of Convertible Preferred Stock \| $								$ 1,300,000
Private Placement [Member] \| Series C Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues								1,213,819
Shares Issued, Price Per Share \| $ / shares								$ 1.071
Private Placement [Member] \| The 2017 Private Placement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								$ 1.26
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								606,910
Warrants and Rights Outstanding, Term								5 years 182 days
Class of Warrant or Right, Vesting Period								180 days
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues												2,900,000
Share Per Each Unit												1
Proceeds from Issuance or Sale of Equity, Total \| $												$ 2,755,000
Share Price \| $ / shares												$ 0.95
The 2018 Public Offering [Member] \| Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit												0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right												1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares												$ 1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Outstanding (in shares)	3,669,277
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22
Number of Shares Issued (in shares)	2,336,154	1,082,946
Average Exercise Price Issued (in dollars per share)	$ 1.07	$ 1.49
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(650,062)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	3,626,643	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 4.17	$ 23.74
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,098,858	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.01	$ 1.45
Number of Shares Expired (in shares)	(194,564)	(12,730)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 10.39
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	3,669,277	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.70	$ 2

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2018 shares
Shares, options (in shares)	3,669,277
Shares, warrants (in shares)	3,626,643
Warrant One [Member]
Shares, warrants (in shares)	221,292
Weighted average remaining life, warrants (Year)	4 years 335 days
Warrant Two [Member]
Shares, warrants (in shares)	1,063,935
Weighted average remaining life, warrants (Year)	3 years 277 days
Warrant Three [Member]
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	3 years 310 days
Warrant Four [Member]
Shares, warrants (in shares)	1,071,776
Weighted average remaining life, warrants (Year)	4 years 273 days
Warrant Five [Member]
Shares, warrants (in shares)	86,086
Weighted average remaining life, warrants (Year)	4 years 273 days
Warrant Six [Member]
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	3 years 21 days
Warrant Seven [Member]
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	1 year 244 days
Warrant Eight [Member]
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	215 days
Warrant Nine [Member]
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	222 days
Warrant Ten [Member]
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	310 days
Warrant Eleven [Member]
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	43 days
Warrant Twelve [Member]
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	32 days
Warrant Thirteen [Member]
Shares, warrants (in shares)	3,626,643
Weighted average remaining life, warrants (Year)
Stock Options One [Member]
Shares, options (in shares)	201,908
Weighted average remaining life, options (Year)	10 years
Stock Options Two [Member]
Shares, options (in shares)	60,000
Weighted average remaining life, options (Year)	9 years 332 days
Stock Options Three [Member]
Shares, options (in shares)	10,000
Weighted average remaining life, options (Year)	9 years 109 days
Stock Options Four [Member]
Shares, options (in shares)	3,000
Weighted average remaining life, options (Year)	9 years 138 days
Stock Options Five [Member]
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	9 years 7 days
Stock Options Six [Member]
Shares, options (in shares)	149,110
Weighted average remaining life, options (Year)	9 years 43 days
Stock Options Seven [Member]
Shares, options (in shares)	23,585
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Eight [Member]
Shares, options (in shares)	86,958
Weighted average remaining life, options (Year)	9 years 167 days
Stock Options Nine [Member]
Shares, options (in shares)	195,931
Weighted average remaining life, options (Year)	9 years 200 days
Stock Options Ten [Member]
Shares, options (in shares)	21,740
Weighted average remaining life, options (Year)	9 years 215 days
Stock Options Eleven [Member]
Shares, options (in shares)	66,451
Weighted average remaining life, options (Year)	9 years 215 days
Stock Options Twelve [Member]
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 222 days
Stock Options Thirteen [Member]
Shares, options (in shares)	41,668
Weighted average remaining life, options (Year)	9 years 215 days
Stock Options Fourteen [Member]
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 222 days
Stock Options Fifteen [Member]
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	9 years 73 days
Stock Options Sixteen [Member]
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	8 years 273 days
Stock Options Seventeen [Member]
Shares, options (in shares)	2,305,790
Weighted average remaining life, options (Year)	8 years 175 days
Stock Options Eighteen [Member]
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	8 years 91 days
Stock Options Nineteen [Member]
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	7 years 237 days
Stock Options Twenty [Member]
Shares, options (in shares)	20,640
Weighted average remaining life, options (Year)	7 years 233 days
Stock Options Twenty One [Member]
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Twenty Two [Member]
Shares, options (in shares)	4,000
Weighted average remaining life, options (Year)	7 years 182 days
Stock Options Twenty Three [Member]
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	7 years 273 days
Stock Options Twenty Four [Member]
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	7 years 262 days
Stock Options Twenty Five [Member]
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Twenty Six [Member]
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	7 years 251 days
Stock Options Twenty Seven [Member]
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	6 years 295 days
Stock Options Twenty Eight [Member]
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty Nine [Member]
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	6 years 182 days
Stock Options Thirty [Member]
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	6 years 273 days
Stock Options Thirty-One [Member]
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	6 years 91 days
Stock Options Thirty-Two [Member]
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	3 years 251 days
Stock Options Thirty-Three [Member]
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 76 days
Stock Options Thirty-Four [Member]
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	3 years 229 days
Stock Options Thirty-Five [Member]
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Thirty-Six [Member]
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 273 days
Stock Options Thirty-Seven [Member]
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	4 years 197 days
Stock Options Thirty-Eight [Member]
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	4 years 197 days
Stock Options Thirty-Nine [Member]
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 14 days
Stock Options Forty [Member]
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 127 days
Stock Options Forty-One [Member]
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 91 days
Stock Options Forty-Two [Member]
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 69 days
Stock Options Forty-Three [Member]
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years
Stock Options Forty-Four [Member]
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	4 years 273 days
Stock Options Forty-Five [Member]
Shares, options (in shares)	3,669,277
Weighted average remaining life, options (Year)

Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Dec. 31, 2018 $ / shares shares
Shares, options (in shares) \| shares	3,669,277
Shares, warrants (in shares) \| shares	3,626,643
Minimum [Member]
Price, options (in dollars per share)	$ 0.62
Warrant exercises, exercise price per share (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares) \| shares	6,455
Warrants 2014 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares) \| shares	94,151
Warrants 2015 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) \| shares	252,333
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2017 [Member]
Shares, warrants (in shares) \| shares	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) \| shares	2,190,758
Warrants 2018 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0.84
Warrants 2018 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.3125
Stock Options 2011 [Member]
Shares, options (in shares) \| shares	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) \| shares	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) \| shares	1,553
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 148.13
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) \| shares	836
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) \| shares	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	100,294
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	2,461,634
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	1,098,858
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.62
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 5 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended							2 Months Ended	3 Months Ended	5 Months Ended	12 Months Ended
Note 5 - Notes Receivable (Details Textual) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Oct. 31, 2017	Feb. 28, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2018	Jul. 31, 2017
Subsequent Event [Member] \| Shelf Registration [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 1,100,000								$ 2,100,000
Advance to Helomics [Member]
Payments to Acquire Notes Receivable							$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable				$ 60,000		$ 67,512
Lease to Purchase Equipment, Down Payment, Percentage						50.00%
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage					8.00%							8.00%
Financing Receivable, Net, Total					$ 1,112,524	$ 1,070,000
Notes Receivable, Term					2 years
Proceeds from Collection of Notes Receivable										$ 0
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total				$ 163,468
Payments to Acquire Notes Receivable		$ 30,000	$ 907,500
Share Exchange Agreement, Outstanding Receivables, Amount Converted					$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables					833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock					5.00%
Investment, Ownership Percent					25.00%
Financing Receivable, Gross		1,165,013								1,165,013	$ 1,165,013
Interest Receivable		$ 29,215								$ 29,215	29,215
Fair Value Adjustment of Notes Receivable											$ (751,330)
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Payments to Acquire Notes Receivable								$ 305,000
Financing Receivable, Gross	1,890,013								$ 1,890,013
Helomics Holding Corp. [Member] \| Subsequent Event [Member] \| Shelf Registration [Member]
Payments to Acquire Notes Receivable	$ 420,000

Note 6 - Convertible Debt and Derivative Liability (Details Textual)	Mar. 31, 2019 USD ($) shares	Oct. 26, 2018	Oct. 03, 2018 $ / shares shares	Dec. 31, 2018 USD ($) yr $ / shares	Sep. 30, 2018 USD ($)	Sep. 28, 2018 USD ($)
Stock Issued During Period, Shares, Inducement for Bridge Loan \| shares			650,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 609.38
Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.155
Class of Warrant or Right, Vesting Period		180 days
Warrants and Rights Outstanding, Term			5 years
Class of Warrant or Right, Fair Value per Warrant \| $ / shares				$ 0.5361
Warrants and Rights Outstanding						$ 574,631
Derivative Liability, Total				$ 272,745	$ 645,008
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0294
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr				5
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.59
Subsequent Event [Member] \| Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	1,336,805
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount						$ 2,297,727
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Interest Guaranteed Period			1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock			70.00%
Debt Instrument, Convertible, Threshold Trading Days			20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares \| shares			2,678,328
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 1
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Subsequent Event [Member]
Debt Instrument, Face Amount	$ 2,865,909
Proceeds from Notes Payable, Total	$ 500,000

Note 7 - Loss Per Share (Details Textual) - shares	12 Months Ended
Note 7 - Loss Per Share (Details Textual) - shares	Dec. 31, 2018	Dec. 31, 2017
Weighted Average Number of Shares, Contingently Issuable	3,294,087
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,295,921	4,716,240
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note 8 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		$ 0
Valuation Allowance Percentage	100.00%	100.00%
Federal Income Tax Expense (Benefit), Continuing Operations, Total	$ 0
Open Tax Year	2014 2015 2016 2017 2018
Unrecognized Tax Benefits, Ending Balance	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
State and Local Income Tax Expense (Benefit), Continuing Operations, Total	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	40,094,472	34,529,255
Operating Loss Carryforwards, Valuation Allowance, Total	9,603,237	8,129,778
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	12,940,458	12,261,799
Operating Loss Carryforwards, Valuation Allowance, Total	1,416,758	$ 245,812
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	421,782
Operating Loss Carryforwards, Valuation Allowance, Total	$ 132,722

Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Depreciation	$ 4,488	$ 3,251
Inventory	6,991	6,950
Compensation accruals	60,905	50,436
Accruals and reserves	77,777	64,732
Charitable contribution carryover	3,972	4,068
Derivatives	57,276
Related party investments	481,652
Intangibles	2,020
NQSO compensation	1,019,139	766,648
NOL and credits	9,655,388	7,479,505
Total deferred tax assets	11,369,608	8,375,590
Deferred tax liabilities:
Original issue discount	(216,891)
Total deferred tax liabilities	(216,891)
Net deferred tax assets	11,152,717	8,375,590
Less: valuation allowance	(11,152,717)	(8,375,590)
Total

Computers and office equipment

Leasehold improvements

Manufacturing Tooling

Demo Equipment